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Abstract 
The endothelial barrier is essential for vascular function, and its disruption may play a 
major role in the development of cardiovascular diseases.  An increase in cAMP levels 
tightens the endothelial barrier by enhancing junction formation, and this is, in part, 
mediated by activation of exchange protein directly activated by cAMP (Epac).  Vascular 
endothelial cells express vascular endothelial cadherin (VE-cadherin), and connexins 37, 40 
and 43. Re-distribution of VE-cadherin in human coronary artery endothelial cells (HCAECs), 
induced by EGTA treatment or blocking VE-cadherin-VE-cadherin interactions through pre-
treatment with anti-VE-cadherin primary antibody, triggered a subsequent re-distribution 
of Cx37 that was reversible. Epac activation with the Epac-selective agonist 8-pCPT induced 
a re-distribution of VE-cadherin and connexin 37 to sites of cell-cell contact in HCAECs, 
increasing the co-localisation of these two proteins, as detected by immunocytochemistry.  
This increased co-localisation was completely blocked by Epac1 siRNA. To test whether the 
re-distribution of Cx37 induced by Epac activation resulted in the formation of new 
functional gap junction channels, Lucifer yellow dye transfer was examined in HCAECs 
under varying conditions. Epac activation in HCAECs enhanced gap junction intercellular 
communication (GJIC), and this increase was completely blocked by the Epac inhibitor 
HJC0197. 8-pCPT addition was also shown to induce a transient increase in the intracellular 
calcium concentration in HCAECs, as detected with the calcium indicator Fluo-4. This 
calcium transient was independent of protein kinase A (PKA), and occurred in the absence 
of extracellular calcium, but was inhibited by the presence of the endoplasmic reticulum 
calcium ATPase inhibitor cyclopiazonic acid (CPA), indicating that Epac primarily mediated 
the increase, and that intracellular stores were the predominant source of calcium. 
Furthermore, the calcium transient induced by 8-pCPT was considerably reduced by the 
Epac inhibitor ESI-09 and completely inhibited by the Epac inhibitor HJC0197. Together, 
these data suggest that Epac strengthens the endothelial barrier through re-distribution of 
VE-cadherin and Cx37. In addition, GJIC is enhanced by Epac activation and there is a rise in 
intracellular calcium, a second messenger that can be transferred to adjacent cells through 
GJIC. It may be possible, therefore, that these effects of Epac promote endothelial cell- 
smooth muscle cell communication and therefore Epac could play a role in the regulation 
of vascular tone.  
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1.1 - Introduction 
The endothelium lines the lumen of the vasculature and acts as an important barrier. The 
endothelium is formed from a single layer of endothelial cells while multiple layers of 
smooth muscle cells form the tunica media. These two cell types are separated by the 
internal elastic lamina, however endothelial cells project through holes in this lamina to 
directly contact the vascular smooth muscle cells at the myoendothelial junction 
(MEJ)(Heberlein, Straub et al. 2009, Lilly 2014). The integrity of the endothelial barrier is 
essential for proper vascular function, and endothelial dysfunction is a hallmark for 
vascular diseases including atherosclerosis (Vanhoutte 2009). Homocellular junctions 
between endothelial cells include adherens junctions (AJ), formed by cadherins, and gap 
junctions (GJ), formed by connexins, and dynamic regulation of these junctions is 
fundamental to the role of the endothelium. Figure 1.1 represents the basic structure of an 
artery.  
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Figure 1.1: Structure of an artery  
This schematic represents the major components of an artery. The lumen is lined by a 
single layer of endothelial cells (green), the surface of which is coated with a negatively-
charged layer of glycosaminoglycans, proteoglycans and adsorbed plasma proteins, 
forming the glycocalyx (black lines). The basement membrane (thin yellow line) and the 
internal elastic lamina (grey) divide the endothelial cells from the multiple layers of 
smooth muscle cells (red) forming the tunica media. The smooth muscle cells are lined 
externally by the external elastic lamina which is encased within the tunica adventitia 
composed primarily of collagen. 
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1.2 - Development of the vasculature  
The primitive vasculature develops from the mesodermal germ layer during embryogenesis 
(Coffin and Poole 1988, Heimark, Degner et al. 1990). Hemangioblasts develop in the yolk 
sac mesoderm and form clusters of cells termed blood islands (Nishikawa, Hirashima et al. 
2001), and these bipotential stem cells form both angioblasts and hematopoietic cells 
(Asahara and Kawamoto 2004).  Angioblasts form the endothelial cells which comprise the 
tunica intima lining the lumen of the vasculature (Coffin and Poole 1988, Heimark, Degner 
et al. 1990), while the hematopoietic cells are the progenitors to the blood cells. Vascular 
endothelial growth factor (VEGF), produced by perivascular cells, induces proliferation and 
migration of these angioblasts within the extracellular matrix (ECM), forming the primitive 
vascular plexus, a process termed vasculogenesis (Shalaby, Rossant et al. 1995). This 
primitive network of vessels is subsequently extended by the sprouting of capillaries in a 
process termed angiogenesis (Risau 1997, Risau, Esser et al. 1998). The basal lamina 
separates the endothelial layer from interstitial collagens of the extracellular matrix (Liu 
and Senger 2004). During resting conditions, endothelial cell contact with laminin I of the 
basal lamina induces a quiescent state in the endothelial cells. During angiogenesis, 
however, sprouting endothelial cells are exposed to collagen I, a component of the ECM, 
and this interaction promotes disruption of cell-cell contacts between endothelial cells and 
capillary morphogenesis, thereby allowing the vascular remodelling required for 
angiogenesis (Liu and Senger 2004).  
 
1.3 - The glycocalyx and the endothelial barrier 
The vascular endothelium is lined by a negatively-charged surface coat of 
glycosaminoglycans, proteoglycans and adsorbed plasma proteins termed the glycocalyx 
(Luft 1966, Pries, Secomb et al. 2000). The negative charge of the glycocalyx is important in 
the control of endothelial permeability, inhibiting the attachment of both red blood cells 
(Busch, Ljungman et al. 1979, Ryan and Ryan 1984, Damiano 1998, Secomb, Hsu et al. 
2001) and leukocytes (Mehta and Malik 2006). Furthermore, this layer selectively regulates 
the passage of molecules based on their charge (Adamson, Huxley et al. 1988, Bansch, 
Nelson et al. 2011) and acts as a mechanosensor detecting changes in blood flow (Florian, 
Kosky et al. 2003, Curry and Adamson 2012). Digestion of the frog mesenteric artery 
glycocalyx with pronase results in a 2.5 fold increase in capillary hydraulic conductivity (Lp), 
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indicating the importance of this layer in the maintenance of the endothelial barrier 
(Adamson 1990).  
 
1.4 - The extracellular matrix 
The extracellular matrix (ECM) makes a major contribution to endothelial barrier function 
(Qiao, Wang et al. 1995, Moy, Winter et al. 2000), and disruption of the ECM directly 
disturbs the endothelial barrier, increasing endothelial permeability (Partridge, Jeffrey et al. 
1993). The ECM in direct contact with the endothelium is termed the basement membrane 
and is comprised of two layers, the basal lamina and the reticular lamina (Paulsson 1992).  
The basement membrane consists primarily of collagen IV, laminin, fibronectin, entactin, 
chondroitin sulphate and heparin sulphates (perlecan and syndecan) (Kalluri 2003). The 
basal lamina is further subdivided into a layer in direct contact with the endothelium, the 
lamina rara which contains primarily laminin, and a layer closer to the connective tissue, 
termed the lamina densa which contains type IV collagen. The components of the basal 
lamina are derived from the endothelial cells which it underlies, while the structures of the 
reticular lamina are synthesised by cells of the underlying connective tissue. The first stage 
in the formation of the ECM requires secretion of laminin by the endothelial cells. These 
laminin polymers are then able to bind β1-integrins on the endothelial cells (Albelda, Daise 
et al. 1989, Languino, Gehlsen et al. 1989). In addition to laminin, endothelial cells also 
produce collagen IV polymers  (Kalluri 2003) and these directly interact with laminin 
polymers in the extracellular space. The result is the formation of a scaffold to which other 
ECM proteins are then able to attach, ultimately forming a basement membrane of high 
elasticity and tensile strength (Kalluri 2003). The release of such ECM proteins from the 
endothelial cells is evident only during vasculogenesis and angiogenesis (Akhta, Carlso et al. 
2001, Kalluri 2003) and interaction between the ECM and the endothelial cells (through 
integrins) inhibits endothelial proliferation and migration (Form, Pratt et al. 1986). 
 
1.4.1 - Endothelial cell–ECM interactions: Integrins and focal adhesions  
Focal adhesions were initially identified through electron microscopy as electron-dense 
plaques associated with actin filament bundles (Abercrombie, Heaysman et al. 1971). These 
junctions allow firm association between cells and the ECM, are formed by members of the 
integrin family of transmembrane proteins, and link directly to actin filaments of the 
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cytoskeleton. Integrins are type I transmembrane glycoproteins that form heterodimers on 
endothelial cells and act as receptors for proteins of the ECM (Ruoslahti 1991). These 
heterodimers are specifically expressed at focal adhesions on endothelial cells, primarily at 
the abluminal side of the endothelium, thereby allowing direct endothelium-ECM 
interaction (Burridge, Fath et al. 1988).  Integrins are transmembrane proteins consisting of 
a large ectodomain and a normally small cytoplasmic domain (Ruoslahti 1991), and 
subtypes are defined by unique combinations of alpha and beta subunits (Albelda, Daise et 
al. 1989). Endothelial cells express numerous integrin subunit compositions, among which 
are the fibronectin receptor α5β1 (Tarone, Stefanuto et al. 1990), the laminin and collagen 
receptor α1β1 (Defilippi, van Hinsbergh et al. 1991) and a multifunctional receptor that 
binds fibronectin, collagen and laminin α3β1 (Albelda, Daise et al. 1989, Cheng and Kramer 
1989, Tarone, Stefanuto et al. 1990). Integrins interact with the Arg-Gly-Asp (RGD) domain 
of ECM proteins (Cheng and Kramer 1989, Conforti, Zanetti et al. 1989, Lampugnani, 
Resnati et al. 1991) and integrins bind various ECM proteins including fibronectin, laminin 
and collagen. Addition of a synthetic peptide to competitively disrupt integrin-ECM 
interactions induces endothelial cell rounding and increased endothelial permeability 
(Stickel and Wang 1988, Wu, Ustinova et al. 2001). Furthermore, in intact vessels, peptides 
inhibiting integrin-fibronectin or integrin-vitronectin interactions induce increased 
permeability of the venular endothelial barrier (Wu, Ustinova et al. 2001). In addition to 
extracellular interactions, integrins also play a role in intracellular interactions with the 
actin cytoskeleton. The short cytoplasmic tail of integrins binds various actin-binding 
proteins including vinculin, α-actinin and filamin (Geiger, Bershadsky et al. 2001). These 
actin-binding proteins subsequently bind signalling molecules and therefore link integrins 
to downstream signalling events. Filamin can bind RhoA, Rac and Cdc42 (Ohta, Suzuki et al. 
1999), members of the Rho family of GTPases which can modulate the actin cytoskeleton. 
Similarly, the hinge region of vinculin interacts with both the Arp2/3 complex, recruiting 
this complex to new sites of integrin aggregation (DeMali, Barlow et al. 2002), and 
phosphatidylinositol 4,5-bisphosphate (PIP2), both of which are involved in the regulation 
of the actin cytoskeleton (further detail on these signalling events will be detailed under 
“Section 5.1.9 – Rap1 activates Rac through Tiam1 and Vav2”). Integrins also interact with 
kinases, and Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that 
indirectly interacts with the cytoplasmic domain of the β-subunit of integrins (Brakebusch 
and Fassler 2003, Geiger, Spatz et al. 2009). This kinase is activated by tyrosine 
phosphorylation in response to integrin activation induced by cell-cell interaction and 
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adhesion (Schlaepfer and Mitra 2004). Activated FAK is subsequently able to bind to, and 
phosphorylate, WASP (Wiskott-Aldrich syndrome protein) which induces actin 
polymerisation (Zigmond 2000), thereby stabilising endothelial cell-cell contacts and 
strengthening the barrier function. Global deletion of FAK in mice is embryonically lethal at 
E8.5 as the endothelial cells are unable to migrate to form the mature vasculature (Ilic, 
Kovacic et al. 2003). Similarly, endothelial cell-specific deletion of FAK produces mice with 
apparently normal vascular development during early embryonic stages, but after E12.5 
angiogenic defects are evident in the embryo, yolk sac and placenta, and embryos die at 
E13.5 (Shen, Park et al. 2005). These results indicate the importance of integrin 
engagement with the ECM for proper function of the endothelial barrier as disruption of 
this interaction results in increased endothelial permeability, hemorrhage and edema 
(Partridge, Jeffrey et al. 1993, Shen, Park et al. 2005). Integrins have also been implicated in 
the progression of several diseases including cancer (Desgrosellier and Cheresh 2010) and 
Alzheimers (Grace and Busciglio 2003). 
 
1.5 - Endothelial cell-cell contact 
The region of contact between adjacent endothelial cells varies dependent upon tissue and 
vessel type. In microvascular endothelium, endothelial cell contact domains are typically 
0.5-0.9 µm in length (Franke, Cowin et al. 1988), while in arteries cell-cell contact sites can 
be between 3-10 µm (Rhodin 1974, Franke, Cowin et al. 1988). The intercellular gap 
between adjacent endothelial cells is typically 10-20 nm outside the regions of direct cell-
cell contact (Franke, Cowin et al. 1988), and this intercellular cleft allows the selective 
paracellular passage of small molecules and ions.  
 
 
1.6 - Endothelial cell architecture 
 
Endothelial cells contain three primary cytoskeletal components; actin microfilaments, 
intermediate filaments and microtubules, and all three components play a role in the 
regulation of the endothelial barrier.  
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1.6.1  - Intermediate filaments and complexus adhaerens 
 
Intermediate filaments are designated as such due to their average diameter of 10 nm, 
which is between that of actin microfilaments (typically 7 nm) and microtubules (25 nm) 
(Ishikawa, Bischoff et al. 1968). In endothelial cells, intermediate filaments are composed 
of polymers of vimentin and cytokeratin (Patton, Yoon et al. 1990), and these filaments 
display no polarity and can extend their length from either end (Mehta and Malik 2006). In 
epithelial cells, intermediate filaments are involved in cell-cell junctions and cell-ECM 
junctions at desmosomes and hemidesmosomes, respectively. These interactions involve 
the transmembrane proteins desmoglein and desmocollin, which are members of the 
cadherin family (Mechanic, Raynor et al. 1991, Garrod and Chidgey 2008). Endothelial cells 
do not develop desmosomes (Franke, Cowin et al. 1988, Rubin 1992, Lampugnani and 
Dejana 1997). Vimentin can be linked to AJs in structures similar to desmosomes, however, 
and these are termed complexus adherens (Schmelz and Franke 1993, Schmelz, Moll et al. 
1994, Valiron, Chevrier et al. 1996, Kowalczyk, Navarro et al. 1998).  γ-catenin forms a 
complex with VE-cadherin (further details in “Section 4.1.2.2.2”) and this catenin is able to 
link vimentin to VE-cadherin through the intermediate filament-binding protein  
desmoplakin, thereby linking the AJ to the intermediate filament network (Shasby, Ries et 
al. 2002). Similarly, the AJ armadillo protein p0071 also binds desmoplakin, thereby 
providing an alternative link between the AJ and the intermediate filament network 
(Valiron, Chevrier et al. 1996, Calkins, Hoepner et al. 2003). The interaction between AJ 
components and the intermediate filament network is disrupted by inflammatory 
mediators, and 60 seconds histamine treatment is sufficient to disturb the intermediate 
filament/γ-catenin/VE-cadherin interaction (Shasby, Ries et al. 2002). Interestingly, 
however, vimentin knock-out mice lack endothelial cell intermediate filaments but no 
abnormalities in phenotype or cell architecture were detected (Colucci-Guyon, Portier et al. 
1994), indicating either a redundancy of intermediate filaments or a potential 
compensatory effect of other cytoskeletal components. In vivo inactivation of the 
desmoplakin gene, on the other hand, results in vascular defects including a reduced 
number of capillaries (Gallicano, Bauer et al. 2001). This defective vascular development 
was hypothesised to be due to a lack of correct organisation of the complexus adhaerens. 
Interestingly, the desmoplakin knock out phenotype was more severe than that detected in 
γ-catenin null embryos, thereby indicating the redundancy between armadillo proteins 
(Gallicano, Bauer et al. 2001).  
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1.6.2 - Microtubules 
 
Microtubule networks provide pathways for the motor proteins dynein and kinesin, 
thereby allowing intracellular transport of proteins throughout the cell (Wade and Hyman 
1997, Krylyshkina, Kaverina et al. 2002). Microtubules are formed from heterodimers 
organised by self-assembly of α and β tubulins, each with a molecular mass of 55 kDa 
(Chrétien and Wade 1991). These subunits interact in a head-to-tail fashion to form 
protofilaments aligned lengthwise along the microtubule (Chrétien and Wade 1991, Wade 
and Hyman 1997). These protofilaments then form lateral contacts with adjacent 
protofilaments to construct a hollow tube with a lumen diameter of approximately 12 nm 
(Kikkawa, Ishikawa et al. 1994). Typically, 13 or 14 protofilaments assemble to make a 
single microtubule, dependent upon the cell type (Chretien, Metoz et al. 1992).  These rigid 
hollow rods span the cell from the nucleus to the periphery, resisting compression of the 
cell by opposing actin-myosin contractility (Mehta and Malik 2006). Unlike intermediate 
filaments, microtubules are polarised, with a faster-growing plus-end which is attached to 
the cortical actin layer on the inner face of the plasma membrane, and a slower-growing 
minus end. This plus-end is composed of β tubulin that binds to and hydrolyses GTP to GDP, 
thereby allowing ‘dynamic treadmilling’ where the microtubule switches between addition 
and removal of tubulin dimers to allow lengthening and shortening of the microtubule, 
respectively (Waterman-Storer and Salmon 1997, Grego, Cantillana et al. 2001). The minus 
end is composed of α tubulin and is able to bind to GTP but not hydrolyse it into GDP. 
These minus ends are typically joined at a common attachment site known as the 
microtubule-organising centre (MTOC). Although microtubules do not directly interact with 
cell junctions they mediate delivery of cell junction components to the cell surface and 
specifically to sites of cell-cell contact (Vincent, Xiao et al. 2004). p120 catenin, a 
component of the AJ complex, directly interacts with the heavy chain of the microtubule 
motor protein kinesin in non-endothelial cells (Chen, Kojima et al. 2003, Yanagisawa, 
Kaverina et al. 2004). As previously mentioned, these motor proteins regulate vesicular 
trafficking and therefore microtubule-delivery of AJ components may be targeted to the AJ 
by p120 catenin, thereby enhancing the endothelial barrier. In addition to components of 
the AJ, microtubules also mediate the delivery of connexin hemichannels to the plasma 
membrane to form functional gap junction channels (Jordan, Solan et al. 1999, Lauf, 
Giepmans et al. 2002, Shaw, Fay et al. 2007). These proteins can be selectively targeted to 
sites of cell-cell contact through preferential tethering of the microtubule plus-end at AJs. 
This involves microtubule plus-end tracking proteins called TIPS. EB1 is a dimeric TIP that 
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associates directly with this region of the microtubule. EB1 also has dual binding sites for a 
component of the dynein/dynactin complex, p150 (Glued), at its C-terminus (Berrueta, 
Tirnauer et al. 1999, Askham, Vaughan et al. 2002).  β-catenin, a component of AJs, also 
binds dynein and therefore is suggested to link the microtubule plus-end to AJs 
(Chausovsky, Bershadsky et al. 2000, Ligon, Karki et al. 2001).  In support of this 
preferential targeting of microtubule plus-ends to sites of cell-cell contact, Shaw et al. 
(2007) identified that the microtubule plus-end approached gap junction plaques more 
frequently than the remainder of the cortical membrane in HeLa cells transfected with the 
gap junction component Cx43. In addition, these experiments also identified that siRNA 
knock down of EB1, p150 (Glued) and β catenin disrupted gap junction formation in these 
transfected HeLa cells (Shaw, Fay et al. 2007). Similarly, inhibition of the motor protein 
activity of kinesin-1 (Krylyshkina, Kaverina et al. 2002) or addition of the depolymerising 
agent nocodazole (Verin, Birukova et al. 2001), resulted in decreased cell-substrate 
adhesion and increased endothelial permeability, respectively.  The microtubule network is 
therefore essential for proper endothelial barrier function.  
 
 
1.6.3 - The actin network 
 
The actin network plays the greatest role in the control of endothelial permeability out of 
the three cytoskeletal components discussed here, and this is primarily due to its 
involvement in endothelial contraction. Endothelial F-actin exists in one of three subtypes 
within the cell cytoskeleton; the outer membrane skeleton, a cortical actin rim, and 
numerous cytosolic stress fibres. The outer membrane skeleton and the cortical actin rim 
are composed of short F-actin filaments, while stress fibres are formed from long F-actin 
bundles. The outer membrane skeleton is primarily composed of networks of spectrin 
fibres which are responsible for the interaction between cadherins, catenins and the 
cortical actin rim (further detail under “Section 4.1.2.2.2”). The cortical actin rim is 
responsible for the generation of outward centrifugal tension, ultimately ensuring the cell 
does not collapse in on itself due to the centripetal tension generated by the actin stress 
fibres (see below). The cytoplasmic actin stress fibres are closely associated with myosin 
motor proteins which track along the fibres to form actomyosin contractile bundles. As 
such, the endothelial contractile machinery consists of actin and non-muscle myosin, and 
requires ATP, calcium and calmodulin to generate contractile force (Surapisitchat and 
Beavo 2011). Bundles of polymerised actin and myosin filaments form the stress fibres 
which traverse the cell and form the primary elements of the endothelial cell contractile 
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machinery (Dudek and Garcia 2001). Actinomyosin-generated endothelial contraction 
requires phosphorylation of myosin light chain (MLC) on Ser19, termed mono-
phosphorylation, or on both Ser19 and Thr18, termed di-phosphorylation, mediated by 
MLC kinase (MLCK) (Goeckeler and Wysolmerski 1995). MLCK is a calcium/calmodulin-
dependent enzyme and therefore explains the requirement for calcium for actinomyosin-
generated contraction (Mehta and Malik 2006). In human endothelial cells, MLCK is a 214 
kDa protein encoded from a single gene on chromosome 3 (Dudek and Garcia 2001). 
Inflammatory mediators typically promote endothelial contraction to induce inter-
endothelial cell gap formation to allow enhanced paracellular transport. Endothelial cell 
MLCK -/- mice are protected from increased lung vascular permeability induced by the 
injection of lipopolysaccharide (LPS) due to an inability to stimulate endothelial cell 
contraction (Wainwright, Rossi et al. 2003). Endothelial barrier stabilisers, on the other 
hand, typically inhibit endothelial cell contraction to prevent enhanced paracellular 
transport and tighten the endothelial barrier. Specific factors promoting or inhibiting 
endothelial contraction are detailed under “Section 1.12 - Barrier de-stabilisers” and 
“Section 1.13 - Barrier stabilisers”.  
 
In addition to the regulation of endothelial contraction, the actin cytoskeleton is also 
involved in the regulation of the endothelial barrier through interaction with components 
of anchoring, occluding and communicating junctions. In endothelial cells, the primary 
anchoring junctions are the adherens junctions (AJs). The occluding junctions of the 
vascular endothelium are the tight junctions (TJs) which were originally thought to form an 
impermeable barrier to paracellular transport but are now considered to act as selective 
inhibitors to such transport. Finally, the communicating junctions of the endothelium allow 
the direct exchange of chemical and electrical signals between adjacent cells, and are 
termed gap junctions (GJs). All three junction types are shown in Figure 1.2. 
 
 
 
 
 
 
 
 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Cell junctions in endothelial cells 
Three main types of cell junctions are found in vascular endothelial cells; tight 
junctions, adherens junctions and gap junctions. Tight junctions (red) are primarily 
formed from occludin and claudin with a contribution from ZO-1 and other junctional 
adhesion molecules (JAMs). In epithelia and other polarised cells, these are restricted 
to the apical region, however in endothelial cells tight junctions show a less restricted 
distribution. In endothelial cells, adherens junctions (AJs, blue) are formed primarily 
from VE-cadherin, although N-cadherin is also expressed in these cells. Cadherins 
interact with members of the Armadillo family of proteins to link to the actin 
cytoskeleton. Gap junctions (green) are formed from connexin proteins and connexin 
37, 40 and 43 are expressed in the vascular endothelium. These junctions are channels 
that allow the direct exchange of ions and second messengers between adjacent cells.  
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1.7  - Adherens junctions 
Endothelial cell adherens junctions consist primarily of vascular endothelial-cadherin (VE-
cadherin) complexes, which include catenins, and nectins (Noda, Zhang et al. 2010), the 
latter of which are likely to mediate initial cell-cell contacts allowing cadherin interaction 
and the formation of mature adherens junctions (AJs) (Wallez and Huber 2008). Nectins are 
part of the immunoglobulin family with four subtypes (1-4), of which nectin 2 and nectin 3 
are expressed in endothelial cells (Lopez, Aoubala et al. 1998). Nectin interaction is 
calcium-independent and can be either homotypic or heterotypic, binding to other nectin 
subtypes (Takai, Irie et al. 2003). The C-terminus of nectin interacts directly with the PDZ 
(postsynaptic density protein-95/ discs large/ ZO-1) domain of the actin-binding protein AF-
6, and the nectin/AF-6 complex associates with both tight junctions and AJs (Takahashi, 
Nakanishi et al. 1999, Takai and Nakanishi 2003). Nectin is therefore able to recruit further 
AJ components to the AJ (Irie, Shimizu et al. 2004).  
 
Cadherins are responsible for the calcium-dependent homotypic or hetertypic interaction 
of AJs (see Figure 1.3). These surface glycoproteins have a molecular mass of 120-140 kDa 
(Geiger and Ayalon 1992), and were initially identified within AJs through electron 
microscope analysis (Boller, Vestweber et al. 1985, Volk and Geiger 1986) and 
immunofluorescence (Volk, Geiger et al. 1984, Volk and Geiger 1986). Cadherins are 
comprised of a long extracellular domain, a transmembrane domain and a short 
cytoplasmic domain. The extracellular region consists of the N-terminus and 5 cadherin-like 
repeats (Liaw, Cannon et al. 1990, Lampugnani, Resnati et al. 1992). These 5 external 
domains are subdivided into two groups; EC1-3 are interhomologous ectodomains, each 
approximately 110 amino acids long, while EC4 and EC5 are less homologous repeats 
(Takeichi 1990). It is these extracellular domains that determine the specificity of cadherin-
cadherin interactions and allow the formation of trans-oligomers between adjacent cells 
(Liaw, Cannon et al. 1990, Lampugnani, Resnati et al. 1992), while modification of the EC5 
domain affects the reactivity and stability of the cadherin molecule (Ozawa, Hoschützky et 
al. 1990). Each extracellular region (EC1-5) expresses 2 putative calcium-binding sites 
(Ringwald, Schuh et al. 1987, Ozawa, Engel et al. 1990), and a single amino acid substitution 
in the calcium binding site of EC1 has the ability to abolish the adhesive potential of the 
molecule (Ozawa, Engel et al. 1990). Similarly, culture in low calcium medium induces 
splitting of AJs (Nilsson, Fagman et al. 1996). Taken together, this indicates the calcium-
dependent nature of cadherin interactions. The presence of extracellular calcium also 
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protects cadherins from proteolytic degradation (Yoshida and Takeichi 1982, Vestweber 
and Kemler 1985), with cadherins displaying increased sensitivity to trypsinisation in the 
absence of calcium (Takeichi 1988). The cytoplasmic tail of cadherins is highly conserved 
between subtypes, although this region shows no similarity to the respective region in 
desmogleins or desmocollins, which are additional members of the cadherin family (Geiger 
and Ayalon 1992). This lack of similarity may allow these desmosome/hemi-desmosome 
components to bind to intermediate filaments instead of actin filaments like classical 
cadherins. The cadherin cytoplasmic tail is sub-divided into 2 functional domains; the 
juxtamembrane domain and the COOH-terminal domain. The juxtamembrane domain is 
responsible for cadherin-p120 catenin and cadherin-p0071 interactions, and the COOH-
terminus binds to either β-catenin or γ-catenin in a mutually-exclusive manner (Zhurinsky, 
Shtutman et al. 2000, Bazzoni and Dejana 2004). With the exception of T-cadherin, a 
truncated form of cadherin with no cytoplasmic domain (Vestal and Ranscht 1992), 
cadherin-catenin interaction is essential for maturation of the AJ (Nagafuchi and Takeichi 
1988, Ozawa, Ringwald et al. 1990). Classical cadherins are subdivided into Type I and Type 
II cadherins. Type I cadherins, such as neural-cadherin (N-cadherin) and epithelial-cadherin 
(E-cadherin), express a conserved histadine-alanine-valine (HAV) tripeptide motif in EC1, 
while type II cadherins, including VE-cadherin, lack this sequence (Blaschuk, Sullivan et al. 
1990, Tanihara, Sano et al. 1994, Halbleib and Nelson 2006). Numerous cadherin subtypes 
exist but for the purpose of this study only those identified within vascular endothelial cells 
will be detailed. As previously mentioned, VE-cadherin forms the predominant cadherin of 
endothelial AJs. In addition to this cadherin, endothelial cells have also been shown to 
express N-cadherin (Navarro, Caveda et al. 1995, Liebner, Gerhardt et al. 2000, Williams, 
Williams et al. 2001), T-cadherin (Ivanov, Philippova et al. 2001), placental-cadherin (P-
cadherin) (Rubin 1992) and VE-cadherin 2 (protocadherin 12) (Telo, Breviario et al. 1998, 
Rampon, Prandini et al. 2005). T-cadherin has been identified in the endothelial cells of 
human aorta tissue sections (Ivanov, Philippova et al. 2001), while P-cadherin expression 
has been identified in endothelial cells through PCR analysis but not through antibody 
staining (Rubin 1992). VE-cadherin 2 has been identified at inter-endothelial junctions, 
primarily in endothelium undergoing angiogenesis, and interestingly has a completely un-
related cytoplasmic tail to other cadherins (Telo, Breviario et al. 1998). N-cadherin, 
although widely expressed in endothelial cells, is typically not involved in AJs as it is out-
competed for membrane distribution by VE-cadherin (Salomon, Ayalon et al. 1992, 
Navarro, Ruco et al. 1998). Further detail on the competitive nature between VE-cadherin 
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and N-cadherin is detailed under “Section 4.4.11 - N -cadherin in HCAECs”. Although not 
significantly involved in inter-endothelial junctions, N-cadherin is thought to promote 
communication with mesenchymal cells also expressing N-cadherin in vivo, including 
pericytes, smooth muscle cells and astrocytes (Geiger and Ayalon 1992). Indeed, N-
cadherin has been identified clustered at the basal surface of endothelial cells, directly in 
contact with pericytes and astrocytes in the brain (Liebner, Gerhardt et al. 2000). Further 
detail on VE-cadherin and its interaction with catenins can be found in Chapter 4: 
Connexins and Cadherins in HCAECs and HCASMCs.  
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Figure 1.3: Classical cadherin structure 
This schematic represents the structure of a classical cadherin such as VE-cadherin or 
N-cadherin. The extracellular region consists of the N-terminus and 5 extracellular 
domains (EC1-5), each of which expresses two calcium-binding sites (yellow). The 
transmembrane domain (T.D) is shown in green. The cytoplasmic domain (C.D, blue) is 
sub-divided into a juxtamembrane domain where the armadillo proteins p120 and 
p0071 bind (represented in red), and a COOH-terminal domain where either β-catenin 
or γ-catenin bind (represented in red). β-catenin and γ-catenin are able to bind α-
catenin which binds α-actinin (green) and links the cadherin/catenin complex to the 
actin cytoskeleton (purple). 
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1.8 - Tight junctions 
Tight junctions were originally identified by electron microscopy as distinct points where 
the outer layers of the lateral membranes of adjacent endothelial cells fused (Farquhar and 
Palade 1963). These junctions are considered to represent approximately 20% of the total 
junctional complexes in endothelial cells (Wojciak-Stothard, Potempa et al. 2001), and 
consist of claudins, occludins and junctional adhesion molecules (JAMs) (Noda, Zhang et al. 
2010). These occluding junctions regulate paracellular permeability and maintain cell 
polarity, effectively dividing the endothelial cell membrane into an apical region that is 
directed towards the vessel lumen, and a basolateral region that faces the perivascular 
space (Bazzoni and Dejana 2004).  Tight junctions vary markedly in their distribution 
patterns in different vascular beds, depending upon the requirement for endothelial 
permeability. Freeze fracture studies identified that arterial segments of the 
intrapulmonary vasculature display approximately twice as many tight junctions as venular 
segments from the same vascular bed (Schneeberger 1982). Similarly, large artery 
endothelial cells have been shown to display a well-developed tight junction system while 
tight junctions of capillaries are less complex (Wallez and Huber 2008). Furthermore, the 
blood-brain barrier (BBB) and blood-retinal barrier (BRB) which require an almost 
impermeable endothelial barrier are both rich in tight junctions (Wallez and Huber 2008). 
Post-capillary venules are the predominant site of increased endothelial permeability 
induced by inflammatory mediators, and these vessels have poorly organised tight 
junctions (Bazzoni and Dejana 2004).  
 
 
1.8.1 – Tight junction components 
1.8.1.1 - ZO-1 
Zonula occludins-1 (ZO-1) was the first intracellular component of tight junctions to be 
discovered, and was named after the alternative name for the tight junction, the zonula 
occludins (Stevenson, Siliciano et al. 1986). Three subtypes of ZO proteins exist, and these 
belong to a family of membrane-associated guanylate kinases (MAGUK) (Bazzoni and 
Dejana 2004). These proteins consist of a PDZ domain , an SH3 (Src homology 3) domain 
and a guanylate kinase domain (Bazzoni and Dejana 2004). Calcium-dependent intercellular 
adhesion is required for localisation of ZO-1 to tight junctions (Siliciano and Goodenough 
1988). Once at the tight junction, ZO-1 becomes insoluble in non-ionic detergents, 
indicating a strong association with the cortical actin rim (Anderson, Stevenson et al. 1988). 
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This cytoskeletal interaction is supported by co-precipitation of ZO-1 with F-actin (Itoh, 
Nagafuchi et al. 1997, Fanning, Jameson et al. 1998), an interaction that requires a 220 
amino acid region in the C-terminal half of ZO-1, termed the actin-binding region (ABR) 
(Fanning, Ma et al. 2002). Indeed, it appears that this ABR is required for accumulation of 
ZO-1 at the free edge of cells prior to cell-cell contact formation, and once established, at 
the tight junction (Fanning, Ma et al. 2002). The N-terminal domain of ZO-1 interacts with 
the C-terminal domain of the gap junction component connexin 43 (Cx43) in cardiac 
myocytes, and therefore provides a link between tight junctions and gap junctions 
(Toyofuku, Yabuki et al. 1998). Indeed, over-expression of a dominant-negative mutant 
form of ZO-1 lacking the N-terminal domain required for Cx43 interaction led to re-
distribution of Cx43 away from sites of cell-cell contact (Toyofuku, Yabuki et al. 1998).  
 
1.8.1.2 - Occludin 
 
In 1993 occludin was the first transmembrane protein to be identified in tight junctions 
through the use of monoclonal antibodies raised against the junctional fraction of chick 
liver cells (Furuse, Hirase et al. 1993). This 65 kDa protein consists of 4 putative membrane-
spanning domains, 2 extracellular loops and cytoplasmic N- and C-termini (Furuse, Hirase et 
al. 1993). Occludin is exclusively localised to the tight junction in both epithelial and 
endothelial cells, and cell-cell adhesion is likely to be dependent upon the conserved first 
extracellular loop as synthetic peptides corresponding to this region inhibit adhesion (Van 
Itallie and Anderson 1997). Occludin is not required for tight junction formation and 
requires claudin expression to localise to tight junctions (Furuse, Sasaki et al. 1998), but this 
protein is associated with enhanced tight junction barrier function. This is reflected in the 
expression of 18-fold more occludin protein in human arterial endothelial cells than human 
venous endothelial cells, a region that is targeted for increased endothelial permeability 
during inflammation (Kevil, Okayama et al. 1998). Furthermore, occludin is highly 
expressed in the endothelial cells forming the BBB and BRB and its down-regulation is 
associated with stroke (Brown and Davis 2002) and diabetes (Antonetti, Barber et al. 1998), 
diseases that involve the regulation of permeability in the BBB and BRB, respectively. 
Occludin -/- mice, however, show no gross alterations in endothelial tight junction 
morphology (Saitou, Furuse et al. 2000), indicating that a loss of occludin may be 
compensated for by increased adherens junctions or additional tight junction components. 
These mice do, however, display chronic inflammation and hyperplasia of the gastric 
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epithelium, suggesting that occludin may play a role in other, unknown, downstream 
processes (Saitou, Furuse et al. 2000).  
 
1.8.1.3 - Claudin 
 
Claudin proteins are the primary component of endothelial tight junctions and are capable 
of both homophilic binding and heterophilic binding (between various claudin subtypes) 
(Furuse, Sasaki et al. 1999, Furuse and Tsukita 2006). Like occludins, claudins also consist of 
4 membrane-spanning regions, 2 extracellular loops and 2 cytoplasmic termini (Bazzoni and 
Dejana 2004). These 22 kDa proteins, however, display no sequence similarity to occludin 
(Morita, Furuse et al. 1999). Endothelial cells specifically express claudin 5, claudin 3, 
claudin 11 and claudin 15 (Furuse, Sasaki et al. 1999, Kiuchi-Saishin, Gotoh et al. 2002, 
Wolburg, Wolburg-Buchholz et al. 2003, Enerson and Drewes 2006). Claudin 5 is the 
predominant form found in endothelial tight junctions, and claudin 5-deficient mice display 
a selective impairment in the BBB function for molecules smaller than 800 Da and die 
approximately 10 hours after birth (Nitta, Hata et al. 2003). Different claudin subtypes 
produce various tight junction profiles; claudin 1-based tight junctions are continuous and 
associated with the inner face of the inner lipid monolayer, while claudin 2-based tight 
junctions are fragmented and associated with the inner face of the outer lipid monolayer 
(Furuse, Sasaki et al. 1998). Claudin 5 is also located at the E-face of the plasma membrane, 
and such tight junctions are considered to be more ‘leaky’ than those associated with the 
P-face (Furuse, Sasaki et al. 1998, Morita, Sasaki et al. 1999). In addition to its extracellular 
interactions, the cytoplasmic domain of claudin also interacts with the first PDZ domain of 
ZO-1 (Itoh, Furuse et al. 1999).  
 
1.8.1.4 - JAMs 
 
Junctional adhesion molecules (JAMs) are additional components of endothelial tight 
junctions (Martin-Padura, Lostaglio et al. 1998). JAMs are a family of single-pass 
transmembrane adhesive proteins of the immunoglobulin superfamily (Aurrand-Lions, 
Duncan et al. 2000). These proteins have a long extracellular domain that allows 
homophilic adhesive activity, thereby reducing paracellular permeability (Martin-Padura, 
Lostaglio et al. 1998). JAMs also possess a cytoplasmic PDZ domain that may allow JAMs to 
recruit signalling molecules to the tight junction complex (Ebnet, Schulz et al. 2000). Three 
subtypes exist; JAM-A, JAM-B and JAM-C. JAM-A (also called hu-JAM) is a 32 kDa 
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glycoprotein expressed at both epithelial and endothelial intercellular junctions, in addition 
to the surface of platelets and leukocytes (Martin-Padura, Lostaglio et al. 1998, Williams, 
Martin-Padura et al. 1999). The extracellular domain of JAM-A contains 2 immunoglobulin-
like domains, C-terminal folds and the N-terminal (Williams, Martin-Padura et al. 1999). 
JAM-A is also capable of binding both the tight junction component ZO-1 and the actin-
binding protein AF-6 (Bazzoni, Martinez-Estrada et al. 2000, Ebnet, Schulz et al. 2000). 
Addition of a blocking antibody or recombinant fragment of JAM-A inhibits transepithelial 
electrical resistance (TER), a marker of a tight endothelial barrier (Liang, DeMarco et al. 
2000). Unlike JAM-A, JAM-B is restricted to inter-endothelial junctions, particularly in post-
capillary endothelial cells and lymphatic vessels (Cunningham, Arrate et al. 2000, Palmeri, 
van Zante et al. 2000). The final form, JAM-C, is expressed only in endothelial cells and is 
able to bind firmly to the Fc region of JAM-B (Arrate, Rodriguez et al. 2001).  
Endothelial cell-specific adhesion molecule (ESAM) is a transmembrane immunoglobulin 
protein related to JAMs that is expressed in endothelial tight junctions and mediates 
homotypic binding (Hirata, Ishida et al. 2001). ESAM binds MAGI in the cytoplasm, 
recruiting it to cell-cell contacts (Wegmann, Ebnet et al. 2004). MAGI is an adaptor protein 
that interacts with adherens junctions, and ESAM therefore provides an additional link 
between tight junctions and adherens junctions. Coxsackievirus and adenovirus receptor 
(CAR) is an additional immunoglobulin-like protein with a similar extracellular profile to 
JAMs (Cohen, Shieh et al. 2001). CARs participate in tight junction assembly and regulate 
paracellular permeability (Cohen, Shieh et al. 2001).  
 
Additional components of endothelial tight junctions include cingulin (Citi, Sabanay et al. 
1988), 7H6 (Satoh, Zhong et al. 1996), Rab3b (Weber, Berta et al. 1994) and Rab13 
(Zahraoui, Joberty et al. 1994). In contrast to the traditional view of tight junctions as an 
impermeable barrier to paracellular transport, these structures are now considered to act 
as paracellular channels, selectively allowing passage of specific molecules, and thereby 
contributing to the regulation of endothelial permeability (Bazzoni and Dejana 2004).  
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1.9 - Gap junctions 
Gap junctions (GJs)  form between adjacent cells to provide a low-resistance pathway for 
direct cell-cell communication via the exchange of chemical signals and electrical current 
(Carter and Ogden 1994). Gap junctions are essential for proper cell-cell communication 
and few terminally-differentiated cells do not communicate via these channels (skeletal 
muscle cells, erythrocytes and circulating lymphocytes) (Kumar and Gilula 1996).  Within 
the vasculature, these channels are able to form both within, and between, cell layers and 
therefore mediate both endothelial cell-endothelial cell communication, and 
communication between the endothelium and additional vascular cells (including smooth 
muscle cells and pericytes) (Figueroa, Isakson et al. 2004). These channels are relatively 
non-selective, with a pore diameter of approximately 2 nm (De Mazière, Analbers et al. 
1993, Goldberg, Valiunas et al. 2004), allowing the passive transfer of ions and second 
messenger molecules up to ~ 1,200 Da  (Simpson, Rose et al. 1977, Elfgang, Eckert et al. 
1995, Veenstra, Wang et al. 1995, Sáez, Berthoud et al. 2003). Gap junction channels are 
involved in a number of processes including the transmission of action potentials between 
excitable cells, such as in the heart (Simon, Goodenough et al. 1998), the passive diffusion 
of metabolites and nutrients (Goldberg, Lampe et al. 1999), and the exchange of second 
messengers such as calcium, inositol-1,4,5-trisphosphate (IP3) and cyclic nucleotides (Saez, 
Connor et al. 1989). Interestingly, the exchange of calcium between GJ-coupled cells has 
been shown as a wave approaching the GJ and subsequently appearing in the neighbouring 
cell in transfected HeLa cells (Paemeleire, Martin et al. 2000, Evans and Martin 2002). 
Similarly, in rat aortic endothelial cells, changes in membrane potential were found to 
rapidly propagate between adjacent cells as detected by whole-cell patch clamp 
experiments (Carter and Ogden 1994). Rat pulmonary microvessel endothelium has also 
been shown to display longitudinal calcium waves in situ, presumably propagated by such 
GJ channels (Carter and Ogden 1994). Interestingly, Cx43 GJ aggregations in endothelial 
cells have been shown to measure approximately 8 times as large as aggregations in 
smooth muscle cells from the same vascular bed (Haas and Duling 1997), and as such 
endothelial cells have been proposed to represent a more permissive pathway for the 
longitudinal conduction of signals along the vessel wall. In the vasculature, such 
communication between adjacent cells is essential for the proper control of both 
endothelial barrier function and to mediate changes in vessel diameter in response to 
changes in blood flow  (Dora 2001, Berman, Martin et al. 2002). Gap junction structure and 
formation, as well as details on connexin proteins and subtypes, is detailed in Chapter 4: 
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Connexins and Cadherins in HCAECs and HCASMCs. The effect of gap junction dysfunction 
in disease and knock out models is also detailed in this chapter. Gap junction turnover is 
detailed in Chapter 5: Control of Cadherin and Connexin Distribution, and gap junction 
selectivity and gating is detailed in Chapter 6: Functional Effect of Epac activation in 
HCAECs.  
 
1.10 - cAMP 
1.10.1 - Generation of cAMP – Adenylate cyclases  
Cyclic adenosine monophosphate (cAMP) is a small water-soluble second messenger 
generated by adenylate cyclases (ACs) on ligand binding to a G-protein-coupled receptor 
(GPCR). Due to its ability to rapidly diffuse throughout the cytosol, cAMP is utilised to 
mediate a number of downstream signalling events. Binding of a specific extracellular signal 
to the GPCR induces a conformational change that allows the receptor to activate the 
associated trimeric GTP-binding protein (G-protein). This G-protein is coupled to a large 
multi-pass transmembrane protein, adenylyl cyclase (AC), which displays its catalytic 
domain on the cytosolic surface of the plasma membrane. Activation of this membrane 
protein induces the generation of cAMP from ATP. The resting concentration of cAMP 
within the cell is typically less than 10 nM but this concentration can increase up to 20 fold 
within seconds on binding of the appropriate ligand to the GPCR (Real-time monitoring of 
cAMP levels in living endothelial cells: thrombin transiently inhibits adenylyl cyclase 6, 
werthmann, 2009). Such ligands include epinephrine, norepinephrine and prostaglandin, 
among others. Several isoforms of ACs exist and AC6 is the predominant isoform expressed 
in endothelial cells (Stevens, Nakahashi et al. 1995). AC6 is a type IV calcium-inhibitable AC 
that is responsible for the majority of cAMP synthesised in endothelial cells (Stevens, 
Nakahashi et al. 1995, Cioffi, Moore et al. 2002). In contrast to AC6, AC8 is a calcium-
stimulable AC, and over-expression of AC8 in endothelial cells using an adenoviral construct 
induces an elevation in cAMP (Cioffi, Moore et al. 2002). In addition to membrane-tethered 
ACs, soluble ACs also localise outside of membranous compartments (Sayner, Alexeyev et 
al. 2006). These ACs synthesize cAMP in a cytosolic pool and interestingly this alternative 
pool of cAMP produces different downstream effects to that generated in the membrane 
compartment, thereby highlighting the importance of cAMP compartmentalisation for 
specific downstream signalling events (Sayner, Alexeyev et al. 2006, Prasain, Alexeyev et al. 
2009).  
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1.10.2 - Degradation of cAMP – Phosphodiesterases  
The intracellular concentration of cAMP is also regulated by phosphodiesterases (PDEs). 
PDEs decrease the intracellular concentration of cAMP or cGMP by degrading the 
phosphodiester bond in these second messenger molecules. As a result, cAMP is 
hydrolysed to adenosine 5’-monophosphate (5’AMP). Various isoforms of PDEs exist and 
endothelial cells primarily express the cGMP-stimulated PDE2, the cGMP-inhibited PDE3, 
the cAMP-specific PDE4 and the cGMP-specific PDE5 (Netherton and Maurice 2005). Within 
endothelial cells, cAMP hydrolysis is primarily mediated by PDE3 and PDE4 (Lugnier and 
Schini 1990, Netherton and Maurice 2005). The relative contribution of these PDEs appears 
to vary between vascular beds and over the culture period. Early passage bovine aortic 
endothelial cells (BAECs, passages 4-6) typically express both PDE2 and PDE4, while BAECs 
at passage 10 and later predominantly express PDE4 (Ashikaga, Strada et al. 1997). PDEs 
also appear to be at least partly responsible for the compartmentalisation of cAMP. 
PDE4D4 is a splice variant of PDE4 expressed in pulmonary microvasulature endothelial 
cells and detected in plasma membrane fractions (Creighton, Zhu et al. 2008). PDE4D4 
interacts with α-II spectrin, a component of the actin cytoskeleton that localises to the 
inner surface of the plasma membrane (Creighton, Zhu et al. 2008). The interaction 
between PDE4D4 and α-II spectrin therefore inhibits the spread of cAMP away from the 
membrane pool. Additional endothelial PDE isoforms include the calcium/calmodulin-
regulated PDE1 and the cAMP-specific PDE7A (Keravis, Komas et al. 2000, Miro, 
Casacuberta et al. 2000).  
 
1.11 - The cAMP pathway in endothelial cells 
Three classes of proteins containing cyclic nucleotide-binding (CNB) domains have been 
shown to be regulated by cAMP; cAMP-dependent protein kinase (PKA), cyclic nucleotide-
gated ion channels and exchange proteins directly activated by cAMP (Epacs)(Rehmann 
2013). 
1.11.1 - Protein Kinase A 
The cAMP-dependent protein kinase (PKA) was first identified in rabbit skeletal muscle by 
Walsh et al. in 1968, and is, as its name suggests, entirely dependent upon cAMP for its 
activation (Walsh, Perkins et al. 1968). PKA holoenzymes consist of two regulatory subunits 
(R) each of which contain two cAMP-binding sites, and two catalytic (C) subunits that carry 
out the kinase activity of PKA. The binding of four cAMP molecules to a dormant PKA 
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holoenzyme results in a conformational change that releases the two C subunits from the 
regulatory subunit-cAMP complex, thereby activating PKA. Two R subunit classes are 
known to exist and it is these that distinguish between Type I and Type II holoenzymes 
(Corbin, Keely et al. 1975). Local cAMP levels must exceed threshold for PKA activation to 
occur, and four cAMP molecules are required for dissociation of the regulatory complex 
and activation of PKA. cAMP is rapidly metabolised to adenosine monophosphate (AMP) by 
phosphodiesterases leading to re-binding of the regulatory subunit. This may suggest that 
PKA must be co-localised with adenylate cyclase or contained within a cellular 
compartment that is able to concentrate cAMP levels in order to retain its kinase activity. In 
addition, PKA is a multifunctional enzyme, with over 30 hormones known to utilise its 
activation for downstream signalling (Coghlan, Bergeson et al. 1993). PKA 
compartmentalisation therefore provides a means to rapidly respond to local increases in 
cAMP concentrations and also regulate the downstream targets phosphorylated by PKA. 
The Type II R subunit previously mentioned is responsible for this compartmentalisation, 
and hormones preferentially activate each holoenzyme in a tissue-specific manner 
(Coghlan, Bergeson et al. 1993). In rat hepatocytes, for example, 0.1 µM -5 µM db-cAMP 
activates Type I PKA while elevation to 10 µM db-cAMP triggers activation of Type II PKA, 
with glucagon causing a similar response (Byus, Hayes et al. 1979).  PKA holoenzymes are 
known to associate with the plasma membrane (Rubin, Erlichman et al. 1972), the golgi 
complex, the cytoskeleton and secretory granules (Joachim and Schwoch 1990). Joachim 
and Schwoch (1990) identified both the Type I and Type II PKA to be localised within the 
cisternae of the rough endoplasmic reticulum (rER) and in the golgi complex of rat pancreas 
and parotid cells, with the secretory granules of the parotid acinar cells also preferentially 
expressing Type II PKA (Joachim and Schwoch 1990). Interestingly, the proportion of Type II 
PKA within these secretory granules was found to increase on application of the cAMP 
agonist isoproterenol, indicating a role of Type II PKA in cAMP-mediated amylase secretion. 
Furthermore, Type II PKA was also localised to the Golgi complex in cells of the nervous 
system (De Camilli, Moretti et al. 1986), epithelial cells and fibroblasts (Nigg, Schafer et al. 
1985). A-kinase anchoring proteins (AKAPs) have been found to tether Type II PKA to such 
specific subcellular locations through interaction with its RII subunit (Carr, Hausken et al. 
1992). Indeed, all AKAPs have been shown to possess a conserved RII-binding site thought 
to be constructed of amphipathic helices (Carr, Hausken et al. 1992, Carr, Stofko-Hahn et al. 
1992). In addition to the RII-binding domain, all AKAPs also contain a unique targeting 
domain which determines the specific subcellular localisation of the AKAP/PKA complex 
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(Coghlan, Bergeson et al. 1993). The AKAP MAP2, for example, links Type II PKA to 
microtubules  (Obar, Dingus et al. 1989), and is the primary microtubule-associated protein 
in cells of the mammalian central nervous system (De Camilli, Moretti et al. 1986, Obar, 
Dingus et al. 1989). This AKAP binds the RII domain of PKA via an 83 amino acid stretch at 
its N-terminal end, and microtubules via its microtubule-binding domain at its carboxyl-
terminus, and thus forms a Microtubule-AKAP-PKA complex, successfully localising this 
kinase to a specific subcellular location (Obar, Dingus et al. 1989). A further example is 
AKAP150, which directly associates with the calcium-binding protein calmodulin via its 
amino terminal domain (Carr, Stofko-Hahn et al. 1992). Similar to MAP2, the RII-binding 
domain of AKAP150 is also located at the opposite terminal to the subcellular structure-
binding domain, and is located on the carboxyl-terminal domain. As a result, AKAP150 and 
Type II PKA co-localise in the dendrites of cultured hippocampal neurons (Coghlan, 
Bergeson et al. 1993). This close-association with the post-synaptic membrane positions 
PKA near to ionotrophic glutamate receptors which, when phosphorylated by PKA, are 
desensitised to the signal transduction across the synaptic membrane (Carr, Stofko-Hahn et 
al. 1992). In addition to phosphorylation of target proteins at the specific subcellular 
location, the AKAP/PKA complex is also likely to be responsible for phosphorlaytion of the 
AKAP itself as these proteins contain consensus PKA phosphorylation sites (Carr, Stofko-
Hahn et al. 1992). As a result of such anchoring complexes, up to 75% of Type II PKA is 
attached to subcellular structures, and the remaining 25% of this subtype, and all of Type I 
PKA, is soluble and cytoplasmic (Coghlan, Bergeson et al. 1993). As a kinase, PKA is 
responsible for the phosphorylation of various proteins which either results in their 
activation or inactivation, depending on the target protein and the phosphorylation site. 
With regards to the endothelial barrier, the main function of PKA appears to be the 
inhibition of endothelial cell contraction. The requirement for phosphorylation of myosin 
light chain (MLC) by MLC kinase (MLCK) for endothelial cell contraction has already been 
detailed (see “Section 1.6.3 - The actin network”). PKA is capable of phosphorylating, and 
therefore inactivating, MLCK (Verin, Gilbert-McClain et al. 1998). PKA also phosphorylates 
RhoA on Ser188, thereby inactivating this GTPase (Lang, Gesbert et al. 1996, Ellerbroek, 
Wennerberg et al. 2003, Qiao, Huang et al. 2003). RhoA is a major regulator of actin-
myosin-induced endothelial cell contraction (Carbajal and Schaeffer 1999) and 
microinjection of constitutively active Rho, V14Rho, induces endothelial cell contraction 
(Essler, Amano et al. 1998). ROCK (Rho kinase), is a downstream effector of RhoA which  
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Figure 1.4: A brief overview of the PKA pathway 
This schematic represents the basic PKA pathway in endothelial cells. Intracellular cAMP 
elevation induced by adenylate cyclase activity (AC, yellow) triggers binding of 4 cAMP 
molecules (purple) to the two regulatory domains (blue) of the PKA holoenzyme. This induces a 
conformational change that releases the two catalytic domains (green) from the regulatory 
subunit-cAMP complex, activating PKA and allowing it to act as a kinase.  PKA is able to 
phosphorylate both MLCK and RhoA and therefore inhibits endothelial cell contraction and 
barrier disruption. cAMP may be dephosphorylated into 5’AMP by phosphodiesterases (PDEs), 2 
common examples of which are shown in red (PDE3 and PDE4). PKA can also be anchored to 
specific subcellular locations via A Kinase anchoring proteins (AKAPs). Map2 is shown here as an 
example of an AKAP that tethers Type II PKA to microtubules.  
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stimulates phosphorylation of the regulatory subunit of myosin light chain phosphatase 
(PP1), decreasing its phosphatase activity and thereby inducing contraction (Essler, Amano 
et al. 1998, Birukova, Smurova et al. 2004). Increased Rho phosphorylation at Ser188 in 
pulmonary endothelial cells decreases the association between Rho and ROCK and 
attenuates Rho signalling (Lang, Gesbert et al. 1996). Similarly, PKA also phosphorylates the 
GTP-dissociation inhibitor, GDI, which promotes loss of GTP from RhoA thereby inactivating 
it and inhibiting contraction (Qiao, Holian et al. 2008). Interestingly, the PKA inhibitor H89 
frequently used in the literature has been shown to also effect other kinases including 
ROCK, and as such may have un-desired downstream effects (Leemhuis, Boutillier et al. 
2002, Murray 2008). In addition to this direct inactivation of endothelial contraction, PKA 
also mediates a similar inhibition through activation of Rac, a member of the Rho family of 
small GTPases. This activation is proposed to be via activation of the guanine nucleotide 
exchange factors (GEFs) specific for Rac1, Tiam1 and Trio which have consensus PKA 
phosphorylation sites (O'Connor and Mercurio 2001). Phosphorylation of these GEFs results 
in Rac1 activation that is dependent upon the involvement of the actin-binding protein 
vasodilator-stimulated phosphoprotein (VASP), β1-integrin binding and proper PKA 
compartmentalisation via AKAPs (Schlegel, Burger et al. 2008). The role of Rac in 
strengthening of the endothelial barrier is detailed further under “Section 5.1.9”. 
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1.11.2 - Cyclic nucleotide-gated ion channels 
The second class of proteins capable of sensing cAMP concentration via their CNB domains 
are cyclic nucleotide-gated ion chanels. These ion channels are permeable to both 
monovalent and divalent cations and show varying selectivities for cAMP and cGMP 
depending on their physiological role (Zagotta and Siegelbaum 1996). The rod-type 
nucleotide-gated nonselective cation channel CNG1, for example, has been identified in 
vascular endothelial cells and vascular smooth muscle cells and is involved in calcium entry 
(Yao, Leung et al. 1999). 
 
1.11.3 - Epac  
The third class of proteins capable of sensing cAMP concentration via their CNB domains 
are exchange proteins directly activated by cAMP (Epac), which were independently 
identified by two groups in 1998 (De Rooij, Zwartkruis et al. 1998, Kawasaki, Springett et al. 
1998). De Rooij and co-workers observed that the forskolin-induced activation of Rap1 to 
its GTP-bound form in Chinese hamster ovary cells was not inhibited by the cAMP-
dependent protein kinase (PKA) inhibitor H-89 (De Rooij, Zwartkruis et al. 1998). Rap1 is a 
member of the Ras family of small G-proteins and plays a role in signal transduction 
cascade. It binds and hydrolyses GTP, the former state acting as an ‘on’ switch while the 
latter as an ‘off’ switch.  Thus, activation of these G-proteins requires the exchange of GDP 
for GTP and this is catalysed by guanine nucleotide exchange factors (GEFs).  As such a GEF 
was required for the cAMP-induced activation of Rap1 that was independent of PKA, De 
Rooij et al. (1998) searched for proteins with sequence homology to GEFs for Rap1 and to 
cAMP-binding sites. An 881-amino acid protein was identified with such a homology, and 
the cAMP-binding sites of this protein, termed Epac, showed significant sequence 
homology to those of PKA and cyclic nucleotide-gated ion channels (De Rooij, Zwartkruis et 
al. 1998). Furthermore, the N-terminal GEF domain of Epac was also found to share 
significant homology with the Rap1-specific GEF Crk SH3-domain-binding guanine-
nucleotide releasing factor (C3G)(Gotoh, Hattori et al. 1995, De Rooij, Zwartkruis et al. 
1998). Within the C-terminal catalytic region of Epac, a Ras-exchange motif (REM) was also 
identified (De Rooij, Zwartkruis et al. 1998). This REM domain is found in all Ras- and Rap1- 
specific GEFs and is important in stabilisation of the GEF structure (Boriack-Sjodin, Margarit 
et al. 1998, De Rooij, Rehmann et al. 2000). The cAMP-binding site of Epac  was identified 
in the N-terminal region, and later this group identified the ability of the cAMP-binding site 
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of Epac1 (and the B site of Epac2, detailed later) to act as an auto-inhibitory domain, 
blocking interaction between the catalytic region of Epac and Rap1 in the absence of cAMP 
(De Rooij, Rehmann et al. 2000). Removal of these cAMP-binding sites produces 
constitutively active Epac1 and Epac2 (De Rooij, Zwartkruis et al. 1998). At the same time, 
work by Kawasaki et al. (1998) on a novel brain-enriched gene related to signalling in the 
striatum identified 2 genes with cAMP-binding motifs and motifs for Ras GEFs (Kawasaki, 
Springett et al. 1998).  These proteins, termed cAMP-GEFI and cAMP-GEFII, were found to 
be responsible for forskolin-induced activation of Rap1 within 10 seconds of forskolin 
application. Both the Epac protein identified by De Rooij et al. (1998), and the cAMP-GEF 
proteins identified by Kawasaki et al. (1998), showed cAMP-induced, PKA-independent 
activation of Rap1 (and not R-Ras), and as such the terms Epac1/cAMP-GEFI and 
Epac2/cAMP-GEFII are interchangeable in the literature. Further work on Epac2 has 
identified its expression of a second N-terminal CNB domain (termed site A)(Rehmann, Das 
et al. 2006). This A site CNB domain shows much lower affinity for cAMP than the B site 
present in both Epac1 and Epac2 (De Rooij, Rehmann et al. 2000), and does not display the 
inhibitory effect of the B site (Rehmann, Das et al. 2006). The N-terminal region of Epac 
also contains a Dishevelled, Egl-10, Pleckstrin (DEP) domain which is responsible for 
membrane-localisation of this protein (De Rooij, Rehmann et al. 2000). In addition to Rap1, 
both Epac1 and Epac2 also activate Rap2A in vitro and in vivo (De Rooij, Rehmann et al. 
2000). Repac (related to Epac, MR-GEF) is a constitutive activator of Rap1 and Rap2, 
consisting of only a catalytic domain and is therefore not regulated by cAMP (De Rooij, 
Rehmann et al. 2000, Bos, De Rooij et al. 2001). The Ras-binding domain of Repac does, 
however, show sequence homology with the corresponding regions in Epac1 and Epac2 (De 
Rooij, Rehmann et al. 2000). Further information on Epac’s activity as a GEF and its role in 
stabilisation of the endothelial barrier is detailed in Chapter 5: Control of Cadherin and 
Connexin Distribution.  
 
1.12 – Endothelial barrier de-stabilisers 
Inflammatory mediators released on vascular injury typically induce increased endothelial 
permeability through inhibition of the cAMP pathway and stimulation of contraction. 
Examples of such factors are thrombin, bradykinin, histamine, vascular endothelial growth 
factor (VEGF), tumour necrosis factor α (TNF-α), lipopolysaccharides (LPS) and reactive 
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oxidant species (ROS). As such, several of these factors are used experimentally to disrupt 
the endothelial barrier and increase permeability, particularly thrombin, histamine and LPS. 
 
1.12.1 - Thrombin  
Thrombin is a pro-coagulant serine protease generated by proteolytic cleavage of the 
inactive proenzyme prothrombin by factor V (a protein of the coagulation system) and 
factor X (also termed prothrombinase due to its enzymatic activity) (Grand, Turnell et al. 
1996). Prothrombin is produced in the liver and once converted to its active form has a 
short half-life in the circulation (approximately 5 minutes) and therefore thrombin itself can 
only produce a local response (Esmon 2004).  Protease-activated receptor 1 (PAR-1) is the 
receptor on endothelial cells that responds to thrombin binding (Vu, Hung et al. 1991, 
Gerszten, Chen et al. 1994). This GPCR is a member of the 7 transmembrane domain 
receptor family that is activated through its own ligation. Thrombin binding to PAR-1 
induces proteolysis of the extracellular extension of PAR-1 between Arg41 and Ser42 (Vu, 
Hung et al. 1991, Gerszten, Chen et al. 1994). This cleavage then allows the receptor to 
bind its own ligand domain and thus activate the associated G-proteins G12, G13, Gαq and Gαi 
(Barr, Brass et al. 1997, Coughlin 2000, Macfarlane, Seatter et al. 2001). The alpha -subunits 
of G12 and G13 bind the Rho GEF p115 to initiate the activation of Rho GTPases (Hart, Jiang 
et al. 1998, Kozasa, Jiang et al. 1998). Gαq activates phospholipase Cβ (PLCβ) (Taylor, Chae 
et al. 1991) to generate diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3) from 
PIP2. Gαi inhibits adenylate cyclases (Taussig, Tang et al. 1994, Dessauer, Tesmer et al. 
1998). The response to thrombin is therefore predominantly mediated by three pathways; 
activation of RhoA and the downstream signalling events that this induces, increased 
cytosolic calcium concentration due to IP3-mediated release from the endoplasmic 
reticulum (ER), and inhibition of cAMP generation. The endothelial response to thrombin 
addition is rapid, with a decrease in intracellular cAMP levels evident within 30 seconds 
(Baumer, Spindler et al. 2009) and an almost 2 fold increase in endothelial cell monolayer 
contractile force (Kolodney and Wysolmerski 1992) peaking at 5 minutes (Goeckeler and 
Wysolmerski 1995). Similarly, 10 nM thrombin induces an increase in the concentration of 
activated RhoA within 1 minute (Qiao, Huang et al. 2003).  The role of RhoA in inducing 
endothelial cell contraction has been previously discussed (see “Section 1.11.1 - Protein 
Kinase A”). Actin-myosin-mediated endothelial cell contraction requires intracellular 
calcium, and the increase in calcium stimulated through PLCβ-mediated IP3 generation 
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therefore promotes endothelial contraction. In addition to calcium release, thrombin also 
stimulates store-operated calcium entry (SOCE) (Ahmmed, Mehta et al. 2004) to maintain 
the endothelial contraction for up to 2 hours (Goeckeler and Wysolmerski 1995). Thrombin 
induces phosphorylation of the SOCE channel transient receptor potential channel 1 
(TRPC1) within 1 minute of application, and this modification promotes re-filling of the ER 
calcium store (Ahmmed, Mehta et al. 2004). Indeed, antisense depletion of TRPC1 in 
cultured endothelial cells, or inhibition of TRPC1 with the anti-TRPC1 primary antibody 
reduces calcium entry by 50% and decreased endothelial permeability in response to 
thrombin (Brough, Wu et al. 2001, Ahmmed, Mehta et al. 2004).  
 
 
1.12.2 - Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is produced by perivascular cells and is involved 
in the stimulation of proliferation and endothelial barrier destabilisation required for 
angiogenesis and vascular remodelling (Eriksson and Alitalo 1999, Mehta and Malik 2006). 
Endothelial cells express two phosphotyrosine-containing transmembrane receptors for 
VEGF; the Fms-like tyrosine kinase receptor (Flt-1, also called VEGFR1) and the kinase insert 
domain-containing receptor (KDR, also called VEGFR2)(Mehta and Malik 2006). The VEGFR2 
receptor is responsible for the VEGF-induced increase in endothelial permeability (Esser, 
Lampugnani et al. 1998). Downstream signalling events induced by activation of VEGFR2 
triggers phosphorylation of adherens junction components which promotes their 
dysfunction and increased paracellular permeability  (Esser, Lampugnani et al. 1998). 
Specifically, VEGF induces the activation of the Rac-specific GEF Vav2 through Src activity 
(Chou, Wang et al. 2002). Rac subsequently activates p21-activated kinase (PAK) which 
phosphorylates VE-cadherin at Ser665. The phosphorylated form of Ser665 acts as a 
docking site for β-arrestin 2, and VE-cadherin is endocytosed (Gavard and Gutkind 2006). A 
further link between VEGFR2 and VE-cadherin also exists; VEGFR2 forms a complex with 
VE-cadherin, an interaction that is likely mediated by β-catenin (Carmeliet, Lampugnani et 
al. 1999). This cadherin-VEGFR2 complex is required for proper endothelial response to the 
VEGF signal and endothelial cell survival (Carmeliet, Lampugnani et al. 1999, Shay-Salit, 
Shushy et al. 2002). Indeed, VE-cadherin null mice suffer endothelial apoptosis and 
embryonic lethality at E9.5 due to a lack of transmission of the endothelial cell survival 
signal by VEGF (Carmeliet, Lampugnani et al. 1999).  
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1.13 – Endothelial barrier stabilisers 
In response to inflammation several factors are released to inhibit excessive permeability 
and barrier disruption. These barrier stabilisers typically employ mechanisms involving 
cAMP elevation, thereby counteracting the de-stabilising pathways detailed above. 
Examples of such factors include sphingosine-1-phosphate (S1P), angiopoetin 1 (Ang1), 
epinephrine/ adrenaline, norepinephrine/noradrenaline, prostaglandin, prostacyclin, atrial 
natriuretic peptide (ANP) and hepatocyte growth factor (HGF). Much like barrier de-
stabilisers, several of these factors are also used experimentally to stabilise the endothelial 
barrier and decrease permeability, particularly Ang-1 and prostaglandin E2 (PGE2).  
 
1.13.1 - Angiopoetin 1 
 
Ang1 is a vascular growth factor released from smooth muscle cells, pericytes and 
monocytes following barrier disruption (Moss 2013). Ang1 is then able to act as a ligand for 
the tyrosine kinase receptor, Tie-2, expressed specifically on endothelial cells. This kinase 
subsequently phosphorylates and thereby activates PI3 kinase (phosphatidylinositol-4,5-
biphosphate 3-kinase, PI3K), which activates Rac1, a process that requires the scaffold 
protein IQ domain GTPase-activating protein (IQGAP1) (Kuroda, Fukata et al. 1998, Ho, 
Joyal et al. 1999, David, Ghosh et al. 2011, Moss 2013). Ang1 also triggers the 
phosphorylation of the RhoGAP P190, which inhibits RhoA activity and therefore 
actinomyosin contraction (Jho, Mehta et al. 2005, Mammoto, Parikh et al. 2007). Through 
the activation of Rac1, and the inhibition of RhoA, Ang1 maintains the barrier during resting 
conditions and also prevents the permeability-increasing effects of histamine and 
bradykinin (Thurston, Rudge et al. 2000, Pizurki, Zhou et al. 2003, David, Kumpers et al. 
2013). Interestingly, angiopoetin 2 (Ang2) has opposing actions to Ang1, and is released 
from the Weibel-Palade bodies of endothelial cells where it is stored during periods of 
vascular growth and inflammation (Maisonpierre, Suri et al. 1997). Indeed, patients with 
severe systemic inflammation or sepsis express reduced levels of Ang1 and increased levels 
of Ang2 (David, Kumpers et al. 2013). This highlights the role of both forms of angiopoetin 
in angiogenesis; Ang2 for the initial barrier de-stabilisation to allow vessel growth, and 
Ang1 for maturation of the newly-formed vessels.  
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1.13.2 - Prostaglandin E2  
PGE2 is a GPCR-agonist that protects the endothelial barrier through cAMP elevation and 
activation of both the PKA and Epac/ Rap pathways (Farmer, Bernier et al. 2001, Birukova, 
Zagranichnaya et al. 2007, Kobayashi, Tsubosaka et al. 2013). PGE2 is a product of the 
arachidonic acid metabolic pathway, is synthesised by vascular endothelial cells, and binds 
the prostonoid receptors EP1-4 on these cells (Alfranca, Iniguez et al. 2006). Binding of 
PGE2 to the Gs-coupled receptors EP2 or EP4 leads to activation of adenylate cyclase and 
elevation of intracellular cAMP concentration (Bos, Richel et al. 2004). Through activation 
of the PKA and Epac pathways, PGE2 is able to attenuate the hyperpermeability induced by 
the inflammatory mediator bradykinin (Farmer, Bernier et al. 2001). Similarly, prostacyclin 
(PGI2) is also a GPCR-agonist and its synthetic analog, beraprost, activates the PKA and 
Epac pathways to decrease endothelial permeability (Birukova, Zagranichnaya et al. 2007).  
As such, beraprost is used as treatment for pulmonary hypertension (Howard and Morrell 
2005).  
 
 
1.14 - Pathological conditions involving dysregulation of the endothelial barrier  and 
therapeutic potential 
Barrier disruption plays a key role in a number of pathological conditions ranging from 
systemic inflammation and oedema formation to atherosclerosis. Endothelial barrier 
disruption induced by LPS, TNF-α or thrombin are at least in part due to the loss of 
intracellular cAMP and Rac1 inactivation (Dellinger, Levy et al. 2013). Elevation of cAMP 
and Rac1 activation mediated through either the PKA or Epac/Rap pathways therefore 
offers a potential mechanism for stabilisation of the barrier. Systemic application of cAMP-
elevating agents dobutamine and norepinephrine are effective for volume expansion in 
acute inflammation (De Backer, Creteur et al. 2006, Stephens, Uwaydah et al. 2011). 
Similarly, introduction of phosphodiesterase (PDE) inhibitors such as rolipram enhance the 
survival rates in animal models of systemic inflammation (Lin, Adamson et al. 2012, Schick, 
Wunder et al. 2012). Such PDE inhibitors, however, may not provide an efficient 
therapeutic target as the D4 splice variant of PDE4, PDE4D4, restricts cAMP to a membrane 
pool and inhibition of this PDE may increase the cytosolic pool of cAMP which can lead to 
increased permeability and barrier disruption (Creighton, Zhu et al. 2008). It is therefore 
necessary to identify a more appropriate therapeutic target for barrier stabilisation and 
activation of the Epac/rap pathway may provide such a mechanism 
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1.15 – Hypothesis  
cAMP has long been recognised as an important stabiliser of the endothelial barrier. Since 
its discovery as a novel cAMP effector, Epac has been implicated in the cAMP-mediated 
decrease in endothelial permeability. The effect of Epac has previously been shown to be 
mediated by re-organisation of VE-cadherin. Cadherins and connexins are closely 
associated and as such a re-organisation of VE-cadherin is likely to affect the connexin 
distribution. We hypothesised that Epac activation in HCAECs enhances the endothelial 
barrier through re-distribution of cadherins and connexins, with a subsequent increase in 
gap junctional intercellular communication. In addition, Epac activation in HCAECs was 
hypothesised to trigger a rise in intracellular calcium concentration. This rise in intracellular 
calcium concentration, if stimulated in vivo, in combination with enhanced direct cell-cell 
communication via gap junctions, could trigger smooth muscle cell hyperpolarisation and 
therefore regulate vascular tone.  
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2.1 – Materials  
2.1.1 – Cell culture  
Cryopreserved human coronary artery endothelial cells (HCAECs, Cat no. C 12221, Lot no. 
0113008.7) and human coronary artery smooth muscle cells (HCASMCs, Cat no. C 12511, 
Lot no. 9052004.5) were purchased from Promocell (Heidelberg, Germany) at passage 2 
(P2). HCAECs were cultured in Promocell endothelial cell medium MV 2 (Cat no. C-22022) 
with the addition of Promocell endothelial cell growth medium MV 2 supplement mix (Cat 
no. C-39226), with a final supplement concentration of (per ml): 5% v/v fetal calf serum,  5 
ng epidermal growth factor (recombinant human), 10 ng basic fibroblast growth factor 
(recombinant human), 20 ng insulin-like growth factor (Long R3 IGF-1), 0.5 ng vascular 
endothelial growth factor 165 (recombinant human), 1 µg ascorbic acid and 0.2 µg 
hydrocortisone. HCASMCs were cultured in Promocell smooth muscle cell growth medium 
2 (Cat no. C-22062) supplemented with Promocell smooth muscle cell growth medium 2 
supplement mix (Cat no. C-39267), giving a final supplement concentration of (per ml): 5% 
v/v fetal calf serum, 0.5 ng epidermal growth factor (recombinant human), 2 ng basic 
fibroblast growth factor (recombinant human) and 5 µg insulin (recombinant human).  
 
2.1.2 – Animals  
Male Wistar rats (200-300 g, Charles River Laboratories, Massachusetts, USA) were 
humanely killed via exposure to a rising concentration of CO2 followed by cervical 
dislocation, in accordance with Schedule 1 of the Animals (Scientific Procedures) Act 1986.   
 
2.1.3 – Primary antibodies  
Polyclonal rabbit anti-human von Willebrand Factor (vWF) primary antibody (Cat no. 
A0082) and monoclonal mouse anti-human CD31 (cluster of differentiation 31) primary 
antibody (Cat no. M0823) were purchased from Dako (Denmark). Monoclonal mouse anti-α 
smooth muscle actin (α-actin) primary antibody was purchased from Sigma-Aldrich (Cat no. 
A 2547). Monoclonal mouse anti-calponin primary antibody was purchased from Sigma-
Aldrich (Cat no. C2687). Polyclonal rabbit anti-mouse connexin primary antibodies were 
purchased from Source Bioscience (San Antonio, USA; anti-Cx37 Cat no. CX37A11-A, anti-
Cx40 Cat no. CX40-A, anti-Cx43 Cat no. CX43A11-A). Monoclonal mouse anti-human 
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cadherin primary antibodies were purchased from BD Biosciences (Oxford, UK; N-cadherin 
Cat no. 610921, VE-cadherin Cat no. 610252). Anti-Epac1 monoclonal mouse primary 
antibody was purchased from Cell Signalling (USA; Cat no. 4155S) for Western blot. Anti-
Epac1 monoclonal mouse primary antibody was purchased from Santa Cruz Biotechnology 
(USA; Cat no. Sc-28366) for immunocytochemistry.  Monoclonal anti-actin mouse primary 
antibody was purchased from Sigma-Aldrich (Cat no. A 4700). Anti-IP3R primary antibodies 
were kindly provided by Dr. Svetlana Voronina, University of Liverpool. Polyclonal rabbit 
anti-IP3R1 primary antibody was originally sourced from Cell Signalling (USA; Cat no. 
3763S), and both rabbit anti-IP3R2 antibodies were provided by Dr. David Yule (University 
of Rochester, USA). Dilutions of all primary antibodies are detailed under individual 
experiments.  
 
2.1.4 – Secondary antibodies  
2.1.4.1 – Immunocytochemistry and Immunohistochemistry 
Alexa fluor 488-conjugated goat anti-rabbit (Cat no. A-11034), Alexa fluor 488-conjugated 
goat anti-mouse (Cat no. A-11029) and Alexa fluor 594-conjugated goat anti-mouse IgG 
(Cat no. A-11032) secondary antibodies were purchased from Molecular Probes (USA). All 
secondary antibodies are highly cross-adsorbed. 
 
2.1.4.2 – Western blot 
Goat anti-rabbit horseradish peroxidase-conjugated (HRP-conjugated) secondary antibody 
was purchased from Sigma-Aldrich (Cat no. A0545) and goat anti-mouse HRP-conjugated 
secondary antibody was purchased from Fitzgerald Industries International (Cat no. 43C-
CB1569-FIT, Stratech, Suffolk, England).  
 
2.1.5 – Agonists 
The Epac-specific agonist 8-(4-Chlorophenylthio)-2’-O-methyladenosine-3’, 5’-cyclic 
monophosphate, acetoxymethyl ester (8-pCPT, Cat no. C 051) was purchased from Biolog, 
Life Science Institute, Germany.  The cAMP-elevating agent forskolin (Fsk, Cat no. CN-100-
0010) was purchased from Enzo Life Sciences, Inc., USA.  
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2.1.6 - Antagonists 
Myristoylated PKI(14-22) amide (PKI), a protein Kinase A-inhibitor, was purchased from 
Enzo Life Sciences (Cat no. P-210, 5 µM), Cyclopiazonic acid (CPA), an inhibitor of 
endoplasmic reticulum calcium ATPase, was purchased from Sigma-Aldrich (Cat no. C1530, 
10 µM), and Ryanodine was purchased from Merck Millipore (Germany, Cat no. 559276, 30 
µM). The cell-permeant Epac1 and Epac2 inhibitors HJC0197 (Cat no. C 136) and ESI-09 (Cat 
no. B 133) were purchased from BioLog (Life Science Institute, Germany).  
 
2.1.7 – Reagents  
All reagents were purchased from Sigma-Aldrich (Gillingham, UK) BDH (Poole, UK) or Fisher 
Scientific (Loughborough, UK), unless otherwise stated, and at a grade suitable to 
experiments. Solutions were made using ultra high quality (UHQ) water (18 MΩ resistance).  
 
2.2 - Methods 
2.2.1 – Cell culture  
HCAECs and HCASMCs were grown in T75 flasks containing 25 ml fully-supplemented media 
and passaged approximately every 72-96 hours. When 80-90% confluent, the media was 
aspirated and the cells washed with 25 ml warm Dulbecco’s Phosphate Buffered Saline 
(DPBS, no Ca2+/Mg2+). The DPBS was then removed and replaced with 1.2 ml warm 0.25% 
w/v Trypsin-EDTA (Cat no. 25200-056, Gibco, Life Technologies, UK). Cells were incubated 
at 37˚C/ 5% CO2 using a LEEC Precision 190D incubator for 20 seconds. Tapping of the flask 
facilitated dislodging cells, and this was confirmed under a light microscope. The trypsin 
was neutralised with 9 ml fully-supplemented media. Cells were then sub-cultured at the 
desired density (calculated using a haemocytometer [Neubauer double cell, rhodium-
coated, Cat no. AC1000, Hawksley, Sussex, UK]). This typically equalled a dilution of 1:3.  
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2.2.2 -  Western blot 
2.2.2.1 – Preparation of rat tissue lysate  
Rat heart and kidney were dissected into 5 mm3 sections in solution containing (in mM): 
137 NaCl, 0.44 NaH2PO4H2O, 0.42 Na2HPO4, 4.17 NaHCO3, 5.6 KCl, 1 MgCl2, 10 HEPES, 2 
CaCl, pH adjusted to 7.4 using NaOH. Chilled 1% v/v protease inhibitor cocktail (Sigma-
Aldrich, Cat no. P8340) in lysis buffer (1 M Trizma HCl, 250 mM NaCl, 3 mM EDTA, 3 mM 
EGTA, 0.5% v/v Triton X-100, pH adjusted to 7.6) solution was added to a chilled 3 ml 
pestle/mortar homogenizer and the tissue lysed manually.  The tissue lysate was then 
centrifuged at 18,200 g for 10 minutes at 4˚C. The supernatant was transferred to a 1.5 ml 
microcentrifuge tube (Eppendorf) kept on ice, and the pellet discarded. A portion of 
supernatent was kept without sample buffer for use in a Bicinchonic acid (BCA) protein 
assay and frozen at -20˚C. The remaining samples were mixed at a 1:1 ratio with x2 sample 
buffer (Sigma-Aldrich, Cat no. S3401) and heated in a dry heating block (Labnet Accublock 
digital dry bath) at 98˚C for 10 minutes to denature the proteins. Protein lysates were 
allowed to cool on ice and, if not required immediately, stored at -20˚C for up to 4 months. 
 
2.2.2.2 – Preparation of cultured cell lysate  
HCAECs and HCASMCs were seeded at a density of 100,000 cells/ml in a 10 cm cell culture 
Petri dish in 10 ml fully-supplemented media, and cultured until 80-90% confluent 
(approximately 48 hours). The dish was then transferred to a tray containing crushed ice, 
the media aspirated and immediately replaced with 5 ml ice-cold DPBS. With the dish still 
on ice, the DPBS was removed and replaced with 500 µl ice-cold 1% v/v protease 
inhibitor/lysis buffer solution for 5 minutes, tilting the dish gently to ensure even coverage. 
A 25 cm cell scraper (Sarstedt, Cat no. 83.1830) was used to dislodge cells by dragging 
across the culture surface. The cell suspension was then transferred to a chilled 1.5 ml 
microcentrifuge tube (Eppendorf) and centrifuged at 18,200 g for 10 minutes at 4˚C. 
Typically, 150 µl of the supernatant was kept for use in a BCA protein assay and frozen at -
20˚C. The remaining supernatant was mixed with x5 sample buffer (Sigma-Aldrich) and 
heated at 98˚C for 10 minutes in a dry heating block. The cell lysate was then allowed to 
cool on ice and stored at -20˚C for up to 4 months if not required immediately.  
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2.2.2.3 – BCA protein assay 
A Pierce Bicinchonic Acid (BCA) assay kit (Thermo Scientific, Cat no. 23227) was used to 
determine the total protein concentration of lysates. The protein standards were made 
using the bovine serum albumin (BSA) diluted in lysis buffer to produce 9 concentrations (in 
µg/ml): 2000, 1500, 1000, 750, 500, 250, 125, 25 and 0. Each unknown sample (cultured 
cell/rat tissue lysate) and standard dilutions were duplicated for measurements. Unknown 
samples were used neat or at a 5 fold dilution. Working Reagent was made according to 
manufacturer’s instructions (50 parts reagent A: 1 part reagent B). 50 µl of each BSA 
standard and unknown sample was aliquoted into 1.5 ml microcentrifuge tubes. 1 ml of 
Working Reagent was added and vortexed. All samples were incubated in a water bath 
(Grant) at 37˚C for 30 minutes. The protein concentration was measured using a Jenway 
spectrophotometer (Genova, 1690) as absorbance at 562 nm.  
 
2.2.2.4 – Casting of the SDS-PAGE gel 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their size. A 10-well 10% resolving gel was made by 
combining 4.3 ml 30% w/v  Acrylamide (Biorad, 16100158), 3.3 ml resolving buffer stock (2 
M Trizma base, pH 8.8), 130 µl 10% w/v SDS, 930 µl 87% v/v glycerol, 4.4 ml UHQ water, 60 
µl 10% w/v ammonium persulfate and 13 µl TEMED. 10% resolving gel was poured 
between the glass plates, topped up with isopropanol and allowed to set at room 
temperature for approximately 45 minutes. Once set, 4% stacking gel was made by 
combining 840 µl 30% w/v Acrylamide, 1.5 ml stacking buffer stock (0.5 M Trizma base, pH 
6.8), 60 µl 10% w/v SDS, 3.8 ml UHQ water, 53 µl 10% w/v ammonium persulfate and 11 µl 
TEMED. The stacking gel was added between the plates and a comb inserted to form 10 
wells for the addition of lysate. The stacking gel was allowed to set at room temperature 
for approximately 45 minutes.  
 
2.2.2.5 – Running the Western blot 
The cell culture and rat tissue lysates were heated in a dry heating block at 98˚C for 5 
minutes to ensure denaturing of the proteins, then transferred to ice. 7 µl of rainbow 
protein mass marker (Amersham full-range rainbow MW marker, Cat no. RPN800E) and 25 
µl of each lysate was added to the wells. The gels were run at 120 V for 1 hour in SDS 
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running buffer (25 mM Tris base, 192 mM Glycine and 3.5 mM SDS). Separated proteins 
were then transferred to nitrocellulose membrane (Amersham Hybond ECL, RPN303D) in 
transfer buffer containing 25 mM Trizma base, 192 mM Glycine and 20% v/v methanol, at 
110 V for 1 hour. To keep the temperature low during transfer, the cell containing the gels 
and nitrocellulose membranes was encased in crushed ice. Membranes were washed twice 
in Tris buffered saline with TWEEN (TBST, 20 mM Trizma base, 137 mM NaCl, 0.1% v/v 
TWEEN 20, pH 7.6) and submerged in Ponceau S solution for 5 minutes to inspect protein 
transfer. After satisfactory protein banding was confirmed the membranes were washed in 
TBST on the rocker for 5 minutes, twice, to remove the dye. The membrane was then 
blocked with TBST containing 5% or 1% w/v non-fat powdered milk (Marvel) for 1 hour at 
room temperature on a rocker (Labnet Rocker 25). The membrane was placed in a 
continuous bag cut to size, 1 ml of the appropriate diluted primary antibody was added, 
and the bag was sealed and incubated at 4˚C overnight. Primary antibodies were typically 
used at 200-500 fold dilution in TBST with 5% or 1% w/v non-fat milk. The next day, the 
membranes were quickly rinsed in TBST twice. Membranes were then washed three times 
with TBST on the rocker for ten minutes each. Nitrocellulose membranes were then 
incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody on the 
rocker at room temperature for 2 hours. HRP-conjugated secondary antibodies were used 
at a 10,000 fold dilution (mouse) or 5,000 fold dilution (rabbit) in TBST with 5% or 1% w/v 
milk solution. Following incubation with the secondary antibody membranes were again 
washed briefly with TBST twice and then washed with TBST on the rocker for ten minutes, 
repeated three times. Enhanced Chemiluminescence solutions 1 and 2 (ECL, Amersham, 
Cat no. RPN2109) were mixed in equal volume and 3 ml added to one membrane for 1 
minute. The membranes were drained of excess ECL solution, slotted into a plastic wallet 
(Lyreco) and fixed into the hypercasette (Amersham Biosciences).  
 
2.2.2.6 – Processing the photographic film 
In a dark room, photographic film (Amersham Hyperfilm ECL high performance 
chemiluminescence film, Cat no. 28906836) was inserted into the hypercasette. Incubation 
period for the film typically ranged between 5–10 minutes, unless otherwise stated. The 
photographic film was processed using Kodak photographic solutions (Kodak GBX fixer and 
developer). Once films were dry, bands were sized using the rainbow ladder as reference. 
Developed films underwent densitometric analysis using Image J software.  
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2.2.2.7 – Re-blotting of Western blot membrane  
Some experiments required the nitrocellulose membrane to be re-used. Membranes were 
re-hydrated with TBST for 30 minutes-1 hour then stripped of antibodies by incubating with 
a solution containing 100 mM β-mercaptoethanol, 2% w/v SDS, and 62.5 mM Tris base (pH 
6.7) for 10 minutes, twice. Membranes were then washed twice with TBST and blocked as 
normal with TBST containing 1% or 5% w/v non-fat milk for up to 1 hour at room 
temperature. Membranes were then incubated with the primary antibody overnight at 4˚C 
and the normal Western blotting procedure resumed.  
 
2.2.3 – Immunofluorescence  
2.2.3.1 – Immunocytochemistry  
2.2.3.1.1 – Plating of cultured cells 
Size 1 coverslips (diameter, 13 mm) were flame-sterilised, coated with 1% v/v poly D-lysine 
(PDL, Millipore, Cat no. A-003-E) and incubated for 2 hours at 37°C/5% CO2. Coverslips were 
then washed twice with UHQ water and allowed to dry under sterile conditions. Coverslips 
were placed in a 24-well cell culture plate and cells seeded at a density of 100,000 cells per 
well in 2 ml fully-supplemented medium (Promocell). UHQ water was added to empty wells 
to create a humidified environment. Cells were cultured at 37˚C/5% CO2 typically for 48 
hours.  
 
2.2.3.1.2 – Fixation, quenching and permeabilisation of cultured cells 
Once 90% confluent (approximately 48 hours post-seeding), cells were fixed. Culture media 
was aspirated and cells washed with 1 ml DPBS.  DPBS was removed and cells were fixed 
with 1 ml 2% w/v Paraformaldehyde (PFA, w/v in PBS containing [in mM] 2.7 KCl, 1.5 
KH2PO4, 137 NaCl, 8 Na2HPO4, pH 7.4) for 10 minutes at room temperature. The fixative 
was removed and quenched with 1 ml 100 mM Glycine buffer (pH 7.4) per well for 10 
minutes at room temperature. Occasionally culture plates were stored prior to 
permeabilisation and in these plates Glycine buffer was replaced with DPBS containing 10 
mM sodium azide, and stored at 4˚C. Using a fine-ended pasteur pipette (SLS select, 
PIP4101) 3 ml permeabilisation solution (0.1% v/v Triton X-100 in PBS, pH adjusted to 7.4 
using 1 M NaOH) was added to each well and incubated at room temperature for 10 
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minutes to make intracellular epitopes accessible. Permeabilised cells were subsequently 
washed with 2 ml PBS for 5 minutes at room temperature, 3 times.  
 
2.2.3.1.3 – Antibody labelling of cultured cells 
Permeabilised cells were incubated with 200 µl antibody diluting solution for 30 minutes at 
room temperature to block non-specific binding sites. Antibody diluting solution contained 
2% v/v goat serum, 0.05% v/v Triton X-100, 1% w/v bovine serum albumin in sodium citrate 
buffer (SSC, containing in mM; 150 NaCl and 15 Na3 Citrate), pH 7.2. Antibody diluting 
solution was then removed and replaced with 200 µl diluted primary antibody per well and 
incubated at 4˚C overnight. The following day the cells were washed with 1 ml antibody 
wash solution (150 mM NaCl, 15 mM Na3 Citrate and 0.05% v/v Triton X-100, pH 7.2) for 10 
minutes at room temperature, 3 times.  Primary antibodies were visualised using 
fluorescent Alexa fluor 488-conjugated goat anti-rabbit, Alexa fluor 488-conjugated goat 
anti-mouse or Alexa fluor 594-conjugated goat anti-mouse IgG secondary antibodies, all 
diluted 500 fold. 200 µl of the appropriate secondary antibody was added to each well and 
incubated in the dark for up to 2 hours at room temperature.  The cells were then washed 
with antibody wash solution for 10 minutes at room temperature, 3 times. Exposure to 
light was avoided as much as practical and cells were covered with aluminium foil. 
Coverslips were post-fixed with 1 ml 2% w/v PFA in PBS for 10 minutes at room 
temperature then re-washed with antibody wash solution. Coverslips were then immersed 
into UHQ water, twice, and allowed to air dry in the dark for 2 hours. They were then 
mounted onto individual glass slides with 20 µl mounting medium (Dako, S3023) containing 
5 nM 4’,6’-diamidino-2-phenylindole (DAPI, Molecular probes, Cat no. D3571) for counter-
staining of the nuclei. Slides were left to dry overnight at room temperature in the dark.  
 
2.2.3.2 – Immunohistochemistry  
2.2.3.2.1 – Dissection of rat tissue  
Rat tissue was dissected in solution containing (in mM): 137 NaCl, 0.44 NaH2PO4H2O, 0.42 
Na2HPO4, 4.17 NaHCO3, 5.6 KCl, 1 MgCl2, 10 HEPES and 2 CaCl2 (pH adjusted to 7.4). 5 mm 
sections of rat artery were isolated and embedded up-right in CRYO-M-BED embedding 
compound (Bright Instruments) on a cork disk and frozen in a bath of isopentane super-
cooled in liquid nitrogen. The resulting tissue blocks were used immediately or stored at -
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20˚C for up to 4 months. Tissue blocks were cut into 8-12 µm thick sections using a cryostat 
(Leica CM1950 or Bright Instruments 3050 microtome).  
 
2.2.3.2.2 - Fixation, quenching and permeabilisation of tissue slices 
Rat artery slices were transferred to gelatine-coated slides (0.2% w/v gelatine and 0.02% 
w/v chromic (III) potassium sulphate in UHQ water) and enclosed using a Dako wax pen 
(Dako, S200230-2) to create a hydrophobic barrier. Tissue sections were fixed using 2% w/v 
PFA in PBS, incubated for 5 minutes at room temperature. The fixative was aspirated and 
excess removed using laboratory tissue. Un-reacted aldehyde was quenched with 100 mM 
Glycine buffer (pH 7.4, see Immunocytochemistry solutions) for 10 minutes at room 
temperature. Glycine was removed and permeabilising solution (pH 7.4, see 
Immunocytochemistry solutions) was added to the sections for 10 minutes. Slides were 
then rinsed with PBS for 5 minutes at room temperature, 3 times.  
 
2.2.3.2.3 – Antibody labelling of tissue sections 
After permeabilisation, the slices were inspected using a light microscope (Nikon TMS) to 
ensure that they were still firmly attached to the slide glass. The tissue slices were 
incubated with 200 µl antibody diluting solution (pH 7.2, see Immunocytochemistry 
solutions) for 30 minutes at room temperature to block non-specific binding. Antibody 
diluting solution was removed and immediately replaced with diluted primary antibody at 
the appropriate dilution, and incubated at 4˚C overnight. Primary antibodies were typically 
used at 200-500 fold dilution using antibody diluting solution. The following day, tissue 
sections were washed with antibody wash solution (pH 7.2, see section “2.2.3.1.3 – 
Antibody labelling of cultured cells”) for 10 minutes at room temperature, 3 times. After 
the final wash, the slices were incubated with 200 µl diluted Alexa fluor 488-conjugated 
goat anti-rabbit or Alexa fluor 594-conjugated goat anti-mouse IgG secondary antibodies in 
the dark at room temperature for up to 2 hours. Secondary antibodies were used at 500 
fold dilution. Tissue sections were washed with antibody wash solution for 10 minutes at 
room temperature, 3 times. Slices subsequently underwent 2 washes with UHQ water and 
allowed to air dry for 2 hours at room temperature in the dark. Once dry, slices were 
mounted using 13 mm, size 1 coverslips, and Dako mounting medium containing 5 nM DAPI 
for nuclear visualisation.  
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2.2.3.3 – Visualisation of labelled cells and tissue slices  
A Leica laser-scanning confocal microscope (Leica SP2 AOBS) was used to visualise the 
labelled cultured cells (x63 oil objective) and tissue sections (x10 dry objective). Samples 
labelled with Alexa fluor 488-conjugated secondary antibody were excited at 488 nm with 
an argon-ion laser, and the emission light captured at 510-560 nm. Samples labelled with 
Alexa fluor 594-conjugated secondary antibody were excited at 594 nm using a helium-
neon laser and the emission light captured at 610-660 nm. For the detection of DAPI 
nuclear staining, a Mai Tai infra-red laser (Spectra-Physics) was used for two-photon 
excitation at a wavelength of 740 nm, providing the working excitation of 370 nm. Software 
analysis of the data was carried out using Leica confocal software Lite. 
 
2.2.4 – Small interfering RNA (siRNA) knockdown of Epac1  
Two siRNA duplexes for Epac1 (duplex 6 [Hs_RAPGEF3_6, 5 nM] and 7 [Hs_RAPGEF3_7, 5 
nM]) were purchased from Qiagen at a stock concentration of 20 µM. Both Epac1 siRNA 
duplexes were used in combination at a total concentration of 10 nM, unless otherwise 
stated. AllStars Negative control siRNA (Qiagen, 20 nM, Cat no. 1027281) was used at a 
final concentration of 10 nM and provided a non-silencing control duplex. All steps were 
carried out under sterile conditions using Greiner Bio-one RNAse-free tips (100 µl: Cat no. 
772288, 200 µl: Cat no. 739288, 1000 µl: Cat no. 740288) and Life Technologies PCR tubes 
(Cat no. AM12230) to ensure all plastics were nuclease- free. 
 
2.2.4.1 – Plating of HCAECs 
Cultured HCAECs were seeded at a density of 100,000 cells per well in a 6-well cell culture 
plate, and incubated at 37˚C/5% CO2. After 24 hours cells were 70% confluent and ready for 
transfection.  
 
2.2.4.2 - Epac1 siRNA transfection of HCAECs 
Each siRNA duplex was aliquoted into individual sterile RNase-free 0.5 ml microfuge tubes 
(Ambion, Life Technologies, Cat no. AM12300) and diluted in 250 µl Opti-MEM (Opti-MEM I 
Reduced Serum Medium, GlutaMAX, Gibco, Life Technologies, Cat no. 51985-026) to the 
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appropriate concentration. RNAiMAX Lipofectamine transfection reagent (Invitrogen, Cat 
no. 13778-075) was diluted in Opti-MEM at a concentration of 1% to give a final 
concentration of 0.1% v/v in 2500 µl Opti-MEM. 250 µl 1% v/v Lipofectamine/Opti-MEM 
mix was added to each siRNA-containing microfuge tube, triturated 10 times and left at 
room temperature for 30 minutes to allow complex formation between the siRNA duplexes 
and the transfection reagent. The fully-supplemented endothelial cell media (Promocell) 
was removed from the 35 mm dishes and 2 ml Opti-MEM was added to each dish. 500 µl of 
the siRNA duplex/Lipofectamine mix was distributed evenly across the dish in a drop-wise 
manner, and the cells were incubated at 37˚C/5% CO2 for 4 hours. Dishes were then 
washed twice with 2 ml DPBS (Gibco) and 2 ml fully-supplemented culture media replaced. 
Transfected cells were incubated at 37˚C/5% CO2 for 48 hours.  
 
2.2.4.3 – Quantification of Epac1 knockdown after Epac1 siRNA transfection 
To monitor the time course of knock-down, cells were lysed at 24, 48 and 72 hours post-
transfection and run through a SDS-page gel Western blot, targeting Epac1 (cell signalling, 
4155S). Membranes were then re-blotted with mouse anti-actin primary antibody (Sigma-
Aldrich, Cat no. A 4700) at a 500 fold dilution. 
 
2.2.5 – Lucifer yellow scrape assay 
2.2.5.1 – Plating of HCAECs 
Cultured HCAECs were seeded at a density of 300,000 cells per dish in 35 mm glass-bottom 
tissue culture dishes (Greiner Bio-One) pre-coated with 1% v/v PDL. Cells were then 
incubated for 24-48 hours, and once 90% confluent were ready for use in a Lucifer yellow 
scrape assay.  
 
 
2.2.5.2 – Lucifer yellow dye addition, scrape production and imaging of HCAECs 
Lucifer yellow CH lithium salt (Molecular probes, Cat no. L-453) was used at a final 
concentration of 0.1% w/v in PBS (containing calcium chloride and magnesium), and stored 
in the dark until required. In control dishes the media was aspirated, 500 µl 0.1% w/v 
Lucifer yellow added to the glass centre of the dish and two scrapes made using a surgical 
blade (Feather size 15, World Precision Instruments Inc., USA, Cat no. 500242) intersecting 
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at the centre of the dish. The dish was then moved to a dark drawer for 2 minutes to allow 
the dye to penetrate the damaged cells with minimal photobleaching. After the incubation 
period the dye was aspirated and the dish washed twice with 2 ml PBS (containing calcium 
chloride and magnesium). The PBS wash was removed and 2 ml of the magnesium- and 
calcium chloride-containing PBS replaced. The dish was then immediately imaged using a 
Leica laser-scanning confocal microscope. 
 
 
2.2.5.3 – Lucifer yellow scrape assay in the presence of 8-pCPT or forskolin 
A subset of scrape dye transfer experiments were conducted in the presence of either the 
Epac-selective agonist 8-pCPT or the cAMP-elevating agent forskolin. Forskolin was used at 
a concentration of 10 µM in fully-supplemented HCAEC media and 8-pCPT was used at a 
concentration of 5 µM in fully-supplemented HCAEC media. The dishes were incubated 
with either agonist for 30 minutes at 37˚C/5% CO2 prior to the dye addition. Following 
removal of the agonist the scrape proceeded as in the control condition (media removal, 
500 µl 0.1% w/v Lucifer yellow dye addition, scrape, 2 minutes incubation, wash twice with 
PBS, replace PBS, imaging).  
 
 
2.2.5.4 – Lucifer yellow scrape assay in the presence of Epac antagonists 
Additional experiments required pre-incubation with the Epac antagonists HJC0197 
(BioLog, Cat no. C 136) or ESI-09 (BioLog, Cat no. B 133) prior to incubation with 8-pCPT or 
Fsk. HJC0197 and ESI-09 are membrane-permeable inhibitors of both Epac1 and Epac2.  
These dishes were incubated with either HJC0197 or ESI-09 at a concentration of 5 nM in 
fully-supplemented HCAEC media at 37˚C/ 5% CO2 for 10 minutes. This solution was then 
aspirated and replaced with media containing the Epac antagonist and either 8-pCPT (5 
µM) or Fsk (10 µM) for 30 minutes at 37˚C/ 5% CO2. Again, following the incubation with 
both the Epac antagonist and the subsequent incubation with the agonist the dish then 
underwent the scrape assay as previously described. All dishes were visualised using a Leica 
laser-scanning confocal microscope as previously mentioned, with a x10 dry objective. All 
dishes were excited at 488 nm with an argon-ion laser and the emitted light captured at 
528 nm. Although 488 nm is the upper limit of Lucifer yellow excitation, sufficient light was 
emitted to allow comparison. All images were captured within 10 minutes of the dye 
removal. 
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2.2.6 – Fluo-4 live calcium imaging of HCAECs 
Cultured HCAECs were seeded at a density of 150,000 cells per dish in 35 mm glass-bottom 
tissue culture dishes (Greiner Bio-One, Cat no. 627861), and incubated at 37˚C/ 5% CO2 for 
24 hours. Cell-permeant Fluo-4 AM (Molecular Probes, Cat no. F14201) was loaded at a 
concentration of 10 µM in PBS. Fluo-4 AM-containing PBS was pre-warmed, and the culture 
media was then aspirated from the 35 mm glass-bottom tissue culture dish and 100 µl of 
PBS containing 10 µM Fluo-4 AM added to the glass section at the centre of the dish. Fluo-4 
is excited at 488 nm by an argon-ion laser and fluorescence intensity increases when 
calcium concentration rises. The dish was subsequently incubated for 20 minutes at 37˚C/ 
5% CO2. Following this incubation period, the Fluo-4 AM solution was aspirated and the 
culture surface washed twice with 2 ml PBS (containing calcium chloride and magnesium). 
The dish was then incubated with 2 ml PBS at 37˚C/ 5% CO2 for 20 minutes. Following this 
20 minute wash the PBS was replaced with fresh PBS (either with calcium chloride and 
magnesium or just with magnesium). A control image was taken using the x40 oil 
immersion lens. 2 µl of the required agonist (8-pCPT at 5 µM or forskolin at 10 µM) was 
then added to the centre of the dish and an image captured every 10 seconds.  
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Chapter 3:  
Characterisation of Rat Tissues and Human Cells 
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Aims of this chapter:  
 
 To examine the expression of endothelial markers vWF and CD31 in HCAECs 
through Western blot analysis and immunocytochemical technique 
 To examine the expression of vascular smooth muscle markers α-actin and 
calponin in HCASMCs through Western blot analysis and immunocytochemical 
technique 
 To ensure that these characteristic markers did not change throughout the culture 
period 
 To compare the expression profiles of these endothelial and smooth muscle 
markers in the cultured cells to that observed in rat coronary and mesenteric 
arteries  
 
Key findings of this chapter: 
 
 HCAECs express the endothelial markers vWF and CD31 throughout passages 6-10 
 HCAECs express both IP3R1 and IP3R2  
 HCASMCs express the smooth muscle markers α-actin and calponin throughout 
passages 7-11 
 Rat coronary and mesenteric artery endothelium expressed vWF 
 Rat coronary and mesenteric artery smooth muscle cells expressed α-actin and 
calponin 
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3.1 - Introduction 
The specific area of vasculature of interest for this research was that of the coronary 
arteries, and as such the cultured cells purchased from Promocell were extracted from 
human coronary artery endothelium and tunica media (HCAECs and HCASMCs, 
respectively) of right and left coronary arteries (including anterior descending and 
circumflex branches). In order to closely reflect the cultured cells the rat tissue used was 
sourced from rat right and left coronary arteries. In addition, to further verify the 
antibodies used throughout this study, rat mesenteric artery and rat heart lysate were used 
in immunohistochemical and Western blot analysis, respectively.  
In addition to the specific antibodies mentioned below, staining of the nucleus was also 
achieved using 5 nM Dako 4’-6diamidino-2-phenylindole (DAPI). This fluorescent dye binds 
to double-stranded DNA and was applied to the pre-labelled coverslips, as outlined under 
“2.2.3.1.3 - Antibody labelling of cultured cells”. Dilutions of both primary and secondary 
antibodies were optimised using varying concentrations. The dilutions ultimately selected 
provided the best conditions for selective binding of the antibodies. During 
Immunofluorescence protocols, antibody labelled cells and tissue slices were viewed under 
consistent conditions, with the same gain and offset. 
 
3.1.1 - Characterisation of Human Coronary Artery Endothelial Cells (HCAECs) 
HCAECs (Promocell, Cat no. C-12221, lot no. 0113008.7) were characterised using the 
endothelial-specific markers von Willebrand Factor (vWF) and CD31 ([Cluster of 
Differentiation 31] also referred to as Pecam-1 [Platelet/Endothelial Cell Adhesion 
Molecule 1] in the literature (Pusztaszeri, Seelentag et al. 2006)).  
vWF is a frequently used endothelial marker (Zanetta, Marcus et al. 2000).  vWF is a 
glycoprotein secreted by an endothelial cell-specific storage organelle, the Weibel-Palade 
body (for reference, vWF is also produced by megakaryocytes (Nachman, Levine et al. 
1977, Tomer 2004)). vWF aids blood clotting by mediating the adhesion of platelets to 
subendothelial connective tissue, and a failure to synthesize this glycoprotein results in 
impaired coagulation after injury, a condition known as von Willebrand disease, a subtype 
of Haemophilia (Sadler 1998). 
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CD31 is a type 1 integral membrane glycoprotein that is responsible for a considerable 
proportion of endothelial cell intercellular junctions (Albelda, Muller et al. 1991, Cao, 
O'Brien et al. 2002). As such, this glycoprotein plays a key role in angiogenesis and the 
formation of new vessels (DeLisser, Christofidou-Solomidou et al. 1997, Sheibani, Newman 
et al. 1997). 
 
3.1.2 - Characterisation of Human Coronary Artery Smooth Muscle Cells (HCASMCs) 
HCASMCs (Promocell, Cat no. C-12511, lot no. 9052004.5) were characterised through the 
detection of both smooth muscle α-Actin (α-actin) and calponin. It was of particular 
importance that this cell type was thoroughly characterised as HCASMCs (and indeed all 
vascular smooth muscle cells) typically exist along a spectrum of phenotypes comprising 
two extremes; a quiescent, contractile phenotype and a synthetic phenotype characterised 
by increased production of extracellular matrix proteins (Beamish, He et al. 2010). Cultured 
cells typically exist in a contractile state; however HCASMCs are capable of shifting 
between these phenotypes (Worth, Rolfe et al. 2001). A change from the contractile 
phenotype of HCASMCs can be detected by a decrease in the expression of contractile 
marker proteins (i.e. α-actin), and this typically occurs in smooth muscle cells cultured for 
an extended period of time (Rensen, Doevendans et al. 2007). This was why cell cultures 
were continuously monitored for any change in phenotype, and why promocell (the 
company of purchase) recommended a maximum of 15 population doublings. To ensure 
the reliability of the data and to make results applicable to a consistent and reproducible 
population, HCASMC (and HCAEC) cultures were not maintained beyond passage 11.  
Smooth Muscle α-actin is well established as a principle marker for smooth muscle cells 
across the vasculature (Gabbiani, Schmid et al. 1981, Vandekerckhove and Weber 1981, 
Fatigati and Murphy 1984). α-actin is one of six actin isoforms identified in mammalian 
cells, and is unique among these isoforms in that it is primarily restricted to vascular 
smooth muscle cells (McHugh, Crawford et al. 1991). It is this specificity that makes α-actin 
a common marker for smooth muscle cells of the vasculature. α-actin plays a fundamental 
role in maintaining the structure and integrity of the cell, and thus is involved in cell 
motility and migration, highlighting its role in distinguishing between synthetic (migratory) 
and contractile smooth muscle cells (Rensen, Doevendans et al. 2007).   
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More recently, calponin has become a major marker for the characterisation of smooth 
muscle cells due primarily to its high specificity for this cell type (Frid, Shekhonin et al. 
1992, Duband, Gimona et al. 1993, Miano, Carlson et al. 2000). Calponin is a calcium-
binding protein that is linked to the contractile machinery of smooth muscle cells through 
its interaction with α–actin (Gimona, Kaverina et al. 2003). 
 
3.1.3 - Characterisation of rat tissue 
In addition to the analysis of individual cell populations in culture, it was also necessary to 
examine the characteristics of the cell types in situ. In an ideal situation human tissue 
would be used as such a control but this was not possible for this project. Dissected rat 
coronary and mesenteric arteries provided the whole artery samples required for such 
immunohistochemical analysis. 
 
3.2- Results 
A combination of Western blot, immunocytochemistry and immunohistochemical 
techniques was used to characterise HCAECs, HCASMCs and rat tissues. 
3.2.1 - Total protein concentration 
Total protein concentrations of all cultured cell and rat tissue lysates were recorded using a 
BCA protein assay kit (full details under “2.2.2.3 BCA protein assay”). Initial recording of 
undiluted rat heart lysate total protein concentration indicated a consistently high level of 
protein within this lysate (data not shown). As such, subsequent experiments comparing 
the total protein concentrations of rat tissue and cultured human cells involved the use of 
rat heart lysate at a 5 fold dilution, unless otherwise stated. Preliminary data from the BCA 
protein assay can be seen in Figure 3.1. Rat heart lysate, even when used at this 5 fold 
dilution, recorded a total protein concentration of approximately 1.5 fold higher than that 
of the highest cell culture lysate recording (HCASMC P8). All primary human cells expressed 
relatively similar protein concentrations during these preliminary experiments (for full 
details refer to Supplementary Figure 1 in Appendix).  
A further check on overall protein concentration was used in the form of the ‘house-
keeping’ protein actin. This ubiquitously-expressed protein was examined in all human cell 
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culture lysates via Western blot. This allowed the verification that protein concentrations 
between the two cell types (HCAECs and HCASMCs) were comparable, and that the protein 
concentration did not decline over a number of passages (maximum 11). Data for actin 
expression in HCAECs and HCASMCs can be seen in Figure 3.2 below, with a single band at 
42 kDa in both HCAEC and HCASMC lysates. In order to ensure efficient staining of both 
HCAECs and HCASMCs, actin was also used as an immunocytochemistry control antibody, 
and comparative actin staining using a Alexa fluor 488 (green) secondary antibody in 
HCAECs and HCASMCs can be seen in Figure 3.3 below. Actin was identified diffusely 
distributed throughout the cell in both HCAECs and HCASMCs, with areas of staining 
associated with the cytoskeletal framework (Figure 3.3B). Comparable maximum AF488 
signal intensities were recorded in HCAECs and HCASMCs (169 arbitrary units (AU) and 203 
AU, respectively).  
The total protein concentration of all HCAEC and HCASMC lysates used in experiments 
were found to be comparable and consistent. Importantly, no decline in total protein 
concentration was reported over the culture period. Furthermore, when used at a 5 fold 
dilution, rat heart lysate provided a reliable control throughout experiments due to its high 
protein concentration.  
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Figure 3.1: BCA Protein Assay of rat tissue and HCAEC and HCASMC lysates 
Total protein concentration for HCAEC (blue) and HCASMC (green) lysates between passages 7-
10, and rat heart lysate (red) at a 5 fold dilution. The protein concentration of HCAEC and 
HCASMC lysates are comparable while the high total protein concentration of rat heart lysate is 
evident, even at a 5 fold dilution. Absorbance recorded using spectrophotometer set at 562 nm. 
N=2. 
 
Figure 3.2: Western blot of actin in HCAECs and HCASMCs 
Human cultured cell lysates (P7-P10) targeted with mouse anti-actin primary antibody (x500 
dilution, 5% non-fat powdered milk), subsequently targeted with HRP-conjugated goat anti-
mouse secondary antibody (x10,000 dilution, 5% non-fat powdered milk). Single band at 42 kDa.  
10 minutes exposure. HCAEC, N=4. HCASMC, N=7. 
     HCAEC lysate  
 
 
     HCASMC lysate 
 
 
     Heart lysate (x5 dilution) 
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Figure 3.3: Immunocytochemistry of Actin expression in HCAECs and HCASMCs 
Immunofluorescent labelling of Actin (green) in HCAECs is shown in A and in HCASMCs in B. Actin 
was identified throughout the cell in both HCAECs and HCASMCs, with comparable fluorescence 
intensity (mean amplitudes of 22.24 AU and 39.82, respectively). DAPI nuclear staining is 
represented in blue. Mouse anti-actin primary antibody and AF488-tagged goat anti-mouse 
secondary antibody were used at x500 dilution. HCAECs, N=2. HCASMCs, N=3. 
  
 
71 
 
3.2.2 - Characterisation of HCAECs 
3.2.2.1 - vWF 
Preliminary experiments identified vWF in HCAECs as a smudge of banding in the region of 
76- 225 kDa (Figure 3.4). Comparable banding between passages 6-10 (P6-P10) of HCAECs 
was detected, suggesting no decline in protein expression or change in characteristics of 
the cell population.  
The distribution pattern of vWF in HCAECs was examined through immunocytochemistry 
techniques and is shown in Figure 3.5. Labelling of the anti-vWF primary antibody with an 
AF488-conjugated secondary antibody (green) identified vWF within the Weibel-Palade 
bodies of the endothelial cells (Figure 3.5).  
 
3.2.2.2 - CD31 
Preliminary experiments identified CD31 in P6-P10 HCAEC lysate as a single band at the 
MW of 135 kDa (Figure 3.6). Similar preliminary experiments also identified CD31 through 
immunocytochemistry, as shown in Figure 3.7. The involvement of CD31 in intercellular 
junctions is reflected in its identification along cell borders in HCAECs, as identified by the 
white arrows (Figure 3.7B). This membranous staining was supplemented by additional 
low-level staining (approximately 100 AU) throughout the cell (Figure 3.7A and 3.7B).  
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76 kDa 
 P7       P8        P9      P10       P6      
Figure 3.4: Western blot of vWF in HCAECs  
HCAEC lysate (P6-P10) targeted with rabbit anti-human von Willebrand Factor (vWF) primary 
antibody (x500 dilution, 5% non-fat powdered milk), subsequently targeted with HRP-
conjugated goat anti-rabbit secondary antibody(x5,000 dilution, 5% non-fat powdered milk). 
Continuous smear of banding in the high molecular weight regions, typical of vWF banding. 5 
minutes exposure. N=1. 
 
Figure 3.5: Immunocytochemistry of vWF expression in HCAECs  
Immunofluorescent labelling of vWF (green) in HCAECs is shown in A and B. vWF is localised 
within the cigar-shaped Weibel-Palade bodies of these endothelial cells. DAPI nuclear staining is 
represented in blue. Rabbit anti-vWF primary antibody was used at a x300 dilution and the 
AF488-tagged goat anti-rabbit secondary antibody was used at x500 dilution. N=3. 
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Figure 3.6: Western blot of CD31 in HCAECs  
HCAEC lysate (P6-P10) targeted with mouse anti-human CD31 primary antibody (x500 dilution, 
1% non-fat powdered milk), subsequently targeted with HRP-conjugated goat anti-mouse 
secondary antibody(x10,000 dilution, 1% non-fat powdered milk). Primary band at 135 kDa.  5 
minutes exposure. N=2. 
Figure 3.7: Immunocytochemistry of CD31 expression in HCAECs  
Immunofluorescent labelling of CD31 (green) in HCAECs is shown in A and B. CD31 is localised at 
the cell membrane (white arrows) supplemented by low-level staining (approximately 100 AU) 
throughout the cell. DAPI nuclear staining is represented in blue. Mouse anti-CD31 primary 
antibody and AF488-tagged goat anti-mouse secondary antibody were used at x500 dilution. 
N=2. 
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3.2.2.3 – IP3 receptor expression  
Immunocytochemical labelling of two IP3 receptor isoforms appeared to identify expresion 
of IP3R1 and IP3R2 in HCAECs (Figure 3.8). During these preliminary experiments, distinct 
areas of punctate staining were evident for both receptor subtypes, however IP3R1 
appeared to be more extensively expressed in HCAECs than IP3R2. Two antibodies against 
either the C-terminus (Figure 3.8B) or the N-terminus (Figure 3.8C) of IP3R2 were used.   
 
3.2.2.4 - Characterisation of HCAECs - Summary 
Primary human coronary artery endothelial cells were successfully characterised 
throughout their culture period through both Western blot analysis and 
immunocytochemistry. The endothelial marker CD31 was correctly identified at the 
appropriate molecular weight of 135 kDa and the HRP-conjugated secondary antibody 
targeted against the anti-vWF primary antbody displayed smeared banding. In support of 
this, confocal microscopy images identified expression of both vWF and CD31 in the 
Weibel-Pallade bodies and at cell membranes, respectively. 
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Figure 3.8: Immunocytochemical analysis of IP3R expression in HCAECs  
IP3R1 distribution in HCAECs is shown in A. Preliminary experiments indicate that extensive 
staining for IP3R1 is evident throughout the cells. The 2 antibodies against the C- (B) and N-
terminus (C) of IP3R2 show distinct areas of punctate staining for this IP3R in HCAECs. DAPI 
nuclear staining is shown in blue. The anti-IP3R primary antibodies were used at a 200 fold 
dilution, and the anti-rabbit secondary antibody at a 500 fold dilution. N=1. 
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3.2.3 - Characterisation of HCASMCs 
3.2.3.1 - Detection of Endothelial Markers in HCASMCs – Negative Control 
HCASMCs were labelled for both vWF and CD31 to ensure a pure smooth muscle cell 
culture. The preliminary results of this negative control experiment are shown in Figure 3.9. 
No staining for either endothelial cell marker was identified in the lysates of HCASMC 
populations. P10 endothelial cell lysate was used as a positive control. Although a single 
band was detected at approximately 225 kDa in P10 and p11 HCASMC lysates labelled for 
vWF, this is not the smear of banding reliably produced by vWF and was therefore 
disregarded.  
 
3.2.3.2 - α-actin 
α-actin has a molecular weight of 42 kDa and was identified as a single band in cultured 
HCASMCs throughout passages 7-11, as shown in Figure 3.10. Banding was consistent 
throughout the culture period, and no decline in protein expression, or change in 
characteristics, was observed. The distribution of α-actin in the HCASMCs was examined 
using immunocytochemistry techniques (Figure 3.11). An AF488-conjugated secondary 
antibody (green) directed against the anti- α-actin primary antibody was used to visualise 
α-actin. During these preliminary experiments, α-actin was found to be associated with the 
cytoskeleton in a uni-directional pattern (Figure 3.11) typical of contractile vascular smooth 
muscle cells.  
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Figure 3.9: Western blot of endothelial markers in HCASMCs as negative control 
HCASMC lysate (P10 and P11) targeted with two endothelial cell-specific markers; vWF and 
CD31. Primary and secondary antibodies used at dilutions previously detailed (vWF: 500/5,000 
and CD31: 500/10,000) in 5% and 1% non-fat powdered milk, respectively. HCAEC lysate acted 
as positive control with smeared banding when probed for vWF, and single band at 135 kDa 
when targeted with CD31. No banding for either endothelial cell-specific marker in either P10 or 
P11 HCASMC lysates. 5 minutes exposure. For vWF, N=2. For CD31, N=1. 
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Figure 3.10: Western blot of α-actin in HCASMCs  
HCASMC lysate (P7-P11) targeted with mouse anti-α smooth muscle actin primary antibody 
(x500 dilution, 5% non-fat powdered milk), subsequently targeted with HRP-conjugated goat 
anti-mouse secondary antibody (x10,000 dilution, 5% non-fat powdered milk). Single band at 42 
kDa.  48 hours exposure. N=3. 
Figure 3.11: Immunocytochemistry of α-actin expression in HCASMCs  
Immunofluorescent labelling of α-actin (green) in HCASMCs is shown in A and B. α -actin shows 
clear association with the cytoskeleton. DAPI nuclear staining is represented in blue. Mouse anti-
α smooth muscle actin primary antibody was used at x300 dilution, and the AF488-tagged goat 
anti-mouse secondary antibody was used at x500 dilution. N=2. 
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3.2.3.3 - Calponin 
Calponin was successfully identified in P7-P11 HCASMC lysates as a single band at the MW 
of 34 kDa (Figure 3.12). Calponin was also identified through immunocytochemistry, with 
an AF488-conjugated secondary antibody directed against the anti-calponin primary 
antibody (Figure 3.13). These preliminary experiments identified calponin distributed 
throughout the cell with areas of membranous and cytoskeletal association. Image A was 
also labelled with DAPI (blue) to determine the region of the nuclei (Figure 3.13A).  
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 P7       P8        P9       P10      P11      
Figure 3.12: Western blot of calponin in HCASMCs  
HCASMC lysate (P7-P11) targeted with mouse anti-calponin primary antibody (x500 dilution, 5% 
non-fat powdered milk), subsequently targeted with HRP-conjugated goat anti-mouse secondary 
antibody(x10,000 dilution, 5% non-fat powdered milk). Primary band at 34 kDa.  10 minutes 
exposure. N=5. 
Figure 3.13: Immunocytochemistry of calponin expression in HCASMCs  
Immunofluorescent labelling of calponin (green) in HCASMCs is shown in A and B. Calponin is 
distributed diffusely throughout the cell with moderate association with the cytoskeleton. 
DAPI nuclear staining is represented in blue. Mouse anti-calponin primary antibody was used 
at x200 dilution, and the AF488-tagged goat anti-mouse secondary antibody was used at 
x500 dilution. N=2. 
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3.2.3.4 - Characterisation of HCASMC - Summary 
Through Western blot and immocytochemical analysis HCASMCs were shown to maintain a 
consistent phenotype throughout the culture period. This phenotype was skewed towards 
the contractile end of the continuous spectrum of smooth muscle cell phenotypes, 
highlighted by consistent α-actin staining during preliminary experiments (Figure 3.9). 
Identification of relatively consistent calponin staining throughout passages 7-11 further 
highlighted the maintenance of a single phenotype throughout culture.  
 
3.2.4 - HCAEC and HCASMC Cell Culture Images 
Photographs of cell cultures were taken throughout the culture period using a light 
microscope at x10 magnification (Figure 3.14). HCAECs (Figure 3.14A) displayed a 
cobblestone appearance while the HCASMCs (Figure 3.14B) had a more stellate or spindle-
shaped morphology during these preliminary experiments. In order to ensure reliability 
throughout experiments, if any cell cultures varied from these phenotypes, or changes to 
proliferation rate or general cell behaviour were observed, the cultures were abandoned. 
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Figure 3.14: Typical HCAEC and HCASMC phenotype  
Cell culture photographs of HCAECs (A) and HCASMCs (B). The HCAECs display the cobblestone 
appearance typical of cultured endothelial cells (A). HCASMCs of the contractile phenotype 
present a stellate form with numerous processes (B). Images recorded at x10 magnification. 
N=2. 
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3.2.5 - Characterisation of Rat Tissue 
3.2.5.1 - Immunocytochemistry 
vWF was identified in the single layer of endothelial cells of the rat coronary artery during 
preliminary experiments (Figure 3.15A & 3.15B). In addition, vWF was also identified in the 
endothelium lining the lumen of the rat mesenteric artery in these experiments (Figure 
3.15C & 3.15D, and 3.15E & 3.15F). In Figure 3.15B DAPI nuclear staining is shown in blue.  
Figure 3.16 shows preliminary α-actin staining within the multiple layers of smooth muscle 
cells of the tunica media in rat coronary (Figure 3.16A & 3.16B)  and mesenteric (Figure 
3.16C & 3.16D) arteries. Initial experiments identified calponin in rat coronary arteries 
(Figure 3.17A & 3.17B) and mesenteric arteries (Figure 3.17C & 3.17D). This smooth muscle 
marker was also identified distributed throughout the multiple smooth muscle layers 
during these experiments. 
 
3.2.5.2 - Western blot 
The smooth muscle markers α-actin and calponin were identified in rat heart lysate used at 
a 5 fold dilution (Figure 3.18). α-actin was identified as a strong band at 42 kDa (Figure 
3.18A), and calponin as a single band at 34 kDa (Figure 3.18B). This lysate provided a 
consistently reliable source of smooth muscle marker protein staining, and provided a 
control for future experiments. 
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Figure 3.15: Immunohistochemistry of vWF expression in rat coronary and mesenteric 
arteries 
Immunofluorescent labelling of vWF (green) is shown in rat coronary artery (A & B) and 
mesenteric artery (C & D and E & F). vWF is restricted to the single endothelial cell layer lining 
the lumen of these vessels. DAPI nuclear staining is represented in blue (B). Image D is the same 
as C with a brightfield image overlay. Images E and F are the same section as C and D at a higher 
magnification.  Rabbit anti-vWF primary antibody was used at x300 dilution and the AF488-
tagged goat anti-rabbit secondary antibody was used at x500 dilution. N=2. 
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Figure 3.16: Immunohistochemistry of α-Actin expression in rat coronary and 
mesenteric arteries 
Immunofluorescent labelling of α-Actin (green) is shown in rat coronary artery (A & B) and 
mesenteric artery (C & D). α-Actin was identified within the multiple layers of smooth muscle 
cells forming the Tunica Media of the vessel wall. Images B and D display the brightfield image 
overlay of the corresponding section shown in A and C, respectively. Mouse anti-α smooth 
muscle Actin primary antibody was used at x300 dilution, and the AF488-tagged goat anti-
mouse secondary antibody was used at x500 dilution. N=1. 
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Figure 3.17: Immunohistochemistry of Calponin expression in rat coronary and 
mesenteric arteries 
Immunofluorescent labelling of calponin (green) is shown in rat coronary artery (A & B) and 
mesenteric artery (C & D). Calponin was identified within the smooth muscle layers of both 
vessels. Images B and D display the brighfield image overlay of the corresponding section shown 
in A and C, respectively. Mouse anti-calponin primary antibody was used at x200 dilution, and 
AF488-conjugated goat anti-mouse secondary antibody used at x500 dilution. N=1. 
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Figure 3.18: Western blot of SMC markers in rat heart lysate 
Western blot analysis identified α-smooth muscle Actin (A) and calponin (B) within rat heart 
lysate. Mouse anti-α smooth muscle Actin and anti-Calponin primary antibodies were both used 
at x500 dilution in 5% non-fat powdered milk. The HRP-conjugated goat anti-mouse secondary 
antibody was used at x10,000 dilution in 5% non-fat powdered milk. Films shown represent 48 
hours exposure (α-Actin) and 5 minutes exposure (Calponin). For α-actin, N=2. For calponin, 
N=3. 
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3.2.6 - Immunocytochemistry Negative Controls 
Two negative control conditions were routinely carried out during immunocytochemistry 
experiments. The first was to label the cultured cells directly with the AF488-conjugated 
secondary antibody without prior incubation with a primary antibody. Two examples of the 
results obtained for this condition in HCAECs and HCASMCs are displayed in Figure 3.19A & 
3.19B. Neither HCAECs nor HCASMCs showed any AF488 signal above 42 AU, and as such 
this level was taken to be background auto-fluorescence and set as the threshold for all 
immunocytochemistry experiments. The second negative control condition was to label the 
cultured cells with the incorrect AF488-conjugated secondary antibody. The example 
shown in Figure 3.19C shows HCAECs labelled with the mouse anti-actin primary antibody 
and the AF488-conjugated goat anti-rabbit secondary antibody. No AF488 signal was 
detected above 8 AU.  
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Figure 3.19: Immunohistochemistry negative controls 
Labelling of HCAECs (A) and HCASMCs (B) with an AF488-conjugated secondary antibody 
without the application of a primary antibody. No staining was detected above 42 AU for either 
experiment so this was set as the level for background staining. B is displayed with a brightfield 
image overlay. C shows labelling of HCAECs with the goat anti-rabbit AF488-conjugated 
secondary antibody after labelling of the cells with the mouse anti-actin primary antibody. 
Mouse anti-actin primary antibody and AF488-tagged goat anti-rabbit secondary antibody were 
used at x500 dilution. N=2. 
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3.3 –Discussion 
3.3.1 – Characterisation of HCAECs 
Preliminary Western blot and immunocytochemistry experiments indicated that HCAECs 
expressed the endothelial markers vWF and CD31 throughout the culture period. vWF was 
identified as a smudge of banding in the high molecular weight region (Figure 3.4), staining 
that is typical of vWF banding due to its multimeric structure (Ruggeri and Ware 1993). 
Labelling of vWF with an AF488-conjugated secondary antibody identified its distribution 
within the Weibel-Palade bodies of the endothelial cells, and the elongated shape of these 
specialised lysosomal structures is typical of vWF staining in vascular endothelial cells 
(Weibel and Palade 1964, Wagner, Olmsted et al. 1982). HCAECs were further 
characterised using an additional endothelial marker, CD31. CD31 has a molecular weight 
of 135 kDa and is detected as a single band via Western blot (Stockinger, Gadd et al. 1990), 
as shown in Figure 3.6.  The role played by CD31 in the regulation of endothelial cell 
intercellular junctions (Albelda, Muller et al. 1991, Cao, O'Brien et al. 2002) is highlighted by 
its identification at the membrane of HCAECs, as in Figure 3.7. HCAECs were also shown to 
express the IP3 receptors IP3R1 (Figure 3.8A) and IP3R2 during preliminary experiments 
(Figure 3.8B and Figure 3.8C), with IP3R1 appearing to be the predominant receptor 
subtype.  
 
3.3.2 - Characterisation of HCASMCs 
HCASMCs are well known to exist in numerous states along a spectrum of phenotypes from 
the extremes of quiescent and contractile cells, to those of a synthetic phenotype 
(Gabbiani, Schmid et al. 1981, Absher, Woodcock-Mitchell et al. 1989, Frid, Shekhonin et al. 
1992, Worth, Rolfe et al. 2001, Rensen, Doevendans et al. 2007). As such, both Western 
blot analysis and immunocytochemical labelling of the smooth muscle markers α-actin and 
calponin was utilised to monitor the HCASMC phenotype throughout culture. Preliminary 
Western blot experiments identified α-actin as a single band at 42 kDa throughout 
passages 7-11 (Figure 3.10). Preliminary immunocytochemical staining for α-actin also 
identified this protein clearly associated with the cytoskeleton (Figure 3.11), and this uni-
directional pattern is typical of smooth muscle cells of the contractile phenotype (Worth, 
Rolfe et al. 2001), and specifically HCASMCs, as demonstrated in work by (Grenier, Sandig 
et al. 2009) and (Beamish, He et al. 2010). Furthermore, additional preliminary experiments 
using the smooth muscle marker calponin re-enforced our hypothesis that these cells were 
of the contractile phenotype, as this calcium-binding protein is linked to the contractile 
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machinery of smooth muscle cells through its interaction with α–actin (Gimona, Kaverina et 
al. 2003) and can be seen arranged in a longitudinal orientation (Figure 3.13B). The lack of 
banding for either endothelial marker (vWF or CD31) in preliminary negative control 
experiments again implied that the HCASMC culture was purely smooth muscle cells (Figure 
3.9).  
The cultured HCASMCs were shown to display the elongated, spindle-shaped morphology 
typical of the contractile smooth muscle cell phenotype, and not the cobblestone 
morphology typically seen with those of the synthetic phenotype, as indicated by the 
preliminary experiments shown in Figure 3.14B (Absher, Woodcock-Mitchell et al. 1989, 
Rensen, Doevendans et al. 2007). Similarly, preliminary data indicated the HCAECs to have 
the cobblestone appearance typical of endothelial cells throughout the vasculature (3.14A) 
(Malek and Izumo 1996, Borg-Capra, Fournet-Bourguignon et al. 1997).  
 
3.3.3 - Characterisation of rat tissues 
Rat coronary and mesenteric arteries provided a suitable in vivo tissue for comparison with 
the cultured human cells. Both rat coronary and mesenteric arteries showed staining for 
vWF on the border of the vessel lumen in preliminary experiments, clearly identifying the 
endothelial cell layer (Figure 3.15), and this staining is typical of the endothelial marker in 
the rat vasculature (Roberts, Kamishima et al. 2013). Preliminary data also indicated the 
expression of α-actin within the multiple layers of smooth muscle cells forming the bulk of 
the tunica media of rat coronary and mesenteric arteries (Figure 3.16). This staining is 
typical of α-actin expression in a variety of vascular beds (Skalli, Ropraz et al. 1986, Frid, 
Shekhonin et al. 1992), including coronary arteries (Cai, Koltai et al. 2003).  Similarly, 
calponin was also identified within this layer of the vasculature during these experiments 
(Figure 3.17), again reflecting its identification in the literature (Su, Xie et al. 2013).  
 
3.3.4 – Concluding remarks 
Preliminary Western blot and immunofluorescence data indicated that the primary HCAECs 
and HCASMCs expressed the characteristic markers of endothelial cells and smooth muscle 
cells, respectively. As such, these cultured cells were considered suitable representatives of 
their respective tissue and deemed appropriate for further experimental use. 
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Chapter 4:  
Connexins and Cadherins in HCAECs and HCASMCs 
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Aims of this chapter:  
 
 To use Western Blot analysis to determine whether HCAECs and HCASMCs express 
connexins (connexins 37, 40 and 43) and cadherins (VE-cadherin and N-cadherin)  
 To use immunocytochemical technique to examine the distribution of these 
connexins and cadherins in HCAECs and HCASMCs 
 To use  immunocytochemical technique to determine whether these junctional 
proteins co-localise in HCAECs 
 
 
Key findings of this chapter: 
 
 HCAECs  and HCASMCs express Cx37, Cx40 and Cx43, as determined by Western 
blot analysis and immunocytochemistry 
 Cx37 and Cx43 appeared to be the predominant connexins expressed in HCAECs 
 Cx43 appeared to be the primary connexin expressed in HCASMCs 
 HCAECs express both VE-cadherin and N-cadherin, as determined by Western blot 
analysis and immunocytochemistry 
 HCASMCs express N-cadherin, as determined by Western blot analysis and 
immunocytochemistry 
 Co-localisation between VE-cadherin and Cx37, Cx40 and Cx43 was identified at the 
membrane in HCAECs. VE-cadherin and Cx37 appeared to show the most extensive 
co-localisation  
 No co-localisation between N-cadherin and Cx37 or Cx40 was detected in HCAECs. 
Isolated areas of co-localisation between N-cadherin and Cx43 was observed in a 
subset of HCAECs 
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4.1 - Introduction  
Cadherins and connexins form adherens junctions (AJs) and gap junctions (GJs), 
respectively, and are two of the major contributors to endothelial cell-cell communication 
and maintenance of the endothelial barrier (Van Rijen, van Kempen et al. 1997, Yeh, 
Rothery et al. 1998, Evans and Martin 2002, Noda, Zhang et al. 2010). The vascular 
endothelium primarily expresses VE-cadherin and N-cadherin, while only the former is 
thought to be responsible for AJs (Salomon, Ayalon et al. 1992, Navarro, Ruco et al. 1998). 
Vascular endothelial cells also express Cx37, Cx40 and Cx43 (Van Rijen, van Kempen et al. 
1997, Yeh, Rothery et al. 1998, Evans and Martin 2002). The formation of AJs is considered 
to be a precursor for the formation of functional GJs (Wallez and Huber 2008), and as such 
the overlap of the expression profiles of these junctional components was examined in 
HCAECs.  
 
4.1.1 – Gap Junctions 
4.1.1.1 - Gap junction structure and formation 
Connexins are the hydrophilic proteins in vertebrates that, upon interaction, form the 
intercellular gap junction channel (see Figure 4.1) (Goodenough 1974, Dejana, Corada et al. 
1995, Yeh, Rothery et al. 1998, Evans and Martin 2002). Connexins were first identified by 
Goodenough in 1974 as bands identified at 10,000 Da in SDS-PAGE analysis. Innexins 
represent the proteins forming GJ channels in invertebrates, however these display little 
sequence homology to their vertebrate counterparts (Evans and Martin 2002). The 
assembly of connexins into functional GJ channels involves a number of tightly regulated 
steps. The connexin proteins are initially synthesised by membrane-bound ribosomes like 
most plasma membrane proteins (Rahman, Carlile et al. 1993, Falk, Kumar et al. 1994). 
These newly-formed proteins are then inserted into the endoplasmic reticulum (ER) 
membrane, and time-lapse imaging of green fluorescent protein-tagged connexins has 
shown that these proteins are routed through the golgi apparatus prior to transport to the 
plasma membrane (Thomas, Jordan et al. 2005). For the formation of active GJ channels, 
the connexin proteins must oligomerize to form a hexameric structure, formed from 6 
connexin proteins, termed a connexon (Musil and Goodenough 1993, Diez, Ahmad et al. 
1999, Das Sarma, Meyer et al. 2001). This oligomerisation is thought to be a sequential 
process that is initiated in the ER, specifically within the endoplasmic-golgi-intermediate 
compartment (ERGIC), and to be completed upon arrival at the golgi complex (Diez, Ahmad 
et al. 1999, Das Sarma, Meyer et al. 2001). In support of this, assembled oligomers were 
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identified at the ER membrane of cells transfected with Cx32 (Kumar, Friend et al. 1995), 
and the identification of connexin oligomers within subcellular fractions of rat  hepatocytes 
(Rahman, Carlile et al. 1993, Falk, Kumar et al. 1994). Post-golgi carriers originating at the 
distal side of the golgi apparatus, and the trans-golgi network, then mediate the delivery of 
the connexon hemichannels to the plasma membrane (Segretain and Falk 2004, Thomas, 
Jordan et al. 2005). Microtubules have also been implicated in the regulation of the 
delivery of connexons to the cell surface. Experiments involving connexins labelled with 
fluorescent proteins have shown the preferential tethering of the microtubule growing end 
(the plus end) at adherens junctions, thereby indicating that microtubules can directly 
target these hemichannels to sites of cell-cell contact (Jordan, Solan et al. 1999, Lauf, 
Giepmans et al. 2002, Shaw, Fay et al. 2007). The formation of a diffuse cell-surface rim of 
fluorescently-tagged connexins prior to the appearance of punctate gap junctions, 
however, indicates that the post-golgi carriers randomly fuse with the plasma membrane 
and that subsequent lateral diffusion of connexins, within the plane of the plasma 
membrane, to sites of cell-cell contact allows the formation of function GJ channels 
(Thomas, Jordan et al. 2005). This is supported by the observation that connexon 
hemichannels can float freely within the cortical membrane, as detected by fluorescence 
recovery after photobleaching (FRAP) studies (Lauf, Giepmans et al. 2002). It appears that 
different connexin subtypes may undergo differential delivery to the plasma membrane as 
Cx43 delivery to the cell surface was inhibited by both brefeldin A (BFA) and nocodazole, 
while Cx26 was inhibited by BFA alone (Thomas, Jordan et al. 2005), indicating that Cx26 
delivery to the plasma membrane does not involve microtubules or that microtubule-
disrupted delivery can be compensated for. Once at the plasma membrane, the connexon 
of one cell joins that of an adjacent cell to form an intercellular channel, separated by a gap 
of approximately 2-3 nm, as identified by transmission electron microscopy (Revel and 
Karnovsky 1967). Open extra-junctional connexon hemichannels have also been identified, 
as shown by the induction of permeability to the dye Lucifer yellow on a reduction in 
extracellular calcium concentration in Xenopus oocytes transfected with Cx46 (Paul, 
Ebihara et al. 1991). This has since also been shown in Novikoff hepatoma cells (Li, Liu et al. 
1996, Stout, Goodenough et al. 2004). Once a functional channel is established, connexons 
aggregate into GJ plaques through clustering of the channels at sites of cell-cell contact 
(Fujimoto, Nagafuchi et al. 1997, Gaietta, Deerinck et al. 2002, Lauf, Giepmans et al. 2002). 
New hemichannels initially associate with the periphery of the GJ plaque, and as GJs at the 
centre of the plaque are internalised for degradation the newer GJs migrate towards the 
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centre of the plaque (Gaietta, Deerinck et al. 2002, Lauf, Giepmans et al. 2002, Segretain 
and Falk 2004, Laird 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Structure of a gap junction channel 
This schematic represents a gap junction (GJ) channel formed from connexin (Cx) 
subunits. Six connexin subunits combine to form a connexon hemichannel (left image). 
Two connexon hemichannels, one from each cell, unite to form a GJ channel with a 
pore diameter of approximately 2 nm (right image). These channels directly link the 
cytoplasm of two adjacent cells and are relatively non-selective allowing the passive 
transfer of ions and second messenger molecules up to ~ 1,200 Da.  
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4.1.1.2 – Connexins 
Connexin proteins consist of 4 transmembrane domains (M1-M4), cytoplasmic N-terminal 
and C-terminal tails, 2 extracellular loops (E1 and E2), and a single intracellular loop (see 
Figure 4.2). The two disulphide-linked extracellular loops are arranged as anti-parallel β-
sheets that project into the intercellular gap, and have been shown to be crucial for the 
docking of two hemichannels on adjacent cells to form a functional GJ channel (Krutovskikh 
and Yamasaki 2000) and for determining the compatibility of two hemichannels (White, 
Bruzzone et al. 1994, White, Paul et al. 1995). In addition, a set of three cysteine residues 
expressed in each extracellular loop (E1 and E2) may help to retain the rigid structure of the 
extracellular region that allows docking between two hemichannels (Kumar and Gilula 
1996). As such, connexin mimetic peptides created from short amino acid sequences found 
in the extracellular loops of various connexins act as reversible inhibitors of gap junctional 
intercellular communication (GJIC) (Evans and Boitano 2001). The extracellular loops are 
highly conserved; however the single intracellular loop linking transmembrane domains M2 
and M3 is variable among connexin subtypes and species (Evans and Martin 2002). The 
amino-terminal tail has been shown to be necessary for insertion of connexon 
hemichannels into the plasma membrane (Martin, Steggles et al. 2000), and this may be a 
result of the interaction of this region of the protein with other proteins. The carboxyl tail 
of Cx43, for example, interacts with the tight junction proteins ZO-1 (Giepmans and 
Moolenaar 1998) and occludin (Kojima, Sawada et al. 1999), the microtubule component 
tubulin (Giepmans, Verlaan et al. 2001) and the adherens junction-associated protein β-
catenin (Ai, Fischer et al. 2000), among others. As such, similar interactions between the 
connexin tail and intracellular components may regulate the insertion of the protein into 
the cell membrane, particularly as connexin protein tails express presumptive Src homology 
2 (SH2), SH3 and PDZ domain –binding regions (Brosnan, Scemes et al. 2001).  
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Figure 4.2: Typical connexin structure 
Connexins typically consist of 4 transmembrane domains (M1-M4, green), cytoplasmic 
N-terminal and C-terminal tails, 2 extracellular loops (E1 and E2), and a single 
intracellular loop. The extracellular loops are generally accepted to be essential for the 
docking of two hemichannels to form a functional GJ channel. The N-terminal tail is 
necessary for insertion of connexon hemichannels into the cell membrane. The major 
differences between different connexin subtypes are determined by the sequence of 
motifs contained within the C-terminal region. This figure is adapted from Figure 1 of  
“The Gap Junction Communication Channel” (Kumar and Gilula 1996).  
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4.1.1.3 – Connexin subtypes 
As has already been hinted at, different subtypes of connexins exist. Connexins are 
primarily divided between 2 classes; α- and β-connexins (a minor γ class also exists but this 
won’t be detailed further here) (Evans and Martin 2002). Cx37, Cx40 and Cx43 are classified 
as α-connexins, hence their alternative names α4, α5 and α1, respectively (Kumar and 
Gilula 1996). The major differences between all connexins is determined by the sequence 
of motifs contained within the intracellular carboxy tail as the amino terminal tail is 
conserved among connexins (Evans and Martin 2002). GJs can form three types of 
functional channels; homotypic gap junctions where all 12 connexin subunits are identical, 
heterotypic gap junctions where each of the two hemichannels contains 6 identical 
connexins but the connexin type in each hemichannel is different to that displayed on the 
adjacent cell (White, Bruzzone et al. 1994, Brink 1998), or heteromeric gap junctions where 
each hemichannel contains more than one type of connexin, although normally restricted 
to the same class of connexin (α/β) (Jiang and Goodenough 1996, Evans and Martin 2002) 
(see Figure 4.3). Cx43, an α-type connexin, cannot form functional channels with Cx32, a β-
type connexin (White, Paul et al. 1995).  Some connexin subtypes, however, cannot form 
functional gap junctional channels with other subtypes, even when both are from the same 
class. Cx40 and Cx43, for example, fail to form functional GJs with each other (Elfgang, 
Eckert et al. 1995, White, Paul et al. 1995, Haubrich, Schwarz et al. 1996). Purkinje fibres of 
the conducting system of the heart express Cx40 while the ventricular myocardium 
predominantly expresses Cx43. The failure of Cx40 to form functional channels with Cx43 
may prevent inappropriate activation of the ventricular myocardium by the purkinje fibres 
and thus contribute to the specialised electrical characteristics of this region (Bruzzone, 
Haefliger et al. 1993). GJ plaques can also be subdivided into various forms; a random 
mixture of homomeric or heteromeric connexins (or a combination of both), as detected in 
hepatic cells (Nicholson, Dermietzel et al. 1987, Traub, Look et al. 1989), segregated 
homomeric connexons in distinct areas within a single GJ plaque, as detected within the 
epidermis (Risek, Klier et al. 1994), or homomeric connexons that arrange into separate 
plaques and possibly even localise to distinct areas of the membrane, as identified in the 
epithelial cells of the thyroid gland (Guerrier, Fonlupt et al. 1995). Vascular endothelial cells 
express Cx37, Cx40 and Cx43 (Van Rijen, van Kempen et al. 1997, Yeh, Rothery et al. 1998, 
Evans and Martin 2002). Triple immuno-gold labelling at the EM-level has also revealed 
that GJs within aortic endothelial cells commonly contain all 3 connexin types (Yeh, Rothery 
et al. 1998). Some variation in connexin expression does exist between different vascular 
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beds, with large artery smooth muscle cells relying almost exclusively on Cx43, while in 
smaller muscular arteries and arterioles Cx43 expression is lower and GJIC is compensated 
for by increased Cx40 expression (Little, Beyer et al. 1995). As previously mentioned, 
heterocellular GJs occur between smooth muscle and endothelial cells at the 
myoendothelial junction (MEJ), thereby allowing direct endothelial cell- smooth muscle cell 
communication (Little, Beyer et al. 1995).  
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Figure 4.3: Potential arrangements of connexin subtypes to form a gap junction 
This diagram shows the 3 types of GJ channel that can be formed from the various connexin 
subtypes. Homotypic GJs consist of 12 identical connexins (all green in left image). Heterotypic 
GJs consist of 2 connexin subtypes; the connexin subtype within each hemichannel is identicial, 
but different to the connexin subtype forming the adjacent hemichannel (centre image, green 
and blue represent two connexin subtypes). Heteromeric GJs can be formed from 2 or more 
connexin subtypes and each hemichannel contains more than one connexin subtype (right 
image, green and blue represent two connexin subtypes).  
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4.1.1.4 – Gap Junction channels in disease and knock out models 
Direct cell-cell communication through gap junction channels is essential for survival. 
Different connexin proteins do, however, possess the ability to compensate for the loss of a 
single connexin subtype. Deletion of either Cx37 or Cx40 in mouse models results in no 
apparent vascular effects and the resulting mice are viable (Simon and McWhorter 2002). 
Double knock-out models (Cx37 -/- x Cx40 -/-), however, are embryonic lethal with embryos 
displaying gross vascular defects (Simon and McWhorter 2002). With regards to the 
dysregulation of GJ formation and the onset of disease, amino-terminal mutations in Cx43 
are associated with non-syndromic deafness (Liu, Xia et al. 2001) and viscera-atrial 
heterotaxia, a severe heart malformation (Dasgupta, Martinez et al. 2001).  
 
 
4.1.2 - Cadherins 
4.1.2.1 - VE-cadherin  
VE-cadherin mRNA is detected at the onset of vasculogenesis in the mouse embryo and 
expression is primarily restricted to vascular endothelial cells (Breier, Breviario et al. 1996). 
In addition, extra-endothelial expression of VE-cadherin has been noted in kidney 
podocytes (Cohen, Klingenhoff et al. 2006) and circulating endothelial progenitor cells 
(Peichev, Naiyer et al. 2000). VE-cadherin is distributed primarily to the border of 
endothelial cells and staining is reminiscent of silver nitrate staining of cell junctions 
(Heimark, Degner et al. 1990). The VE-cadherin promoter contains 3 domains important for 
the restriction of VE-cadherin expression to primarily within endothelial cells. The proximal 
domain promotes transcription in a cell-type dependent manner while the additional 2 
regions act to negatively control inappropriate VE-cadherin transcription in non-endothelial 
cells (Gory, Vernet et al. 1999). Proteases, such as neutrophil elastase or cathepsin G, which 
are either released by, or displayed upon the surface of, stimulated neutrophils, cleave VE-
cadherin to disrupt endothelial AJs and allow neutrophil transmigration (Carden, Xiao et al. 
1998, Hermant, Bibert et al. 2003). VE-cadherin can also be degraded by matrix 
metalloproteinases (MMPs) (Herren, Levkau et al. 1998, Wu and Huang 2003) and through 
clathrin-dependent endocytosis and lysosomal targeting (Xiao, Garner et al. 2005). VE-
cadherin expression is essential for survival and null mutations are embryonic lethal due to 
incomplete vascular development (Vittet, Buchou et al. 1997, Carmeliet, Lampugnani et al. 
1999, Gory-Faure, Prandini et al. 1999).  
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As previously mentioned, cadherin-catenin interaction is essential for maturation of the AJ, 
and truncation of the β-catenin-binding domain of VE-cadherin is lethal in mice (Carmeliet, 
Lampugnani et al. 1999). The cytoplasmic domain of VE-cadherin contains binding sites for 
a number of armadillo proteins, including p120 catenin, p0071, β-catenin and γ-catenin 
(see below)(Knudsen, Soler et al. 1995, Ohkubo and Ozawa 1999, Calkins, Hoepner et al. 
2003). The structure of VE-cadherin is represented in Figure 1.3 in Chapter 1. 
 
4.1.2.2– Armadillo proteins as the accessory proteins of AJs 
4.1.2.2.1 - p120 catenin and p0071  
 
p120 catenin is an armadillo protein that is bound to the juxtamembrane domain of VE-
cadherin and enhances AJ stability (Yap, Niessen et al. 1998, Ohkubo and Ozawa 1999, 
Thoreson, Anastasiadis et al. 2000). Association between VE-cadherin and p120 catenin in 
this membrane-proximal region inhibits interaction between VE-cadherin and the ubiquitin 
ligase Hakai, and p120 catenin association with VE-cadherin therefore prevents cadherin 
degradation (Vincent, Xiao et al. 2004). Furthermore, p120 catenin negatively regulates 
RhoA activity and promotes Rac activation through interaction with Vav2, which stabilises 
the AJ (Anastasiadis, Moon et al. 2000, Noren, Liu et al. 2000, Anastasiadis and Reynolds 
2001, Iyer, Ferreri et al. 2004) (further details on this pathway are detailed under “Section 
5.1.9”). p120 catenin, unlike β-catenin and γ-catenin which also bind VE-cadherin, does not 
interact with the actin cytoskeleton or actin-binding proteins (Thoreson, Anastasiadis et al. 
2000, Reynolds and Roczniak-Ferguson 2004). p0071 is an additional armadillo protein that 
binds to the juxtamembrane domain of VE-cadherin through its armadillo repeat domain 
(Calkins, Hoepner et al. 2003). This protein also binds to the intermediate filament-binding 
protein desmoplakin, as previously mentioned, and therefore provides a link between the 
AJ complex and the intermediate filament network (Valiron, Chevrier et al. 1996, Calkins, 
Hoepner et al. 2003). 
 
4.1.2.2.2 - β-catenin and γ-catenin 
 
β-catenin and γ-catenin are homologous, containing between 10-13 armadillo repeats 
(Nieset, Redfield et al. 1997). β-catenin bound to cadherin is stabilised at the plasma 
membrane, while un-associated β-catenin in the cytosol is rapidly degraded (Bazzoni and 
Dejana 2004). When free in the cytosol, β-catenin is phosphorylated by casein kinase Iα and 
glycogen synthase kinase-3 (GSK-3), and phosphorylated β-catenin is then ubiquitinated 
and degraded in proteasomes (Liu, Li et al. 2002). Such an extra-junctional  β-catenin pool 
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is able to regulate gene expression through translocation to the nucleus and interaction 
with the transcription factors t-cell factor (TCF), adenomatous polyposis coli (APC) and 
lymphoid enhancer factor-1 (LEF1) (Fan, Frey et al. 2003). Interaction between β-catenin 
and these transcription factors results in the transcription of intercellular adhesion 
molecule 1 (ICAM-1) which is required for neutrophil transmigration (Eastman and 
Grosschedl 1999, Fan, Frey et al. 2003). These interactions are part of the Wnt signalling 
cascade required for transcriptional regulation (Eastman and Grosschedl 1999, Fan, Frey et 
al. 2003). When β-catenin is bound to VE-cadherin at the AJ complex it is not free to initiate 
such transcription and therefore neutrophils cannot transmigrate through the endothelium 
and an effective barrier is maintained. Indeed, in conditions of pathological angiogenesis, 
β-catenin is identified primarily within the nucleus or cytoplasm and not at the plasma 
membrane (Blankesteijn, van Gijn et al. 2000). Un-associated γ-catenin also binds to these 
transcription factors and therefore plays a similar role to β-catenin in the regulation of the 
endothelial barrier (Miravet, Piedra et al. 2002). As previously mentioned, γ-catenin also 
allows association between VE-cadherin and the vimentin intermediate filament-binding 
protein desmoplakin, thereby providing a further link between the AJ and the intermediate 
filament network (Shasby, Ries et al. 2002).  
 
VE-cadherin is able to bind to either β-catenin or γ-catenin in a mutually-exclusive manner, 
and these catenins subsequently link the AJ complex to α-catenin which is capable of 
binding the actin-binding protein α-actinin (Knudsen, Soler et al. 1995). α-catenin does not, 
however, simultaneously associate with both the cadherin/catenin complex and actin fibres 
(Yamada, Pokutta et al. 2005). Epithelial protein lost in neoplasm (EPLIN) has been 
identified as a potential stable link between the cadherin/catenin complex and the actin 
cytoskeleton as this protein binds to α-catenin and actin filaments simultaneously (Abe and 
Takeichi 2008).  
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4.2 – Methods 
4.2.1 - Co-staining of cadherins and connexins in HCAECs 
Cadherins were visualised using a AF594-tagged secondary (red) antibody directed against 
the mouse anti-cadherin primary antibodies. Connexins were labelled with a AF488-tagged 
secondary (green) antibody directed against the rabbit anti-connexin primary antibodies. 
Overlap of AF594 and AF488 staining, and thus co-expression of cadherins and connexins, 
represented as yellow staining in the resulting immunofluorescent Leica images. 
 
4.3 - Results 
4.3 .1 – Connexin 37 in HCAECs and HCASMCs 
4.3.1.1 - Western Blot 
Protein lysate made using rat kidney cortex, kidney pyramid and heart was used as a 
positive control in Western blot identification of Cx37. Kidney cortex constitutes the 
external portion of the kidney and contains the renal corpuscles and part of the renal 
tubules for filtration of liquid waste. The kidney pyramids comprise a section of the renal 
medulla, the region of the kidney containing, among other structures, the Loop of Henle. 
Both kidney pyramid and kidney cortex lysates were used in ‘neat’ forms while heart lysate 
was used at a 3 fold dilution due to high reading of total protein concentration using a BCA 
assay, as detailed under “Section 3.2 Total Protein Concentration” (Figure 3.1). Figure 4.4A 
shows preliminary banding for Cx37 at the appropriate molecular weight (MW) of 37 kDa in 
rat kidney cortex, kidney pyramid and heart lysates. The heart lysate provided a cleaner 
positive result for connexin targeting, even after just 10 minutes exposure.  
 
Cx37 was then identified in HCAEC and HCASMC lysates. Figures 4.4B and 4.4C show Cx37 
banding in passage 7 HCAEC lysate, and passage 8 HCASMC lysate, from preliminary 
experiments. Lysates from the cultured cells required an extended exposure period of 24 
hours. This reflects the lower total protein concentration level present within the cultured 
cell lysates when compared to the rat tissue lysates, as detailed under “Section 3.2 Total 
Protein Concentration” (Figure 3.1). None the less, the Cx37 antibody appears to detect a 
protein of the expected molecular weight.  
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Figure 4.4: Western blot of Cx37 in rat tissues, HCAECs and HCASMCs 
Expression of Cx37 within rat kidney cortex (KC), kidney pyramid (KP) and heart (H, 3 fold 
dilution) was identified through Western blot analysis (A), showing banding at 37 kDa. Banding 
at this MW was also identified in HCAEC P7 and HCASMC P8 lysates (B and C). The polyclonal 
rabbit anti-connexin 37 primary antibody was used at a x200 dilution and the goat anti-rabbit 
secondary antibody at a x5,000 dilution, both in 1% non-fat powdered milk. The membranes 
were exposed to the photographic film for 10 minutes (rat tissues) and 24 hours (cultured cells). 
N=1.  
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4.3.1.2 - Immunohistochemistry and Immunocytochemistry  
Next, immunofluorescent technique was used to examine the distribution pattern of Cx37 
in the rat renal vasculature, HCAECs and HCASMCs. Cx37 was identified primarily in the 
endothelial lining of the rat kidney vessel during preliminary experiments (Figure 4.5A).  
Figure 4.5B reflects the localisation of Cx37 within HCAECs to both the perinuclear region 
and the cell membrane. Cx37 expression in HCASMCs in contrast, was minimal (Figure 
4.5C), with only isolated areas displaying fluorescence intensity above background levels. In 
addition, Cx37 appeared to display no real nuclear association in HCASMCs.  
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Figure 4.5: Immunofluorescent analysis of Cx37 expression in rat kidney, HCAECs and 
HCASMCs 
Distribution pattern of Cx37 within rat tissue and cultured human cells using an AF488-tagged 
secondary antibody (green) is shown in A (kidney vessel), B (HCAECs) and C (HCASMCs).  Cx37 is 
evident primarily in the endothelium of the kidney vessel (A). Cx37 is localised to both the 
perinuclear region (DAPI nuclear staining in blue), and the cell membrane of the endothelial cells 
(B). Cx37 staining in HCASMCs was minimal with only small areas of punctate staining (C). The 
anti-Cx37 primary antibody was used at a 200 fold dilution, and the anti-rabbit secondary 
antibody at a 500 fold dilution. Image C is at a lower magnification. Kidney vessel, N=2. HCAEC, 
N=7. HCASMC, N=3.  
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4.3.2 - Connexin 40 in HCAECs and HCASMCs 
4.3.2.1 - Western Blot 
Cx40 was successfully identified in rat kidney cortex, kidney pyramid and heart lysates at 
the MW of 40 kDa during preliminary experiments (Figure 4.6A). Cx40 banding was also 
observed at 40 kDa in both HCAEC and HCASMC lysates during preliminary experiments, as 
shown in Figures 4.6B and 4.6C. Identification of the band in cultured cell lysates required 
an extended exposure time (24 hours vs. 10 minutes), reflecting the lower total protein 
concentration of the cultured cells when compared to rat tissue. 
 
4.3.2.2 - Immunohistochemistry and Immunocytochemistry  
The distribution of Cx40 was then examined in rat kidney and cultured human cells. 
Isolated areas of punctate Cx40 staining were identified in the rat kidney during preliminary 
experiments (Figures 4.7A & 4.7B). Similarly, Figures 4.7C & 4.7D represent Cx40 staining in 
HCAECs. This protein was identified surrounding the nucleus, supplemented by moderate 
expression at the membranes of the cobblestone-like endothelial cells. Figures 4.7E & 4.7F 
show the distribution of Cx40 throughout the elongated HCASMCs as identified during 
preliminary experiments. Cx40 was also identified arranged into longitudinal networks 
within these smooth muscle cells, possibly showing association with the actin cytoskeleton 
(Figure 4.7F).  
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Figure 4.6: Western blot of Cx40 in rat tissues, HCAECs and HCASMCs 
Cx40 expression within rat kidney cortex (KC), kidney pyramid (KP) and heart (H, 3 fold dilution) 
was identified through Western blot analysis (A), with banding at 40 kDa. A single distinct band 
at this MW was also identified in P9 and P10 lysates of HCAECs (B) and a strong band was 
identified in P9 and P10 lysates of HCASMCs (C). The rabbit anti-Cx40 primary antibody was used 
at a x200 dilution and the goat anti-rabbit secondary antibody at a x5,000 dilution, both in 1% 
non-fat powdered milk. The membranes were exposed to the photographic film for 10 minutes 
(rat lysate) and 24 hours (human cultured cell lysate), respectively. For kidney, HCAECs and 
HCASMCs, N=1. Heart, N=2.  
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Figure 4.7: Immunofluorescent analysis of Cx40 expression in rat kidney, HCAECs and 
HCASMCs 
Distribution pattern of Cx40 within rat tissue and cultured human cells using an AF488-tagged 
secondary antibody (green) is shown in A&B (rat kidney), C&D (HCAECs) and E&F (HCASMCs). 
Cx40 staining in rat kidney was minimal with only small areas of punctate staining (A&B). Within 
HCAECs, Cx40 was identified in close association with the nucleus and as patchy areas of 
membrane staining (C&D). Cx40 can be seen as diffuse staining throughout the HCASMCs with 
marginal association with the cytoskeleton (F). DAPI nuclear stain is shown in blue. The anti-Cx40 
primary antibody was used at a 200 fold dilution, and the anti-rabbit secondary antibody at a 
500 fold dilution. Image D is at a higher magnification. Kidney, N=2. HCAEC, N=5. HCASMC, N=4 
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4.3.3 - Connexin 43 in HCAECs and HCASMCs 
4.3.3.1 - Western Blot 
Preliminary Western blot experiments were carried out using rat kidney cortex, kidney 
pyramid and heart lysates. A single band was present at the appropriate MW of 43 kDa in 
both kidney lysates (Figure 4.8A). Although Cx43 is well established in the literature as the 
primary connexin expressed within heart tissue (Evans and Martin 2002), the heart lysate 
showed a smudge of banding, most likely due to excess protein (Figure 4.8A). During these 
experiments, Cx43 was identified as a single band throughout passages 6-10 of both 
HCAECs and HCASMCs (Figures 4.8B and 4.8C). Relatively high concentration of this protein 
within both HCAECs and HCASMCs was expected in the short exposure time of 10 minutes 
required to expose the band (compared to the 24 hours required to record Cx37 protein 
expression in the same cell lysates, Figures 4.8B and 4.8C), although this could be due to 
higher efficiency of the Cx43 primary antibody.  
4.3.3.2 - Immunohistochemistry  
The distribution of Cx43 within both rat tissue and cultured human cells was then examined 
using immunofluorescent technique. Figures 4.9A and 4.9B show preliminary results for 
Cx43 expression in rat kidney and renal vasculature. Although the majority of the AF488 
staining evident was background, distinct areas of true AF488 expression were identified, 
primarily within the vasculature supplying this tissue. Figures 4.9C and 4.9D represent Cx43 
distribution in the same section of rat coronary artery with (Figure 4.9D) and without 
(Figure 4.9C) a brightfield overlay image. Figures 4.9E and 4.9F are the same images at a 
higher magnification. The patency of the lumen of the rat coronary artery section allows 
clear identification of the distribution of Cx43.  This junctional protein is clearly evident 
throughout both the single endothelial cell layer and a large proportion of the multiple 
smooth muscle cell layers forming the tunica media. Figures 4.9G & 4.9H represent Cx43 
distribution in rat mesenteric artery during preliminary experiments, showing staining in 
both the endothelial layer and the smooth muscle layers.  
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Figure 4.8: Western blot of Cx43 in rat tissue, HCAECs and HCASMCs 
Expression of Cx43 within rat kidney cortex (KC), kidney pyramid (KP) and heart (H, 3 fold 
dilution) was detected through Western blot analysis (A). A single clear band was evident in the 
rat kidney tissue at the appropriate MW of 43 kDa. The rat heart lysate displayed a smudge of 
banding across multiple MW’s. A single band at 43 kDa was identified in passages 6-10 of HCAEC 
and HCASMC lysates, respectively (B and C). The rabbit anti-connexin 43 primary antibody was 
used at a x200 dilution and the goat anti-rabbit secondary antibody at a x5,000 dilution, both in 
1% non-fat powdered milk. The membranes were exposed to the photographic film for 5 
minutes (rat tissue) and 10 minutes (human cultured cell lysate), respectively. For kidney, 
HCAECs and HCASMCs, N=1. Heart, N=3.  
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Figure 4.9: Immunohistochemical analysis of Cx43 expression in rat tissue 
Distribution pattern of Cx43 within rat tissues using an AF488-tagged secondary antibody (green) 
is shown in A&B (kidney), C&D/E&F (coronary artery) and G&H (mesenteric artery). Cx43 
expression in rat kidney was restricted primarily to the vasculature (A & B). C&D represent Cx43 
distribution throughout the endothelial and smooth muscle layers of the rat coronary artery, 
with (D) and without (C) a brightfield image overlay. E&F are the same images at a higher 
magnification. G&H show low-level Cx43 expression in the endothelial and smooth muscle layers 
of the rat mesenteric artery. The anti-Cx43 primary antibody was used at a 200 fold dilution, and 
the anti-rabbit secondary antibody at a 500 fold dilution. DAPI nuclear staining is shown in blue in 
images A and B. N=2. 
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4.3.3.3 - Immunocytochemistry 
Figures 4.10A shows Cx43 distribution in HCAECs, and 4.10B shows Cx43 distribution in 
HCASMCs. In HCAECs, Cx43 showed punctate near-membrane staining, with weaker 
staining throughout the cell interior. In HCASMCs, Cx43 was found to form aggregations 
across the cell, but appeared to be absent from the nucleus (Figure 4.10B). No distinct 
sections of membrane-associated Cx43 expression were identified in the HCASMCs (Figure 
4.10B). 
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Figure 4.10: Immunocytochemical analysis of Cx43 expression in HCAECs and 
HCASMCs 
Cx43 distribution in HCAECs is shown in A. Cx43 was identified diffusely throughout the cell and 
as discontinuous patches at the cell membrane. DAPI (blue) highlights nuclear Cx43 staining in 
HCAECs (A).  Cx43 distribution in HCASMCs is shown in B. Cx43 was identified in aggregations 
throughout smooth muscle cells. No distinct sections of near-membrane or nuclear Cx43 were 
identified in HCASMCs (B). Antibody dilutions as previously detailed. HCAECs, N=6. HCASMCs, 
N=5.  
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4.3.4 – VE-cadherin in HCAECs and HCASMCs 
 
4.3.4.1 - Western Blot 
During preliminary experiments, VE-cadherin was identified as the darkest band in HCAEC 
lysate (P6 and P10) at the MW of 130 kDa (Figure 4.11). Other bands were also observed 
and this may be because the membranes had to be exposed to photographic film for 50 
hours (typical exposure periods ranged from 5-10 minutes for most other experiments). 
Indeed, HCASMC (P6) lysate shows these fainter bands, but the 130 kDa band is absent 
(Figure 4.11). The specificity of VE-cadherin was therefore further examined using 
immunocytochemistry. 
 
4.3.4.2 - Immunocytochemistry  
Immunofluorescent technique was used to examine the distribution pattern of VE-cadherin 
in HCAECs (Figure 4.12). Figure 4.12A shows the distribution of VE-cadherin as detected 
with the AF488-conjugated secondary antibody. Figures 4.12B and 4.12C show the 
distribution of VE-cadherin as detected with the AF594-conjugated secondary antibody. 
Figure 4.12C is at a higher magnification. The staining of VE-cadherin appears discontinuous 
(Figure 4.12C), and it appears as though numerous short processes extend into the cell 
(Figure 4.12B). A notable proportion of the imaged cells also displayed perinuclear and 
general intracellular localisation of VE-cadherin, against the DAPI nuclear staining 
represented in blue (Figure 4.12A).  
 
4.3.4.3 - VE-cadherin Summary  
VE-cadherin is expressed by HCAECs as discontinuous membranous patches, with a 
proportion of cells also displaying perinuclear and general intracellular localisation of this 
junctional protein. A lack of VE-cadherin expression by HCASMCs was confirmed through 
Western blot targeting of the protein.  
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Figure 4.11: Western blot of VE-cadherin in HCAECs and HCASMCs  
Expression of VE-cadherin by HCAECs (P6 and P10 lysate) was identified through Western blot 
analysis, showing a dense band at 130 kDa. HCASMC lysate (P6) acted as a negative control for 
this endothelial-specific protein. The mouse anti-VE-cadherin primary antibody was used at  
x200 dilution and the goat anti-mouse secondary antibody at  x10,000 dilution, both in 1% non-
fat powdered milk. The membrane was exposed to the photographic film for 50 hours. N=1. 
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Figure 4.12: Immunocytochemical analysis of VE-cadherin expression in HCAECs 
The distribution pattern of VE-cadherin within HCAECs was identified using both an AF488-
tagged secondary antibody (A, green), and an AF595-tagged secondary antibody (B & C, red). 
VE-cadherin was identified primarily at the membrane as discontinuous segments of staining. 
Moderate perinuclear staining was identified in some cells (A). DAPI nuclear staining is shown in 
blue. The anti-VE-cadherin primary antibody was used at a 200 fold dilution, and the secondary 
antibody at a 500 fold dilution. Image C is at a higher magnification. N=6.  
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4.3.5  - N- Cadherin in HCAECs and HCASMCs 
4.3.5.1 - Western Blot and Immunocytochemistry 
N-cadherin was identified at the MW of 130 kDa in HCAEC (P6 and P10) and HCASMC (P6) 
lysates during preliminary experiments (Figure 4.13).  The distribution of N-cadherin was 
then examined in HCAECs and HCASMCs through the use of immunocytochemical 
techniques. N-cadherin was identified at both the cell membrane and diffusely throughout 
HCAECs (Figure 4.14). Areas of peak signal were detected at the membrane, accompanied 
by relatively high fluorescence throughout the cell (Figure 4.14A). The membrane-bound N-
cadherin appears to localise primarily at the leading edge of the cell, as highlighted by the 
white arrows in Figure 4.14A. Unlike VE-cadherin expression in HCAECs, N-cadherin 
expression in these cells does not display inward projections from the cell membrane, and 
the distribution is more continuous and less zipper-like (Figure 4.14A). Accumulations of N-
cadherin staining into small aggregations were observed in HCAECs (white arrow, Figure 
4.14B). 
Preliminary immunocytochemistry experiments showed that N-cadherin distribution in 
HCASMCs was very similar to the expression pattern of this protein within HCAECs (Figure 
4.15). As with HCAEC cultures, HCASMCs showed N-cadherin localisation to the cell 
membrane, once again represented as small sections of staining with a preference for the 
leading edge of the cell, as highlighted by the white arrow in Figure 4.15A. Aggregations of 
N-cadherin signal can also be seen in HCASMCs (Figure 4.15B), again similar to the 
expression profile of this protein in HCAECs. 
The distribution pattern of N-cadherin in cultured HCAECs and HCASMCs was similar. Both 
cell populations display N-cadherin staining at the cell membrane and accumulations 
throughout the cell. In addition, both HCAECs and HCASMCs express N-cadherin as large 
segments of membrane staining, contrasting the zipper-like, discontinuous appearance of 
VE-cadherin in HCAECs. N-cadherin displayed no inward projections from the membrane, 
unlike those seen with VE-cadherin in HCAECs.  Membranous N-cadherin appeared to 
localise primarily to specific sites in both HCAECs and HCASMCs.  
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Figure 4.13: Western blot of N-cadherin in HCAECs and HCASMCs  
Expression of N-cadherin by HCAEC (P6 and P10) and HCASMC (P6) lysates was identified 
through Western blot analysis, showing a single band at 130 kDa. The mouse anti-N-cadherin 
primary antibody was used at x300 dilution and the goat anti-mouse secondary antibody at 
x10,000 dilution, both in 1% non-fat powdered milk. The membrane was exposed to the 
photographic film for 10 minutes. N=1.  
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Figure 4.14: Immunocytochemical analysis of N-cadherin expression in HCAECs  
The distribution pattern of N-cadherin in HCAECs was identified using both an AF488-tagged 
secondary antibody (A, green), and an AF595-tagged secondary antibody (B, red). N-cadherin 
appeared discontinuously across the membrane (white arrows in A). Accumulations of N-
cadherin were observed throughout the HCAECs (white arrow in B). The anti-N-cadherin primary 
antibody was used at a 200 fold dilution, and the secondary antibody at a 500 fold dilution. DAPI 
nuclear staining is shown in blue. N=7.  
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4.4.2.2 - N-cadherin Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Immunocytochemical analysis of N-cadherin expression in HCASMCs  
The distribution pattern of N-cadherin in HCASMCs was identified using an AF595-tagged 
secondary antibody (A & B, red). N-cadherin displayed both membranous and cytoplasmic 
staining. Cytoplasmic accumulations of N-cadherin are evident in both A and B. The white arrow 
in image A highlights the strong staining of N-cadherin at specific sites of the cell membrane.  
DAPI nuclear staining is shown in blue. Antibody dilutions as previously detailed. N=1. 
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4.3.6 -  Connexin and VE-Cadherin Co-staining in HCAECs 
 
4.3.6.1 - VE-cadherin and Cx37 
 
VE-cadherin and Cx37 were labelled in HCAECs through immunocytochemistry (Figure 
4.16). VE-cadherin was labelled using an AF594-conjugated (red) secondary antibody 
(Figures 4.16A-4.16C), while Cx37 was labelled using an AF488-conjugated (green) 
secondary antibody (Figures 4.16A, 4.16B & 4.16D). These preliminary experiments 
identified areas of overlap between Cx37 and VE-cadherin distribution as yellow patches at 
the cell membrane (Figures 4.16A and 4.16B, white arrows), but not inside the HCAECs. 
Areas of membranous Cx37 devoid of VE-cadherin staining were also identified.  
 
4.3.6.2 - VE-cadherin and Cx40 
VE-cadherin (red) and Cx40 (green) were labelled in HCAECs through immunocytochemistry 
(Figure 4.17). Small areas of overlap between membranous Cx40 and VE-cadherin 
expression were observed in HCAECs (yellow; Figure 4.17C). Areas of co-localisation were 
not identified in all HCAECs imaged. Areas of near-membrane Cx40 without VE-cadherin 
overlap were identified.  
 
4.3.6.3 - VE-cadherin and Cx43 
VE-cadherin (red) and Cx43 (green) were labelled in HCAECs through immunocytochemistry 
(Figure 4.18). Isolated sections of VE-cadherin and Cx43 co-staining (yellow) were identified 
at the cell membranes of a number of HCAECs imaged (Figure 4.18C, white arrow). Sections 
of Cx43 near-membrane staining devoid of VE-cadherin staining were also identified.  
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Figure 4.16: Immunocytochemistry of VE-cadherin and Cx37 co-localisation in HCAECs 
VE-cadherin (red) was primarily restricted to the membrane as discontinuous patches (A-C). 
Cx37 (green) was identified surrounding the nucleus and as isolated segments of membrane 
staining (A, B & D). Co-localisation of VE-cadherin and Cx37 (yellow) was identified at the cell 
membrane, as indicated by the white arrows (B). Image B represents overlap of images C and D.  
Antibody dilutions as previously detailed. DAPI nuclear staining in blue. N=2. 
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Figure 4.17: Immunocytochemistry of VE-cadherin and Cx40 co-localisation in HCAECs 
VE-cadherin (red) was identified as patches throughout the membrane with inward projections 
(A & C). Cx40 (green) was associated primarily with the nucleus (shown by DAPI nuclear staining 
in blue), with isolated areas of membrane association, as highlighted by the white arrow (B & C).  
Image C represents overlap of images A and B. Isolated areas of co-localisation between VE-
cadherin and Cx40 (yellow) were identified at restricted points of the membrane (C). Areas of 
overlap between Cx40 and VE-cadherin expression were not identified in all HCAECs imaged. 
Antibody dilutions as previously detailed. N=3. 
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Figure 4.18: Immunocytochemistry of VE-cadherin and Cx43 co-localisation in HCAECs 
VE-cadherin (red) was primarily restricted to the membrane (A & C), while Cx43 (green) was 
identified throughout the cell and at the cell membrane (B & C). Image C represents overlap of 
images A and B. Small areas of co-localisation (yellow) were identified at the membrane of the 
HCAECs imaged, as highlighted by the white arrow (C). Antibody dilutions as previously detailed. 
DAPI nuclear staining is shown in blue. N=3. 
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4.3.6.4 - Quantification of Connexin and VE-cadherin Co-localisation 
Figure 4.19 displays the quantification of co-localisation between VE-cadherin and 
connexins 37, 40 and 43 in HCAECs. Three Image J plugins were utilised to quantify the 
degree of overlap in the expression profiles of these junctional proteins. The plugins used 
were; Manders’ Overlap Coefficient, Co-localisation Finder plugin and Intensity Correlation 
Analysis. Full details of the quantification process for each plugin can be found in the 
Appendix under “Supplementary information on the quantification of cadherin and 
connexin co-localisation using Image J plugins”. 
 
4.3.6.5 - VE-cadherin and Connexin Co-localisation - Summary 
Moderate overlap between Cx37 and VE-cadherin expression at the cell membrane was 
identified in HCAECs. Overlap appeared as small areas of punctate staining, with no 
extended regions of co-staining. Small areas of Cx40 and VE-cadherin co-expression were 
also identified in these endothelial cells. These areas of overlap were restricted to the 
membrane, and only in a subset of the cells imaged. Membrane Cx43 and VE-cadherin 
expression overlap was observed in HCAECs. The co-staining was limited to the membrane 
and areas of Cx43 membrane staining without VE-cadherin staining were noted. The most 
extensive overlap between VE-Cadherin and the connexins targeted was identified 
between Cx37 and VE-cadherin.  
 
4.3.7 - Connexin and N-Cadherin Co-staining in HCAECs 
4.3.7.1 - N-cadherin and Cx37   
N-cadherin (red) and Cx37 (green) were labelled in HCAECs during preliminary 
immunocytochemistry experiments (Figure 4.20). No observable co-localisation between N-
cadherin and Cx37 (yellow) was identified within the HCAEC culture, with membranous 
staining of both junctional proteins appearing mutually exclusive (Figure 4.20C). Peaks in N-
cadherin expression appeared external to areas of Cx37, thus preventing overlap.   
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Figure 4.19: Quantification of Connexin and VE-cadherin co-localisation in HCAECs 
Three types of Image J plugins were used to quantify co-localisation between VE-cadherin and 
Cx37, Cx40 and Cx43; Manders’ Overlap Coefficient, Co-localisation Finder plugin and Intensity 
Correlation Analysis. Full details of quantification process can be found in the Appendix under 
“Supplementary information on the quantification of cadherin and connexin co-
localisation using Image J plugins”. For VE-cadherin and Cx37, N=2. For VE-cadherin and 
Cx40, and VE-cadherin and Cx43, N=3. 
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Figure 4.20: Immunocytochemistry of N-cadherin and Cx37 co-localisation in HCAECs 
N-cadherin (red) expression was identified throughout the cell and also at the cell membrane (A 
& C). Cx37 (green) was distributed to the perinuclear region and restricted areas of the HCAEC 
membrane (B & C).  Image C represents overlap of images A and B. No co-localisation between 
Cx37 and N-cadherin (yellow) could be identified (C). Antibody dilutions as previously detailed. 
N=2. 
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4.3.7.2 - N-cadherin and Cx40 
Figure 4.21 shows labelling of N-cadherin (red) and Cx40 (green) in HCAECs during 
preliminary immunocytochemistry experiments. No overlap between N-cadherin and Cx40 
expression (yellow) was identified (Figure 4.21C). DAPI nuclear staining shown in blue 
suggests that a proportion of N-cadherin expression in HCAECs is localised to the nucleus 
(Figure 4.21C). 
 
4.3.7.3 - N-cadherin and Cx43 
N-cadherin (red) and Cx43 (green) were labelled in HCAECs in preliminary 
immunocytochemistry experiments (Figure 4.22). Few isolated areas of overlap between 
Cx43 and N-cadherin expression (yellow) were identified at the membrane (Figure 4.22C). 
Overlap was not identified in all HCAECs imaged and in most cells the two junctional 
proteins appeared mutually exclusive (Figure 4.22D, higher magnification).  
Figure 4.23 shows labelling of N-cadherin (red) and Cx43 (green) in HCASMCs during 
preliminary immunocytochemistry experiments. Small isolated areas of overlap between N-
cadherin and Cx43 expression (yellow) were identified in the HCASMCs (Figures 4.23E and 
4.23F, white arrow). These areas of co-localisation appeared to be closely associated with 
the nucleus, as shown by the DAPI nuclear staining (blue). Considerable areas of 
membranous N-cadherin expression devoid of Cx43 co-expression were identified (Figure 
4.23F).  
 
4.3.7.4 - N-cadherin and Connexin Co-localisation - Summary 
In summary, no observable co-localisation was identified in HCAECs between N-cadherin 
and either Cx37 or Cx40. Conversely, isolated areas of overlap were identified between N-
cadherin and Cx43 in both HCAECs and HCASMCs. These areas appeared to be closely 
associated with the nucleus, as shown by the DAPI staining.  
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Figure 4.21: Immunocytochemistry of N-cadherin and Cx40 co-localisation in HCAECs 
N-cadherin distribution (red) was identified both throughout the cell and at the membrane (A & 
C). Low-level Cx40 (green) expression was detected throughout the cells with isolated areas of 
punctate staining at the membrane (B & C).  Image C represents overlap of images A and B. No 
overlap between Cx40 and N-cadherin distribution (yellow) could be identified (C). Antibody 
dilutions as previously detailed. N=1. 
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Figure 4.22: Immunocytochemistry of N-cadherin and Cx43 co-localisation in HCAECs 
N-cadherin (red) was identified both throughout the cell and at the HCAEC membrane, forming 
small aggregations of staining (A, C & D). Cx43 (green) was identified as both diffuse staining 
throughout the cell and areas of membranous staining (B, C & D).  Image C represents overlap of 
images A and B. Small areas of co-localisation between Cx43 and N-cadherin (yellow) were 
identified in isolated cells, primarily at the membrane (C).  Image D is at a higher magnification. 
Antibody dilutions as previously detailed. N=2. 
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Figure 4.23: Immunocytochemistry of N-cadherin and Cx43 co-localisation in 
HCASMCs 
N-cadherin (red) was identified both throughout the cell and at the HCASMC membrane (A, B, E 
& F). Cx43 (green) appeared diffusely throughout the cell (C, D, E & F). Images E and F represent 
overlap of images A/C and B/D, respectively.   Small areas of co-localisation between Cx43 and 
N-cadherin (yellow) were identified in isolated cells (white arrow, E & F).  Antibody dilutions as 
previously detailed. N=1. 
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4.4 – Discussion 
4.4.1 – Cx37 in rat tissues 
Cx37 was identified in both the rat kidney cortex and kidney pyramid tissue lysates in 
preliminary experiments using Western blot (Figure 4.4A). Similarly, preliminary 
immunohistochemical analysis identified Cx37 primarily within the vasculature of the rat 
kidney (Figure 4.5A). This data is in agreement with the work of Arensbak et al. who 
identified Cx37-containing gap junctions in the endothelium of the pre-glomerular 
arterioles in rats (Arensbak, Mikkelsen et al. 2001). In addition, work completed by 
Takenaka and co-workers (2008) also found Cx37-containing gap junctions in the 
endothelium of rat post-glomerular vessels (although this was not the case in mice, where 
Cx43 was expressed) (Takenaka, Inoue et al. 2008). It should be noted that work completed 
by Stoessel et al. highlighted the expression of Cx37 in the ascending limb of the loop of 
Henle and distal tubule and, to a lesser degree, the proximal tubule and collecting duct of 
rats (Stoessel, Himmerkus et al. 2010). Our preliminary immunohistochemistry results 
indicate only very low-level Cx37 staining in the kidney outside the vasculature; however it 
is likely that this Cx37 contributed to that detected through Western blot.   
Preliminary data also indicated the expression of Cx37 in rat heart lysate (Figure 4.4A), 
supporting the previous identification of Cx37 within the endothelium lining of the heart, 
the endocardium, as well as within the endothelial lining of coronary blood vessels  
(Willecke, Heynkes et al. 1991, Delorme, Dahl et al. 1997). Despite the lack of Cx37 
expression within the myocardium, as outlined by Delorme et al., sufficient protein existed 
to allow detection even when the lysate was used at a 3 fold dilution, as in our 
experiments. Taken together, preliminary data suggested Cx37 is expressed in the rat 
kidney and heart, and as such these tissues were used as a positive control for the anti-
Cx37 primary antibody used in experiments.  
 
4.4.2 – Cx37 in HCAECs 
HCAECs were found to express Cx37 in preliminary Western blot and immunocytochemistry 
experiments (Figures 4.4B and 4.5B). In immunocytochemistry, this junctional protein was 
identified in two primary locations; at the cell membrane and surrounding the nucleus 
(Figure 4.5B). Membranous Cx37 staining was strong, present in all cells imaged and 
arranged into continuous segments along the cell border. The intracellular Cx37 identified 
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in these endothelial cells could be in the process of being translated and transported to the 
membrane for interaction with other cells, or being internalised and degraded. Our findings 
are supported by previous work completed by Yeh and co-workers who identified Cx37 
expression in both rat and human coronary artery endothelium (Yeh, Rothery et al. 1998, 
Yeh, Lai et al. 2000). Furthermore, Cai et al. (2001) also identified Cx37 within the 
endothelium of the coronary vasculature of the dog, from the level of the artery through to 
the capillary, through both immunoconfocal microscopy and transmission electron 
microscopy (TEM). It should be noted however, that variation in the distribution of Cx37 
within the coronary vasculature of different species exists, as van Kempen et al. failed to 
identify Cx37 within the bovine coronary vasculature, despite identifying its expression in 
the endothelium of both the rat and micropig coronary artery (Van Kempen and Jongsma 
1999). However, this work was carried out on whole tissue sections and the expression of 
Cx37 within the bovine tissue may have been too low for detection.  The discrepancies in 
Cx37 distribution in the coronary vasculature may be due to the high sensitivity of this 
protein to haemo-dynamic changes (Cai, Koltai et al. 2001). Sections taken from branch 
points in the coronary vasculature are likely to display a higher expression profile for this 
protein, compared to sections taken from other areas of the coronary arterial system, due 
to the high sheer stress exerted on the vessel at these sites.  
 
4.4.3 – Cx37 in HCASMCs 
Cultured HCASMCs were found to express Cx37 in preliminary Western blot and 
immunocytochemistry experiments (Figures 4.4C and 4.5C). In immunocytochemistry, Cx37 
expression was minimal with only isolated areas of punctate staining with fluorescence 
intensity above that considered background (~100 AU, Figure 4.5C). Furthermore, no 
membrane-association was identified for Cx37 in HCASMCs, and indeed even nuclear-
association was marginal (DAPI nuclear staining shown in blue).  This protein was, however, 
identified within HCASMC lysate when targeted by Western blot. Cai et al. identified no 
Cx37 within the smooth muscle cells of the coronary vasculature of the dog under normal 
conditions, but they did detect this protein within these cells during collateral vessel 
growth of the coronary arterial system (Cai, Koltai et al. 2001). Moreover, their work 
suggested that this alteration in connexin expression was a result of the smooth muscle 
cells adopting a synthetic phenotype, a process which occurs during vessel damage and 
allows such collateral vessel growth to occur. As such, it may be that the smooth muscle 
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cells displaying punctate Cx37 expression in our results are shifting towards a synthetic 
phenotype. As previously mentioned, this can occur in culture but if this did occur in our 
HCASMCs, these cells were in the minority of the population (more detail on confirmation 
of the contractile nature of the cultured HCASMCs can be found under “3.1.2 
Characterisation of Human Coronary Artery Smooth Muscle Cells (HCASMCs)”). It is also 
worth considering the precise location from which the purchased HCASMCs were obtained. 
Promocell state that the smooth muscle cells are obtained from the right and left coronary 
arteries, including the left anterior descending coronary artery and the circumflex coronary 
artery. van Kempen and co-workers identified high Cx37 expression in the smooth muscle 
cells of the larger arteries of the rat coronary arterial system, but no Cx37 within the 
smooth muscle cells of the smaller arteries (Van Kempen and Jongsma 1999). As such, this 
may explain the differences in the detection rate of Cx37 within the smooth muscle cells of 
the coronary artery.  
 
4.4.4 – Cx40 in rat tissues 
Cx40 was identified in both the rat kidney cortex and kidney pyramid tissue lysates during 
preliminary Western blot experiments (Figure 4.6A). Preliminary immunohistochemical 
data indicated that the expression of Cx40 was minimal within rat kidney tissue; however 
isolated areas of punctate staining were identified (Figures 4.7A & 4.7B). In support of this 
data, the literature details expression of Cx40 within both rat and human kidney. Much like 
Cx37, Cx40 was also identified in the endothelium of the renal vasculature (Arensbak, 
Mikkelsen et al. 2001). Indeed, this work highlighted Cx40 as the dominant connexin within 
the pre-glomerular vasculature. Furthermore, Cx40 mRNA has been identified in the 
tubules and collecting ducts of the rat kidney (Takenaka, Inoue et al. 2008, Kurtz, Madsen 
et al. 2010).  
Cx40 was also identified in rat heart lysate during Western blot experiments (Figure 4.6A). 
This preliminary result is supported by work completed by Gros et al. (1994) which 
reported expression of Cx40 within various structures of the conducting system, including 
the Bundle of His and Purkinje fibres, despite a lack of expression within working 
ventricular myocytes (Gros, Jarry-Guichard et al. 1994). This data confirmed that published 
by Bastide and co-workers in 1993, which detected Cx40 within the conductive bundles of 
rat myocardium (Bastide, Neyses et al. 1993). Cx40 has also been identified in the atrial 
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myocardium of other mammals, including guinea pig and human (Gros, Jarry-Guichard et 
al. 1994, Vozzi, Dupont et al. 1999). This data, combined with our preliminary results, 
suggests expression of Cx40 in the rat kidney and heart, thus providing a positive control 
for the anti-Cx40 primary antibody used in experiments.  
 
4.4.5– Cx40 in HCAECs 
HCAECs were found to express Cx40 during preliminary Western blot and 
immunocytochemistry experiments (Figures 4.6B and 4.7C & 4.7D). In 
immunocytochemistry, Cx40 was identified both surrounding the nucleus and as small 
sections of membrane staining (Figure 4.7C and 4.7D). Such staining was not identified in all 
cells, and the degree of Cx40 expression varied markedly from cell to cell. As previously 
mentioned the cells displaying a high concentration of perinuclear Cx40 could be in the 
process of either translating and transporting the protein for expression at the membrane, 
or internalising and degrading it. Larson et al. (1997) have previously noted that differences 
in connexin expression in individual cells within the same population may reflect cells in 
different growth stages, and although this was primarily with respect to Cx37 and Cx43, this 
may partly explain the varying Cx40 expression seen here (Larson, Wrobleski et al. 1997). In 
support of our preliminary data, the literature details identification of Cx40 within the 
endothelium of both the rat and dog coronary artery (Yeh, Rothery et al. 1998, Cai, Koltai et 
al. 2001).  Indeed, work completed by Little and co-workers (1995) concluded that Cx40 
punctations in endothelial cells of resistance vessels were significantly larger than those 
identified in the smooth muscle of the same vessels (P≤0.05, N=80 for SMC, N=86 for EC) 
(Little, Beyer et al. 1995). 
 
4.4.6– Cx40 in HCASMCs 
Cx40 was identified in cultured HCASMCs through Western blot and immunocytochemistry 
experiments using an AF488-tagged secondary antibody (Figures 4.6C and 4.7E & 4.7F). 
Preliminary immunocytochemistry data indicated a diffuse distribution of Cx40 throughout 
the coronary artery smooth muscle cells, forming small cytoplasmic aggregations (Figure 
4.7E), and potentially representing localisation of the protein within trafficking vesicles. In 
addition, Cx40 appeared to be associated with the cytoskeleton of the cell, presenting in 
longitudinal networks along the length of the cell (Figure 4.7F). Cai et al. failed to identify 
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any Cx40 within the smooth muscle cells of the dog coronary artery (Cai, Koltai et al. 2001), 
however this may be due to the whole-tissue analysis of this vessel and the lack of large 
clusters of Cx40-containing channels in this tissue (Beny and Connat 1992). In support of 
our data, van Kempen and co-workers identified Cx40 in smooth muscle cells of the larger 
arteries of the rat and bovine coronary system (Van Kempen and Jongsma 1999), however 
they failed to identify Cx40 in the smooth muscle cells of the smaller arterioles of the rat 
coronary vasculature. Work published by Giepmans et al. details the direct interaction 
between Cx43 and microtubules in rat epithelial T51B cells (Giepmans, Verlaan et al. 2001) 
and the existence of a similar relationship between microtubules and Cx40 in HCASMCs 
should be considered. 
 
4.4.7 – Cx43 in rat tissues 
Preliminary Western blot data indicates the expression of Cx43 in both the rat kidney 
cortex and kidney pyramid tissue lysates(Figure 4.8A). Similarly, preliminary 
immunohistochemical examinations identified Cx43 within rat kidney tissue sections, 
particularly within the renal vasculature (Figures 4.9A & 4.9B).  Supporting our results, 
Arensbak et al. identified Cx43 mRNA in rat renal vasculature and Kurtz et al. identified 
Cx43 localisation within the juxtaglomerular apparatus of the human kidney (Arensbak, 
Mikkelsen et al. 2001, Kurtz, Madsen et al. 2010).  
Western blot analysis identified Cx43 as a smudge of banding across multiple molecular 
weights in rat heart lysate (Figure 4.8A). Cx43 is well established as the primary connexin 
within the mammalian heart and this result was likely due to excess protein (Beyer, Kistler 
et al. 1989, Van Kempen, Fromaget et al. 1991). Indeed, further work by Gourdie et al. has 
identified co-localisation of Cx40 with Cx43 within rat atrioventricular nodal tissue and 
Purkinje fibres (Gourdie, Severs et al. 1993).  
Immunohistochemistry of rat coronary artery slices during preliminary experiments 
identified Cx43 within both the endothelium and the multiple smooth muscle layers of this 
vessel (Figures 4.9C & 4.9D and 4.9E & 4.9F). The literature contains little definitive 
information on the expression profile of Cx43 within the coronary vasculature, however, 
van Kempen and co-workers identified low levels of this connexin in the smooth muscle 
cells of the larger arteries of the rat coronary vasculature (Van Kempen and Jongsma 1999). 
In contrast, they could not identify any Cx43 in the smooth muscle cells of the smaller 
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arterioles of the rat coronary system. This work highlighted the variable distribution 
patterns of Cx43 within different mammals, as the expression pattern of Cx43 was 
completely reversed in bovine coronary arteries (localisation to distal/smaller arterial 
smooth muscle cells and not proximal/larger arterial smooth muscle cells). Published work 
by Yeh et al. identified a lack of Cx43 expression within rat coronary artery endothelium, 
despite identifying this connexin within other muscular arteries (mesenteric resistance, 
hepatic and tail arteries) (Yeh, Rothery et al. 1998).  Taken together, this data suggest a 
high degree of variability in the expression pattern of Cx43 within the coronary vasculature, 
both within and between different species. Similarly, preliminary immunohistochemistry 
investigations of rat mesenteric artery slices also identified Cx43 within both the 
endothelial and smooth muscle layers of this vessel (Figures 4.9G & 4.9H). Stronger Cx43 
staining was identified within the smooth muscle compared to that localised to the 
endothelium, however areas of punctate staining did exist within these endothelial cells 
(Figure 4.9G). In support of our preliminary data, Hong and Hill also identified Cx43 
expression within the endothelium and tunica media of rat elastic arteries, including the 
superior mesenteric artery (Hong and Hill 1998). Taken together, Cx43 appears to be 
expressed in the rat kidney, heart, and coronary and mesenteric vasculature. 
 
4.4.8 – Cx43 in HCAECs 
HCAECs were found to express Cx43 during preliminary Western blot and 
immunocytochemistry experiments (Figures 4.8B and 4.10A). In immunocytochemistry, 
Cx43 was found to be distributed diffusely throughout the cell and at sections of 
membrane staining (Figure 4.10A). As previously mentioned, literature on the distribution 
pattern of Cx43 within the coronary vasculature is limited and the majority of reports fail to 
identify this junctional protein within the coronary endothelium. Published work by Cai et 
al. and Yeh et al. for example, found no evidence of Cx43 expression in either the dog or 
human coronary artery endothelium, respectively (Yeh, Dupont et al. 1997, Cai, Koltai et al. 
2001). Larson et al. however, did identify Cx43 messenger RNA within bovine, porcine, rat 
and human microvascular endothelial cells via Northern blot analysis (Larson, Haudenschild 
et al. 1990). The lack of Cx43 expression within the former studies may be a result of 
whole-tissue analysis. Our studies involved identification of the Cx43 expression pattern in 
individual HCAECs, and as such, even low-level expression could be detected. Despite the 
lack of definitive evidence in the literature, our preliminary data indicates the expression of 
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Cx43 within cultured HCAECs, and this result is believed to be real due to the consistent 
banding for the protein (P6-P10) in the Western blot experiments (Figure 4.8B).  
 
4.4.9– Cx43 in HCASMCs 
Cx43 was identified in HCASMCs through Western blot and immunocytochemistry analysis 
(Figures 4.8C and 4.10B). Unlike HCAECs, HCASMCs displayed no clear segments of 
membranous Cx43 and instead displayed cytoplasmic aggregations of the protein 
throughout the cells during preliminary experiments. In addition, no nuclear Cx43 staining 
was identified in HCASMCs (Figure 4.10B). Again, little detail of Cx43 expression within 
HCASMCs can be found in the literature, with Cai and co-workers again finding no evidence 
of this protein within smooth muscle cells of the dog coronary artery (Cai, Koltai et al. 
2001). Gourdie et al., however, have published data confirming the expression of Cx43 
within smooth muscle cells of the vasculature of the avian heart (Gourdie, Green et al. 
1993) and Larson et al. once again identified Cx43 mRNA in bovine, porcine, rat and human 
microvascular smooth muscle cells (Larson, Haudenschild et al. 1990).  
While it is possible that the types and levels of connexins expressed by cells, particularly 
smooth muscle cells, can change in culture, as detailed by Stutenkemper et al. 
(Stutenkemper, Geisse et al. 1992), it seems unlikely that the consistent Cx43 expression 
observed in both HCAECs and HCASMCs is due to a change in cell phenotype. Furthermore, 
considerable Cx43 expression was also identified within whole slices of rat coronary artery 
during preliminary investigations (Figures 4.9C & 4.9E).  Indeed, the expression of Cx43 
within large elastic arteries, including the aorta from which the coronary arteries stem, and 
other resistance vessels, is well established (Bruzzone, Haefliger et al. 1993, Little, Beyer et 
al. 1995).  
In conclusion, our preliminary data suggests expression of connexins 37, 40 and 43 in 
cultured primary HCAECs. Furthermore, at least 2 connexins, Cx40 and Cx43, were found to 
be expressed by cultured primary HCASMCs, as evidenced by both Western blot and 
immunocytochemistry. 
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4.4.10 – VE- cadherin  
Preliminary Western blot and immunocytochemistry experiments found HCAECs to express 
VE-cadherin (Figures 4.11 & 4.12), while VE-cadherin was absent from HCASMCs (Figure 
4.11). In immunocytochemistry, VE-cadherin was found to be distributed primarily to the 
membrane as discontinuous patches (Figure 4.12). In addition, some cells were found to 
express perinuclear staining for VE-cadherin. It is well-established that VE-cadherin is 
almost entirely restricted in its expression to vascular endothelial cells (Lampugnani, 
Resnati et al. 1992, Breviario, Caveda et al. 1995). Furthermore, the localisation of VE-
cadherin was shown to be primarily to the membrane (Dejana 1997), supporting our 
immunocytochemistry results.  With regards to HCAECs, Kondapalli and co-workers (2004) 
also found human coronary artery endothelial cells to express VE-cadherin, and indeed 
they highlighted its relationship with the armadillo protein p-120 catenin, a known 
cadherin complex-associated protein (Kondapalli, Flozak et al. 2004). Research carried out 
by Navarro et al. also identified a similar VE-cadherin distribution pattern in vivo (artery 
and vein from human lymph node) (Navarro, Ruco et al. 1998). As previously mentioned for 
connexins, cells displaying cadherin protein expression near the nucleus could be in the 
process of either translating and transporting the protein for expression at the membrane, 
or internalising and degrading it. Our results also highlighted short intra-cellular projections 
of VE-cadherin from the cell membrane (Figure 4.12B). These projections may be a result of 
accumulation of newly synthesised VE-cadherin at actin filament tips due to Myosin-x 
trafficking of the protein from the Golgi apparatus (Harris and Nelson 2010). This is 
normally evident in sub-confluent cells as new cadherin complexes are forming and may be 
due to a temporary lack of sufficient cell-cell contact sites for the degree of VE-cadherin 
available near the membrane (Almagro, Durmort et al. 2010). Alternatively, such short lines 
of VE-cadherin staining at right angles to the endothelial cell border were also identified by 
(Spindler, Peter et al. 2011), who hypothesised that these represented multiple lateral cell 
protrusions inter-digitating along tortuous cell contacts in the x-y plane. It should also be 
noted that the potential for the expression of an additional VE-cadherin subtype exists. This 
cadherin was termed VE-cadherin 2 by Telo et al. (Telo, Breviario et al. 1998) who identified 
its distribution in heart microvascular endothelial cells. Like VE-cadherin, VE-cadherin 2 was 
also found to localise to intercellular junctions and exhibit adhesive properties. However, 
unlike VE-cadherin, VE-cadherin 2 does not bind to catenins and does not modify 
paracellular permeability, cell migration or growth, all of which are important functions of 
VE-cadherin 
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4.4.11 - N -cadherin in HCAECs 
Preliminary experiments identified N-cadherin in HCAECs through both Western blot and 
immunocytochemistry (Figures 4.13 & 4.14). In immunocytochemistry, N-cadherin was 
found to localise to specific sites of the cell membrane (white arrows, Figure 4.14A), and to 
form aggregations throughout the cell (white arrow, Figure 4.14B), potentially representing 
localisation within trafficking vesicles. Our data is supported by the literature examining N-
cadherin in endothelial cells of the vasculature (Suzuki, Sano et al. 1991, Dejana 1997, 
Lampugnani and Dejana 1997). Unlike VE-cadherin, N-cadherin is not endothelial cell-
specific and is originally known for its expression in neurons, as reflected in its full name, 
Neural-cadherin (Takeichi 1990, Grunwald 1993). It should be noted, however, that 
research in the chick embryo has highlighted that during development vascular 
endothelium was not found to express N-cadherin, despite other tissues of mesodermal 
origin expressing this junctional protein (Hatta, Takagi et al. 1987). The membranous 
distribution of N-cadherin within vascular endothelial cells is also well-established 
(Salomon, Ayalon et al. 1992, Navarro, Ruco et al. 1998). Unlike VE-cadherin, Salomon et al. 
(1992) identified N-cadherin diffusely throughout the whole cell membrane in human 
endothelial cells, and not localised to sites of cell-cell contact (Salomon, Ayalon et al. 1992). 
Again, Navarro and co-workers (1998) found that N-cadherin is present throughout the 
membrane, while VE-cadherin localises at cell-cell contacts (Navarro, Ruco et al. 1998). 
Work by this group also found that similar amounts of α- and β- catenins and plakoglobin 
(γ-catenin) associate with VE- and N-cadherin, but that p120 catenin shows a preference 
for the VE-cadherin complex (Navarro, Ruco et al. 1998). As mentioned earlier, Kondapalli 
and co-workers  (2004) showed an interaction between the HCAEC VE-cadherin complex 
and p120 catenin (Kondapalli, Flozak et al. 2004). Further work by Navarro et al. (1998), 
however, identified that the dominance of VE-cadherin over N-cadherin at sites of cell-cell 
contact was not a result of a defect in N-cadherins’ ability to associate with catenins 
(Navarro, Ruco et al. 1998). Moreover, a loss of adhesive ability of N-cadherin and a higher 
degree of tyrosine phosphorylation (known to weaken adherens junctions) were also ruled 
out, indeed Navrarro et al. (1998) found VE-cadherin to display a higher degree of 
phosphorylation than N-cadherin (Navarro, Ruco et al. 1998). Ultimately, the short Arg621-
Pro702 sequence in the VE-cadherin cytoplasmic tail was found to be required, and 
sufficient, for N-cadherin exclusion from sites of cell-cell contact. The authors hypothesised 
the need for VE-cadherin dominance at cell-cell contacts to prevent undesired signalling 
through N-cadherin during formation of vascular structures. A direct result of the dominant 
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nature of VE-cadherin in endothelial cells is that it is this junctional protein that primarily 
constitutes the homotypic interactions between adjacent cells. As such, N-cadherin is able 
to interact with N-cadherin expressed on alternative cell types not expressing the 
endothelial-specific VE-cadherin, thereby allowing a direct interaction between endothelial 
cells and smooth muscle cells of the vasculature (Bazzoni and Dejana 2004, Sabatini, Zhang 
et al. 2008). The distribution of N-cadherin to restricted sections of the membrane of 
HCAECs (Figure 4.14A) may reflect this need to interact with other vascular cells distributed 
in adjacent layers of the vessel wall. Moreover, the accumulations of N-cadherin that we 
observed near the membrane of HCAECs (Figure 4.14B) are potentially a result of this 
competition between VE-cadherin and N-cadherin for membrane space.  
  
4.4.12 - N -cadherin in HCASMCs 
HCASMCs were found to express N-cadherin, as shown by preliminary Western blot and 
immunocytochemistry experiments (Figures 4.13 & 4.15). By immunocytochemistry, N-
cadherin was found to be expressed as small aggregations throughout the cell and as small 
segments of membrane staining (Figure 4.15). Similar to that observed in HCAECS, N-
cadherin in HCASMCS also appeared to show membrane expression at one particular site of 
the cell (Figure 4.15B). Work by Hatta and co-workers (1987) detailed the transient 
expression of N-cadherin in smooth muscle cells during development, unlike that observed 
in endothelial cells (Hatta, Takagi et al. 1987). The distribution pattern of N-cadherin in 
cultured cells was found to be similar to that displayed in vivo (Navarro, Ruco et al. 1998). 
Furthermore, Gilbertson-Beadling and co-workers (1993) have shown that cultured 
endothelial cells can bind vascular smooth muscle cells in an N-cadherin-dependent 
manner in vitro (Gilbertson-Beadling and Fisher 1993).  
In conclusion, preliminary experiments identified both VE-cadherin and N-cadherin in 
cultured HCAECs. VE-cadherin was primarily localised to sites of cell-cell contact as 
discontinuous patches, while N-cadherin was distributed across the cell membrane. Our 
data points towards a key role for VE-cadherin in HCAEC-HCAEC interaction. In addition, 
HCASMCs were also found to express N-cadherin. This junctional protein was expressed at 
the membrane as small segments, favouring one border of the cell, highlighting N-cadherin 
as a potential key player in HCAEC-HCASMC adhesion.  
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4.4.13 - Connexin and Cadherin Co-localisation Discussion 
Distinct areas of co-localisation were identified between VE-cadherin and Connexins 37, 40 
and 43 in HCAECs. During preliminary investigations, VE-cadherin and Cx37 showed clear 
areas of overlap at the cell membrane, however, areas of membranous Cx37 devoid of VE-
cadherin expression were detected (Figures 4.16A & 4.16B). Overlap between VE-cadherin 
and Cx40 distribution was evident but was not observed in all HCAECs imaged (Figure 
4.17C), and VE-cadherin co-localisation with Cx43 was restricted to isolated sections of the 
membrane (Figure 4.18C). Co-localisation between N-cadherin and connexins 37, 40 and 43 
was also examined. No overlap between N-cadherin and Cx37 (Figure 4.20C) or Cx40 was 
detected (Figure 4.21C) during preliminary experiments. During similar preliminary 
investigations, isolated areas of overlap were detected between N-cadherin and Cx43 in a 
subset of HCAECs imaged (Figure 4.22C).  
Co-localisation between cadherins and connexins is a direct result of the requirement for 
adherens junctions as a precursor to gap junction formation. As previously detailed, 
formation of nascent gap junctions requires a reduced intercellular distance between 
plasma membranes of adjacent cells brought about by the establishment of cell-cell 
contacts mediated by adherens junctions (Fujimoto, Nagafuchi et al. 1997). It is generally 
accepted that connexons are delivered to the plasma membrane by post-Golgi carriers at 
random and migrate laterally in the plane of the membrane bilayer (Loewenstein 1981, 
Thomas, Jordan et al. 2005). On approaching a region of cell-cell contact these channel 
precursors are able to associate with connexins on the adjacent cell membrane and 
ultimately form functional gap junctions. As a result, a diffuse cell-surface rim of connexin 
protein can be imaged prior to the appearance of punctate gap junctions (Thomas, Jordan 
et al. 2005). As these sites of cell-cell contacts are directly mediated by adherens junctions, 
formed from cadherins, the accumulation of connexin proteins at membrane regions 
expressing cadherins is expected. This self-trap model of gap junction formation allows 
rapid accumulation of connexins at sites of cell-cell contact (10-1 – 10-3 seconds) 
(Loewenstein 1981). Furthermore, the bending moments of the membrane are 
hypothesised to prevent connexins from migrating laterally once a cell-cell contact is 
established (Loewenstein 1981).  An alternative hypothesis on connexin distribution at the 
membrane is offered by Levine et al. (1993) who suggest that once connexin proteins are 
inserted into the membrane their movement is directed by electrophoresis and as such is 
modulated by membrane potential (Levine, Werner et al. 1993). Independent of the 
process through which connexins migrate in the plasma membrane, these proteins can only 
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dock with adjacent connexin proteins on opposing cells, and thus form functional gap 
junctions, when the intervening distance is reduced by the formation of adherens 
junctions.  
Further evidence for the requirement for adherens junctions prior to gap junction 
formation comes from the formation of the compacted embryo.  Connexins are first 
identified at the 4-cell stage  (Nishi, Kumar et al. 1991, Fléchon, Degrouard et al. 2004)  but 
these exist only as cytoplasmic stores (Musil and Goodenough 1993). Functional gap 
junction formation and Lucifer yellow dye transfer between blastomeres does not occur 
until the 8-cell stage when the embryo has undergone compaction (McLachlin, Caveney et 
al. 1983, Fléchon, Degrouard et al. 2004). Removal of extracellular calcium causes loss of 
the compacted shape of the embryo (Aghion, Gueth-Hallonet et al. 1994) and a loss of 
intercellular coupling (Goodall 1986), and so cadherins were identified as the components 
responsible for the formation of the compacted embryo, and thus gap junction formation. 
Further work by Aghion et al. (1994), and others, identified that E-cadherin is 
phosphorylated in the mouse embryo at the 8-cell stage, just prior to compaction (Sefton, 
Johnson et al. 1992, Aghion, Gueth-Hallonet et al. 1994), and as such this cadherin was 
hypothesised to be responsible for compaction and the initiation of gap junctional 
intercellular communication (GJIC).  
The calcium-dependent nature of adherens junctions provides further evidence for the 
close association between cadherins and connexins. It is well-established that blocking of 
calcium-dependent adhesion prevents the formation of new gap junction channels (Atsumi 
and Takeichi 1980, Davidson, Baumgarten et al. 1984, Kanno, Sasaki et al. 1984, Jongen, 
Fitzgerald et al. 1991) and that GJIC is increased under elevated levels of extracellular 
calcium (Jongen, Fitzgerald et al. 1991). In addition to calcium removal, addition of 
fragments against cadherins also disrupts cadherin-cadherin interactions and results in 
reduced GJIC as detected by dye transfer (Kanno, Sasaki et al. 1984, Meyer, Laird et al. 
1992). Whether the antibody fragments prevent the acquisition of the close membrane-
membrane association required for adherens junction and gap junction formation, or 
whether the Fab fragments prevent transmembrane signalling that allows junction 
formation, is unknown. Interestingly, Fab fragments of antibodies for extracellular domains 
of Cx43 have also been found to block adherens junction formation in re-aggregating 
Novikoff hepatoma cells (Meyer, Laird et al. 1992), further highlighting the close interaction 
between cadherins and connexins. Transfection of L-CAM (E-cadherin) cDNA into mouse 
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sarcoma s180 fibroblasts, which are not normally capable of GJIC, results in the formation 
of functional gap junctions (Mege, Matsuzaki et al. 1988, Musil and Goodenough 1991), 
again highlighting the requirement for adherens junctions prior to gap junction formation. 
An additional explanation for the requirement for adherens junction formation prior to gap 
junction formation is the need for cell recognition. Gap junctions are required for the 
correct progression of development and as such adherens junction formation ensures that 
the correct cells are interacting, thereby regulating this process  (Jongen, Fitzgerald et al. 
1991).  
Direct association between cadherins and connexins has been detected through interaction 
with the cadherin-associated protein β-catenin (Ai, Fischer et al. 2000). The short 
intracellular tail of VE-cadherin is linked to β-catenin in addition to other Armadillo family 
proteins (Navarro, Caveda et al. 1995, Navarro, Ruco et al. 1998, Ferber, Yaen et al. 2002, 
Taddei, Giampietro et al. 2008). Cx43 has also been found to bind to β-catenin in cultured 
neonatal rat cardiomyocytes, indeed association with this protein promotes transcription 
of Cx43 (Ai, Fischer et al. 2000). In addition, VE-cadherin also associates with α-catenin 
through its interaction with β-catenin (Breviario, Caveda et al. 1995) and co-localisation of 
connexins 26, 32 and 43 with this protein further highlights the close association between 
connexins and cadherins (Fujimoto, Nagafuchi et al. 1997, Wu, Tsai et al. 2003). Literature 
on the direct co-localisation of cadherins with connexins is limited, however, co-localisation 
of  N-cadherin with Cx43, and E-cadherin with Cx26 and Cx32, have been shown through 
immunocytochemical analysis of mouse neural crest cells and immunohistochemistry of 
mouse liver, respectively (Fujimoto, Nagafuchi et al. 1997, Xu, Li et al. 2001). Although the 
literature primarily details co-localisation between N-cadherin and connexins, our 
extensive VE-cadherin staining at the membrane limits the capacity for N-cadherin 
membrane association and as such N-cadherin/ connexin co-localisation at the membrane 
is restricted in our cells. 
 
4.4.14 – Concluding remarks 
Preliminary experiments identified connexins 37, 40 and 43 in HCAECs and HCASMCs. In 
addition, both VE-cadherin and N-cadherin were identified in HCAECs, and N-cadherin 
alone in HCASMCs. Distinct co-localisation between VE-cadherin and Cx37 at the 
membrane was identified in HCAECS during preliminary experiments, suggesting a close 
association between these two junctional components.  
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Chapter 5: 
Control of Cadherin and Connexin Distribution  
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Aims of this chapter:  
 
 To examine the effect of cadherin disruption (through pre- incubation with the 
anti-VE-cadherin  primary antibody and EGTA calcium chelation) on cadherin and 
connexin distribution in HCAECs 
 To determine the expression profile of Epac1 and Epac 2 in HCAECs 
 To examine the effect of Epac activation on connexin and cadherin distribution in 
HCAECs 
 To examine the effect of inhibition of Epac (through siRNA transfection and Epac 
antagonists ESI-09 and HJC0197) on connexin and cadherin distribution in HCAECs 
 
 
Key findings of this chapter: 
 
 Cadherin disruption results in a change in HCAEC morphology from a flattened 
sheet to isolated colonies of rounded cells  
 Cadherin disruption triggers re-distribution of VE-cadherin and Cx37 to restricted 
points of the HCAEC membrane   
 VE-cadherin is required for the formation of new adherens junctions and gap 
junctions at sites of cell-cell contact in HCAECs, and for the flat sheet-like 
morphology observed under control conditions 
 Epac1 is expressed by HCAECs 
 Epac activation promotes its relocation to the membrane within 30 minutes  
 Epac activation triggers VE-cadherin and Cx37 re-distribution to the membrane, 
significantly enhancing their co-localisation  
 The enhanced co-localisation between VE-cadherin and Cx37 mediated by Epac 
activation is completely blocked by both transfection with Epac1 siRNA, and 
incubation with the Epac antagonists ESI-09 and HJC0197 
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5.1 - Introduction  
5.1.1 – Disruption of the endothelial barrier 
The importance of cell-cell junctions, particularly cadherins, in maintenance of the 
endothelial barrier has previously been detailed (Section 1.7 – Adherens junctions and 
Section 4.1.2 - Cadherins). Factors that disrupt the distribution of cadherins and connexins 
therefore provide an insight into the mechanisms regulating the maintenance of the 
endothelial barrier.  Historically, disruption of adherens junctions has typically been carried 
out by one of two methods: (i) blocking specific cadherin interactions by pre-incubation 
with the antibody Fab fragments against the required cadherin (Kanno, Sasaki et al. 1984, 
Meyer, Laird et al. 1992), or (ii) removal of extracellular calcium (Berry and Friend 1969, 
Volberg, Geiger et al. 1986, Volk, Volberg et al. 1990, Kartenbeck, Schmelz et al. 1991, 
Cullere, Shaw et al. 2005). As such, our experiments involved pre-incubation with the anti-
VE-cadherin primary antibody, and/or removal of extracellular calcium by EGTA treatment.  
 
5.1.2 – Enhancement of the endothelial barrier 
cAMP has long been known to act as a regulator of the endothelial barrier, and an increase 
in its intracellular concentration evokes a reduction in endothelial permeability (Section 
1.11). As discussed in Chapter 1, Epac is a novel cAMP effector that is able to mediate 
endothelial barrier stabilisation. As such, the distribution of Epac and the effect of 
activation and inhibition of this Rap GEF was examined using the Epac-specific agonist 8-
pCPT-AM (8-pCPT), and Epac antagonists HJC0197 and ESI-09, respectively.  
 
5.1.3 – Gap junction turnover 
High-resolution fluorescence microscopy, in combination with time-lapse imaging, has 
revealed that gap junctional plaques are highly dynamic structures (Falk 2000, Jordan, 
Chodock et al. 2001, Martin, Blundell et al. 2001). Indeed, connexins display a short half-life 
of 1-3 hours in many cell cultures (Musil, Beyer et al. 1990, Laird, Puranam et al. 1991). This 
is a very rapid turnover when compared to other membrane proteins, the adult 
acetylcholine receptor, for example, has a half-life of approximately 10 days (Salpeter 
1999). It should be noted, however, that not all connexins are degraded so rapidly; Cx46 in 
the lens has a half-life of approximately 1 day (Jiang, Paul et al. 1993). The turnover of 
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connexin expression at the membrane is regulated by both proteosomal and lysosomal 
degradation, as evidenced through the use of proteosomal inhibitors (ALLN, MG132 or 
lactacystin) and lysosomal inhibitors (leupeptin and E-64) (Laing, Tadros et al. 1997), and is 
ubiquitin-dependent (Rütz and Hülser 2001, Somekawa, Fukuhara et al. 2005). During 
endocytosis, both membranes of the GJ complex are internalised into one of the cells, 
forming a double-membrane vacuole termed a connexosome or annular gap junction 
(Jordan, Chodock et al. 2001, Segretain and Falk 2004). Caveolins have been linked to the 
removal of connexins from the plasma membrane, particularly as connexins have been 
shown to interact with caveolin-1, a component of caveolae (Schubert, Schubert et al. 
2002). The pathway of connexin degradation involves an enzymatic cascade during which 
multiple ubiquitin molecules are attached to the connexin (Schwartz and Ciechanover 
1999). The ubiquitinated connexin protein is then degraded by the 26S proteosome 
complex. 
 
5.1.4 - Epac distribution 
Epac1 is widely distributed and was identified in all human tissues tested (De Rooij, 
Zwartkruis et al. 1998), with particular enrichment in the heart and kidney. Epac2, 
however, shows a more restricted distribution with predominant expression in the brain 
(Kawasaki, Springett et al. 1998). These expression profiles are reflected in the implication 
of Epac1 in cardiac hypertrophy (Morel, Marcantoni et al. 2005), and Epac2 in autism 
(Woolfrey, Srivastava et al. 2009, Penzes, Woolfrey et al. 2011). 
 
5.1.5 – Epac is a GEF for Rap1  
Ras proximate 1 (Rap1), a member of the Ras family of proteins, is a small G-protein that 
takes an inactive GDP-bound or an active GTP-bound state. GEFs, such as Epac, dissociate 
the bound GDP from Rap, allowing the GTP in the cytosol to bind and activate Rap (Bos, De 
Rooij et al. 2001). GTPase-activating proteins (GAPs), on the other hand, induce the 
hydrolysis of the bound GTP to revert Rap to its inactive GDP-bound form. Two isoforms of 
Rap1 exist, Rap1a and Rap1b, and these share 95% amino acid similarity (Klinz, Seifert et al. 
1992). Similarly, Rap1 and Rap2 share 70% homology and differ by only one residue in their 
effector domains (De Rooij, Rehmann et al. 2000). Three second messengers are known to 
activate Rap1; calcium, diacylglycerol (DAG) and cAMP (Bos, De Rooij et al. 2001, Guo, 
Kumahara et al. 2001, Schmitt and Stork 2001). In human platelets, α-thrombin stimulates 
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a rise in intracellular calcium that results in increased Rap1 activation within 30 seconds of 
application, and this increase in Rap1 activity is inhibited by addition of the calcium 
chelating agent BAPTA-AM (Franke, Akkerman et al. 1997). A combination of factors can 
also be responsible for an increase in Rap1 activation, as is seen in human neutrophils 
(M'Rabet, Coffer et al. 1998). In these cells, both the calcium ionophore ionomycin and the 
DAG mimetic 12,13-tetradecanoyl phorbol acetate (TPA) induced an increase in Rap1 
activation (M'Rabet, Coffer et al. 1998). Furthermore, Zwartkruis and co-workers (1998) 
found fibroblasts to increase Rap1 activation as a result of either a rise in intracellular 
calcium, release of DAG, or an increase in cAMP synthesis. Rap1 has previously been shown 
to be closely associated with cellular membranes (Bos, De Rooij et al. 2001, Bivona, Wiener 
et al. 2004). Unlike other Ras proteins which are primarily identified at the plasma 
membrane, Rap1 is typically localised to the Golgi complex, and has been shown to co-
localise with markers for the medial cisternae of the golgi apparatus (Beranger, Goud et al. 
1991).  
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Figure 5.1: Activation of Epac 
The above diagram gives a brief overview of the activation of Epac. In its inactive state, 
the regulatory domain of Epac (blue) inhibits the guanine exchange activity of the 
catacyltic domain of Epac (green). Adenylate cyclases (AC, yellow) elevate intracellular 
concentrations of cAMP (purple). cAMP subsequently binds to the regulatory domain of 
Epac (blue), dissociating it from the catalytic domain (green) and therefore preventing 
auto-inhibition of the catalytic domain. Once activated, Epac can then bind to inactive 
GDP-bound Rap (red and grey) and promote the exchange of its GDP for GTP, thereby 
activating Rap (red and orange). Active Rap then has numerous downstream effects, 
primarily involving modulation of the actin cytoskeleton. This figure is adapted from 
Figure 1 of “cAMP signalling in the vasculature: the role of Epac (exchange protein 
directly activated by cAMP)”(Roberts and Dart 2014).  
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5.1.6 - Additional Rap1 GEFs 
The role of Epac as a GEF for Rap1 has been previously detailed (above). Other proteins 
also possess the ability to convert GDP-bound Rap to its GTP-bound form and thereby 
activate this protein. Crk SH3-domain-binding guanine-nucleotide releasing factor (C3G) 
was the first RapGEF identified with the characteristic CDC25 homology domain and Ras 
exchange motif (REM) (Tanaka et al. 1994, Gotoh, Hattori et al. 1995). C3G is cAMP/PKA 
dependent and is targeted to the plasma membrane on activation (Okada et al. 1998, Wang 
et al. 2006). Interestingly, C3G has been shown to directly interact with E-cadherin during 
the first stages of junction formation, prior to formation of a mature AJ (Hogan et al. 2004). 
Indeed, inhibition of C3G prevents translocation of E-cadherin to sites of cell-cell contact, 
therefore indicating a role of C3G in the recruitment of this cadherin to cell junctions.  
The calcium and DAG-regulated guanine nucleotide exchange factors (CalDAG-GEFs/CD-
GEFs) activate Rap1 and Rap2, and as their name suggests bind, and are activated by, both 
calcium and DAG (Kawasaki, Springett et al. 1998, Yamashita, Mochizuki et al. 2000). 
CalDAG-GEFI can activate Rap1A (Kawasaki, Springett et al. 1998, Yamashita, Mochizuki et 
al. 2000), while CalDAG-GEFIII can activate both Rap1A and Rap2A (Yamashita, Mochizuki 
et al. 2000). On addition of the DAG mimetic TPA, CalDAG-GEFIII translocates to the plasma 
membrane but is insensitive to increased levels of calcium, potentially suggesting CalDAG-
GEFI as the primary regulator of Rap1 activation by calcium and CalDAG-GEFIII as the main 
regulator of Rap1 activation by DAG (Bos, De Rooij et al. 2001).  
PDZ-GEFs are ubiquitously expressed activators of Rap (De Rooij, Boenink et al. 1999). In 
addition to the REM and catalytic GEF domains expressed by all Rap-GEFs, PDZ-GEFs posess 
an additional 2 regulatory domains(De Rooij, Boenink et al. 1999). One of these regulatory 
domains is the PDZ domain and the second is a structure that is related to the cAMP-
binding domains of Epac and PKA (RCBD)(De Rooij, Boenink et al. 1999). As occurs in Epac, 
the RCBD serves as a negative regulatory domain for PDZ-GEF catalytic activity, and  PDZ-
GEFs are capable of activating Rap1 and Rap2 but not R-ras (De Rooij, Boenink et al. 1999).  
 
Phospholipase C ε (PLCε) is an additional Rap1-GEF (Jin, Satoh et al. 2001), and more detail 
on this GEF will be discussed later in this section as PLC ε is also activated by Rap (see 
Section 5.1.10).  
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5.1.7 - Rap1 GAPs  
GTPase-activating proteins (GAPs) hydrolyse the bound GTP to revert Rap to its inactive 
GDP-bound form. Rap1 has low intrinsic GTPase activity due to its lack of a conserved 
glutamine residue at position 61 (Polakis, Rubinfeld et al. 1991), and as such GAPs are 
essential to reverse the activity of GEFs. Rap1GAP is a ubiquitously expressed GAP, and the 
first Rap1-specific GAP to be identified (Polakis, Rubinfeld et al. 1992). This GAP suppresses 
both endogenous Rap1 activity and db-cAMP-induced Rap1 activity (Somekawa, Fukuhara 
et al. 2005). In addition to GAPs, Rap1 activity is also suppressed by phosphodiesterases 
(PDEs) which rapidly metabolise cAMP to AMP.  
 
5.1.8 - Rap1 activity 
Rap1 is an important regulator of the actin cytoskeleton (Yamamoto, Harada et al. 1999, 
Boettner, Govek et al. 2000, Bos, De Rooij et al. 2001, Cullere, Shaw et al. 2005). Rap1 
interacts with a number of proteins, including the cytoskeletal anchoring protein AF-6, and 
the GTPase Rac. AF-6 is capable of binding actin, the actin cytoskeleton regulator Profilin, 
and the tight junctional component ZO-1 (Section 1.8 - Tight junctions)(Yamamoto, Harada 
et al. 1999, Boettner, Govek et al. 2000). In addition, AF-6 also contains two N-terminal 
Ras-binding domains (RBDs), one of which binds active Ras and Rap1 with high affinity 
(Linnemann, Geyer et al. 1999). These RBDs allow the formation of a complex between 
Rap1 and cytoskeletal components. Evidence of such a complex comes from the co-
localisation of AF-6 and Rap1 at adherens junctions (Boettner, Govek et al. 2000). 
Furthermore, increased cAMP and Epac activity, both known to activate Rap1, has 
previously been shown to increase the continuity of AF-6 staining along cell-cell contacts 
(Cullere, Shaw et al. 2005).  
 
5.1.9 – Rap1 activates Rac through Tiam1 and Vav2 
Rac is part of the Rho family of small GTPases and is activated by Rap1, as evidenced by 
reduced Rac activation on expression of the Rap inhibitor Rap1GAP (Maillet, Robert et al. 
2003). Rap1-dependent phosphorylation of the Rac1-specific GEFs Tiam1 and Vav2 is 
required for the activation of Rac1 (Lampugnani, Zanetti et al. 2002, Birukova, 
Zagranichnaya et al. 2007, Birukova, Burdette et al. 2010, Lampugnani, Orsenigo et al. 
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2010). Active Rac1 stimulates the actin-related protein (arp) 2/3 complex (Weed, Karginov 
et al. 2000, Head, Jiang et al. 2003) through the  Wiskott-Aldrich syndrome protein(WASP), 
an example of which is Neural-WASP (N-WASP) (Takenawa and Miki 2001). In its inactive 
state, the region of N-WASP that binds the Arp2/3 complex, the VCA (verprolin-homology 
(V) domain, cofilin-homology (C) domain and acidic (A) domain) region at the C-terminus, is 
masked (Takenawa and Miki 2001). Co-operative binding of Cdc42 (an additional Rho 
GTPase) and phosphatidylinositol 4,5-biphosphate (PtdIns (4,5)P2  or PIP2) unmasks the VCA 
region and allows N-WASP to bind to, and activate, the Arp2/3 complex (Takenawa and 
Miki 2001). In addition, the WASP-family verprolin-homologous (WAVE) proteins, 
specifically WAVE2, also mediate Rac-induced activation of the Arp2/3 complex (Takenawa 
and Miki 2001). Both N-WASP and WAVE2 are expressed in vascular endothelial cells 
(Yamazaki, Suetsugu et al. 2003, Rajput, Kini et al. 2013). Once activated, the Arp2/3 
complex initiates actin nucleation (Machesky and Hall 1997) and cortactin is rapidly 
recruited to these nucleation sites where it stabilises the newly-generated cortical actin 
fibres (Weaver et al. 2001, Ciano, Nie et al. 2002). Rac-induced recruitment of cortactin is 
dependent on its direct interaction with both F-actin, via its R region, and the Arp2/3 
complex, via its Arp2/3 –binding N-terminal acidic tail (Weed, Karginov et al. 2000, Uruno, 
Liu et al. 2001, Head, Jiang et al. 2003). Indeed, the N-terminal domain of cortactin is 
responsible for the targeting of this protein to actin-enriched patches (Uruno, Liu et al. 
2001). An additional pathway through which Rac promotes increased actin filament 
assembly, is through the activation of phosphatidylinositol-4-phosphate 5-kinase (PIP5K) 
(Janmey and Stossel 1987, Tolias, Cantley et al. 1995, Bishop and Hall 2000). Rac activates 
this kinase, directly promoting the increased formation of PIP2 from phosphatidylinositol-4-
phosphate (PIP4)(Janmey and Stossel 1987). PIP2 is then available to bind to actin capping 
proteins such as Gelsolin, inducing their release from the actin-filament barbed ends, and 
promoting actin polymerisation (Janmey and Stossel 1987). The elevated levels of PIP2 also 
enhance the Cdc42/ PIP2-mediated activation of the Arp2/3 complex, further promoting 
actin polymerisation. Ultimately, the Rap1/Rac pathway results in an enhanced cortical 
actin rim and a decrease in actin stress fibres (Albertinazzi, Cattelino et al. 1999, 
Somekawa, Fukuhara et al. 2005). These alterations to the cytoskeleton have been shown 
to be blocked by Epac1 siRNA, inhibition of Rap1 and inhibition of Rac1 (Kooistra, Corada et 
al. 2005, Baumer et al. 2009). 
There is some controversy surrounding the role of tyrosine phosphorylation on the 
recruitment of cortactin. Some groups suggest that protein kinase C (PKC) -mediated 
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phosphorylation of cortactin at Tyr421 results in its translocation to the periphery (Van 
Damme, Brok et al. 1997, Rossé, Lodillinsky et al. 2014), however, Weed et al. (1998) were 
unable to detect changes in the level of cortactin tyrosine phosphorylation on Rac-
mediated cortactin re-distribution (Weed, Du et al. 1998). 
Rac also stabilises the endothelial barrier through the inhibition of RhoA-induced 
contraction. Rac1 inhibits RhoA via activation of the RhoGAP p190, thereby preventing MLC 
phosphorylation, actin-myosin-mediated contraction, and increased paracellular 
permeability (Mammoto, Parikh et al. 2007).  
 
5.1.10 – Rap activates Phospholipase C 
In addition to signalling through Rac, increasing evidence suggests that Rap, particularly 
Rap2b, also mediates the activity of a specific phospholipase C (PLC) isoform, PLCε (Bos, De 
Rooij et al. 2001, Schmidt, Evellin et al. 2001, Evellin, Nolte et al. 2002, Williams, Sarkar et 
al. 2008, Ravikumar, Sarkar et al. 2010, Harris and Rubinsztein 2012). PLC isoforms are 
classified into 7 groups; PLCα, PLCβ, PLCγ, PLCδ, PLCε, PLCξ and PLCη (Schmidt, Evellin et al. 
2001, Song, Hu et al. 2001, Evellin, Nolte et al. 2002). All PLC isoforms contain two regions 
of high sequence homology and these form the catalytic domain responsible for the 
hydrolysis of PIP2 to form inositol-1,4,5-trisphosphate (IP3) and DAG (Schmidt, Evellin et al. 
2001, Song, Hu et al. 2001). In addition to this catalytic domain and a C2 domain, all PLC 
isoforms, except PLCε, also contain a PH domain and an EF-hand domain (Song, Hu et al. 
2001). PLCε shows further variation in its expression of two C-terminal Ras-associating (RA) 
domains and a Ras-GEF domain. PLCε can therefore bind, activate, and be activated by, 
Ras-like GTPases (Kelley, Reks et al. 2001, Song, Hu et al. 2001). The RA2 domain of PLCε 
specifically binds the GTP-bound forms of both Ha-Ras and Rap but not the GDP-bound 
forms of these proteins, or R-Ras, RaIA, RhoA, Rac1 or Cdc42 (Kelley, Reks et al. 2001, Song, 
Hu et al. 2001). Despite lacking the EF-hand domains present in all other PLC isoforms, PLCε 
activity is calcium-dependent, with maximal activity at 10 µM calcium (Song, Hu et al. 
2001). The activation of PLC ε by Rap2b has been implicated in the regulation of autophagy 
(Williams, Sarkar et al. 2008, Ravikumar, Sarkar et al. 2010, Harris and Rubinsztein 2012). 
Willaims et al. (2008) identified that forskolin application activated the Rap2b/PLCε 
pathway, increasing intracellular calcium and activating Ca2+ cysteine proteases (calpains), a 
necessary step in the inhibition of autophagy. This pathway, which was also induced by the 
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Epac-selective agonist 8-pCPT, was successfully blocked by dominant-negative Rap2b, 
supporting the hypothesis of direct Rap2b/ PLC interaction (Williams, Sarkar et al. 2008). 
Furthermore, the nature of the intracellular calcium release was elucidated through the 
over-expression of cytosolic IP3 kinase A, which blocked the IP3-mediated release of calcium 
from the ER, again implicating PLC in this pathway (Williams, Sarkar et al. 2008). The role of 
Epac in this pathway is supported by work published by Schmidt et al. (2001) which shows 
that application of an adenylate cyclase inhibitor resulted in a reduction in forskolin-
induced PLC activity by 50-70%, whilst the PKA inhibitor H89 had no effect (Schmidt, Evellin 
et al. 2001). In addition, this group also found that over-expression of Epac1 resulted in an 
increase in forskolin-induced PLC activation by 40-50%, and that inactivation of Rap, via 
application of the clostridium difficile toxin B-1470, decreased forskolin-induced PLC 
activation by approximately 70% (Schmidt, Evellin et al. 2001). In addition to Rap2b, PLCε 
has also been shown to interact with Rap1A via its RA2 domain (Jin, Satoh et al. 2001, 
Kelley, Reks et al. 2001, Song, Hu et al. 2001, Song, Satoh et al. 2002, Edamatsu, Takenaka 
et al. 2011). Furthermore, as previously mentioned, PLCε also has GEF activity for Rap1 (Jin, 
Satoh et al. 2001), thereby acting as a positive-feedback loop. Activation of PLCε results in 
its translocation to specific subcellular locations (Song, Hu et al. 2001). This group identified 
that application of epidermal growth factor (EGF) to COS-7 cells resulted in an increase in 
the association of PLCε with the plasma membrane within 5 minutes, a re-distribution that 
was blocked by addition of the dominant-negative form of Ha-Ras (Song, Hu et al. 2001). 
Interestingly, an enrichment of green fluorescent protein-tagged PLCε was also identified at 
the perinuclear region on EGF application, and this PLCε was found to co-localise with 
constitutively active Rap1A (Rap1AG12V) (Song, Hu et al. 2001). Song et al. hypothesised that 
this Rap1A-mediated perinuclear re-distribution of PLCε may play a role in the regulation of 
the Golgi complex. Indeed, both Rap1A and PKC (a downstream PLC effector, detailed later) 
have both been found at the Golgi complex (Beranger, Goud et al. 1991, De Matteis, Santini 
et al. 1993). PLCε has been found to be widely distributed, with particularly high expression 
in brain, lung, heart and skeletal muscle tissues (Kelley, Reks et al. 2001, Lopez, Mak et al. 
2001, Sorli, Bunney et al. 2005). Although Lo Vasco et al. (2011) failed to identify PLCε 
expression in HUVECs (Lo Vasco, Pacini et al. 2011), this PLC isoform has been detected in 
endothelial cells of other vascular beds (Schmidt, Evellin et al. 2001, Ruisanchez, Dancs et 
al. 2014).  
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5.1.11 – The role of Protein Kinase C in the Epac pathway 
Protein Kinase C (PKC) is part of the serine-threonine family of kinases and is subdivided 
into classical PKCs (cPKCs), novel PKCs (nPKCs) and atypical PKCs (aPKCs) (Newton and 
Messing 2010). cPKCs are activated by calcium and DAG, nPKCs are activated by DAG but 
not calcium, and aPKCs are activated by lipids and by phosphorylation (Newton and 
Messing 2010). PKCε is classified as an nPKC due to its direct activation by DAG, and this 
PKC isoform has been shown to play a role in the downstream signalling of PLCε (Schmidt, 
Evellin et al. 2001, Bos 2003, Oestreich, Malik et al. 2009). Indeed, Oestreich et al. (2009) 
identified PKCε as the major isoform involved in Epac/ PLCε responses. Immature, un-
phosphorylated PKCε is associated with the anchoring protein CG-NAP (centrosome and 
Golgi localized PKN-associated protein), and is identified at the Golgi apparatus (Takahashi, 
Mukai et al. 2000). Following phosphorylation and activation, PKCε translocates to specific 
subcellular locations through its interaction with additional anchoring proteins. In human 
glioma cells, for example, active PKCε has been shown to interact with the receptor for 
activated C-kinase (RACK1) which results in the regulation of integrin-mediated cell 
adhesions (Besson, Wilson et al. 2002). PKCε has been identified in the endothelium of 
bovine aorta (Rask-Madsen and King 2008) and coronary veins (Monti, Donnini et al. 2010, 
Monti, Donnini et al. 2013). 
 
5.2 - Methods 
5.2.1 – Direct blocking of cadherin-cadherin interactions  
Pre-incubation of confluent HCAECs with 10 µg/ml of the anti-VE-cadherin primary 
antibody (BD Biosciences, USA) in fully-supplemented HCAEC media acted as a block to the 
formation of VE-cadherin-mediated adherens junctions (AJs). Immunocytochemistry 
experiments were performed as previously detailed under “2.2.3.1.2 - fixation, quenching 
and permeabilisation of cultured cells”. The fixed HCAECs were examined for VE-cadherin 
distribution (antibody dilutions; x200 primary antibodies, x500 secondary antibodies). The 
protocol used was adapted from ones used by Abraham et al. and Corada et al. (Corada, 
Liao et al. 2001, Abraham, Yeo et al. 2009). To ensure that other components added in 
combination with the commercial antibody, such as sodium azide, were not influencing the 
distribution of VE-cadherin, the anti-VE-cadherin primary antibody was heat-inactivated by 
boiling for 1 hour prior to incubation. HCAECs pre-incubated with both the intact anti-VE-
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cadherin antibody and the heat-inactivated anti-VE-cadherin antibody were examined for 
VE-cadherin distribution. The distribution of Cx37, Cx40 and Cx43 was also identified in 
HCAECs pre-treated with the intact anti-VE-cadherin antibody. 
 
5.2.2 – Cadherin disruption through removal of extracellular calcium  
The calcium-dependent nature of cadherin interaction and AJ formation has been detailed 
previously (Section 1.7 – Adherens junctions). The effect of disruption of both homotypic 
(VE-cadherin-VE-cadherin) and the less frequent heterotypic (VE-cadherin-N-cadherin) AJs 
was examined through treatment of HCAECs with EGTA. Confluent HCAECs were switched 
to media containing 5 mM EGTA for 30 minutes at 37°C/ 5% CO2. Following this treatment, 
the cells were either washed twice with fully-supplemented media and re-incubated for 1-4 
hours and fixed, or fixed immediately without calcium restoration. The fixed cells were 
stained for VE-cadherin, N-cadherin and connexins 37, 40 and 43, using an AF488-
conjugated secondary antibody (Antibody dilutions; x200 primary antibodies, x500 
secondary antibodies).  
 
5.2.3 – Examination of Epac distribution in HCAECs 
Two types of commercially available anti-Epac1 antibodies were used. The Cell Signalling 
anti-Epac1 monoclonal mouse primary antibody (Cat no. 4155S) was used in Western blot 
(Price, Hajdo-Milasinovic et al. 2004, Yan, Mei et al. 2013) while the Santa Cruz anti-Epac1 
monoclonal mouse primary antibody (Cat no. Sc-28366) was used for both 
immunocytochemistry and Western blot (Banales, Masyuk et al. 2009, Purves, Kamishima 
et al. 2009).  
 
5.2.4 – Activation of Epac in HCAECs 
The Epac-specific agonist 8-(4-Chlorophenylthio)-2’-O-methyladenosine-3’, 5’-cyclic 
monophosphate, acetoxymethyl ester (8-pCPT, 5 µM) was used to selectively activate Epac, 
and not PKA, in HCAECs. 8-pCPT was identified as a novel Epac-selective agonist by Enserink 
et al. in 2002 (Enserink, Christensen et al. 2002). Through amino acid sequence analysis, 
this group identified that the highly-conserved glutamate residue that forms hydrogen 
bonds with the 2’-hydroxyl of the cAMP ribose group, necessary for cAMP – PKA 
interaction, is absent from the cAMP-binding domains of both Epac1 and Epac2 (high-
affinity site B).  Introduction of a 2’-methoxyl group in place of this 2’-hydroxyl group in 
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cAMP was found to specifically activate Epac and not PKA (Enserink, Christensen et al. 
2002). Indeed, this compound was found to be more efficient in its Epac activation than 
cAMP, with half-maximal Epac1 activation detected on application of 2.2 µM 8-pCPT, 
compared to 30 µM cAMP (Enserink, Christensen et al. 2002). The Epac-specific nature of 8-
pCPT was demonstrated by its inability to activate type-I and type-II holoenzymes of PKA, 
as detected by a lack of increased cAMP response element-binding (CREB) protein 
phosphorylation on 8-pCPT application, even at 100 µM (Enserink, Christensen et al. 2002). 
In addition, olfactory and pacemaker cyclic nucleotide-gated ion channels contain the 
conserved glutamate in their cAMP-binding domain and therefore, like PKA, require the 2’-
hydroxyl of the cAMP ribose group for activation (Enserink, Christensen et al. 2002). 
Furthermore, the presence of a hydrophobic pCPT substitution on 2′-O-Me-cAMP also 
provides increased membrane permeability, further enhancing the activity of this 
compound (Enserink, Christensen et al. 2002, Holz, Chepurny et al. 2008). Since its 
identification as a suitable Epac-specific agonist, 8-pCPT has been used in a variety of cell-
signalling experiments (Christensen, Selheim et al. 2003, Kang, Joseph et al. 2003, 
Rehmann, Schwede et al. 2003, Gloerich and Bos 2010).  
 
 
5.3 - Results 
 
5.3.1 – Disruption of HCAEC cadherin interactions  
 
5.3.1.1 – Incubation with the anti-VE-cadherin primary antibody 
 
To determine whether disruption of VE-cadherin interactions resulted in a re-distribution of 
cadherins and connexins, HCAECs were pre-incubated with the anti- VE-cadherin primary 
antibody (10 µg/ml) for 5 hours at 37°C/ 5% CO2. 
 
5.3.1.1.1 - VE-cadherin immunocytochemistry 
Figure 5.2 shows preliminary staining of VE-cadherin in control (Figure 5.2A), VE-cadherin 
antibody-treated (Figure 5.2B), and heat-inactivated antibody-treated HCAECs (Figure 
5.2C). Under control conditions, VE-cadherin distribution (green) in HCAECs was identified 
as diffuse staining throughout the cell, supplemented by discontinuous segments of 
membrane staining (Figure 5.2A). The morphology of the HCAECs was typical of that 
162 
 
observed in cultures at 90-100% confluence, with a single layer of cells in an almost-
continuous sheet (see Figure 3.14 in Chapter 3).  
On incubation with the anti-VE-cadherin primary antibody, the HCAECs formed small 
dispersed colonies (Figure 5.2B). The morphology changed to small rounded cells in closely-
packed clumps, and the DAPI staining showed the distance between nuclei of adjacent cells 
was reduced.  The increase in VE-cadherin signal may be a result of the additional primary 
antibody introduced to the experiment as a blocker of VE-cadherin interactions (Figure 
5.2B). Following the disruption of VE-cadherin interactions, VE-cadherin was found to 
localise to parts of the membrane, as highlighted by the white arrows in Figure 5.2B.  
When the HCAECs were incubated with the heat-inactivated anti-VE-cadherin primary 
antibody, the cell morphology was similar to that of control experiments (Figure 5.2C). Cells 
maintained a flattened appearance without isolated colonies, in contrast to those pre-
incubated with the intact primary antibody. Furthermore, the distance between the nuclei 
of adjacent cells appeared unaffected by incubation with the heat-inactivated antibody 
(Figure 5.2C). In addition, VE-cadherin was found to be distributed as discontinuous 
sections across the membrane (Figure 5.2C). As in the antibody-blocked cells, the increase 
in fluorescence may be a result of the pre-incubation with the anti-VE-cadherin primary 
antibody (Figure 5.2C).  
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Figure 5.2: Immunocytochemistry of control and intact and heat-inactivated anti-VE-
cadherin primary antibody treated HCAECs 
Under control conditions, VE-cadherin (green) distribution in HCAECs was observed as 
discontinuous staining across the cell membrane (A). Low-level staining was also observed 
diffusely throughout the cell. The morphology of the HCAECs showed a continuous flattened 
sheet. Following 5 hours incubation at 37˚C/ 5% CO2 with 10 µg/ml of the mouse anti- VE-
cadherin primary antibody, the morphology of the HCAECs changes to clumps of cells forming 
isolated colonies (B). VE-cadherin distribution was altered in a number of cells to that of one 
restricted to specific membrane sections, as indicated by the white arrows (B). Incubation with 
the heat-inactivated anti- VE-cadherin primary antibody resulted in little change in HCAEC 
morphology (C). DAPI nuclear staining is represented in blue. Antibody dilutions as previously 
stated. N=1. 
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5.3.1.1.2 - Connexin immunocytochemistry 
To determine whether VE-cadherin disruption had an effect on connexin distribution, 
HCAECs pre-incubated with the anti-VE-cadherin antibody were labelled for connexin 37, 
40 and 43 distribution in a series of preliminary experiments (Figure 5.3). Under control 
conditions, HCAECs were found to be distributed in a continuous sheet typical of HCAECs in 
culture (Figures 5.3A, 5.3B & 5.3C).  Following incubation with the anti-VE-cadherin primary 
antibody, cells appeared as isolated colonies of rounded cells, as previously shown (Figures 
5.3D, 5.3E & 5.3F).  
Following pre-incubation with the anti-VE-cadherin primary antibody, Cx37 was found to 
accumulate at restricted sites of the membrane, as shown by the white arrows in Figure 
5.3D. This Cx37 distribution was reminiscent of the re-localisation of VE-cadherin observed 
following treatment with the same blocking antibody. Similarly, Cx40 also appeared to re-
distribute to restricted regions of the membrane (white arrow, Figure 5.3E). Cx43 
distribution appeared largely unchanged following the disruption of VE-cadherin 
interactions (Figure 5.3F), with a patchy membranous localisation, with little restriction to 
specific regions of the HCAEC membrane.   
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Figure 5.3: Immunocytochemistry of connexins in HCAECs under control conditions 
and following pre-incubation with anti-VE-cadherin primary antibody  
Cx37, Cx40 and Cx43 distribution in HCAECs under control conditions (A-C). Following 5 hours 
incubation at 37˚C/ 5% CO2 with 10 µg/ml of the mouse anti- VE-cadherin primary antibody, 
Cx37 distribution was identified as aggregations at restricted segments of the membrane, as 
highlighted by the white arrows (D).  Cx40 distribution was also found to re-locate to specific 
regions of the membrane (white arrow, E). Conversely, Cx43 distribution appeared largely 
unaltered (F). DAPI nuclear staining is represented in blue. Antibody dilutions as previously 
stated. N=1. 
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5.3.1.1.3 - Incubation with the anti-VE-cadherin primary antibody - Summary 
Blocking of VE-cadherin interactions changed HCAEC morphology from sheets to isolated 
colonies of cells during preliminary experiments. Heat-inactivated anti-VE-cadherin 
antibody was ineffective during these experiments. Following incubation with the anti-VE-
cadherin antibody, VE-cadherin relocated to restricted sites of the membrane. Staining of 
Cx37 and Cx40 appeared to follow the re-location of VE-cadherin.  
 
 
5.3.1.2 - EGTA treatment of HCAECs 
5.3.1.2.1 - EGTA treatment, no calcium restoration 
Adherens junctions are calcium-dependent and break apart in the absence of extracellular 
calcium. As such, the effect of EGTA treatment (5 mM for 30 minutes at 37°C/ 5% CO2) was 
examined on cadherin and connexin distribution in HCAECs. 
During preliminary experiments, cadherin distribution was identified in HCAECs under 
control conditions and following EGTA treatment (Figure 5.4). Under control conditions, 
HCAEC morphology was identified as a continuous flattened sheet of cells. Following 30 
minutes incubation with 5 mM EGTA, the appearance of HCAECs became segregated 
rounded cells (Figures 5.4B & 5.4D), a morphology similar to that observed following pre-
incubation with the anti-VE-cadherin primary antibody (Figure 5.2B, above). This change in 
HCAEC morphology appeared more extensive than that recorded under incubation with the 
cadherin-blocking primary antibody, as cells were almost entirely isolated from each other, 
instead of forming colonies.  
In untreated HCAECs, VE-cadherin was identified as discontinuous patches of membrane 
staining with low-level staining throughout the cell (Figure 5.4A). Following EGTA 
treatment, VE-cadherin appeared to re-distribute to restricted points of the cell membrane, 
as highlighted by the white arrows in Figure 5.4B. This re-localisation of VE-cadherin was 
similar to that observed following incubation with the anti-VE-cadherin primary antibody. 
Under control conditions, N-cadherin was distributed both throughout the cell and at the 
HCAEC membrane, displaying increased expression at restricted sections of the cell border 
(Figure 5.4C). Following EGTA treatment, N-cadherin appeared to remain consistently 
expressed across the HCAEC membrane, with only minimal association with restricted sites 
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of the membrane (Figure 5.4D). The increased maximum AF488 signal intensity recording 
for both VE-cadherin (Figure 5.4B) and N-cadherin following EGTA treatment (Figure 5.4D), 
may reflect the change in HCAEC morphology.  
 
5.3.1.2.2 - EGTA treatment and 1 hour calcium restoration in the presence of the anti-VE-
cadherin primary antibody 
To determine whether the adherens junctions are able to re-form following calcium 
restoration, HCAECs were subjected to EGTA treatment followed by a 1 hour calcium 
restoration phase (fully-supplemented HCAEC media). To determine whether the anti-VE-
cadherin antibody was able to block the re-formation of these adherens junctions, the 
calcium restoration phase was also performed in the presence of the anti-VE-cadherin 
primary antibody.  
 
5.3.1.2.2.1 - VE-cadherin immunocytochemistry 
Preliminary experiments identified VE-cadherin distribution in HCAECs following EGTA 
treatment, 1 hour calcium restoration and 1 hour calcium restoration in the presence of 
the anti-VE-cadherin primary antibody (Figure 5.5). Following incubation with EGTA, VE-
cadherin (green) re-located to restricted points of the membrane and HCAECs formed 
isolated rounded cells (Figure 5.5A). The short distance between membrane VE-cadherin 
and DAPI nuclear staining (blue) highlights the rounded morphology adopted by the 
HCAECs following EGTA treatment. The confocal image (Figure 5.5A) further highlights the 
preference of the re-distributed VE-cadherin for restricted sections of the cell membrane. 
Following removal of the calcium-chelating agent and 1 hour’s calcium restoration in fully-
supplemented media, HCAEC morphology started to return to control conditions (Figure 
5.5B) with VE-cadherin located at sites of cell-cell contact (white arrow) and cells forming a 
more continuous sheet, indicating that the EGTA-induced re-distribution of VE-cadherin is 
reversible. When the calcium restoration was performed in the presence of the anti-VE-
cadherin primary antibody (Figure 5.5C), the HCAECs displayed a rounded morphology 
more similar to that observed immediately after EGTA treatment. Furthermore, VE-
cadherin appeared to remain localised to restricted segments of the HCAEC membrane 
(Figures 5.5C). 
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Figure 5.4: Immunocytochemistry of cadherin expression in HCAECs under control 
conditions and following EGTA treatment 
Under control conditions, HCAEC morphology appeared as a flattened and continuous sheet (A 
& C), VE-cadherin was identified as discontinuous staining across the cell (A), and N- cadherin 
was distributed both at the cell membrane and diffusely across the cell (C). HCAECs formed 
isolated rounded cells after treatment with 5 mM EGTA for 30 minutes at 37°C/ 5% CO2 (B & D). 
VE-cadherin re-located to restricted points of the membrane (B, white arrows). N-cadherin 
distribution after EGTA treatment (D) did not mirror the un-even appearance seen with VE-
cadherin staining (B). DAPI nuclear staining is shown in blue. Antibodies diluted as previously 
detailed. N=1.  
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Figure 5.5: Immunocytochemistry of VE-cadherin expression in HCAECs following 
EGTA treatment, 1 hour calcium restoration and 1 hour calcium restoration in the 
presence of anti-VE-cadherin primary antibody. 
Following 30 minutes 5 mM EGTA treatment at 37°C/ 5% CO2, VE-cadherin re-located to 
restricted points of the membrane and HCAECs appeared rounded (A). Following removal of 
EGTA and 1 hour’s calcium restoration (fully-supplemented media, 37°C/ 5% CO2), HCAEC 
morphology started to return to control conditions (B). Increased VE-cadherin cell-cell contacts 
were observed after 1 hour’s calcium restoration (B, white arrow). C represents VE-cadherin 
distribution in HCAECs following calcium restoration (1 hour) in the presence of the anti-VE-
cadherin primary antibody. These HCAECs displayed a morphology similar to that observed 
immediately after EGTA treatment, with rounded cells and a restricted VE-cadherin distribution. 
DAPI nuclear staining is shown in blue. Antibody dilutions as previously detailed. N=1. 
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5.3.1.2.2.2 - Cx37 immunocytochemistry 
Preliminary experiments identified Cx37 distribution in HCAECs following EGTA treatment, 
1 hour calcium restoration and 1 hour calcium restoration in the presence of the anti-VE-
cadherin primary antibody (Figure 5.6). EGTA treatment triggered a re-distribution of Cx37 
to restricted sites of the membrane (Figure 5.6A). Calcium restoration for 1 hour (Figure 
5.6B), appeared to result in a partial return of Cx37 distribution to that of control 
conditions, with Cx37 localising to areas of cell-cell contact (white arrows). When the 1 
hour calcium restoration period was carried out in the presence of 10 µg/ml of the anti-VE-
cadherin primary antibody (Figure 5.6C), Cx37 appeared to partially re-locate to the 
membrane but not at sites of cell-cell contact. Under these conditions, Cx37 appeared to 
continue to show a restricted membranous distribution (Figures 5.6C). 
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Figure 5.6: Immunocytochemistry of Cx37 expression in HCAECs following EGTA 
treatment, 1 hour calcium restoration and 1 hour calcium restoration in the presence 
of anti-VE-cadherin primary antibody. 
Following 30 minutes 5 mM EGTA treatment at 37°C/ 5% CO2, Cx37 re-located to restricted 
points of the membrane and HCAECs appeared rounded (A). Calcium restoration (fully-
supplemented media, 37°C/ 5% CO2) caused a restoration of CX37 cell-cell interactions (white 
arrows, B). C represents Cx37 distribution in HCAECs following calcium restoration in the 
presence of the anti-VE-cadherin primary antibody. Under these conditions, Cx37 was identified 
at the membrane but not at sites of cell-cell contact. DAPI nuclear staining is shown in blue. 
Antibody dilutions as previously detailed. N=1. 
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5.3.1.2.2.3 - Cx40 immunocytochemistry 
Cx40 distribution was identified during preliminary experiments in HCAECs following EGTA 
treatment, 1 hour calcium restoration and 1 hour calcium restoration in the presence of 
the anti-VE-cadherin primary antibody (Figure 5.7). Treatment with EGTA resulted in a 
diffuse distribution of Cx40 throughout the cell, with only marginal association with the cell 
border (Figure 5.7A). Following calcium restoration in fully-supplemented media, Cx40 
appeared to partially return towards the membrane (Figure 5.7B). The addition of 10 µg/ml 
of the anti-VE-cadherin primary antibody during the calcium restoration phase appeared to 
have little effect on the return of Cx40 to the membrane (Figure 5.7C) and staining 
appeared similar to that observed in Figure 5.7B. Membranous Cx40 did, however, appear 
to display a restricted membranous distribution under these conditions (Figure 5.7C).   
 
5.3.1.2.2.4 - Cx43 immunocytochemistry 
Cx43 distribution was identified in HCAECs following EGTA treatment, 1 hour calcium 
restoration and 1 hour calcium restoration in the presence of the anti-VE-cadherin primary 
antibody during preliminary investigations (Figure 5.8). EGTA treatment triggered a re-
distribution of Cx43 to restricted sites of the membrane (Figures 5.8A). Calcium restoration 
for 1 hour resulted in a re-distribution of Cx43 back towards control conditions with the re-
appearance of Cx43 at sites of cell-cell contact (Figure 5.8B). When the 1 hour calcium 
restoration period was performed in the presence of the anti-VE-cadherin primary 
antibody, Cx43 distribution appeared to still return towards control conditions, despite the 
HCAECs remaining isolated from each other (Figure 5.8C). Some cells did display a 
restricted membranous Cx43 distribution (white arrow, Figure 5.8C).  
 
 
 
 
 
 
 
173 
 
 
 
 
 
 
 
 
 
Figure 5.7: Immunocytochemistry of Cx40 expression in HCAECs following EGTA 
treatment, 1 hour calcium restoration and 1 hour calcium restoration in the presence 
of anti-VE-cadherin primary antibody. 
30 minutes 5 mM EGTA treatment at 37°C/ 5% CO2 did not cause localised aggregations of Cx40, 
unlike that seen in Cx37 (A). B shows Cx40 distribution following removal of EGTA and 1 hour’s 
calcium restoration (fully-supplemented media, 37°C/ 5% CO2). Cx40 distribution appeared to 
partially return to that observed under control conditions, with patches of membrane 
distribution (B). Following calcium restoration (1 hour) in the presence of the anti-VE-cadherin 
primary antibody (C), Cx40 appeared to again partially return towards control conditions, 
although membranous Cx40 distribution appeared restricted. DAPI nuclear staining is shown in 
blue. Antibody dilutions as previously detailed. N=1. 
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Figure 5.8: Immunocytochemistry of Cx43 expression in HCAECs following EGTA 
treatment, 1 hour calcium restoration and 1 hour calcium restoration in the presence 
of anti-VE-cadherin primary antibody. 
Following 30 minutes 5 mM EGTA treatment at 37°C/ 5% CO2, Cx43 partially re-located to 
restricted points of the membrane and HCAECs became rounded (A). Removal of EGTA and 1 
hour’s calcium restoration (fully-supplemented media, 37°C/ 5% CO2) triggered a partial 
restoration of CX43 distribution at the membrane (B). C represents Cx43 distribution in HCAECs 
following calcium restoration (1 hour) in the presence of the anti-VE-cadherin primary antibody. 
Distribution of Cx43 in the presence of the anti-VE-cadherin blocking antibody appears similar to 
the distribution observed in B, with only slight membranous restriction (C, white arrow). The 
HCAECs appear largely isolated from one another. DAPI nuclear staining is shown in blue. 
Antibody dilutions as previously detailed. N=1. 
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5.3.1.2.3 - EGTA treatment and 4 hours calcium restoration 
Following EGTA treatment, incubation of HCAECs with calcium-containing media for 1 hour 
seemed to partially reverse the effect of EGTA. Thus, the effect of 4 hours calcium 
restoration was examined in a series of preliminary experiments. 
 
5.3.1.2.3.1 - VE-cadherin immunocytochemistry 
VE-cadherin distribution was identified in HCAECs under control conditions and after 4 
hours calcium restoration following EGTA treatment (Figure 5.9). Under control conditions 
(Figure 5.9A), VE-cadherin distribution appeared primarily at the membrane, supplemented 
by low-level staining throughout the cell. Following 30 minutes EGTA treatment, the cells 
were incubated in fully-supplemented media for 4 hours at 37°C/ 5% CO2 (Figure 5.9B). VE-
cadherin distribution at the membrane returned to that of control conditions, with 
expression at sites of cell-cell contact, as indicated by the white arrows (Figure 5.9B). These 
cells appeared to show a reduced proportion of nuclear-associated VE-cadherin, as 
highlighted by the DAPI staining (Figure 5.9B).  
 
5.3.1.2.3.2 - Cx37 immunocytochemistry 
Cx37 distribution was identified in HCAECs under control conditions and following 4 hours 
calcium restoration after EGTA treatment (Figure 5.10). Under control conditions, Cx37 
appeared primarily at the membrane with areas of perinuclear distribution (Figure 5.10A). 
Following 4 hours calcium restoration after EGTA treatment (Figure 5.10B), Cx37 at least 
partially returned to the membrane and appeared at sites of cell-cell contact (white arrow). 
These cells appeared to display a reduced amount of perinuclear Cx37, as highlighted by 
overlay of the DAPI and AF488 signal (Figure 5.10B). This pattern was similar to the reduced 
perinuclear VE-cadherin observed in HCAECs under the same conditions (Figure 5.9B).  
 
 
176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Immunocytochemistry of VE-cadherin expression in HCAECs under control 
conditions and following 4 hours calcium restoration after EGTA treatment 
Under control conditions (A), VE-cadherin (green) was identified primarily at the membrane 
with low-level staining throughout the cell. HCAECs were treated with 5 mM EGTA for 30 
minutes at 37°C/ 5% CO2, and then washed twice with DPBS and the fully-supplemented media 
refreshed for 4 hours. Following calcium restoration, HCAEC morphology returned towards that 
of control conditions (B). Expression of VE-cadherin at sites of cell-cell contact was noted (B, 
white arrows). DAPI nuclear staining is shown in blue. Antibodies diluted as previously detailed. 
N=1. 
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Figure 5.10: Immunocytochemistry of Cx37 expression in HCAECs under control 
conditions and following 4 hours calcium restoration after EGTA treatment 
Under control conditions (A), Cx37 (green) was identified primarily at the membrane with areas 
of perinuclear distribution. HCAECs were treated with 5 mM EGTA for 30 minutes at 37°C/ 5% 
CO2, and then washed twice with DPBS and the fully-supplemented media refreshed for 4 hours. 
Localisation of Cx37 to sites of cell-cell contact was observed following calcium restoration (B, 
white arrow). DAPI nuclear staining is shown in blue. Antibodies diluted as previously detailed. 
N=1. 
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5.3.1.2.3.3 - Cx40 immunocytochemistry 
Cx40 distribution was identified in HCAECs under control conditions and following 4 hours 
calcium restoration after EGTA treatment (Figure 5.11). Under control conditions, Cx40 
appeared distributed diffusely throughout the cell with patchy sections of membrane 
staining (Figure 5.11A). Following 4 hours calcium restoration after EGTA treatment, Cx40 
appeared to return towards this control distribution (Figure 5.11B). Expression of Cx40 at 
sites of cell-cell contact is highlighted by the white arrow (Figure 5.11B). The cytoplasmic 
distribution of Cx40 appeared to be restricted to the perinuclear region under this 
condition, as highlighted by overlay of the DAPI and AF488 signal (Figure 5.11B). 
 
5.3.1.2.3.4 - Cx43 immunocytochemistry 
Cx43 distribution was identified in HCAECs under control conditions and following 4 hours 
calcium restoration after EGTA treatment (Figure 5.12). Under control conditions, Cx43 was 
identified diffusely throughout the cell and as discontinuous patches at the cell membrane 
(Figure 5.12A). Following 4 hours calcium restoration after EGTA treatment, Cx43 appeared 
to partially return towards this control distribution (Figure 5.12B). However, a decrease in 
the proportion of cytoplasmic Cx43 was evident in these preliminary experiments (Figure 
5.12B). Expression of Cx43 at sites of cell-cell contact is highlighted by the white arrow 
(Figure 5.12B). 
5.3.1.2.4 - EGTA treatment - Summary 
Incubation of HCAECs with 5 mM EGTA for 30 minutes resulted in a change in morphology 
to isolated rounded cells. This morphology was similar to that observed following cadherin 
disruption using the anti-VE-cadherin primary antibody. Preliminary results indicated that 
EGTA treatment triggered a re-localisation of VE-cadherin to restricted areas of the 
membrane, but that EGTA had little effect on N-cadherin distribution. Cx37 appeared to 
undergo moderate redistribution, primarily to restricted areas of the membrane associated 
with adjacent cells. Little change in Cx40 or Cx43 distribution following EGTA treatment was 
observed. 1 hour calcium restoration triggered a return towards the control distribution of 
VE-cadherin and Cx37, but not Cx40 or Cx43, and was blocked by the addition of 10 µg/ml 
anti-VE-cadherin primary antibody. The effect of the EGTA treatment was reversible as 
after 4 hours calcium restoration the distribution of VE-cadherin, Cx37, Cx40 and Cx43 
returned towards that observed under control conditions.  
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Figure 5.11: Immunocytochemistry of Cx40 expression in HCAECs under control 
conditions and following 4 hours calcium restoration after EGTA treatment 
Under control conditions (A), Cx40 (green) was identified diffusely throughout the cell with 
patchy sections of membrane staining. HCAECs were treated with 5 mM EGTA for 30 minutes at 
37°C/ 5% CO2, and then washed twice with DPBS and the fully-supplemented media refreshed 
for 4 hours. After calcium restoration, Cx40 expression at sites of cell-cell contact can be 
observed (B, white arrow). DAPI nuclear staining is shown in blue. Antibodies diluted as 
previously detailed. N=1. 
 
 
180 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Immunocytochemistry of Cx43 expression in HCAECs under control 
conditions and following 4 hours calcium restoration after EGTA treatment  
Under control conditions (A), Cx43 (green) was identified diffusely throughout the cell with 
patchy sections of membrane staining. HCAECs were treated with 5 mM EGTA for 30 minutes at 
37°C/ 5% CO2, and then washed twice with DPBS and the fully-supplemented media refreshed 
for 4 hours. After calcium restoration, Cx43 was identified at sites of cell-cell contact (white 
arrow, B). DAPI nuclear staining is shown in blue. Antibodies diluted as previously detailed. N=1. 
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5.3.2 – Enhancement of HCAEC cadherin interactions 
 
5.3.2.1 - Epac1 expression in HCAECs 
 
5.3.2 1.1 - Western blot 
Epac1 was identified in HCAEC, HCASMC and rat mesenteric artery smooth muscle cell 
(RMASMC) lysates during a series of preliminary Western blot investigations (Figure 5.13).  
Epac1 expression in HCAECs was detected at 99 kDa by both the Santa Cruz and Cell 
Signalling anti-Epac1 primary antibodies (Figure 5.13A). The Santa Cruz antibody also 
detected proteins at 50 kDa, 43 kDa and 31 kDa (not shown).  Epac1 was also identified in 
P6 HCASMC lysate and RMASMC P7 lysate at 99 kDa (Figure 5.13B).  
 
5.3.2 1.2 - Immunocytochemistry 
Epac1 distribution was examined in HCAECs under control conditions (Figure 5.14). The 
Santa Cruz primary antibody was labelled with a goat anti-mouse AF488-conjugated 
secondary antibody (green). During these preliminary experiments Epac1 was found to be 
distributed diffusely throughout the cell with small areas of membranous staining, as 
indicated by the white arrow in Figure 5.14A. 
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Figure 5.13: Western blot of Epac1 expression in HCAECs, HCASMCs and RMASMCs  
HCAEC (P6 and P10) lysates were examined with mouse monoclonal anti-Epac1 primary 
antibodies from Santa Cruz Biotechnology and Cell Signalling (A). The primary antibodies were 
used at either x100 (Santa Cruz) or x200 (Cell Signalling) dilutions in 1% non-fat powdered milk. 
B shows HCASMCs (SMC, P6) and rat mesenteric artery smooth muscle cells (RSMC, P7) 
examined with Santa Cruz  mouse monoclonal anti-Epac1 primary antibody (x100 dilution in 1% 
non-fat powdered milk). Primary antibodies were subsequently labelled with HRP-conjugated 
goat anti-mouse secondary antibody (x10,000 dilution, 1% non-fat powdered milk). 50 hours 
exposure. N=1. 
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Figure 5.14: Immunocytochemistry of Epac1 expression in HCAECs 
Epac1 (green) is diffusely distributed throughout the cell (A & B), with isolated areas of 
membranous staining, as highlighted by the white arrow in image A. DAPI nuclear staining is 
shown in blue. The Santa Cruz mouse monoclonal anti-Epac1 primary antibody was used at 100 
fold dilution and the AF488-tagged goat anti-mouse secondary antibody used at x500 dilution. 
N=2. 
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5.3.2.2 - Epac2 expression in HCAECs 
5.3.2.2.1 - Western blot 
The presence of Epac2 was examined in rat heart, brain, mesenteric artery and HCAEC 
lysates (Figure 5.15A). Epac2 is believed to be highly expressed in brain (Kawasaki, 
Springett et al. 1998), and heart and mesenteric artery were chosen as representative 
cardiovascular tissues. No clear banding at 126 kDa was identified in any of the lysates 
during these preliminary experiments. Multiple bands at different MWs were identified in 
lysates labelled with the anti-Epac2 primary antibody.  
 
5.3.2.2.2 - Immunocytochemistry  
Epac2 (green) distribution was visualised in HCAECs under control conditions (Figure 
5.15B). Preliminary data indicated low-level Epac2 staining diffusely throughout the cell 
with isolated areas of membranous staining (Figure 5.15B, white arrow). Punctate Epac2 
staining was identified in the nucleus, as shown by the AF488 signal (Figure 5.15B). The 
distribution pattern of Epac2 in HCAECs appeared similar to that observed for Epac1 in 
HCAECs but at a lower level.  
 
5.3.2.3 - Epac1 and Epac2 Summary 
Epac1 was identified in HCAECs using two types of primary antibody. The lack of banding 
corresponding to Epac2 in rat heart, brain, mesenteric artery and HCAEC lysates could 
indicate that the anti-Epac2 primary antibody was not specific to the target protein. Epac1 
was also identified in HCASMC and RMASMC lysates in preliminary investigations.  
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Figure 5.15: Epac2 expression in rat heart, brain, mesenteric artery and HCAECs 
Epac2 expression was examined in rat heart (H), brain (B), mesenteric artery (M) and HCAEC (EC) 
lysates (A). No clear banding at 126 kDa could be identified in any of the lysates. The rabbit 
polyclonal anti-Epac2 primary antibody was used at x100 dilution in 1% non-fat powdered milk. 
The HRP-conjugated goat anti-mouse secondary antibody was used at x10,000 dilution in 1% 
non-fat powdered milk. 30 minutes exposure. Epac2 distribution was examined in HCAECs 
through immunocytochemistry (B). Low-level signal was identified with a pattern similar to that 
of Epac1; diffuse cellular distribution with areas of membrane-association (white arrow). 
Punctate staining appeared to be present in the nucleus as highlighted by DAPI nuclear staining 
(B). N=1. 
186 
 
5.3.2.4 - 8-pCPT addition to HCAECs 
In order to determine the effect of Epac activation on the distribution pattern of cadherins 
and connexins in HCAECs, cells were treated with the Epac-selective agonist 8-(4-
Chlorophenylthio)-2’-O-methyl-cAMP (8-pCPT) in a number of preliminary experiments.  
 
5.3.2.4 1 - Epac1 immunocytochemistry  
Epac1 distribution was examined in HCAECs under control conditions and following 5 
minutes and 30 minutes incubation with the Epac-selective activator 8-pCPT (Figure 5.16). 
Following 5 minutes incubation with 8-pCPT, Epac1 re-organised into small cytoplasmic 
aggregations (Figure 5.16B, white arrows). After 30 minutes of incubation with 8-pCPT, an 
increase in membranous Epac1 was noted (Figure 5.16C, white arrows). HCAEC Epac1 
distribution after 30 minutes Epac activation was markedly different to the diffuse Epac1 
staining observed in HCAECs under control conditions (Figure 5.16A). In addition, these 
cells displayed a greater degree of Epac1 associated with the nucleus, as demonstrated by 
the overlap between nuclear DAPI (blue) and AF488-signal (Figure 5.16C). The association 
of Epac1 into aggregations following 8-pCPT treatment is further highlighted by the 
increased maximum AF488 signal intensity recorded in these cells (Figures 5.16B & 5.16C).  
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Figure 5.16: Immunocytochemistry of Epac1 expression in HCAECs following 8-pCPT 
addition 
Under control conditions, Epac1 was distributed diffusely throughout the HCAECs (A). Following 
5 minutes incubation with 5 µM 8-pCPT at 37˚C/ 5% CO2, Epac1 localised to small intracellular 
aggregations (white arrows, B). After 30 minutes treatment, increased Epac1 was detected in 
the perinuclear region and at the membrane (white arrows, C). DAPI nuclear staining is shown in 
blue. Antibody dilutions as previously stated. N=2. 
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5.3.2.4 2 - VE-cadherin immunocytochemistry  
VE-cadherin distribution was examined in HCAECs under control conditions and following 
30 minutes incubation with the Epac-selective activator 8-pCPT (Figure 5.17). On incubation 
with 5 µM 8-pCPT for 30 minutes at 37˚C/ 5% CO2, VE-cadherin relocates to the membrane, 
forming a more continuous border between adjacent cells (Figure 5.17C; AF488 & Figure 
5.17D; AF594). It was also noted that the short and inward projections from the 
membranous VE-cadherin evident under control conditions, were no longer as extensive 
following Epac activation, suggesting redistribution of VE-cadherin (Figures 5.17C & 5.17D). 
This re-distribution of VE-cadherin was observed in all cells imaged.  
 
5.3.2.4 3 - N-cadherin immunocytochemistry  
N-cadherin distribution was examined in HCAECs under control conditions and following 30 
minutes incubation with 8-pCPT (Figure 5.18). Preliminary data indicated that following 30 
minutes treatment with 5 µM 8-pCPT, N-cadherin was distributed more diffusely 
throughout the cells, with a decreased membranous association (Figures 5.18C & 5.18D).  
 
5.3.2.4 4 - Cadherin immunocytochemistry summary 
8-pCPT application altered the expression profile of both VE-cadherin and N-cadherin in 
cultured HCAECs in preliminary investigations. 30 minutes incubation with 5 µM 8-pCPT 
resulted in a cell membrane lined almost continuously by VE-cadherin, and N-cadherin 
appeared to re-locate away from the membrane.  
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Figure 5.17: Immunocytochemistry of VE-cadherin expression in HCAECs following 8-
pCPT application 
Under control conditions, VE-cadherin distribution in HCAECs was primarily identified as 
discontinuous membranous sections (A & B). Following 30 minutes incubation with 5 µM 8-pCPT 
at 37˚C/ 5% CO2 VE-cadherin formed a continuous border along the membrane of adjacent 
HCAECs (C & D). DAPI nuclear staining is shown in blue. Images A and C labelled with AF488-
tagged secondary antibody, images B and D labelled with AF594-tagged secondary antibody. 
Antibody dilutions as previously stated. N=2. 
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Figure 5.18: Immunocytochemistry of N-cadherin expression in HCAECs following 8-
pCPT application 
Under control conditions, N-cadherin is distributed diffusely throughout HCAECs with distinct 
areas of membranous staining (A & B). After 30 minutes incubation with 5 µM 8-pCPT at 37˚C/ 
5% CO2, N-cadherin appeared to lose this membranous staining (C & D). DAPI nuclear staining is 
shown in blue. Antibody dilutions as previously stated. N=1. 
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5.3.2.4.5 - VE-cadherin and Cx37 co-localisation 
VE-cadherin and Cx37 were labelled in HCAECs under control conditions and following 30 
minutes incubation with 5 µM 8-pCPT (Figure 5.19). Under control conditions, localised 
areas of overlap between VE-cadherin and Cx37 (yellow) were identified at the membrane 
(Figure 5.19E). On incubation with 8-pCPT during preliminary experiments, the 
membranous areas showing yellow increased, suggesting facilitated co-localisation of VE-
cadherin and Cx37 (Figure 5.19F). Low-level perinuclear Cx37 observed under control 
conditions (Figure 5.19C & 5.19E) remained following Epac activation (Figure 5.19D & 
5.19F). The proportion of overlap between VE-cadherin and Cx37 was quantified using 
three types of Image J plugin and this will be discussed later (Section 5.3.2.4.8).  
5.3.2.4 6 - VE-cadherin and Cx40 co-localisation 
VE-cadherin and Cx40 were labelled in HCAECs under control conditions and following 30 
minutes incubation with 5 µM 8-pCPT (Figure 5.20). Under control conditions, small areas 
of VE-cadherin and Cx40 overlap were identified as yellow patches at the membranes of 
HCAECs (Figure 5.20E). On Epac activation with 8-pCPT a small number of cells showed 
increased Cx40 expression at the cell membrane and this resulted in an apparent increase 
in the co-localisation in these cells (Figure 5.20F). However, this was not the pattern 
observed in the vast majority of HCAECs imaged. Furthermore, quantitative analysis 
showed no significant increase in co-localisation between VE-cadherin and Cx40 in HCAECs 
on Epac activation (discussed in Section 5.3.2.4.8). Application of 8-pCPT appeared to cause 
an increase in the localisation of Cx40 to the perinuclear region, as shown in the confocal 
image (Figure 5.20D) with DAPI nuclear staining shown in blue. 
 
5.3.2.4 7 - VE-cadherin and Cx43 co-localisation 
VE-cadherin and Cx43 were labelled in HCAECs under control conditions and following 30 
minutes incubation with 5 µM 8-pCPT (Figure 5.21). Under control conditions, the 
membranes of HCAECs displayed small sections of overlap between Cx43 and VE-cadherin 
(Figure 5.21E). An apparent increase in the co-localisation of Cx43 and VE-cadherin at the 
membrane was detected following Epac activation (Figure 5.21F). The proportion of 
overlap between VE-cadherin and Cx43 was quantified using three types of Image J plugin 
and this will be discussed later (Section 5.3.2.4.8) 
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Figure 5.19: Immunocytochemistry of VE-cadherin and Cx37 distribution in HCAECs 
following 8-pCPT application 
Under control conditions, isolated areas of overlap between VE-cadherin (red, A) and Cx37 
(green, C) distribution were identified as yellow patches at the membrane (E). Following 30 
minutes incubation with 5 µM 8-pCPT at 37˚C/ 5% CO2, there was an increase in the co-
localisation of these two junctional proteins (yellow, F). DAPI nuclear staining is shown in blue. 
Antibody dilutions as previously stated. N=2. 
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Figure 5.20: Immunocytochemistry of VE-cadherin and Cx40 distribution in HCAECs 
following 8-pCPT application 
Under control conditions, isolated areas of overlap between VE-cadherin (red, A) and Cx40 
(green, C) distribution were identified at the membrane (yellow, E). For the majority of cells, 
little increase in co-localisation between VE-cadherin and Cx40 was identified following 30 
minutes incubation with the Epac-selective activator 8-pCPT, although a small number of cells 
showed a marked increase in Cx40 expression at the cell membrane, as seen by the yellow 
staining (F). DAPI nuclear staining is shown in blue. Antibody dilutions as previously stated. N=3. 
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Figure 5.21: Immunocytochemistry of VE-cadherin and Cx43 distribution in HCAECs 
following 8-pCPT application 
In control experiments, small areas of overlap between VE-cadherin (red, A) and Cx43 (green, C) 
were identified at the membrane (yellow, E). Following 30 minutes incubation with 5 µM 8-
pCPT, VE-cadherin and Cx43 co-localisation at the membrane appeared to increase (F). DAPI 
nuclear staining is shown in blue (E). Antibody dilutions as previously stated. N=3. 
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5.3.2.4.8 - Quantification of VE-cadherin and connexin co-localisation after Epac activation 
Three types of Image J plugin were used to quantify co-localisation of VE-cadherin and 
connexins in HCAECs under control conditions and following 8-pCPT treatment (Figure 
5.22). These plugins were; Manders’ Overlap Coefficient (Figure 5.22A, 5.22D & 5.22G), Co-
localisation Finder plugin (Figure 5.22B, 5.22E & 5.22H) and Intensity Correlation Analysis 
(Figure 5.22C, 5.22F & 5.22I). Full details of the quantification process for each plugin is 
described in the Appendix under “Supplementary information on the quantification of 
cadherin and connexin co-localisation using Image J plugins”. Analysis of the co-localisation 
between VE-cadherin and Cx37 is shown in Figure 5.22A- 5.22C. For this quantification N=6 
for control and N=5 for 8-pCPT treatment, where N=number of images analysed, with a 
minimum of 2 experimental repeats. All three plugins identified a significant increase in VE-
cadherin and Cx37 co-localisation on Epac activation (unpaired student’s t-test). Analysis of 
the co-localisation between VE-cadherin and Cx40 is shown in Figures 5.22D- 5.22F. For this 
quantification N=13 for control and N=5 for 8-pCPT treatment, with a minimum of 3 
repeats. No significant change in the co-localisation between VE-cadherin and Cx40 was 
identified by any of the three plugins (unpaired student’s t-test). Analysis of the co-
localisation between VE-cadherin and Cx43 is shown in Figures 5.22G- 5.22I. For this 
quantification N=9 for control and 8-pCPT treatment, with a minimum of 3 repeats. All 
three plugins showed an increase in co-localisation between VE-cadherin and Cx43 on Epac 
activation but only the Intensity Correlation Analysis plugin (Figure 5.22I) found the 
increase to be significant (* P<0.05, unpaired student’s t-test). Figure 5.23 displays the data 
shown in Figure 5.22 in an alternative format where different connexin subtypes are 
aligned for comparison. 
 
5.3.2.4 9 - Connexins and cadherin co-localisation following 8-pCPT - summary 
Following 30 minutes incubation with 5 µM 8-pCPT, there was a significant increase in the 
overlap between Cx37 and VE-cadherin distribution in HCAECs. An increase in the co-
localisation of Cx43 and VE-cadherin at the membrane was also detected, but only 1 Image 
J plugin found this increase to be significant. No increase in the overlap of Cx40 and VE-
cadherin expression at the membrane was detected.  
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Figure 5.22: Quantification of VE-cadherin and Connexin co-localisation in HCAECs 
following 8-pCPT application 
The effect of Epac activation on co-localisation of VE-cadherin and connexins was examined 
using three Image J plugins, Manders’ Overlap Coefficient (A, D & G), Co-localisation Finder 
plugin (B, E & H) and Intensity Correlation Analysis (C, F & I). Application of 5 µM 8-pCPT to 
HCAECs resulted in a significant increase in co-localisation of VE-cadherin and Cx37 in all three 
plugins (A-C). No significant change in co-localisation of VE-cadherin and Cx40 was identified 
following 8-pCPT application (D-F). Only the Intensity Correlation Analysis plugin identified a 
significant increase in co-localisation of VE-cadherin and Cx43 on Epac activation (I). Full details 
of the quantification process can be found in the Appendix under “Supplementary information 
on the quantification of cadherin and connexin co-localisation using Image J plugins”. (* P<0.05, 
** P<0.01, unpaired student’s t-test). For Cx37: N=6 for control and N=5 for 8-pCPT treatment, 
over 2 independent experiments. For Cx40: N=13 for control and N=5 for 8-pCPT treatment, 
over 3 independent experiments. For Cx43: N=9 for control and 8-pCPT treatment, over 3 
independent experiments.  
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Figure 5.23: Quantification of VE-cadherin and Connexin co-localisation in HCAECs 
under control conditions and following 8-pCPT application 
A-C represent co-localisation of VE-cadherin with Cx37, Cx40 and Cx43 under control conditions, 
as quantified using the Manders’ Overlap Coefficient plugin (A), Co-localisation Finder plugin (B) 
and Intensity Correlation Analysis plugin (C). D-F represent co-localisation of VE-cadherin with 
Cx37, Cx40 and Cx43 following incubation with 5 µM 8-pCPT, as quantified using the three 
Image J plugins. Full details of the quantification process can be found in the Appendix under 
“Supplementary information on the quantification of cadherin and connexin co-localisation 
using Image J plugins”. For Cx37: N=6 for control and N=5 for 8-pCPT treatment, over 2 
independent experiments. For Cx40: N=13 for control and N=5 for 8-pCPT treatment, over 3 
independent experiments. For Cx43: N=9 for control and 8-pCPT treatment, over 3 independent 
experiments. 
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5.3.2.5 - Epac1 siRNA transfection of HCAECs 
Passage 6 HCAECs were used for all transfection experiments. Cells were grown to 70% 
confluence in 6-well cell culture plates in fully-supplemented HCAEC media. Full protocol 
details can be found in the Methods chapter under “2.2.5 - Small Interfering RNA (siRNA) 
knockdown of Epac1”. Preliminary titration Western blot experiments identified 10 nM 
Epac1 siRNA (5 nM of each duplex; Hs_RAPGEF3_6 and Hs_RAPGEF3_7) as the optimum 
concentration for transfection to produce Epac1 knockdown without deleterious effects on 
the HCAECs (Figure 5.24). Other concentrations tested include 5 nM of each duplex alone, 
and 25 nM total concentration of the two duplexes combined (Figure 5.24).  5 nM 
appeared insufficient to produce reliable knockdown of Epac1 (Figure 5.24A). 25 nM 
produced similar results to that of 10 nM (Figure 5.24A), and as such 10 nM was selected 
for the following experiments.  
Next, the time course of knock down was investigated. The HCAECs were exposed to the 
siRNA for 24 hours, 48 hours or 72 hours, and Epac1 expression was examined in a number 
of preliminary experiments using Western Blot (Figure 5.25A). Lipofectamine-only and non-
silencing siRNA (10nM) transfections were used as controls, and under these conditions 
Epac1 expression was identified as a single band at 99 kDA (Figure 5.25A). Following 
treatment with 10 nM Epac1 siRNA, Epac1 expression was reduced after 24 hours, and no 
detectable band was seen after 48 hours or 72 hours (Figure 5.25A). Epac1 banding under 
control conditions at 24 hours was lower than that detected at 48 hours and 72 hours 
(Figure 5.25A). This is probably due to lower total protein concentration in the 24 hour 
lysate. 72 hours incubation with the siRNA may have a negative impact on the HCAECs, as 
actin expression after 72 hours was reduced (Figure 5.25B). As such, 48 hours was selected 
as the optimum exposure time for all future experiments.  
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Figure 5.24: Western blot of Epac1 expression in HCAECs following siRNA knockdown 
at varying concentrations 
HCAECs were transfected with varying concentrations of Epac1 siRNA for 48 hours (A). The 
lysate produced from each condition was run on a Western blot and labelled for Epac1 
expression. The membrane was subsequently re-blotted for actin expression (B). Op = Optimem 
only (no transfection agent), NS 5/10/25 = Non-silencing siRNA at 5, 10 and 25 nM, si6 5 = Epac1 
siRNA duplex 6 (Hs_RAPGEF3_6) at 5 nM, si7 5 = Epac1 siRNA duplex 7 (Hs_RAPGEF3_7) at 5 nM, 
si 10/25 = equal amounts of Epac1 siRNA duplexes 6 and 7 at total concentration of 10 nM/25 
nM. Anti-Epac1 monoclonal mouse primary antibody (Cell Signalling, 4155S) was used at 200 
fold dilution. Mouse anti-actin primary antibody was used at 500 fold dilution. Both primary 
antibodies were targeted with the goat anti-mouse HRP-conjugated secondary antibody at a 
10,000 fold dilution. Both primary and secondary antibodies were diluted in 1% non-fat 
powdered milk.  The films were exposed to the membranes for 2 hours (Epac1, A) and 30 
minutes (actin, B). N=2. 
 
 
200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25: Western blot of Epac1 expression in HCAECs following siRNA knockdown 
over 24, 48 and 72 hours 
HCAECs were transfected with Epac1 siRNA duplexes Hs_RAPGEF3_6 and Hs_RAPGEF3_7 at a 
total concentration of 10 nM for 24, 48 or 72 hours. The lysate produced from each condition 
was run through a Western blot and probed for Epac1 expression (A). The membrane was 
subsequently re-blotted for actin expression (B). L = lipofectamine control, NS = non-silencing 
siRNA at 10 nM, si = Epac1 siRNA duplexes 6 & 7, total concentration 10 nM. Anti-Epac1 
monoclonal mouse primary antibody was used at 200 fold dilution. Mouse anti-actin primary 
antibody was used at 500 fold dilution. Both primary antibodies were targeted with the goat 
anti-mouse HRP-conjugated secondary antibody at a 10,000 fold dilution. Both primary and 
secondary antibodies were diluted in 1% non-fat powdered milk.  The films were exposed to the 
membranes for 1 hour (Epac1, A) and 10 minutes (actin, B). For 24 hours, N=2. For 48 hour and 
72 hours, N=6. 
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5.3.2.5.1 - Quantification of Epac1 expression in HCAECs following Epac1 siRNA transfection  
The actin re-blot shown in Figure 5.24B allowed quantification of relative Epac1 expression 
following Epac1 siRNA transfection (Figure 5.26A & 5.26B). Image J was used for 
densitometrical analysis of Epac1 expression under the varying conditions. When 
normalised to actin expression, there was a significant decrease in Epac1 expression 
between non-silencing siRNA treated HCAECs and the Epac1 siRNA transfected HCAECs at 
both 48 hours and 72 hours post-transfection (Figure 5.26A, unpaired student’s t-test, N=8-
14, over 3 independent experiments). When Epac1 expression was normalised to the 
Lipofectamine control transfection of HCAECs, a significant decrease in Epac1 expression 
was identified between the non-silencing control transfection and the Epac1 siRNA 
transfection at all three time points (Figure 5.26B, unpaired student’s t-test, N=4-14, over 3 
independent experiments).  
 
5.3.2.5.2 - Epac1 immunocytochemistry following Epac1 siRNA transfection 
During preliminary experiments, HCAECs transfected with 10 nM Epac1 siRNA 
(Hs_RAPGEF3_6 and Hs_RAPGEF3_7 duplexes) were labelled for Epac1 expression (green) 
after 24, 48 and 72 hours incubation with the siRNA (Figure 5.27B, 5.27C & 5.27G). After 24 
hours exposure to the Epac1 siRNA, Epac1 was found to change from a diffuse distribution 
throughout the cell (Figure 5.27A) to one restricted to one site adjacent to the nucleus 
(Figure 5.27B). This accumulation in Epac1 distribution was also indicated by the increase in 
the maximum AF488 signal from 217 AU (Figure 5.27A) to 254 AU (Figure 5.27B). After 48 
hours exposure, Epac1 expression appeared to be almost entirely absent from the HCAECs, 
with only isolated areas of staining detected (Figure 5.27C). The signal intensity declined to 
58 AU (Figure 5.27C), a level considered background in all immunocytochemistry 
experiments. Similarly, after 72 hours exposure, the Epac1 expression further declined and 
a maximum AF488 signal intensity of 48 AU was recorded (Figure 5.27D). The DAPI nuclear 
staining (blue) shows the re-location of Epac1 to the nucleus (Figure 5.27B).  
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Figure 5.26: Quantification of Epac1 knockdown in HCAECs 
Relative expression of Epac1 following transfection with 10 nM Epac1 siRNA (duplexes 
Hs_RAPGEF3_6 and Hs_RAPGEF3_7) for 24, 48 or 72 hours was quantified by densitometrical 
analysis using Image J. Epac1 expression was normalised to actin expression (A) and 
lipofectamine control (B). L = lipofectamine control, NS = non-silencing siRNA at 10 nM, si = 
Epac1 siRNA duplexes 6 & 7, total concentration 10 nM. (** P<0.01, *** P<0.001, unpaired 
student’s t-test). For A; NS48 N=4, L24/NS24/si24/L48/si48 N=10, L72/NS72/si72 N=14, over 3 
independent experiments.  
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Figure 5.27: Immunocytochemistry of Epac1 expression following Epac1 siRNA 
transfection  
Epac1 (green) distribution was identified in HCAECs under control conditions (A) and following 
24 (B), 48 (C) and 72 (D) hours exposure to 10 nM Epac1 siRNA. Epac1 appeared to re-distribute 
to a restricted region adjacent to the nucleus following 24 hours treatment (B). After 48 hours or 
72 hours, Epac1 expression had declined to a maximum fluorescence intensity of 58 AU (C) and 
48 AU (D), respectively. DAPI nuclear staining is shown in blue. Antibody dilutions as previously 
detailed. N=1. 
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5.3.2.5.3 - Epac2 immunocytochemistry following Epac1 siRNA transfection 
HCAECs transfected with 10 nM Epac1 siRNA (Hs_RAPGEF3_6 and Hs_RAPGEF3_7 
duplexes) were also labelled for Epac2 expression (green) after 48 hours incubation with 
the siRNA (Figure 5.28B). Preliminary data indicated no observable change in the 
expression profile of Epac2 after Epac1 siRNA transfection (Figure 5.28B). However, as the 
Epac2 antibody may not be very selective (Section 5.3.2.2), further experiments with an 
alternative Epac2 antibody would be required to confirm this observation.  
 
5.3.2.5.4 - VE-cadherin immunocytochemistry following Epac1 siRNA transfection and 
addition of 8-pCPT 
HCAECs transfected with 10 nM Epac1 siRNA (Hs_RAPGEF3_6 and Hs_RAPGEF3_7 
duplexes) or 10 nM non-silencing siRNA for 48 hours were labelled for VE-cadherin 
expression (green) under control conditions and following 30 minutes incubation with 5 µM 
of the Epac-selective activator 8-pCPT at 37˚C/ 5% CO2 (Figure 5.29). Preliminary data 
indicated little difference in VE-cadherin staining pattern between Epac1 siRNA transfected 
and non-silencing siRNA transfected HCAECS (Figures 5.29A & 5.29B). On addition of 5 µM 
8-pCPT to the Epac1 siRNA transfected cells (Figure 5.29C), the distribution of VE-cadherin 
at the membrane remained largely discontinuous and patchy, and was not considered to 
be altered from that observed without Epac activation. Transfection of the HCAECs with 10 
nM non-silencing siRNA acted as a control (Figures 5.29B & 5.29D). On addition of 5 µM 8-
pCPT to non-silencing siRNA-treated HCAECs, VE-cadherin formed a more continuous 
border along the HCAECs (Figure 5.29D). This preliminary data suggests that Epac1 siRNA 
knockdown blocks the 8-pCPT-induced VE-cadherin re-distribution in HCAECs.  
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Figure 5.28: Immunocytochemistry of Epac2 expression following Epac1 siRNA 
transfection  
Epac2 (green) distribution was examined in HCAECs under control conditions (A) and following 
48 hours exposure to 10 nM Epac1 siRNA (B). No observable change in Epac2 distribution or 
expression was noted following Epac1 siRNA knockdown. DAPI nuclear staining is shown in blue. 
Antibody dilutions as previously detailed. N=1. 
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Figure 5.29: Immunocytochemistry of VE-cadherin expression following Epac1 siRNA 
transfection and addition of 8-pCPT 
VE-cadherin (red) distribution was identified in HCAECs treated with 10 nM Epac1 siRNA with (C) 
or without (A) Epac1 activation via 8-pCPT addition (5 µM).  10 nM non-silencing siRNA acted as 
a control (B & D). DAPI nuclear staining is shown in blue. Antibody dilutions as previously 
detailed. N=1. 
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5.3.2.5.5 - VE-cadherin and connexin co-localisation following Epac1 siRNA transfection and 
addition of 8-pCPT 
5.3.2.5 5.1 - VE-cadherin and Cx37 
HCAECs transfected with 10 nM Epac1 siRNA (Hs_RAPGEF3_6 and Hs_RAPGEF3_7 
duplexes) for 48 hours were labelled for VE-cadherin (red) and Cx37 (green) without, and 
following, 30 minutes incubation with 5 µM 8-pCPT at 37˚C/ 5% CO2. During preliminary 
experiments, labelling of VE-cadherin and Cx37 in Epac1 siRNA-transfected HCAECs 
identified isolated areas of co-localisation (yellow) between VE-cadherin and Cx37 (Figure 
5.30E). On addition of 5 µM 8-pCPT, little increase in co-localisation between VE-cadherin 
and Cx37 could be detected (Figure 5.30F). On transfection with Epac1 siRNA, Cx37 
appeared to show a strong association with the cytoskeleton, both with (Figure 5.30C) and 
without (Figure 5.30D) 8-pCPT addition. This distribution pattern was considerably different 
to the Cx37 expression profile observed under control conditions. Furthermore, Cx37 
appears to be lining the internal surface of the discontinuous membranous VE-cadherin, 
and again this pattern was displayed both with (Figures 5.30F) and without (Figures 5.30E) 
8-pCPT addition. DAPI nuclear staining (blue) appeared to indicate an increase in the 
proportion of both VE-cadherin and Cx37 associated with the nucleus on 8-pCPT addition 
(Figure 5.30F).  
HCAECs transfected with 10 nM non-silencing siRNA for 48 hours were used as a control 
during these preliminary experiments (Figure 5.31). These cells were also labelled without 
(Figures 5.31A, 5.31C & 5.31E), and following, 30 minutes incubation with 5 µM 8-pCPT 
(Figures 5.31B, 5.31D & 5.31F). Labelling of VE-cadherin and Cx37 in non-silencing siRNA -
transfected HCAECs identified isolated areas of co-localisation (yellow) between VE-
cadherin and Cx37 (Figures 5.31E). These HCAECs also displayed the altered Cx37 
distribution observed in Epac1 siRNA-transfected HCAECs, with Cx37 appearing to be lining 
the internal surface of the discontinuous membranous VE-cadherin (Figure 5.31E). On 
addition of 5 µM 8-pCPT, slight increase in VE-cadherin and Cx37 co-localisation at the 
membrane was detected (Figure 5.31F). Cx37, in particular, appeared to display a pattern 
more similar to that observed under control conditions (Figure 5.31D), and VE-cadherin 
formed a more continuous barrier at the HCAEC membrane (Figure 5.31B). DAPI nuclear 
staining (blue) again appeared to indicate an increase in the proportion of both VE-
cadherin and Cx37 associated with the nucleus on 8-pCPT addition (Figure 5.31F).  
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Figure 5.30: Immunocytochemistry of VE-cadherin and Cx37 expression following 
Epac1 siRNA transfection and addition of 8-pCPT 
VE-cadherin (red, A & B) and Cx37 (green, C & D) distribution was identified in HCAECs treated 
with 10 nM Epac1 siRNA, with (B, D & F) or without (A, C & E) 8-pCPT addition (5 µM). Isolated 
areas of VE-cadherin and Cx37 co-localisation (yellow) were identified in unstimulated Epac1 
siRNA-transfected HCAECs (E). No increase in co-localisation was identified following addition of 
5 µM 8-pCPT (F). DAPI nuclear staining is shown in blue. Antibody dilutions as previously 
detailed. N=1. 
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VE-cadherin and Cx37 co-localisation in Epac1 siRNA-transfected HCAECs was quantified 
using Image J (Figure 5.32). As previously detailed, three plugins were used to analyse the 
change in co-localisation induced by 8-pCPT addition (Figure 5.32A- 5.32C). On incubation 
with 5 µM 8-pCPT for 30 minutes, two of the plugins identified a significant decrease in VE-
cadherin and Cx37 co-localisation in the Epac1 siRNA-transfected HCAECs (Figures 5.32G & 
5.32H, unpaired students t-test, N=2-3). The third plugin identified no change in the 
proportion of VE-cadherin and Cx37 co-localisation (Figure 5.32I). This pattern was the 
reverse of that observed in control HCAECs, which displayed an increase in VE-cadherin and 
Cx37 co-localisation on addition of 8-pCPT.  
VE-cadherin and Cx37 co-localisation in non-silencing siRNA-transfected HCAECs was 
quantified using Image J using the three Image J plugins (Figure 5.32D- 5.32F). On 
incubation with 5 µM 8-pCPT for 30 minutes, two of the plugins identified an increase in 
VE-cadherin and Cx37 co-localisation in the non-silencing siRNA-transfected HCAECs 
(Figures 5.32D & 5.32E), one of which was statistically significant (Figure 5.32D, unpaired 
students t-test, N=2). The third plugin identified no change in the proportion of VE-cadherin 
and Cx37 co-localisation (Figure 5.32F). This pattern is similar to that observed in control 
HCAECs, with an increase in VE-cadherin and Cx37 co-localisation on addition of 8-pCPT. 
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Figure 5.31: Immunocytochemistry of VE-cadherin and Cx37 expression following 
non-silencing siRNA transfection and addition of 8-pCPT 
VE-cadherin (red, A & B) and Cx37 (green, C & D) distribution was identified in HCAECs treated 
with 10 nM non-silencing siRNA, with (B, D & F) or without (A, C & E) 8-pCPT (5 µM). Isolated 
areas of VE-cadherin and Cx37 co-localisation (yellow) were identified in un-stimulated non-
silencing siRNA-transfected HCAECs (E). Slight increase in co-localisation was detected following 
addition of 5 µM 8-pCPT (F). DAPI nuclear staining is shown in blue. Antibody dilutions as 
previously detailed. N=1. 
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Figure 5.32: Quantification of VE-cadherin and Cx37 co-localisation in HCAECs 
following Epac1 siRNA transfection and addition of 8-pCPT 
Under control conditions (A-C), addition of 5 µM 8-pCPT to HCAECs resulted in a significant 
increase in co-localisation of VE-cadherin and Cx37. HCAECs transfected with 10 nM non-
silencing siRNA (D-F) displayed a similar pattern, with one plugin detecting a significant increase 
in co-localisation on 8-pCPT addition (D). HCAECs transfected with 10 nM Epac1 siRNA (G-I) 
showed a reversal of this pattern, with two plugins identifying a statistically significant decrease 
in co-localisation between VE-cadherin and Cx37 on 8-pCPT addition (G & H). (* P<0.05, ** 
P<0.01, unpaired student t-test). For A-C; N=6 for untreated cells and N=5 for 8-pCPT treatment. 
For D-F; N=2. For G-I; N=2 for untreated cells and N=3 for 8-pCPT treatment. 
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5.3.2.5.5.2 - VE-cadherin and Cx40 
HCAECs transfected with 10 nM Epac1 siRNA (Hs_RAPGEF3_6 and Hs_RAPGEF3_7 
duplexes) for 48 hours were labelled for VE-cadherin (red) and Cx40 (green) without, and 
following, 30 minutes incubation with 5 µM 8-pCPT (Figure 5.33). During preliminary 
experiments, labelling of VE-cadherin and Cx40 in Epac1 siRNA-transfected HCAECs (Figures 
5.33A, 5.33C & 5.33E) identified areas of co-localisation (yellow) between these two 
junctional proteins, with a similar pattern to that observed in un-transfected HCAECs. On 
addition of 5 µM 8-pCPT (Figure 5.33B, 5.33D & 5.33F), VE-cadherin and Cx40 co-
localisation appeared to decline (Figure 5.33F). Preliminary data indicated that 
membranous VE-cadherin did not become more continuous as observed in un-transfected 
cells treated with 8-pCPT (Figure 5.33B), and Cx40 appeared to show an increased 
association with the nucleus, as indicated by the DAPI nuclear staining (blue, Figure 5.33F).  
VE-cadherin and Cx40 co-localisation in Epac1 siRNA-transfected HCAECs was quantified 
using three types of Image J plugins (Figure 5.34D- 5.34F). In un-transfected HCAECs, 
application of 5 µM 8-pCPT resulted in no significant change in VE-cadherin and Cx40 co-
localisation in HCAECs (Figure 5.34A- 5.34C, unpaired t-test, N=4). In Epac1 siRNA-
transfected HCAECs, application of 5 µM 8-pCPT resulted in a decrease in VE-cadherin and 
Cx40 co-localisation in two of the plugins (Figure 5.34D & 5.34E), one of which was 
statistically significant (Figure 5.34D, unpaired student t-test, N=4). The third Image J plugin 
identified no change in the proportion of VE-cadherin and Cx40 co-localisation (Figure 
5.34F). 
 
5.3.2.5.5.3 - VE-cadherin and connexin co-localisation following Epac1 siRNA transfection 
and addition of 8-pCPT - summary 
Together, this data suggests that Epac1 knockdown blocks the increased VE-cadherin and 
Cx37 co-localisation in HCAECs triggered by 8-pCPT application. Furthermore, Epac1 
knockdown also appears to decrease VE-cadherin and Cx40 co-localisation on addition of 8-
pCPT.  
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Figure 5.33: Immunocytochemistry of VE-cadherin and Cx40 expression following 
Epac1 siRNA transfection and addition of 8-pCPT 
VE-cadherin (red, A & B) and Cx40 (green, C & D) distribution was identified in HCAECs treated 
with 10 nM Epac1 siRNA, with (B, D & F) or without (A, C & E) 8-pCPT addition (5 µM). Areas of 
VE-cadherin and Cx40 co-localisation (yellow) were identified in un-stimulated Epac1 siRNA-
transfected HCAECs (E). This pattern appeared similar to that observed in un-transfected 
HCAECs. On addition of 5 µM 8-pCPT, VE-cadherin and Cx40 co-localisation appeared to decline 
(F). Cx40 showed strong nuclear-association, as indicated by the DAPI nuclear staining (blue, E & 
F). Antibody dilutions as previously detailed. N=1. 
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Figure 5.34: Quantification of VE-cadherin and Cx40 co-localisation in HCAECs 
following Epac1 siRNA transfection and addition of 8-pCPT 
Under control conditions (A-C), addition of 5 µM 8-pCPT to HCAECs resulted in no significant 
change in co-localisation of VE-cadherin and Cx40. HCAECs transfected with 10 nM Epac1 siRNA 
are represented in D-F. The Manders’ Overlap Coefficient plugin identified a significant decrease 
in co-localisation between VE-cadherin and Cx40 on addition of 8-pCPT (D). The Co-localisation 
Finder plugin showed a similar pattern, although not significant (E).  The Intensity Correlation 
Analysis plugin identified no change in the co-localisation pattern of VE-cadherin and Cx40 on 8-
pCPT addition (F). (** P<0.01, unpaired student t-test). For A-C; N=13 for untreated cells and 
N=5 for 8-pCPT treatment. For D-F; N=4.  
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5.3.2.6 - Epac antagonists 
5.3.2.6.1 - VE-cadherin and Cx37 co-localisation following incubation with Epac antagonists 
and addition of 8-pCPT 
Two types of Epac antagonists, ESI-09 and HJC0197, were used in preliminary experiments 
to examine the effect of Epac inhibition on the 8-pCPT-induced increase in VE-cadherin and 
Cx37 co-localisation.  
 
5.3.2.6 1.1 - ESI-09 
HCAECs were incubated with 5 nM ESI-09 for 10 minutes at 37˚C/ 5% CO2 and labelled for 
VE-cadherin (red) and Cx37 (green) (Figure 5.35). Labelling of VE-cadherin and Cx37 in ESI-
09-treated HCAECs (Figures 5.35A & 5.35C) identified isolated areas of co-localisation 
(yellow) between these two junctional proteins (Figure 5.35E). When HCAECs were treated 
with 5 µM 8-pCPT in the continued presence of ESI-09 (Figures 5.35B, 5.35D & 5.35F), a 
moderate increase in the co-localisation of VE-cadherin and Cx37 was detected (white 
arrows, Figure 5.35F).   
 
5.3.2.6.1.2 - HJC0197 
HCAECs were incubated with 5 nM HJC0197 for 10 minutes at 37˚C/ 5% CO2 and labelled 
for VE-cadherin (red) and Cx37 (green) (Figure 5.36). Labelling of VE-cadherin and Cx37 in 
HJC0197-treated HCAECs (Figures 5.36A & 5.36C) identified isolated areas of co-localisation 
(yellow) (Figure 5.36E), a pattern similar to that observed under control conditions. On 
addition of 5 µM 8-pCPT in the continued presence of HJC0197 (Figures 5.36B, 5.36D & 
5.36F), no increase in co-localisation between VE-cadherin and Cx37 could be detected in 
HCAECs pre-incubated with this antagonist.  
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Figure 5.35: Immunocytochemistry of VE-cadherin and Cx37 expression following ESI-
09 addition 
VE-cadherin (red) and Cx37 (green) distribution was identified in HCAECs following 10 minutes 
incubation with 5 nM ESI-09 at 37˚C/ 5% CO2 (A, C & E). Distribution of both junctional proteins 
appeared as in control conditions with isolated areas of overlap (yellow, E). Addition of 5 µM 8-
pCPT, in the continued presence of ESI-09, for 30 minutes at 37˚C/ 5% CO2 appeared to result in 
a slight increase VE-cadherin and Cx37 co-localisation at the membrane (white arrows, F). DAPI 
nuclear staining is shown in blue. Antibody dilutions as previously detailed. N=2. 
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Figure 5.36: Immunocytochemistry of VE-cadherin and Cx37 expression following 
HJC0197 addition 
VE-cadherin (red) and Cx37 (green) distribution was identified in HCAECs following 10 minutes 
incubation with 5 nM HJC0197 at 37˚C/ 5% CO2 (A, C & E). Distribution of both junctional 
proteins appeared as in control conditions with minimal overlap (yellow, E). Addition of 5 µM 8-
pCPT, in the continued presence of HJC0197, for 30 minutes at 37˚C/ 5% CO2 resulted in little 
alteration in VE-cadherin and Cx37 distribution (B, D & F). No increase in VE-cadherin and Cx37 
co-localisation could be detected following Epac activation. DAPI nuclear staining is shown in 
blue. Antibody dilutions as previously detailed. N=2. 
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5.3.2.6.1.3 - Quantification of VE-cadherin and Cx37 co-localisation following incubation 
with Epac antagonists and addition of 8-pCPT 
VE-cadherin and Cx37 quantification following pre-treatment with the Epac antagonists ESI-
09 and HJC0197 was analysed using three Image J plugins; Manders’ Overlap Coefficient, 
Co-localisation Finder plugin and Intensity Correlation Analysis (Figure 5.37). Under control 
conditions, application of 5 µM 8-pCPT resulted in a significant increase in co-localisation 
between VE-cadherin and Cx37 (Figure 5.37A- 5.37C, unpaired student t-test, N=5-6). In 
ESI-09-treated HCAECs or HJC0197-treated HCAECs, application of 8-pCPT resulted in no 
significant change in co-localisation (Figure 5.37D- 5.37F & 5.37G- 5.37I, unpaired student t-
test, N=7-9). Together, this data suggests that two Epac1 antagonists, ESI-09 and HJC0197, 
block the 8-pCPT-induced increased VE-cadherin and Cx37 co-localisation in HCAECs.  
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Figure 5.37: Quantification of VE-cadherin and Cx37 co-localisation in HCAECs 
following incubation with Epac antagonists ESI-09 and HJC0197 
A-C represent co-localisation of VE-cadherin and Cx37 in HCAECs under control conditions. All 
three Image J plugins identified a significant increase in co-localisation following addition of 5 
µM 8-pCPT for 30 minutes. When HCAECs were pre-incubated for 10 minutes with the 5 nM of 
the Epac antagonist ESI-09, 8-pCPT induced no significant change in VE-cadherin and Cx37 co-
localisation (D-F). Similarly, pre-incubation with 5 nM HJC0197 for 10 minutes resulted in no 
significant effect on VE-cadherin and Cx37 co-localisation following 8-pCPT addition (G-I). (* 
P<0.05, ** P<0.01, unpaired student t-test) For A-C; N=6 for untreated cells and N=5 for 8-pCPT 
treatment. For D-F; N=7. For G-I; N=8 for untreated cells and N=9 for 8-pCPT treatment. 
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5.4 – Discussion 
5.4.1 - Disruption of HCAEC cadherin interactions  
The effect of adherens junction disruption on the distribution pattern of VE-cadherin and 
connexins 37, 40 and 43 was examined by two methods: (i) blocking of VE-cadherin 
interactions by pre-incubation with the anti-VE-cadherin primary antibody, and, (ii) 
disruption of calcium-dependent VE-cadherin homotypic binding by removal of 
extracellular calcium by EGTA treatment. Under both conditions, preliminary data indicated 
that adherens junction disruption had a subsequent effect on HCAEC morphology and 
distribution patterns of VE-cadherin and connexins. Under control conditions, HCAEC 
morphology is flattened, forming an almost continuous sheet of cells (Figure 5.2A and 
Figure 5.4A & 5.4C). Following either 5 hours pre-incubation with 10 µg/ml of the anti-VE-
cadherin primary antibody (Figure 5.2B), or 30 minutes calcium-chelation with 5 mM EGTA 
(Figure 5.4B & 5.4D), adherens junctions were successfully disrupted and the HCAECs broke 
apart from each other forming isolated clusters of rounded cells. The degree of isolation 
was more extensive following the EGTA treatment. This indicates a small contribution of N-
cadherin-mediated adherens junctions, which would not be disrupted by pre-incubation 
with the anti-VE-cadherin primary antibody. In support of this data, Meyer et al. (1992) 
identified that treatment of re-aggregating Novikoff hepatoma cells with Fab fragments of 
antibodies for N-cadherin blocked adherens junction formation and increased inter-
membrane distances (Meyer, Laird et al. 1992). Moreover, on removal of extracellular 
calcium several groups have noted a vigorous contraction of cells away from each other, an 
effect hypothesised to be mediated by the junctional microfilament belt (Volberg, Geiger et 
al. 1986, Volk, Volberg et al. 1990, Kartenbeck, Schmelz et al. 1991).  
On adherens junction disruption (either through pre-incubation with the anti- VE-cadherin 
primary antibody or through calcium chelation), VE-cadherin became restricted to specific 
sites of the cell membrane, losing its even distribution throughout the plasma membrane 
(white arrows in Figure 5.2B and Figure 5.4B). No noticeable change in N-cadherin 
distribution could be detected on EGTA treatment (Figure 5.4D). Cullere et al. (2005) also 
identified a loss of VE-cadherin expression at junctional sites on incubation of human 
pulmonary artery ECs (HPAECs) in low calcium medium for 8 hours (Cullere, Shaw et al. 
2005). Furthermore, Alexander et al. (1998) hypothesised that this loss of membrane-
associated VE-cadherin on calcium chelation was likely to be a result of endocytosis of the 
protein (Alexander, Jackson et al. 1998), a theory that may account for the accumulation of 
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VE-cadherin at restricted membrane sites and the cytoplasmic aggregations observed. This 
theory is supported by the identification of detached zonula adherens plaques containing 
E-cadherin within endocytic vesicles on removal of extracellular calcium in bovine kidney 
epithelial cells (Kartenbeck, Schmelz et al. 1991).  
The re-distribution pattern of VE-cadherin was similar to that observed during preliminary 
experiments for connexin 37, in particular, after VE-cadherin antibody block and EGTA 
treatment (Figure 5.3D and Figure 5.6A). Moderate re-distribution of Cx40 was observed 
after pre-treatment with the anti- VE-cadherin primary antibody (Figure 5.3E), but no 
obvious change in the distribution pattern of Cx43 could be detected after either treatment 
(Figure 5.3F and Figure 5.8A). In support of this, treatment of teratinocarcinoma PCC3 cells 
with the anti-E-cadherin primary antibody (ECCD-1) resulted in a 4-5% decrease in Lucifer 
yellow dye transfer between cells, directly reflecting the decrease in gap junctional 
intercellular communication (Kanno, Sasaki et al. 1984). A similar decline in gap junction-
mediated communication on cadherin disruption was also observed in Novikoff cells 
(Meyer, Laird et al. 1992). Interestingly, this group also identified antibody Fab fragments 
for the first or second extracellular domains of Cx43 to have a negative effect on both 
adherens junction formation and gap junction formation, despite cells displaying inter-
membrane distances similar to those recorded at non-junctional regions of control cells 
(Meyer, Laird et al. 1992). The effect of calcium disruption on gap junctions has also been 
examined and it is generally accepted that gap junctions split on removal of extracellular 
calcium (Jansen, De Vrije et al. 1996, Perkins, Goodenough et al. 1997). Interestingly, it 
appears that unlike cadherins, disrupted connexins may persist at the membrane, with 
Perkins et al. (1997) identifying that gap junction channels disrupted by EGTA treatment 
maintained their connexon lattice pattern at each opposing membrane (Perkins, 
Goodenough et al. 1997). This is further supported by the identification of functional non-
junctional Cx37 and Cx40 hemichannels in monocytes (Wong, Christen et al. 2006) and 
neonatal mouse atrial and ventricular cardiomyocytes (Xu, Kopp et al. 2012), respectively.  
During preliminary experiments, the effect of calcium removal was shown to be reversible 
as cadherin-  and connexin-mediated cell-cell contacts started to re-form after 1 hour 
calcium restoration (Figures 5.5B, 5.6B, 5.7B &  5.8B), and cells appeared as under control 
conditions after 4 hours calcium restoration (Figures 5.9B, 5.10B, 5.11B &  5.12B). This 
result is supported by the literature where restoration of extracellular calcium promotes re-
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formation of cell-cell contacts and gap junctional intercellular communication within 45 
minutes (Cullere, Shaw et al. 2005).  
Addition of the anti-VE-cadherin primary antibody to the calcium-restoration phase of 
preliminary experiments effectively blocked the return to control conditions (Figures 5.5C, 
5.6C, 5.7C & 5.8C), indicating the requirement for VE-cadherin-mediated adherens 
junctions for the formation of cell-cell contacts in HCAECs. Pre-treatment with the anti-N-
cadherin primary antibody was not utilised as a method for adherens junction disruption as 
the antibody used in our experiments targeted the cytoplasmic tail of the protein and as 
such could not be used in un-permeabilised live cells.  
 
5.4.2 – The effect of Epac activation on HCAECs 
5.4.2.1 - Epac immunocytochemistry following 8-pCPT addition 
In order to determine the effect of 8-pCPT on Epac localisation, immunocytochemical 
experiments were carried out using HCAECs (Figure 5.16). In un-stimulated cells, Epac1 is 
thought to be distributed throughout the cell with staining evident at the nuclear envelope, 
in the nucleus, at the plasma membrane, at endomembranes and in the cytosol (Ponsioen, 
Gloerich et al. 2009). During preliminary experiments, such a pattern was evident in 
HCAECs under control conditions (Figure 5.16A). Within 5 minutes of 8-pCPT application (5 
µM) Epac1 was found to re-organise into small cytoplasmic aggregations (Figure 5.16B) 
followed by an increased membranous distribution after 30 minutes (Figure 5.16C). Epac is 
directly and selectively activated by 8-pCPT. Ponsioen et al. (2009) identified that 
application of forskolin or 8-pCPT resulted in Epac1 translocation to the periphery of the 
cell, to within 7 nm of the plasma membrane, within 2 minutes. A similar response has also 
been identified for Epac2 (Li, Asuri et al. 2006). The translocation of Epac1 to the plasma 
membrane was found to be both cAMP-dependent and reliant on the DEP domain 
(Ponsioen, Gloerich et al. 2009, Consonni, Gloerich et al. 2012). As previously detailed, the 
DEP domain is responsible for membrane localisation of the Epac proteins, and disruption 
results in a primarily cytoplasmic distribution of Epac (De Rooij, Rehmann et al. 2000, Bos, 
De Rooij et al. 2001). This 90 amino acid residue globular domain is located within the 
regulatory region, and is closely associated with the cAMP-binding domain (Ballon, Flanary 
et al. 2006, Li, Tsalkova et al. 2011). In the presence of cAMP, Epac1 directly binds to the 
negatively-charged plasma membrane phospholipid phosphatidic acid (PA), thereby 
223 
 
localising Epac to the plasma membrane (Consonni, Gloerich et al. 2012). Importantly, this 
group identified that Epac1 mutants lacking the DEP domain fail to bind PA.  cAMP 
increases solvent exposure of specific regions of the DEP domain in close association with 
arginine 82 (R82), a region identified as essential for cAMP-induced translocation of Epac 
(Ponsioen, Gloerich et al. 2009, Li, Tsalkova et al. 2011). R82 comprises part of the binding 
site for PA, therefore cAMP-induced conformational modification of the DEP domain 
enables direct interaction between Epac and the plasma membrane phospholipid PA, with 
increased binding after 30 minutes exposure to 8-pCPT (Consonni, Gloerich et al. 2012). 
The cAMP-induced re-distribution of Epac from the homogenous cytosolic pool was found 
to be diffusion-driven and not a result of active transport (Ponsioen, Gloerich et al. 2009, 
Consonni, Gloerich et al. 2012). This was supported by the persistence of cAMP-induced 
Epac translocation on disruption of either the actin cytoskeleton (via cytochalasin D) or of 
the microtubule network (via nocodazole) (Ponsioen, Gloerich et al. 2009). Furthermore, 
the cAMP-induced redistribution was found not to be a result of down-stream signalling 
involving Rap (Ponsioen, Gloerich et al. 2009). This group identified that over-expression of 
Rap1GAP, effectively blocking Rap1 and Rap2 activation, had no effect on Epac 
translocation (Ponsioen, Gloerich et al. 2009). Indeed, the DEP domain-mediated 
translocation of Epac to the plasma membrane was identified as a prerequisite for 
activation of Rap at this compartment, and appears to provide a means of selectively 
activating specific subcellular pools of Rap, thereby determining the downstream signalling 
pathway to be activated (Ponsioen, Gloerich et al. 2009). In the current study, when 
HCAECs were treated with 8-pCPT for 5 minutes, Epac1 appeared to organise into 
cytoplasmic aggregations (Figure 5.16B). This may suggest the use of vesicular structures 
for transport of Epac1 to the membrane, an occurrence that was not identified by Ponsioen 
et al. (2009). The existance of a pool of Rap1 at the Golgi complex has previously been 
detailed (Section 5.15). Furthermore, Berger et al. (1994) identified that Rap1 is partly 
localised to vesicular structures and translocated to the membrane on activation in 
platelets and T-lymphocytes (Berger, Quarck et al. 1994). On activation, a subset of Epac1 
may associate with, and activate, this compartment of Rap1, and be transported with it to 
the plasma membrane via such vesicular structures. This hypothesis would account for the 
cytoplasmic aggregations observed after 5 minutes treatment with 8-pCPT.  
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5.4.2.2 - Cadherin immunocytochemistry following 8-pCPT addition 
The effect of Epac activation on the distribution of VE-cadherin and N-cadherin in HCAECs 
was examined using immunocytochemistry techniques (Figure 5.17 and Figure 5.18). 
Addition of 8-pCPT to HCAECs during preliminary experiments appeared to result in a 
reduction of distinct areas of N-cadherin near-membrane staining, with an increased 
cytosolic distribution (Figures 5.18C & 5.18D). During similar experiments, application of 8-
pCPT to HCAECs triggered a re-distribution of VE-cadherin to form a continuous border at 
the membrane (Figure 5.17C & 5.17D). This re-distribution was blocked by transfection of 
HCAECs with Epac1 siRNA (Figure 5.29C). These preliminary results were consistent with 
previous findings (Cullere, Shaw et al. 2005, Fukuhara, Sakurai et al. 2005, Kooistra, Corada 
et al. 2005). Indeed, work by Fukuhara et al. (2005) identified that 0.2 mM 8-pCPT was 
sufficient to dramatically reduce basal endothelial permeability, implying a tighter 
membrane barrier and more adherens junctions, within 30 minutes. This pattern directly 
matches that observed in HCAECs (Figures 5.17C & 5.17D). In addition to a decrease in 
basal permeability, the increase in endothelial permeability induced by application of the 
pro-inflammatory mediator thrombin was also inhibited by 40% on addition of 100 µM 8-
pCPT (Cullere, Shaw et al. 2005, Fukuhara, Sakurai et al. 2005). A similar result was 
observed for vascular endothelial growth factor (VEGF)-induced vascular permeability in 
vivo (Fukuhara, Sakurai et al. 2005). The effect of 8-pCPT on VE-cadherin distribution was 
replicated on application of the cAMP-elevating agents forskolin (FSK) and prostacyclin 
(PGI2), and the effects of all three were insensitive to application of the PKA inhibitor H89 
(Fukuhara, Sakurai et al. 2005). The inhibitory effect of H89 on PKA was confirmed by 
inhibition of phosphorylation of CREB (Fukuhara, Sakurai et al. 2005). Furthermore, 
introduction of the constitutively active form of Epac (EpacΔcAMP) resulted in increased 
VE-cadherin-mediated adhesion, again suggesting Epac as the mediator of the cAMP-
induced increase in membranous VE-cadherin (Fukuhara, Sakurai et al. 2005). The decrease 
in endothelial permeability was entirely dependent upon Epac1 activation, and not Epac2, 
as shown by transfection of endothelial cells with Epac1 siRNA (Kooistra, Corada et al. 
2005). Together these results suggest that the cAMP-induced increase in membranous VE-
cadherin occurs via a PKA-independent pathway that involves Epac1. Epac is a GEF for the 
small G-protein Rap and functions to convert it to its active GTP-bound state (Section 5.15). 
The role of Rap in the Epac-mediated re-distribution of VE-cadherin was elucidated through 
the introduction of the constitutively active form of Rap1 and several Rap1GAPs (Fukuhara, 
Sakurai et al. 2005). The constitutively active form of Rap1, Rap1V12, reduced both basal and 
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thrombin-induced endothelial permeability, and increased VE-cadherin-mediated adhesion 
(Fukuhara, Sakurai et al. 2005). Rap1GAPII inactivates endogenous Rap1 and resulted in an 
increase in basal endothelial permeability and a decrease in the number of adherens 
junctions. Furthermore, this GAP also prevented the reduced permeability and increased 
VE-cadherin-mediated adherens junctions induced by both FSK and PGI2 (Fukuhara, Sakurai 
et al. 2005). This data therefore suggests that the cAMP-induced increase in membranous 
VE-cadherin occurs via the Epac/Rap1 pathway.  
cAMP elevation has also been shown to have an effect on the distribution pattern of N-
cadherin in neonatal rat cardiac myocytes (NRCMs) (Somekawa, Fukuhara et al. 2005). In 
these cells, application of db-cAMP or 8-pCPT induced enhanced N-cadherin distribution at 
cell-cell contacts (Somekawa, Fukuhara et al. 2005). The PKA-specific agonist, 6-Bnz-cAMP, 
had no effect on the distribution pattern of N-cadherin and therefore the Epac pathway 
mediated the cAMP-induced increase in membranous N-cadherin (Somekawa, Fukuhara et 
al. 2005). Much like VE-cadherin, this increased accumulation of N-cadherin at the 
membrane was also inhibited by a Rap1GAP, Rap1GAP1,  and therefore this re-distribution 
is also a result of the Epac/Rap pathway (Somekawa, Fukuhara et al. 2005). No increase in 
membranous N-cadherin could be detected in HCAECs on 8-pCPT application (Figure 5.18C 
& 5.18D). Indeed, cells appeared to show a decline in membranous N-cadherin, and an 
increase in the cytoplasmic distribution of this protein, on Epac activation. VE-cadherin is 
known to show dominance over N-cadherin for expression at the membrane (Section 
4.4.11), with the VE-cadherin cytoplasmic tail promoting N-cadherin exclusion from sites of 
cell-cell contact (Navarro, Ruco et al. 1998). It therefore seems logical that an increase in 
membranous VE-cadherin may result in a decrease in membranous N-cadherin. The 
vascular endothelial cell-specific cadherin, VE-cadherin, is not expressed in cardiac 
myocytes and so N-cadherin does not need to compete for membrane association.  
There is currently no general consensus on the mechanism by which Epac results in VE-
cadherin re-distribution. The literature does suggest three potential mechanisms and these 
are discussed below.  
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5.4.2.2.1 - Epac activation promotes actin re-organisation 
Maintenance of endothelial barrier function requires a cortical actin ring. Epac activation 
has previously been shown to induce an increase in cortical actin, and a decrease in actin 
stress fibres, via the Epac1 /Rap1 /Rac1 / Arp2/3 complex pathway (Section 5.1.9 – Rap1 
activates Rac through Tiam1 and Vav2). Maturation and stabilisation of the adherens 
junction requires attachment of the cadherins to the actin cytoskeleton (Section 1.7 – 
Adherens junctions and Section 4.1.2 - Cadherins). PGI2 and FSK application have been 
shown to increase the proportion of VE-cadherin anchored to the cytoskeleton (Fukuhara, 
Sakurai et al. 2005). Application of the actin de-polymerising agent Cytochalasin D inhibited 
the FSK-induced barrier enhancement and increase in VE-cadherin-mediated cell adhesions 
(Fukuhara, Sakurai et al. 2005). This data suggests that Epac activation increases the 
formation of cortical actin at the periphery of the cell which directly stabilises VE-cadherin-
mediated adherens junctions. Rap1 also stabilises adherens junctions through its effector, 
cerebral cavernous malformation-1 protein (CCM-1) (Lampugnani, Orsenigo et al. 2010). 
CCM-1 associates indirectly with VE-cadherin through β-catenin (Lampugnani, Orsenigo et 
al. 2010), and mutations in human CCM-1 result in defective endothelial cell-cell junctions 
and abnormal vasculature (Dejana, Tournier-Lasserve et al. 2009).  
The permeability-inducing agent thrombin promotes increased phosphorylation of myosin 
light chain (MLC) through the calcium/calmodulin-dependent MLC kinase (MLCK), resulting 
in a loss of peripheral β-catenin and increased stress fibre formation (Tinsley, De Lanerolle 
et al. 2000). Due to its linkage to the cytoskeleton through its interaction with catenins, VE-
cadherin can be physically pulled out of contact with its binding partner on an adjacent cell 
as a result of actin stress fibre-mediated cell contraction (Moy, Van Engelenhoven et al. 
1996). The Epac/Rap pathway is further implicated in the decrease in actin stress fibres 
through inhibition of the Rho pathway, activation of which produces actin stress fibres 
(Ridley and Hall 1992). Therefore, both the increase in cortical actin, and the resulting 
decrease in actin stress fibres, mediated by Epac activation act to stabilise adherens 
junctions.  
The Rac pathway is also involved in the increase in cortical actin observed during 
angiogenesis (Lee, Thangada et al. 1999, Garcia, Liu et al. 2001) and in the response to 
osmotic stress (Ciano, Nie et al. 2002). During angiogenesis, activated platelets release the 
phosphorylated lipid growth factor sphingosine 1-phosphate (Sph-1-P) which binds to Edg 
G-protein-coupled receptors on endtothelial cells. This rapidly triggers Rac GTPase 
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activation which directly activates P21-associated Ser/Thr kinase (PAK). PAK then promotes 
phosphorylation of the actin filament regulatory protein cofilin, through LIM kinase 
activation, and ultimately results in an increase in cortical actin. PAK and its downstream 
effectors may therefore also play a role in the Epac-induced increase in cortical actin.  
  
5.4.2.2.2 - The phosphorylation state of cadherin proteins affects adherens junction 
formation 
The ability of VE-cadherin to form mature adherens junctions is also determined by its 
phosphorylation state. Phosphorylation of cadherins at tyrosine residues correlates with a 
decrease in adhesive strength (Lampugnani and Dejana 1997). The pro-inflammatory 
mediator thrombin, which increases endothelial permeability, promotes disassembly of the 
adherens junction complex and/ or VE-cadherin internalisation through cadherin 
phosphorylation (Harris and Nelson 2010). VEGF stimulation triggers Src tyrosine kinase-
mediated phosphorylation of VE-cadherin on Y658 and Y731, and tyrosine phosphorylation 
of β-catenin (Wallez, Cand et al. 2007, Monaghan-Benson and Burridge 2009). Y658 is 
located within the VE-cadherin binding site for p120 catenin (Potter, Barbero et al. 2005) 
and its phosphorylation prevents VE-cadherin/ p120 catenin interaction, and thus the 
formation of a mature adherens junction.  Similarly, the VEGF-induced Y731 
phosphorylation disrupts VE-cadherin association with β-catenin (Potter, Barbero et al. 
2005, Bubik, Willer et al. 2012). Protein tyrosine phosphatases (PTPs) associate with, and 
dephosphorylate, VE-cadherin. Vascular endothelial receptor-type PTP (VE-PTP) is 
endothelial cell-specific and enhances VE-cadherin-mediated cell adhesion (Nawroth, Poell 
et al. 2002). PTPµ is an additional PTP restricted to endothelial cells (Hellberg, Burden-
Gulley et al. 2002). PTPµ binds RACK1 which is a membrane anchoring protein for active 
PKCε (Besson, Wilson et al. 2002). The Epac1 / Rap1/ PLCε- mediated activation of PKCε has 
previously been detailed (Section 5.1.11 – The role of Protein Kinase C in the Epac 
pathway). This may therefore provide a pathway through which PTPµ is recruited to the 
membrane resulting in signalling that promotes increased VE-cadherin dephosphorylation 
and enhanced adherens junction formation. Downstream signalling mediated by PKC has 
also previously been shown to result in dephosphorylation of p120 catenin (Ratcliffe, 
Smales et al. 1999). RACK1 is also capable of binding the SH2 domain of Src kinase which 
directly inhibits its kinase activity and prevents VE-cadherin phosphorylation (Hellberg, 
Burden-Gulley et al. 2002). Signalling induced by PKC has also previously been shown to 
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result in dephosphorylation of serine-threonine residues of p120-catenin (Ratcliffe, Smales 
et al. 1999). The importance of dephosphorylation on the formation of adherens junctions 
is highlighted by the action of angiopoietin-1. This anti-permeability agent promotes 
endothelial cell barrier function through a decrease in VE-cadherin phosphorylation 
(Gamble, Drew et al. 2000, Lee, Won et al. 2011).  
Vinculin is an actin-binding protein located close to the plasma membrane where actin 
microfilaments terminate (Geiger, Tokuyasu et al. 1980, Werth, Niedel et al. 1983). 
Phosphorylation of vinculin allows this protein to link adhesion plaques to the actin 
cytoskeleton via its tail binding to F-actin (Johnson and Craig 1995). Linkage of the adhesion 
plaque to the cytoskeleton stabilises the adherens junction. Epac activates PKCε via the 
Rap1-mediated activation of PLCε and the production of DAG (5.1.10 – Rap activates 
Phospholipase C). Epac may therefore promote the PKC-mediated phosphorylation of 
vinculin, directly stabilising adherens junctions.  
Interestingly, the hawthorn (Crataegus spp.) extract, WS 1442, which is a herbal treatment 
for moderate heart failure, appears to strengthen the endothelial barrier through the Epac 
pathway detailed here (Bubik, Willer et al. 2012). Thrombin-induced tyrosine 
phosphorylation of Tyr731 of VE-cadherin in HUVECs was blocked by WS 1442. 
Furthermore, WS 1442 application induced cortical actin rearrangement and a decrease in 
thrombin-induced F-actin stress fibre formation. Both effects were found to be mediated 
by the Epac1/Rap1/Rac1 pathway.  
 
5.4.2.2.3 - Epac may enhance trafficking of VE-cadherin from the Golgi complex 
VE-cadherin is trafficked from the Golgi complex to the cell surface in order to form 
nascent adherens junctions. In endothelial cells, Golgi-associated phospholipase A2α 
(cPLA2α) translocates from the cytoplasm to the Golgi complex in response to cell 
confluence (Regan-Klapisz, Krouwer et al. 2009). This movement of cPLA2α to the Golgi 
correlates with the formation of mature adherens junctions (Regan-Klapisz, Krouwer et al. 
2009), which is stimulated on Epac activation (see above). Once at the Golgi, cPLA2α 
traffics VE-cadherin to the cell surface, thereby providing a positive feedback loop for Epac-
induced VE-cadherin-mediated adherens junction formation. The requirement for mature 
VE-cadherin adherens junction for cPLA2α-mediated trafficking of VE-cadherin to the cell 
surface is shown by the reversion of cPLA2α translocation to the Golgi on incubation of 
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endothelial cells with VE-cadherin blocking antibodies (Regan-Klapisz, Krouwer et al. 2009). 
This thereby provides a pathway through which Epac may promote increased trafficking of 
VE-cadherin from the Golgi complex to the membrane.   
 
5.4.2.3 - VE-cadherin and connexin co-localisation following 8-pCPT addition 
To examine whether the Epac-induced re-distribution of VE-cadherin had an effect on the 
distribution of connexins 37, 40 and 43, the expression profile of these connexins, and the 
amount of co-localisation with VE-cadherin, was identified in HCAECs after 30 minutes 
treatment with 5 µM 8-pCPT during a series of preliminary experiments. On Epac 
activation, a significant increase in the co-localisation of VE-cadherin and Cx37 was seen in 
HCAECs (Figure 5.19 and Figure 5.22A- 5.22C). Similarly, an increase in co-localisation was 
also seen between VE-cadherin and Cx43 on Epac activation, however only one Image J 
plugin found this to be significant (Figure 5.21 and Figure 5.22G- 5.22I). No significant 
change in the co-localisation of VE-cadherin and Cx40 was identified in HCAECs treated 
with 8-pCPT during these experiments (Figure 5.20 and Figure 5.22D- 5.22F). Although the 
increase in co-localisation between VE-cadherin and connexins on application of 8-pCPT 
could primarily be a result of the re-distribution of VE-cadherin, the preliminary data clearly 
indicates an increase in membranous Cx37 on Epac activation (Figure 5.19D). The enhanced 
co-localisation between VE-cadherin and Cx37 on 8-pCPT application was inhibited by 
transfection of HCAECs with Epac1 siRNA (Figures 5.32G- 5.32I) and pre-incubation with the 
Epac antagonists HJC0197 (Figures 5.37G- 5.37I) and ESI-09 (Figures 5.37D- 5.37F). 
The literature on the effect of elevations in intracellular cAMP concentration on Cx37 
distribution is sparse. Many studies have, however, identified an increase in near-
membrane Cx43 and increased gap junction intercellular communication (GJIC) on cAMP 
application (Saez, Spray et al. 1986, Mehta, Yamamoto et al. 1992, Atkinson, Lampe et al. 
1995, Burghardt, Barhoumi et al. 1995).   
Changes in the distribution of connexins can be achieved through differential regulation of 
the stages involved in intercellular channel formation, including alterations in the rate of 
synthesis or degradation of connexin mRNA (Mehta, Yamamoto et al. 1992), the transport 
and oligomerisation of connexins (Musil and Goodenough 1991, Musil and Goodenough 
1993), the phosphorylation state of the connexin proteins (Saez, Spray et al. 1986, Van 
Rijen, Van Veen et al. 2000, Duncan and Fletcher 2002), the intercellular distance between 
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adjacent cells (Keane, Mehta et al. 1988, Meyer, Laird et al. 1992), and the internalisation 
of gap junctional plaques (Saez, Gregory et al. 1989). The potential role of the cAMP/Epac 
pathway in the modulation of these factors is discussed here.   
 
5.4.2.3.1 - Epac may promote enhanced connexin mRNA synthesis and transcription  
Elevations in intracellular cAMP have been found to result in enhanced synthesis of 
connexin mRNA and an increased rate of transcription in a number of cells (Mehta, 
Yamamoto et al. 1992, Darrow, Fast et al. 1996, Van der Heyden, Rook et al. 1998).  Work 
by Mehta et al. (1992) in communication-deficient rat Morris hepatoma cells (H5123) 
identified that forskolin addition resulted in a 15-40 fold elevation in Cx43 mRNA, 
accompanied by a 6 fold increase in the Cx43 transcription rate. This forskolin addition 
resulted in enhanced GJIC, as determined by electrical conductance and Lucifer yellow dye 
transfer (Mehta, Yamamoto et al. 1992). Similar results were also observed both with 8-
bromo-cAMP and the phosphodiesterase inhibitor Ro-20-1724 (Mehta, Yamamoto et al. 
1992). These results, and similar findings by Darrow et al. (1996) and van der Hayden et al. 
(1998), however, were only observed after 3-6 hours. As our increase in near-membrane 
connexin 37 was observed after just 30 minutes it is unlikely that in these experiments 
enhanced mRNA synthesis or an increased transcription rate were responsible for the 
increase in membrane-associated Cx37. In addition, these results were induced by cAMP 
elevation and as such the effects may have been mediated by PKA signalling. Prolonged 
exposure of HCAECs to 8-pCPT may have a long-term effect on the distribution of 
connexins, but this was not examined here.  
 
5.4.2.3.2 - Epac may enhance transport of connexin proteins to the plasma membrane on 
cAMP elevation 
cAMP-elevating agents promote enhanced trafficking of connexin proteins from the Golgi 
apparatus to the plasma membrane in numerous cell types (Atkinson, Lampe et al. 1995, 
Burghardt, Barhoumi et al. 1995, Holm, Mikhailov et al. 1999, Paulson, Lampe et al. 2000). 
The use of a chimeric protein composed of Cx43 and a green fluorescent protein (GFP) in 
the rat liver epithelial cell line RLcl9 by Holm et al. (1999), revealed the truly dynamic 
nature of connexins in these cells. Addition of 20 µM forskolin resulted in the formation of 
nascent Cx43 gap junctions within 5-10 minutes and an increase in size of pre-existing 
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junctions. Similarly, work by Burghardt et al. (1995) has shown that addition of 1 mM 8-
bromo-cAMP to these RLcl9 cells resulted in increased GJIC within 2 minutes. When pre-
treated with 1 mM octanol, which reduces the open probability of gap junctions to near 
zero, effectively uncoupling the cells, 8-bromo-cAMP continued to restore GJIC within 
minutes (Burghardt, Barhoumi et al. 1995). To elucidate the factor responsible for the 
cAMP-induced enhanced GJIC, this group treated the cells with 10 µM monensin to inhibit 
distal Golgi function and block translocation from the trans Golgi network to the plasma 
membrane (Burghardt, Barhoumi et al. 1995). Monensin treatment prior to 8-bromo-cAMP 
addition reduced the 8-bromo-cAMP-mediated enhanced GJIC and resulted in an increase 
in vesicular Cx43. The role of enhanced trafficking of connexin proteins to the membrane 
on elevated levels of intracellular cAMP is further evidenced through work by Paulson et al. 
(2000) in Novikoff hepatoma cells. Treatment of these cells with forskolin resulted in 
enhanced trafficking of Cx43 from the endoplasmic reticulum and Golgi apparatus to the 
plasma membrane, with no change in the total amount of Cx43 protein or in the 
phosphorylation state of Cx43 over 2.5 hours (Paulson, Lampe et al. 2000). Furthermore, 
addition of 36 µM Brefeldin A to block intracellular trafficking inhibited the increase in gap 
junction assembly mediated by forskolin (Paulson, Lampe et al. 2000). Such nascent gap 
junctions formed within minutes of addition of cAMP-elevating agents were shown to be 
functional by Atkinson et al. (1995). This group showed that addition of 8-bromo-cAMP 
resulted in increased permeability within 30 minutes, without an increase in the total 
protein concentration of Cx43 (Atkinson, Lampe et al. 1995). Taken together, this data 
suggests that Epac may promote connexin re-distribution to the membrane through 
enhanced trafficking from the Golgi apparatus.  
5.4.2.3.3 - Epac may promote connexin phosphorylation to increase GJIC 
Connexins have been shown to be phosphoproteins either through a shift in their 
electrophoretic mobility, as determined by Western blot, or via direct incorporation of 32P 
(Lampe and Lau 2000). Indeed, Cx26 is the only connexin reported to not be 
phosphorylated, potentially due to its short C-terminal tail (Traub, Look et al. 1989). The 
phosphorylation of connexins is generally considered to result in increased formation of 
functional gap junctions, and enhanced cell-cell communication (Saez, Spray et al. 1986, 
Van Rijen, Van Veen et al. 2000, Duncan and Fletcher 2002). Elevations in intracellular 
cAMP are able to trigger phosphorylation of connexins (Kuo and Greengard 1969, Musil, 
Cunningham et al. 1990). Application of 8-bromo-cAMP to primary rodent hepatocytes 
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results in a 1.6 fold increase in phosphorylated Cx32 within 30-60 minutes, and a 
subsequent 50-75% increase in GJIC (Saez, Spray et al. 1986). Similarly, addition of 300 µM 
8-bromo-cAMP to mouse mammary tumour cells (MMT22) resulted in an increase in the 
phosphorylated form of Cx43, re-distribution of Cx43 into gap junction plaques and an 
increase in Lucifer yellow dye transfer within 30 minutes (Atkinson, Lampe et al. 1995). This 
increase in GJIC was determined to be a result of an increase in the number and size of 
functional gap junctions, as the total cellular content of Cx43 mRNA and Cx43 protein was 
unchanged (Atkinson, Lampe et al. 1995). Darrow et al. (1996) also identified an increase in 
the number and size of Cx43 and Cx45 gap junctions on application of db-cAMP to cultured 
cardiac myocytes. This group, however, also identified a 2-4 fold increase in the total 
amount of Cx43 and Cx45 protein (Darrow, Fast et al. 1996). The increased membranous 
Cx37 observed in HCAECs on Epac activation occurred within 30 minutes, and it therefore 
seems likely that phosphorylation plays a role in this increase. Epac activates the Rap1/ 
Rac1/ PLCε pathway to activate PKCε (Section 5.1.11 – The role of Protein Kinase C in the 
Epac pathway). Similarly, addition of the DAG mimetic TPA, results in PKC activation and 
phosphorylation of Cx43 within 5 – 10 minutes (Musil and Goodenough 1991). PKCε, 
specifically, has also been shown to co-localise with, and promote, connexin 
phosphorylation that results in increased GJIC (Doble, Ping et al. 2000, Duquesnes, 
Derangeon et al. 2010). Both Cx40 and Cx43 have been shown to express phosphorylation 
sites for PKC (Beyer, Reed et al. 1992, Lampe 1994, Traub, Eckert et al. 1994). Application of 
1 mM 8-bromo-cAMP to communication-deficient human hepatoma cells (SKHep1) results 
in increased Cx40-mediated gap junction conductance and a 58% increase in Lucifer yellow 
dye transfer, accompanied by enhanced Cx40 phosphorylation (Van Rijen, Van Veen et al. 
2000). Considerable debate still surrounds the effect of Cx43 phosphorylation on GJIC. 
Rapid turnover of Cx43 gap junctional plaques is associated with loss of phosphorylated 
forms of Cx43 (Laird, Castillo et al. 1995), however, several groups have identified that 
phosphorylation of this connexin results in inhibition of GJIC (Berthoud, Rook et al. 1993, 
Lampe, TenBroek et al. 2000). Specifically, Lampe et al. (2000) identified that PKC-mediated 
phosphorylation of Cx43 at Ser368 resulted in a decrease in GJIC, despite PKA-mediated 
phosphorylation of Cx43 at Ser364 enhancing GJIC (Paulson, Lampe et al. 2000, Tenbroek, 
Lampe et al. 2001). In contrast, Duquesnes et al. (2010) identified that PKCε-mediated 
phosphorylation of Cx43 increased GJIC through enhanced open state probability, an 
increase that was blocked by PKC inhibitors. Interestingly, van Veen et al. (2000) identified 
that TPA-induced PKC activation increased electrical conductance in Cx45-transfected HeLa 
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cells through enhancing the open state probability, but that this was not a result of a 
change in the phosphorylation status of the connexin proteins. In support of this, TPA-
induced PKC activation in corpus cavernosum smooth muscle cells triggered an increase in 
the conductance of Cx43 gap junction channels within 15 minutes (Moreno, De Carvalho et 
al. 1993). This elevated GJIC was a result of a shift to a lower single channel unitary 
conductance, however both forskolin application and TPA addition also resulted in 
markedly elevated levels of Cx43 protein (Moreno, De Carvalho et al. 1993). The differential 
effects of TPA on GJIC may depend on the connexin phosphorylation state prior to TPA 
addition, the PKC isotype expressed in the cell investigated, and the experimental 
conditions. Kwak et al. (1995) identified that TPA-mediated activation of PKC increased gap 
junctional conductance but decreased permeability in neonatal rat cardiomyocytes. This 
resulted from a smaller pore size of the channel, ultimately restricting dye transfer, while 
open state probability or the number of channels was increased (Kwak, Van Veen et al. 
1995). Therefore, if GJIC is determined by dye transfer this may not accurately quantify the 
channel open probability. PKA agonists have been shown to have no effect on the 
conductance of single gap junction channels in SKHep1 cells transfected with Cx43 (Kwak, 
Hermans et al. 1995). Together, this data suggests that PKC, specifically PKCε, is a potential 
regulator of the Epac-mediated enhanced co-localisation between VE-cadherin and Cx37 
and Cx43 in HCAECs. 
Calcium-dependent protein kinases may also play a role in the re-distribution of connexins 
observed after 8-pCPT application to HCAECs. Recently, calcium/calmodulin-dependent 
protein kinase II (CaMKII) has been found to increase conductance at Cx36 gap junctions in 
mouse neuroblastoma (Neuro2A) cells (Del Corsso, Iglesias et al. 2012). The 
Epac/Rap1/Rac1/PLC pathway results in calcium release from the endoplasmic reticulum 
via IP3-mediated receptors (Section 5.1.10 – Rap activates Phospholipase C). 15 serine 
residues have been identified in the C-terminal of Cx43 that are capable of being 
phosphorylated by CaMKII (Huang, Laing et al. 2011). Furthermore, Cx35 in teleost 
Mauthner cells, an ortholog of the mammalian Cx36, has been found to co-localise with 
CaMKII and biochemical analysis has shown that the two proteins associate together 
(Flores, Cachope et al. 2010). Likewise, Cx36 itself has been found to co-localise with, and 
be phosphorylated by, CaMKII in the inferior olive region of the mammalian brainstem  
(Alev, Urscheld et al. 2008). Exposure of astrocytes to high potassium solutions induces an 
increase in Cx43-mediated dye coupling that is promoted by CaMKII, independent of any 
effect on Cx43 expression level or distribution (De Pina-Benabou, Srinivas et al. 2001). The 
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CaMKII-dependent nature of this increase in GJIC is shown by the inhibition of increased 
dye transfer or electrical coupling on addition of calmidazolium (an inhibitor of calmodulin-
regulated enzymes) or KN-93 (a selective CaMKII inhibitor) (De Pina-Benabou, Srinivas et al. 
2001). Interestingly, Cx43 again appears to display alternative responses to 
phosphorylation by this kinase, depending on the cell type. Increased intracellular calcium 
concentration (through ionomycin addition) in stable murine neuroblastoma (Neuro2A) 
cells expressing Cx43 reduced gap junction conductance by 95% (Xu, Kopp et al. 2012). The 
CaMKII 290-309 inhibitory peptide prevented this decline in GJIC. On examination, Cx43 
gap junction channel open probability was found to decline to zero on external ionomycin 
addition. This group therefore concluded that in murine Neuro2A cells Cx43 gap junctions 
are gated closed by CaMKII activity. This is the opposite effect observed for Cx36 gap 
junctions in Neuro2A cells (see above) (Del Corsso, Iglesias et al. 2012). Together, this data 
suggests that calcium-dependent protein kinases may act to phosphorylate connexins on 
Epac activation, and subsequently regulate gap junction formation.   
 
5.4.2.3.4 - The Epac-mediated actin rearrangement and adherens junction formation 
promotes gap junction formation  
Epac activation activates the Rap1 / Rac1 / Arp2/3 complex pathway which results in 
cortactin phosphorylation, increased cortical actin formation and a decrease in actin stress 
fibres, all of which directly promote the formation of new adherens junctions (Section 5.1.9 
– Rap1 activates Rac through Tiam1 and Vav2). This pathway is enhanced by the Epac-
induced activation of PLCε (via Rap1) which converts PIP2 into DAG and IP3. DAG has a 
positive feedback effect on Rac1 activation. DAG also has the ability to activate PKC 
isoforms, specifically PKCε, the downstream signalling of which can trigger the de-
phosphorylation or phosphorylation of various proteins, ultimately stabilising the cortical 
actin rim and the formation of nascent adherens junctions. The requirement for the 
formation of adherens junctions prior to the formation of functional gap junctions is well 
established in the literature (Section 4.4.13). It therefore seems logical that an increase in 
adherens junctions couples adjacent cells more tightly and an increased number of gap 
junctions are able to form. Blocking protein trafficking from the endoplasmic reticulum or 
Golgi complex does not prevent cAMP-induced clustering of Cx43 at the plasma membrane 
(Wang and Rose 1995). This finding suggests that a pool of plasma membrane-associated 
Cx43 must exist that is responsible, at least in part, for the cAMP-induced clustering of gap 
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junctions at sites of cell-cell contact. Furthermore, cAMP-mediated increased Cx43 gap 
junction assembly is still observed in cells incubated at 4°C, a temperature that inhibits 
vesicular trafficking (Li, Liu et al. 1996, Paulson, Lampe et al. 2000). This membranous Cx43 
could serve as a reservoir of subunits to allow expansion of gap junction communication, 
and is activated on the Epac-induced actin rearrangement that promotes the formation of 
adherens junctions.   
Connexins and cadherins have also previously been shown to be directly linked by their 
associated binding proteins (Section 4.4.13). Both Cx43 and VE-cadherin interact with β-
catenin (Ai, Fischer et al. 2000) and ZO-1 (Toyofuku, Yabuki et al. 1998, Somekawa, 
Fukuhara et al. 2005). Indeed, the Wnt-1-induced increased expression of Cx43 at the 
plasma membrane in cardiac myocytes is due to the accumulation of β-catenin (Ai, Fischer 
et al. 2000). It is therefore possible that the increased accumulation of VE-cadherin near 
the plasma membrane on 8-pCPT addition results in translocation of connexins to the 
plasma membrane where they join their opposing connexin on an adjacent cell and form a 
functional gap junction. Furthermore, the clustering of Cx43 observed on elevation of 
intracellular cAMP by Wang and Rose (1995) was found to be enhanced by inhibition of 
glycosylation (via tunicamycin addition). Reduced glycosylation of N-cadherin results in 
increased formation of N-cadherin-containing adherens junctions (Guo, Johnson et al. 
2009). This therefore suggests a direct link between enhanced adherens junction formation 
and increased clustering of Cx43 at the plasma membrane. Together, this data suggests 
that the actin rearrangement and the subsequent increased formation of adherens 
junctions mediated by cAMP-elevating agents or 8-pCPT, is likely to play a role in the 
increased membranous distribution of connexins observed in HCAECs.  
 
5.4.3 – Concluding remarks 
Taken together, this preliminary data suggests that cadherin disruption through incubation 
with both the anti-VE-cadherin primary antibody and EGTA has a direct effect on connexin 
distribution in HCAECs, particularly Cx37. Similarly, an increase in AJ formation induced by 
Epac activation promotes Cx37 re-distribution to near-membrane sites. This Epac-mediated 
enhanced cell-cell communication is hypothesised to be a result of actin reorganisation to 
form a strong cortical actin ring, enhanced transport of junctional proteins to the 
membrane and altered protein phosphorylation.  
 
236 
 
 
 
 
 
 
 
 
 
Chapter 6:  
Functional effect of Epac activation in HCAECs 
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Aims of this chapter:  
 
 To determine if the Epac-induced re-distribution of Cx37 enhances GJIC 
 To examine the effect of Epac activation on intracellular calcium concentrations in 
HCAECs 
 
 
Key findings of this chapter: 
 
 Epac activation by 8-pCPT application resulted in increased Lucifer yellow dye 
transfer between HCAECs, as determined by scrape assay 
 The Epac antagonist HJC0197 completely blocked the 8-pCPT-induced increase in 
dye transfer between HCAECs  
 8-pCPT application resulted in a transient increase in intracellular calcium, as 
reported by the calcium indicator Fluo-4  
 The 8-pCPT-induced rise in intracellular calcium was largely unchanged by either 
removal of extracellular calcium, pre-incubation with ryanodine, or pre-incubation 
with PKI, a PKA inhibitor 
 The 8-pCPT-induced rise in intracellular calcium was completely inhibited by the 
Epac antagonist HJC0197  
 Forskolin application induced a rise in intracellular calcium in HCAECs. However, 
the profile of the calcium transient triggered by forskolin appeared to differ from 
that induced by 8-pCPT 
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6.1 - Introduction 
Following immunocytochemical experiments where Epac activation in HCAECs led to an 
apparent increase in Cx37 distribution at the membrane (Chapter 5), the functional 
consequence of increased gap junctions was assessed. Quantification of Lucifer yellow dye 
transfer through a scrape assay was used to evaluate gap junction intercellular 
communication (GJIC) in HCAECs. The effect of Epac on the intracellular concentration of 
calcium, a second messenger that can be transferred via GJIC, was also examined.  
 
6.1.1 - Selectivity of gap junction channels  
The relative selectivity of different GJ channels is variable, and dependent upon the 
individual connexins forming the channel (Brink and Fan 1989, Elfgang, Eckert et al. 1995, 
Goldberg, Valiunas et al. 2004). Homomeric Cx32 gap junctions, for example, show no 
preference for cAMP or cGMP, while heteromeric GJ channels, composed of both Cx32 and 
Cx26, allow the preferential transfer of cGMP over cAMP (Bevans, Kordel et al. 1998). 
During keratinocyte differentiation, there is a switch in connexin expression from Cx43 and 
Cx26 to Cx31 and Cx31.1 that is accompanied by a decrease in the transfer of large 
molecules, such as the dye Lucifer yellow, which has a molecular weight of 443 Da (Stewart 
1981), even though the cells remained electrically coupled (Brissette, Kumar et al. 1994). 
Indeed, connexins have single channel conductances that range from 20 picoSiemens (pS) 
to several hundrend pS, and homomeric Cx40 channels, for example, show electrical 
conductance of between 120-200 pS (Traub, Eckert et al. 1994, Beblo, Wang et al. 1995, 
Bukauskas, Elfgang et al. 1995).  
 
6.1.2 – Gating of gap junction channels  
Gap junction channels are sensitive to changes in both extracellular and intracellular 
conditions and can close in response to unsuitable or pathological conditions. This has a 
protective function, isolating the cell from its adjacent neighbours and preventing the 
spread of harmful signals or ion concentrations. As such, GJ channels are particularly 
sensitive to changes in voltage, phosphorylation, pH or calcium concentration. Despite this, 
even at transjunctional voltages of 40 mV and pH6.8, GJs can have open probabilities of 
between 0.6-0.9, indicating that most GJ channels are gated-open more often than gated-
closed (Christ and Brink 1999, Goldberg, Valiunas et al. 2004). This high resting open-state 
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probability explains the requirement for selective permeability of different GJ channels, as 
detailed above. Calcium was the first cytoplasmic factor to be identified in the regulation of 
GJ function, with increases in the cytoplasmic concentration of calcium decreasing GJIC 
(Rose and Loewenstein 1976, Loewenstein 1981, Evans and Martin 2002). The gating of GJ 
channels is also regulated by intracellular acidity. The C-terminus of Cx43, for example, is 
pH-sensitive and has been implicated in the gating of Cx43-containing GJ channels on 
changes in intracellular pH (Morley, Taffet et al. 1996). During this process, the mechanism 
of closing appears to operate via the ball-and-chain model, whereby a cytoplasmic region 
of the protein effectively closes the channel pore (Morley, Taffet et al. 1996). Changes in 
voltage also affect the gating-state of the GJ channel. In amphibian blastomeres, junctional 
conductance is maximal at zero transjunctional voltage, and is rapidly decreased by 
movement towards either polarity (Spray, Harris et al. 1979, Harris, Spray et al. 1981). The 
phosphorylation state of the components of the GJ channel also determines the gated-
state of the channel. Increases in tyrosine phosphorylation of Cx43, for example, decreased 
GJIC in various cell types including rat microvascular endothelial cells (Moreno, Sáez et al. 
1994, Cai, Jiang et al. 1998, Lidington, Tyml et al. 2002). Phosphorylation of connexins can 
also alter the rate of channel assembly, with phosphorylation of serines 325, 328 or 330 on 
Cx43 increasing Cx43 GJ formation (Cooper and Lampe 2002).  
 
6.1.3 - Calcium in endothelial cells 
Calcium is a major second messenger in endothelial cells, and can be exchanged directly 
between both endothelial cells, and endothelial cells and smooth muscle cells, via gap 
junctions. The endoplasmic reticulum (ER) accounts for approximately 75% of the total 
intracellular calcium reserve in endothelial cells (Tran, Ohashi et al. 2000), and the total ER 
calcium concentration can reach up to 3 mM (Sambrook 1990, Meldolesi and Pozzan 1998). 
Mitochondria account for the remaining calcium reserve, and mitochondrial calcium is 
typically released following release of calcium from the ER, in a process termed 
mitochondrial calcium-induced calcium release (mCICR)(Tran, Ohashi et al. 2000). 
6.1.3.1 – Calcium release from the endoplasmic reticulum 
In endothelial cells, calcium release from the ER is generally considered to be mediated by 
IP3-induced opening of IP3R channels (Tran, Ohashi et al. 2000, Plank, Wall et al. 2006). IP3 
is generated through the PLC-mediated hydrolysis of PIP2 which forms IP3 and DAG (Section 
240 
 
5.1.10) (Schmidt, Evellin et al. 2001, Song, Hu et al. 2001), and binding of IP3 to the IP3R on 
the ER membrane triggers calcium release from the ER lumen.  Vertebrates express 3 IP3R 
subtypes; IP3R1, IP3R2 and IP3R3 (Ferris, Huganir et al. 1989, Mikoshiba 2007, Zhang, Fritz et 
al. 2011), and vascular endothelium has been shown to express all three isoforms 
(Mountian, Manolopoulos et al. 1999, Ledoux, Taylor et al. 2008). Ryanodine receptors 
(RyRs) are generally not considered to be functionally important in non-excitable cells 
(Bruce, Straub et al. 2003), although they have been identified in endothelial cells of the 
thoracic aorta and mesenteric artery (Lesh, Marks et al. 1993, Kohler, Brakemeier et al. 
2001). It should be noted, however, that agonist-evoked calcium oscillations in non-
excitable cells such as pancreatic acinar cells, parotid acinar cells and intestinal epithelial 
cells, are sensitive to RyR inhibitors and thus RyRs in such cells have been implicated in the 
amplification of signals originating from IP3R channels (Verma, Carter et al. 1996, Straub, 
Giovannucci et al. 2000, Bruce, Shuttleworth et al. 2002). 
 
6.1.3.2 - Store-operated calcium entry 
If calcium release from the ER continues to occur in the absence of extracellular calcium, 
calcium increase will eventually cease to occur as the ER is progressively emptied. 
Furthermore, in addition to IP3-induced calcium release, calcium also leaks from the ER of 
resting cells. It has been known for some time that calcium influx across the cell membrane 
that occurs as a result of ER calcium release is an important part of calcium homeostasis. 
Calcium entry induced by depletion of the ER calcium store is termed store-operated 
calcium entry (SOCE) or capacitative calcium entry (CCE). This event allows re-filling of 
depleted calcium stores to prime the ER for the next calcium release event. The best 
characterised example of SOCE is the calcium current termed ICRAC, where CRAC stands for 
calcium-release-activated calcium (Hoth and Penner 1992, Hogan and Rao 2007). Unlike 
non-selective cation channels discussed later, ICRAC was thought to be highly selective for 
calcium, despite its molecular identity remaining elusive (Hoth and Penner 1992, Zweifach 
and Lewis 1993, Parekh and Penner 1995, Zubov, Kaznacheeva et al. 1999). Originally, this 
mechanism was linked to a family of canonical transient receptor potential channels 
(TRPCs) (Brough, Wu et al. 2001). Generally, TRPC is thought to be a non-selective cation 
channel, and thus under physiological ion gradients, sodium would be the primary ion 
flowing through this channel. It would therefore be surprising if the highly-selective ICRAC 
pathway was explained by the opening of TRPCs. IP3Rs have also previously been linked 
241 
 
with the induction of SOCE through ICRAC (Irvine 1990, Berridge 1995), however more recent 
data has suggested that IP3Rs may actually have an inhibitory effect on SOCE in order to 
prevent calcium overload (Lur, Sherwood et al. 2011). Stromal interaction molecule (STIM), 
expressed in the ER membrane, has since been implicated in the function of ICRAC (Liou, Kim 
et al. 2005, Roos, DiGregorio et al. 2005, Luik, Wu et al. 2006). Two isoforms of STIM exist, 
STIM1 and STIM2, and both act as sensors of calcium concentration in the ER lumen 
through their low-affinity calcium-binding EF hands (Soboloff, Rothberg et al. 2012). On a 
fall in the calcium concentration within the ER, triggered by ER calcium release, calcium 
dissociates from the EF hand of STIM, which leads to an intra-molecular re-arrangement of 
STIM that promotes oligomerisation and translocation of STIM1, visible as puncta in 
immunocytochemical studies (Wu, Buchanan et al. 2006, Lur, Haynes et al. 2009). These 
puncta have since been found to co-localise with sites of calcium entry (Luik, Wu et al. 
2006). The translocation of STIM to sites in close association with the plasma membrane 
causes recruitment of Orai1, a newly-identified calcium channel with a calcium influx 
pattern similar to ICRAC (Potier, Gonzalez et al. 2009). Orai1 forms the calcium-selective pore 
of the channel (Prakriya and Lewis 2006, Taylor 2006, Yeromin, Zhang et al. 2006, Putney 
2007). STIM1 has also been suggested to regulate TRPC for calcium entry, however this 
mechanism of SOCE is still considered relatively controversial (Worley, Zeng et al. 2007, 
Birnbaumer 2009, Lee, Choi et al. 2014). 
As non-excitable cells, endothelial cells lack voltage-dependent calcium channels (VDCCs), 
and therefore SOCE is likely to be the main mechanism of agonist-induced calcium entry 
(Lambert, Kent et al. 1986, Dolor, Hurwitz et al. 1992, Schilling, Cabello et al. 1992). SOCE 
has also been implicated in shear-stress-induced calcium release (Ishida, Takahashi et al. 
1997). 
 
6.1.3.3 - Additional calcium-entry mechanisms 
Calcium entry also occurs via transplasmalemmel calcium entry channels including voltage-
dependent calcium channels (VDCCs) (Bossu, Elhamdani et al. 1992, Tran, Ohashi et al. 
2000) and non-selective cation channels (Gericke, Droogmans et al. 1993, Inazu, Zhang et 
al. 1995, Pasyk, Inazu et al. 1995). VDCCs are thought to have little functional importance in 
endothelial cells (Himmel, Whorton et al. 1993). 
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Non-selective cation channels of importance when considering intracellular calcium 
elevations triggered by a rise in the cytoplasmic concentration of cAMP are cyclic 
nucleotide-gated (CNG) cation channels. These channels are permeable to cations, 
including calcium, and their gating is directly regulated by the intracellular cGMP and/or 
cAMP concentrations. The most well-characterised nucleotide-gated cation channels are 
those in sensory systems including photoreceptors and olfactory sensory neurons (Fesenko, 
Kolesnikov et al. 1985, Kaupp and Seifert 2002). In endothelial cells, both adenosine and 
adrenaline elicit an increase in intracellular cAMP which induces calcium influx through the 
direct activation of CNG ion channels which stimulates the release of nitric oxide (NO), 
prostacyclin and EDHF (Cheng, Leung et al. 2008, Shen, Cheng et al. 2008). Through this 
mechanism, CNG ion channels have been implicated in the endothelial-mediated relaxation 
of vascular smooth muscle cells (Shen, Cheng et al. 2008, Leung, Du et al. 2010, Serban, 
Nilius et al. 2010). As previously mentioned, TRPC channels are also non-selective cation 
channels, and this mechanism of calcium entry is typically activated by PLC stimulation 
(Hofmann, Schaefer et al. 2000, Montell, Birnbaumer et al. 2002). 
 
6.1.3.4. – Removal of calcium from the cytosol 
In addition to calcium entry, cytoplasmic calcium clearance pathways also exist to return 
intracellular calcium concentrations to pre-stimulation levels. The major calcium clearance 
pathway in non-excitable cells is generally considered to be through re-uptake into the ER 
by Sarco/endoplasmic reticulum calcium ATPase (SERCA) pumps (Berridge, Lipp et al. 
2000). This ATP-dependent pump uptakes calcium from the cytosol to counteract ER 
calcium leak, and maintain the calcium load of the ER. SERCA pumps are inhibited by 
thapsigargin and cyclopiazonic acid (CPA) (Berridge, Lipp et al. 2000, Tran, Ohashi et al. 
2000). As such, addition of either thapsigargin or CPA depletes the ER store by virtue of 
calcium leak that cannot be replenished, and therefore prevent calcium release. In addition 
to SERCA pumps, calcium can also be cleared from the cytosol by plasma membrane 
calcium ATPase (PMCA) pumps (Bruce, Straub et al. 2003). PMCA pumps have a relatively 
ubiquitous distribution, and PMCA1 and PMCA4 are expressed in most tissues (Greeb and 
Shull 1989). Calcium can also be removed from the cytoplasm by the Na+/ Ca2+ exchanger. 
This mechanism is electrogenic as one calcium ion is removed from the intracellular 
environment in exchange for three sodium ions entering the cell. This calcium-clearing 
mode is termed forward mode and is particularly important in calcium homeostasis of 
243 
 
cardiac cells (Shigekawa and Iwamoto 2001). This process does not consume ATP directly, 
but depends on the presence of ATP to create the required sodium concentration gradient 
through the sodium pump that consumes ATP. 
 
6.1.4 - Calcium in the control of vascular tone 
The intracellular concentration of calcium in both endothelial and smooth muscle cells 
plays a crucial role in the regulation of vascular tone. As previously mentioned in Chapter 1, 
a rise in smooth muscle cell intracellular calcium concentration triggers contraction of 
these cells, involving actin/myosin cross-bridging. Changes in endothelial cytoplasmic 
calcium concentration can induce vascular relaxation. One of the major mechanisms 
mediating endothelial-induced relaxation involves endothelial-derived hyperpolarising 
factors (EDHFs). The classical EDHF pathway involves a rise in intracellular endothelial 
calcium concentration which triggers the opening of small- and intermediate-conductance 
calcium-sensitive potassium (SKca and IKca) channels. This leads to endothelial cell 
hyperpolarisation as potassium leaves the cell (Dora 2001, Edwards, Feletou et al. 2010). 
This hyperpolarising current can pass directly to adjacent smooth muscle cells via gap 
junctions at the myoendothelial junction (MEJ)(Sandow, Tare et al. 2002, de Wit and 
Griffith 2010). IKca channels have also been identified on endothelial cell projections that 
protrude through gaps in the internal elastic lamina separating the endothelium from the 
tunica media (Sandow, Neylon et al. 2006), and thus potassium is released into the 
extracellular space directly adjacent to the smooth muscle layer. This released potassium 
can activate sodium/potassium-ATPase and inwardly-rectifying potassium channels on 
smooth muscle cells that induces smooth muscle hyperpolarisation, closure of VDCCs and 
thus smooth muscle cell relaxation (Edwards, Dora et al. 1998, Roberts, Kamishima et al. 
2013). 
 
6.1.5 - Calcium measurement in live cells 
Intracellular calcium concentration is typically recorded through the use of calcium-
sensitive dyes. The two most commonly used dyes are Fura-2 (Kang, Chepurny et al. 2001, 
Mayati, Levoin et al. 2012) and Fluo-4 (Yip 2006, Roberts, Kamishima et al. 2013). The type 
of dyes that are often used for experiments are made membrane-permeable by addition of 
acetoxymethyl (AM) groups to allow loading of the cell. Calcium-sensitive dyes often have 4 
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AM groups, and removal of all 4 by intracellular esterases is necessary for the dye to 
become calcium-sensitive. Fura-2 is a ratiometric probe that requires excitation at two 
separate wavelengths, 340 nm and 380 nm, to produce two emission values that can be 
converted to free calcium concentration. Such ratiometric probes allow recording of 
calcium concentration independent of dye concentration, bypassing the issue of 
inconsistent loading of the cells. However, if the AM form of the dye is used, incomplete 
hydrolysis, as well as potential compartmentalisation of the dye to intracellular organelles, 
can be problematic. Non-ratiometric probes such as Fluo-4, on the other hand, are 
stimulated at a single wavelength (488 nm), and the calcium concentration is determined 
by a relative increase in the fluorescence intensity. Issues associated with the use of such 
non-ratiometric dyes typically involve inconsistent loading of cells. Additional calcium-
detection methods include fluorescent protein-based probes that are constructed with a 
calmodulin backbone. Calcium-binding to the calmodulin backbone induces a 
conformational change that alters the fluorescent properties of the bound fluorescent 
protein (Miyawaki, Llopis et al. 1997).  
 
 
6.1.6 Epac and the control of vascular tone 
Physiological agonists binding to Gs-protein-coupled receptors, such as adrenaline 
(epinephrine), which binds to the β2-adrenoceptor, adenosine, which binds to the A2A 
receptor, and prostacyclin, which binds to the EP4 receptor, are classical vaso-relaxing 
agents, and their ability to relax arteries requires, at least in part, intact endothelium (Yen, 
Wu et al. 1988, Kou and Michel 2007, Mitchell, Ali et al. 2008). cAMP and calcium are 
thought to be the predominant second messengers involved in the transduction of such 
vaso-relaxing effects mediated by the endothelium (Kou and Michel 2007, Roberts, 
Kamishima et al. 2013).  The elevation of cAMP is triggered by GPCR-mediated activation of 
adenylate cyclase, and leads to the cAMP-mediated activation of both PKA and Epac. The 
elevation of calcium occurs through the generation of IP3 that triggers the release of 
calcium from the ER. Generally, these two pathways are considered somewhat separately 
as PKA activation is not conventionally linked with a rise in intracellular calcium 
concentration. However, a recent study by Roberts et al. (2013) provided novel evidence 
that Epac activation may trigger a rise in intracellular calcium concentration in rat 
mesenteric artery endothelial cells (Roberts, Kamishima et al. 2013). In this study, addition 
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of 5 µM 8-pCPT was sufficient to relax rat mesenteric artery pre-constricted with 
phenylephrine (3 µM). Further investigation by this group showed that this effect was 
partly endothelium-dependent, as mechanical disruption of the endothelium inhibited the 
relaxation induced by 8-pCPT application. Furthermore, the relaxing effect of the Epac-
specific agonist on pre-constricted arteries was blocked by inhibitors of intermediate- and 
small-conductance calcium-activated potassium (IKca and SKca) channels, Tram-34 (1 µM) 
and apamin (100 nM), respectively (Roberts, Kamishima et al. 2013).  Both IKca and SKca 
channels are thought to be expressed by endothelial cells (Edwards, Dora et al. 1998, 
Ohashi, Satoh et al. 1999), and as their name suggests, are regulated by intracellular 
calcium concentration. Indeed, direct activation of Epac through 8-pCPT application within 
mesenteric endothelial cells loaded with Fluo-4-AM was shown to induce a sustained 
increase in global calcium (Roberts, Kamishima et al. 2013). cAMP has long been known to 
induce vascular relaxation by decreasing cytosolic calcium within smooth muscle cells 
through activation of potassium currents that hyperpolarise the smooth muscle membrane 
and reduce calcium influx by decreasing activity of VDCCs (Nelson, Patlak et al. 1990, 
Nelson and Quayle 1995). Thus, it is possible that Epac activation causes calcium increase in 
endothelial cells which, in turn, activates two classes of calcium-activated potassium 
channels leading to vaso-relaxation.  
 
6.2 – Results 
The functional effect of Epac activation on HCAECs was investigated using Lucifer yellow 
dye transfer to assess GJIC. In addition, the effect of Epac activation on the intracellular 
concentration of the second messenger calcium in HCAECs was experimentally assessed 
through live calcium imaging. 
6.2.1 - Lucifer yellow dye transfer during Epac activation and inhibition 
To determine whether Epac triggers enhanced GJIC in HCAECs, Lucifer yellow dye transfer 
between HCAECs was examined under varying conditions using a scrape assay. As cell 
confluence varied slightly between repeats, control experiments were performed for each 
separate experiment.  Figure 6.1 is a brightfield image of the scrape produced during the 
Lucifer yellow scrape assays in HCAECs. Two scrapes were made across the glass bottom of 
the 35 mm dish, intersecting at right angles at the centre of the dish (full details under 
“Section 2.2.5 – Lucifer yellow scrape assay”).  
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Figure 6.2 shows Lucifer yellow dye transfer between confluent HCAECs in a scrape assay. 
Dye transfer between adjacent HCAECs was analysed under control conditions (Figure 6.2A 
& 6.2B). The images were taken using a x10 (Figure 6.2A) and a x20 (Figure 6.2B) objective 
lens. The signal intensity profile (Figure 6.2C) represents the fluorescence recorded across 
the scrape shown in Figure 6.2B (dashed line). For the experiment shown, a maximum 
distance of approximately 140 µm was recorded for dye transfer from the scrape edge 
under control conditions. Beyond 140 µm the fluorescence dropped to background level. 
The cells displaying the highest concentration of fluorescence (169 AU) were identified at 
the border of the scrape (Figures 6.2B & 6.2C).  
Next, dye transfer was examined between HCAECs pre-incubated with 5 µM 8-pCPT AM at 
37˚C/ 5% CO2 for 30 minutes (Figures 6.2D & 6.2E). The cells displaying the highest 
fluorescence intensity (239 AU) were again identified at the border of the scrape (Figures 
6.2E & 6.2F). The maximum distance of dye transfer was recorded at approximately 530 µm 
(Figure 6.2F), nearly four times the distance recorded under control conditions. Again, 
beyond this distance fluorescence decreased to background level.  
Exposure to the Epac1 antagonists ESI-09 (Figures 6.2G & 6.2H) and HJC0197 (Figures 6.2J 
& 6.2K) prior to Epac activation was also examined using a Lucifer yellow scrape assay. Both 
antagonists were used at 5 nM and incubated with the HCAECs for 10 minutes at 37˚C/ 5% 
CO2 before addition of 5 µM 8-pCPT  AM for 30 minutes (full details under “2.2.6: Lucifer 
yellow scrape dye transfer assay”). HCAECs pre-treated with the Epac antagonist ESI-09 
(Figures 6.2G & 6.2H) displayed a maximum dye transfer distance of approximately 280 µm 
(Figure 6.2I), approximately half of the distance recorded in HCAECs treated with 8-pCPT 
alone. Once again, the cells displaying the highest fluorescence intensity (237 AU) were 
identified at the border of the scrape (Figures 6.2H &6.2I). It should be noted that this high 
level of fluorescence at the scrape border was detected for an extended distance when 
compared to control conditions, and was comparable to that recorded following treatment 
with 8-pCPT alone. Treatment with HJC0197 produced minimal dye transfer between 
HCAECs (Figures 6.2J & 6.2K), with a maximum distance of dye transfer of 80 µm, lower 
than that recorded even under control conditions with no 8-pCPT addition (Figure 6.2L). 
Furthermore, peak fluorescence was recorded at 245 AU, a concentration higher than that 
recorded under any of the previous conditions (Figure 6.2L).  
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A 
Figure 6.1: Brightfield image showing HCAECs used for Lucifer yellow scrape assay 
HCAECs were seeded at 300,000 per 35 mm glass-bottom tissue culture dish. Once 90% 
confluent, a feather size 15 surgical blade was used to produce two scrapes across the dish, 
intersecting in the centre of the dish at right angles to each other. Image taken using a Leica 
laser-scanning confocal microscope with x10 lens (full method details under “2.2.6: Lucifer 
yellow scrape dye transfer assay”).  
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Figure 6.2: Immunocytochemistry of Lucifer yellow dye transfer in HCAECs 
Under control conditions (A & B) dye travelled a maximum distance of ~ 140 µm from the scrape 
edge (C). Following treatment with 5 µM 8-pCPT for 30 minutes at 37˚C/ 5% CO2 (D & E), dye 
travelled a maximum distance of ~ 530 µm from the scrape edge (F). Pre-incubation with 5 nM 
ESI-09 prior to 8-pCPT addition (G & H) resulted in a maximum dye transfer distance of ~ 280 µm 
(I). Pre-treatment with 5 nM HJC0197 (J & K) almost entirely blocked dye spread from the scrape 
edge, with a maximum distance of ~ 80 µm (L). Lucifer yellow CH lithium salt was used at a 
concentration of 0.1% in PBS (containing calcium chloride and magnesium). 4 images were taken 
of each dish. Full details of procedure detailed under “2.2.6: Lucifer yellow scrape dye transfer 
assay”. Scale bars represent 300 µm (x10 lens) and 150 µm (x20 lens). Dashed lines represent 
signal intensity recording profile.  
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The data recorded from 3 separate experiments were first quantified by averaging the 
maximum distance travelled under each of the four conditions (control, + 8-pCPT, ESI + 8-
pCPT and HJC + 8-pCPT). Every dish was subjected to 2 intersecting scrapes, yielding 4 
scrapes as described earlier, and measurements were taken 4 times from each scrape, 
totalling 16 measurements in each condition. This process was repeated for 2 more sets of 
experiments, and the readings from the 3 different sets of experiments were pooled for 
summary results. The individual and summary results are shown in Figure 6.3. All 
recordings detected a significant increase in the distance of dye transfer between control 
conditions and HCAECs pre-treated with 5 µM 8-pCPT (Figure 6.3A P< 0.01, Figure 6.3B P< 
0.001 and Figure 6.3C P< 0.001, one-way ANOVA, N=16). In addition, in experiments 2 and 
3, pre-treatment of HCAECs with Epac antagonists reversed the effect of 8-pCPT (Figure 
6.3B ESI-09 and HJC0197 P< 0.001 and Figure 6.3C ESI-09 P< 0.05 and HJC0197 P< 0.001). 
When the results from the 3 experiments were combined, the compiled data showed a 
significant difference between control and 8-pCPT-treated cells (Figure 6.3D, P< 0.01), and 
this effect was abolished when HCAECs were pre-treated with HJC0197 (Figure 6.3D, P< 
0.01, one-way ANOVA, N=48).  
Together, this data suggests that Epac activation by 8-pCPT results in increased dye transfer 
between adjacent HCAECs in culture, indicating that the newly formed gap junctions at 
sites of cell-cell contact are functional. Furthermore, the Epac antagonist HJC0197 blocked 
the effect of 8-pCPT. The Epac antagonist ESI-09 blocked the effect of 8-pCPT in 2 out of the 
3 experiments.   
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 A B 
C D 
Figure 6.3: Quantification of Lucifer yellow dye transfer in HCAEC scrape assay 
In total, 3 Lucifer yellow experiments were carried out using HCAECs (A-C). Each experiment 
involved the creation of 4 scrapes per condition. An image was taken of each scrape (4 images 
per condition) using the x10 confocal microscope lens. 4 measurements were taken from each 
image (16 measurements per condition, per experiment). Measurements were taken by 
recording the maximum dye spread from the scrape edge (Leica Lite Software). D represents the 
average dye transfer recordings from all experiments. (* P< 0.05, ** P< 0.01, *** P< 0.001 one-
way ANOVA, N=16 for A, B and C, and N=48 for D). 
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6.2.2 - Live calcium imaging of HCAECs 
6.2.2.1 - Effect of 8-pCPT on calcium homeostasis in HCAECs 
Figure 6.4 shows Fluo-4 fluorescence in HCAECs before (Figure 6.4A), 30 seconds after 
(Figure 6.4B), and 60 seconds after (Figure 6.4C) application of 5 µM 8-pCPT. In un-
stimulated HCAECs, Fluo-4 fluorescence was low, suggesting low resting calcium level 
(Figure 6.4A). Application of 5 µM 8-pCPT triggered an increase in the cytoplasmic calcium 
concentration (Figure 6.4B). This rise in calcium was initially uniform in appearance (Figure 
6.4B), but after 60 seconds of 8-pCPT addition, cells showed a spot-like distribution of 
AF488 signal (Figure 6.4C). This is presumably due to the cytoplasmic calcium being 
sequestered into intracellular stores. The bright spots within the cells appear to match 
mitotracker staining of mitochondria, as shown in Figure 6.5. An exception to this transient 
nature of calcium release was seen in cells in the process of cell division, which typically 
showed a sustained elevated calcium level throughout recordings (Figure 6.4B and 6.4C, 
white arrows).  
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Figure 6.4: Confocal images of Fluo-4 -loaded HCAECs 
Image A shows un-stimulated HCAECs loaded with 10 µM Fluo-4 AM. 30 seconds after 
application of 5 µM 8-pCPT, HCAECs showed an increase in AF488 signal intensity, suggesting 
cytoplasmic calcium increase (B). After 60 seconds (C), intracellular calcium largely returned to 
resting level, being apparently sequestered into intracellular compartments. Scale bar 
represents 40 µm. The white arrows in B and C highlight the dividing cells where calcium levels 
remained high. 
 
 
 
 
 
Figure 6.5: Confocal images of Mitotracker -loaded HCAECs 
Image A shows un-stimulated HCAECs loaded with 10 µM Fluo-4 AM. Image B shows the AF488 
signal that appears to be largely contained within intracellular compartments after treatment 
with 5 µM 8-pCPT. Image C shows the HCAECs displayed in images A and B loaded with 
mitotracker (100 nM), after 8-pCPT treatment. The intracellular stores that rapidly sequester the 
calcium (B) have a structure reminiscent of mitochondria (C). Scale bar represents 40 µm. N=3. 
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6.2.2.1.1 - Calcium transients induced by 8-pCPT in the presence of extracellular calcium 
To further characterise the intracellular calcium transients induced by application of 8-
pCPT, images of Fluo-4-loaded HCAECs were taken at 10 second intervals. The change in 
intracellular calcium level was determined by measuring the average signal intensity of the 
region of interest from individual HCAECs. Figure 6.6A shows the time course of the calcium 
transient (mean and SEM) obtained from 100 cells. 8-pCPT was applied between the first 
two frames (0 seconds and 10 seconds), as indicated by the red arrow in Figure 6.6A. 8-
pCPT caused a rapid increase in intracellular calcium levels in HCAECs that peaked at 
approximately 30 seconds. Calcium levels then slowly decreased, reaching the resting level 
after 300 seconds (dotted line, Figure 6.6A). These results show that 8-pCPT application 
causes rapid and transient increase in intracellular calcium in HCAECs.  
 
6.2.2.1.2 - Calcium transients induced by 8-pCPT in the absence of extracellular calcium 
As an increase in intracellular calcium can be produced by calcium influx and/or calcium 
release, experiments were repeated in the absence of extracellular calcium. Figure 6.6B 
shows 8-pCPT stimulation of HCAECs in the presence of 2 mM extracellular calcium (filled 
circles) and HCAECs in calcium-free extracellular solution (open circles). Calcium transients 
induced in the absence of extracellular calcium (open circles, N=74 cells) were similar to 
those induced in the presence of extracellular calcium (filled circles, N=100 cells). Both 
transients peaked at approximately 30 seconds and showed a slow decline to resting levels. 
In the absence of extracellular calcium (open circles), the calcium decline is somewhat 
quicker than that observed when calcium is present in the extracellular solution (filled 
circles). This data indicates that calcium release from intracellular stores is important in the 
8-pCPT-induced calcium transients in HCAECs. Furthermore, the apparent faster calcium 
decrease in the absence of extracellular calcium may indicate calcium influx occurring 
during the declining phase of the calcium transient.  
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Figure 6.6: Calcium transients induced in HCAECs on 8-pCPT application 
HCAECs were loaded with 10 µM Fluo-4 AM. 5 µM 8-pCPT was added to the cells between the 
first and second time points, as indicated by the red arrow in A. Figure A shows the rise in 
intracellular calcium induced by 8-pCPT in the presence of extracellular calcium. The dashed line 
represents the resting level of calcium. Figure B shows the rise in intracellular calcium induced 
by 8-pCPT in the presence (filled circles) and absence of extracellular calcium (open circles). In B, 
the peak in intracellular calcium was observed at approximately 30 seconds for both calcium-
containing and calcium-free extracellular solution. Images were taken every 10 seconds. Image 
A; N=100 cells. Image B open circles; N=74 cells. 
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6.2.2.1.3 - Calcium transients induced by 8-pCPT in the presence of CPA 
To further determine the importance of calcium release in the 8-pCPT-induced calcium 
transient in HCAECs, endoplasmic reticulum (ER) calcium content was depleted. The 
standard techniques for the emptying of ER calcium stores includes pre-incubation with 
cyclopiazonic acid (CPA) or thapsigargin, both of which inhibit  calcium-ATPase pumps in 
the ER membrane. There is a continuous basal ‘leak’ of calcium from the ER and blockage of 
calcium entry into these intracellular stores prevents re-filling and the ER calcium store is 
subsequently depleted. The effect of 8-pCPT application on HCAECs pre-treated with CPA 
was examined in the absence of extracellular calcium (Figure 6.7A). These conditions 
therefore blocked both the release of calcium from the ER stores and the influx of calcium 
from the extracellular solution. Under these conditions, 8-pCPT no longer induced an 
increase in intracellular calcium (N=60 cells).  
 
6.2.2.1.4 - Calcium transients induced by 8-pCPT in the presence of ryanodine 
Calcium release from intracellular stores can occur due to the opening of calcium release 
channels in the membrane of the endoplasmic reticulum or sarcoplasmic reticulum. IP3 
receptors are generally considered to play a major role in this form of calcium release in 
non-excitable cells, including endothelial cells, while ryanodine receptors appear to be 
primarily responsible in striated muscle contraction. With regards to smooth muscle cells, 
the relative importance of IP3 receptors and ryanodine receptors in elevating intracellular 
calcium concentration seems to depend on the type of stimulus. The mode of ryanodine 
effect on ryanodine receptors is thought to be rather complex as it is not only dose-
dependent, but also use-dependent. That said, application of relatively high concentrations 
of ryanodine is expected to block calcium release from intracellular stores via ryanodine 
receptors. Figure 6.7B shows the increase in intracellular calcium induced in HCAECs on 8-
pCPT application in the presence of extracellular calcium and 30 µM ryanodine (N=23 cells). 
Under these conditions, 8-pCPT induced an increase in intracellular calcium, with a peak at 
approximately 30 seconds. This data suggests that the 8-pCPT-induced calcium release 
from HCAEC intracellular stores was largely unaffected by the high dose of ryanodine. This 
result may not be surprising, as there is currently a lack of convincing evidence to suggest 
that endothelial cells express ryanodine receptors or that these are functionally active in 
the release of calcium from the endoplasmic reticulum. HCAECs have previously been 
shown to express at least two subtypes of IP3 receptors (Section 3.2.2.3 – IP3 receptor 
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Figure 6.7: Calcium transients induced in HCAECs on 8-pCPT application with 
disruption of calcium release from intracellular stores 
HCAECs were loaded with 10 µM Fluo-4 AM. 5 µM 8-pCPT was added to the cells between the 
first and second time points. Depletion of the ER calcium store with CPA, and removal of 
extracellular calcium, prevented the 8-pCPT-induced rise in intracellular calcium (A). Treatment 
of HCAECs with 30 µM ryanodine, a concentration thought to be sufficient to block ryanodine 
receptors on the ER, in the presence of extracellular calcium, failed to inhibit the 8-pCPT-
induced rise in intracellular calcium (B). In HCAECs pre-treated with ryanodine, the peak in 
intracellular calcium was observed at approximately 30 seconds, as occurred in HCAECs treated 
with 8-pCPT alone (Figure 6.6, above). Images were taken every 10 seconds. Image A; N=60 
cells. Image B; N=23 cells. 
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Immunocytochemistry of IP3R expression in HCAECs 
expression) and these seem the more likely candidate for calcium release from the 
endoplasmic reticulum. 
 
6.2.2.1.5 - Calcium transients induced by 8-pCPT in the presence of PKI 
As discussed earlier, 8-pCPT is thought to be a useful tool to selectively activate Epac. 
Nonetheless, to determine whether PKA was also involved in the 8-pCPT-triggered 
elevation of intracellular calcium, HCAECs were pre-treated with 5 µM of the myristoylated 
form of the PKA inhibitor, PKI, prior to 8-pCPT application in the presence of extracellular 
calcium (Figure 6.8). PKI is thought to selectively inhibit PKA without affecting Epac activity. 
The open circles show the average PKI result from 64 cells. For comparison, the filled circles 
show the calcium transient induced by 8-pCPT application.  
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Figure 6.8: Calcium transient induced in HCAECs on 8-pCPT application in the 
presence of PKI 
HCAECs were loaded with 10 µM Fluo-4 AM. 5 µM 8-pCPT was added to the cells between the 
first and second time points. PKA activity was inhibited by pre-treatment (20 minutes) of the 
HCAECs with 5 µM PKI. Inhibition of PKA activity appeared to have little effect on the calcium 
transient induced by 8-pCPT addition. Under both conditions, the peak in intracellular calcium 
was observed at approximately 30 seconds. Images were taken every 10 seconds. N=64 cells.  
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6.2.2.1.6 - Calcium transients induced by 8-pCPT in the presence of Epac antagonists 
Next, the effect of two types of Epac antagonist, HJC0197 and ESI-09, on 8-pCPT-induced 
rise in intracellular calcium was examined. These experiments were performed in the 
presence of extracellular calcium. Figure 6.9A shows the average results from 27 cells pre-
incubated with ESI-09. In the presence of ESI-09, the 8-pCPT triggered calcium transient 
was substantially smaller. Figure 6.9B shows the average results from 8 cells pre-incubated 
with HJC0197. In the presence of HJC0197, 8-pCPT did not induce a rise in intracellular 
calcium. Taken together, putative Epac antagonists inhibited the rise in intracellular calcium 
induced by 8-pCPT application in HCAECs.  
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Figure 6.9: Calcium transients induced in HCAECs on 8-pCPT application in the 
presence of the Epac antagonists ESI-09 and HJC0197 
HCAECs were loaded with 10 µM Fluo-4 AM. 5 µM 8-pCPT was added to the cells between the 
first and second time points. Pre-treatment of HCAECs with ESI-09 (20 minutes, 5 nM) 
substantially reduced the 8-pCPT-induced rise in intracellular calcium (A). The resting level of 
calcium in these cells was similar to un-treated HCAECs (Figure 6.6), and a small peak was 
identified at approximately 30 seconds. Pre-treatment of HCAECs with HJC0197 (20 minutes, 5 
nM) prevented the 8-pCPT-induced rise in intracellular calcium (B). Again, the resting level of 
calcium in these cells was similar to un-treated HCAECs. Images were taken every 10 seconds. 
Image A; N=27 cells. Image B; N=8 cells. 
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6.2.2.2 - Calcium transients induced by a β-adrenergic agonist in the presence of 
extracellular calcium 
Next, experiments were performed to investigate the effect of physiological elevation of 
cAMP on calcium homeostasis in HCAECs. Physiological stimuli such as prostaglandin E2 
(PGE2) increase the level of cAMP by binding its receptor, PGE2, which is a Gs-protein 
coupled receptor that activates adenylate cyclase (AC). However, the expression pattern of 
receptors often changes during cell culture, and so physiological agonists may no longer be 
effective in these cells. Nonetheless, a sub-population of cells may still retain the receptors, 
and so the effect of isoproterenol on HCAECs was examined (Figure 6.10). Isoproterenol is 
known to increase cAMP by binding to β1- or β2-adrenoreceptors in vivo. On application of 
10 µM isoproterenol, calcium transients were detected in only three cells (Figure 6.10B, 
white arrows). When 8-pCPT was applied to the same dish after application of 
isoproterenol, a calcium increase was observed in almost all cells (Figure 6.10C). This result 
suggests that the lack of response to isoproterenol is not general experimental failure, but 
rather loss of the β-adrenoreceptors during cell culture. In summary, this experiment 
showed that receptor stimulation did trigger calcium increase in a subset of HCAECs.  
 
6.2.2.3 - Effect of forskolin on calcium homeostasis in HCAECs 
6.2.2.3.1 - Calcium transients induced by forskolin in the presence of extracellular calcium 
In order to circumvent the problem of loss of receptor expression, cAMP was raised in 
HCAECs by forskolin application, which directly activates AC. Figure 6.11A shows the 
average calcium transient induced by the application of 10 µM forskolin in the presence of 
extracellular calcium (N=114 cells). Like 8-pCPT, forksolin application induced a rise in 
intracellular calcium in HCAECs. However, when HCAECs were stimulated with forskolin, 
the time-to-peak was delayed (50 seconds vs 30 seconds), and the rate of calcium decrease 
appeared slower. 
 
6.2.2.3.2 - Calcium transients induced by forskolin in the absence of extracellular calcium 
Next, forskolin was applied to HCAECs bathed in calcium-free extracellular solution. The 
average calcium transient from 30 cells is shown in Figure 6.11B as open circles. The 
calcium transient induced by forskolin in the presence of extracellular calcium is also shown 
for comparison (filled circles). In the absence of extracellular calcium, forskolin still induced  
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Figure 6.10: Calcium transient of HCAECs triggered by application of isoproterenol 
and 8-pCPT 
Image A shows un-stimulated HCAECs loaded with 10 µM Fluo-4 AM. Application of 10 µM 
isoproterenol triggered a calcium increase in only 3 cells (B, white arrows), while most of the 
HCAECs responsded to application of 5 µM 8-pCPT (C). Scale bar represents 40 µm 
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a calcium transient, peaking at approximately 30 seconds (N=30 cells). This data suggests 
that calcium release is an important part of the forskolin-induced rise in intracellular 
calcium.  
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Figure 6.11: Calcium transients induced in HCAECs on forskolin application 
HCAECs were loaded with 10 µM Fluo-4 AM. 10 µM forskolin was added to the cells between 
the first and second time points. Figure A shows the rise in intracellular calcium induced by 
forskolin in the presence of extracellular calcium. Figure B shows the rise in intracellular calcium 
induced by forskolin in the absence of extracellular calcium (open circles). The result from A is 
also shown for comparison (filled circles). In A, the peak in intracellular calcium was observed at 
approximately 50 seconds. In B, the peak in intracellular calcium in the absence of extracellular 
calcium (open circles), was observed at approximately 30 seconds. Images were taken every 10 
seconds. Image A; N=114 cells. Image B open circles; N=30 cells. 
265 
 
6.2.2.3.3 - Calcium transients induced by forskolin in the presence of PKI 
The elevation in cAMP level induced by application of forskolin is thought to activate both 
Epac- and PKA-mediated signal transduction cascades in HCAECS. As the PKA inhibitor, PKI, 
had little effect on the 8-pCPT-induced calcium transient (Figure 6.12), the differences 
between the 8-pCPT-induced and forskolin-induced transients could be attributed to the 
activation of PKA. Thus, forskolin stimulation was carried out using HCAECs pre-treated 
with PKI, in the presence of extracellular calcium (Figure 6.12). This figure summarises the 
results from 71 cells pre-treated with PKI (open circles). The calcium transient induced by 
application of forskolin in the presence of extracellular calcium is also shown for 
comparison (filled circles). When HCAECs were pre-treated with PKI, the forskolin-induced 
rise in intracellular calcium returned toward the basal level more quickly, and the peak was 
comparable to that observed in HCAECs in the absence of PKI. Together, the data suggest 
that the PKA-pathway may contribute to part of the calcium transient induced by forskolin 
application.  
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Figure 6.12: Calcium transient induced in HCAECs on forskolin application in the 
presence of PKI 
HCAECs were loaded with 10 µM Fluo-4 AM. 10 µM forskolin was added to the cells between 
the first and second time points. PKA activity was inhibited by pre-treatment (20 minutes) of the 
HCAECs with 5 µM PKI. In the HCAECs pre-treated with PKI, the calcium transient returned 
towards the resting level more quickly, and the peak was comparable to that recorded in 
HCAECs without PKI (filled circles). Images were taken every 10 seconds. N=71 cells.  
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6.3 - Discussion 
6.3.1 – 8-pCPT application to HCAECs enhances gap junction intercellular communication 
As previously mentioned, GJIC is typically quantified by either the transfer of electrical 
conductance or through dye spread. To determine whether the Epac-mediated re-
distribution of connexins formed nascent functional gap junction channels, Lucifer yellow 
(LY) dye transfer was examined in a scrape assay.  On application of 5 µM 8-pCPT, LY dye 
transfer significantly increased (Figure 6.2D & 6.2E and Figure 6.3D), when compared to un-
stimulated HCAECs (Figure 6.2A & 6.2B, one-way ANOVA, N=16). This increase in dye 
transfer suggests an 8-pCPT-mediated enhancement in HCAEC GJIC. A similar increase in 
GJIC has been observed on cAMP elevation, and 8-pCPT addition, in the literature (see 
Section “5.4.2.3 - VE-cadherin and connexin co-localisation following 8-pCPT addition”) 
(Saez, Spray et al. 1986, Mehta, Yamamoto et al. 1992, Atkinson, Lampe et al. 1995, 
Burghardt, Barhoumi et al. 1995, Mehta, Lokeshwar et al. 1996, Somekawa, Fukuhara et al. 
2005, Duquesnes, Derangeon et al. 2010). Inhibition of Epac activity with the Epac-specific 
antagonist HJC0197 completely blocked the 8-pCPT-induced increase in dye transfer (Figure 
6.2J & 6.2K and Figure 6.3). Together, this data suggests that Epac activation triggers 
enhanced GJIC in HCAECs.  
 
6.3.2 – Epac activation stimulates a transient rise in intracellular HCAEC calcium 
concentration 
The hypothesis that Epac activation increases intracellular calcium concentration was 
tested in HCAECs loaded with Fluo-4-AM. HCAECs were stimulated using 8-pCPT and 
forskolin to activate Epac and adenylate cyclase, respectively. Calcium transients were 
indeed triggered by both 8-pCPT and forskolin in the presence, and absence, of calcium 
(Figure 6.5B and 6.10B). These results also indicate that calcium transients caused by 
application of 8-pCPT or forskolin were due to, at least in part, calcium release from the ER, 
as only after the ER calcium was depleted with CPA did 8-pCPT fail to trigger a calcium 
transient (Figure 6.6A).  
The calcium release is hypothesised to result from opening of IP3 receptors, as blockade of 
ryanodine receptors (RyRs) with high concentrations of ryanodine (30 µM) had little effect 
on the calcium transient induced by 8-pCPT application (Figure 6.6B). In support of this 
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functional evidence, the presence of at least two types of IP3 receptors was detected in 
HCAECs using immunocytochemical techniques (Chapter 3, Figure 3.8).  
In order to further analyse the pattern of calcium transients under various conditions, some 
form of standardisation was necessary. As previously mentioned, Fluo-4 is a single 
wavelength calcium indicator. This means that, unlike ratiometric dyes such as Fura-2, the 
signal emitted by Fluo-4-loaded cells not only depends upon the intracellular calcium 
concentration of the cell, but also the efficiency of dye-loading. Indeed, the signal intensity 
of Fluo-4-loaded HCAECs at rest appears to differ between experiments. Thus, the 
estimation of true calcium concentration that allows direct comparison of calcium 
transients under various conditions is problematic. That said, the overall shape of the 
calcium transient gives an indication of the different calcium handling mechanisms involved 
in the 8-pCPT-induced rise in intracellular calcium. In an attempt to overcome such issues, 
the average signal intensity was normalised against peak intensity to allow the comparison 
of the time-course of calcium transients.  
 
6.3.2.1 – 8-pCPT application triggers calcium release from the ER 
Figure 6.13, below, shows the normalised calcium transients induced by 8-pCPT in the 
presence (filled circles) and absence (open circles) of extracellular calcium. The calcium 
transient occurring in the absence of extracellular calcium (open circles) solely reflects 
calcium release caused by Epac activation. In both conditions, transients reached a peak at 
approximately 30 seconds, but in the absence of extracellular calcium (open circles) the 
increased calcium concentration declines more rapidly. It is possible that this faster decline 
is due to faster calcium removal from the cytoplasm. However, it is more likely that Epac 
activation induced not only calcium release but also calcium influx, and that this influx did 
not occur in the absence of extracellular calcium and therefore the calcium concentration 
had an appearance of faster decline.  
Figure 6.13 also shows the normalised calcium transient induced by 8-pCPT when HCAECs 
were pre-treated with the PKA-inhibitor, PKI, in the presence of extracellular calcium (open 
triangles). The calcium transient under these conditions was largely unchanged to that 
observed without the PKA inhibitor, suggesting that the 8-pCPT-induced calcium transient 
is mediated predominantly via Epac activation. This is consistent with the results where 8-
pCPT-induced calcium transients were inhibited (Figure 6.9B) or substantially reduced 
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(Figure 6.9A) by Epac-specific antagonists HJC0197 and ESI-09, respectively. Both HJC0197 
and ESI-09 are marketed as antagonists to both Epac1 and Epac2 (Chen, Tsalkova et al. 
2012, Almahariq, Tsalkova et al. 2013, Rehmann 2013). Both antagonists are considered to 
act as Epac inhibitors through their general protein denaturing properties that prevents 
Epac’s GEF activity, and are not entirely specific for Epac (Rehmann 2013). Their degree of 
inhibitory effect on 8-pCPT-induced calcium transients may therefore reflect the relative 
selectivity of these Epac antagonists.  
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Figure 6.13: Normalised calcium transients induced in HCAECs on 8-pCPT application  
The average signal intensity for each condition was normalised against the peak intensity to 
allow direct comparison of the time-course of calcium transients. Peak calcium elevation was 
recorded at approximately 30 seconds for each condition. Calcium transients induced by 8-pCPT 
in the presence (filled circles) and absence (open circles) of extracellular calcium are shown. For 
comparison, the transient induced by 8-pCPT following incubation with PKI, in the presence of 
calcium, is also shown (open triangles). 
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6.3.2.2 – cAMP elevation triggers predominantly calcium release but also calcium influx 
Figure 6.14 shows the normalised calcium transients induced by forskolin in the presence 
of extracellular calcium (filled red circles). Forskolin application also induced a calcium 
transient in the absence of extracellular calcium (open red circles), presumably by releasing 
calcium from the ER. In the absence of extracellular calcium, the calcium transient declined 
more quickly, as was observed in the 8-pCPT-induced calcium transient. Again, although it 
is possible that the faster decline could be attributed to increased calcium clearance, it 
seems more likely that forskolin application induced both calcium release and calcium 
influx. In Figure 6.14, the normalised calcium transient induced by 8-pCPT addition in the 
presence of extracellular calcium is also shown for comparison (filled black circles). The 
time-to-peak was longer with the forskolin-induced calcium transient in the presence of 
extracellular calcium (filled red circles, approximately 50 seconds compared to 
approximately 30 seconds for 8-pCPT). Interestingly, the calcium transient induced by 
forskolin in the absence of extracellular calcium (open red circles) was virtually identical to 
that observed with 8-pCPT in the presence of extracellular calcium (filled black circles).  
Figure 6.14 also shows the normalised calcium transient induced by forskolin when HCAECs 
were pre-treated with PKI in the presence of extracellular calcium (open red triangles). PKI 
appeared to have little effect on the shape of the calcium transient at the early stage of the 
recording, but did appear to increase the rate of decline after approximately 100 seconds. 
As PKA is likely to have multiple effects in endothelial cells, it is difficult to interpret the 
data shown in Figure 6.14 without further experiments. Such experiments could involve 
Epac1 siRNA. Indeed, multiple attempts were made to investigate calcium transient using 
HCAECs where Epac was knocked down, however, cells failed to survive the combination of 
siRNA knockdown and live calcium imaging.  
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Figure 6.14: Normalised calcium transients induced in HCAECs on forskolin application  
The average signal intensity for each condition was normalised against the peak intensity to 
allow direct comparison of the time-course of calcium transients. Peak calcium elevation was 
recorded at approximately 50 seconds for HCAECs treated with forskolin in the presence of 
extracellular calcium both with (open red triangles) and without PKI (filled red circles). In the 
absence of extracellular calcium, forskolin induced a peak elevation in intracellular calcium 
within 30 seconds (open red circles).  
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6.3.2.3 - Potential Epac-mediated calcium-release mechanisms 
Evaluation of normalised calcium transients under various conditions indicated that the ER 
plays a major role in the elevation of calcium induced by both 8-pCPT and forskolin. As RyRs 
are generally not considered to be functionally important in calcium release from the ER in 
non-excitable cells, IP3Rs are thought to be the primary ER calcium release channels in 
endothelial cells (Section 6.1.3.1 – Calcium release from the endoplasmic reticulum). cAMP 
has been linked to an increase in the affinity of IP3Rs for IP3 by as much as a factor of 10 in 
the salivary glands of a subspecies of dipteran fly (Schmidt, Baumann et al. 2008). This 
increase in affinity is thought to be mediated by PKA (Schmidt, Baumann et al. 2008) but 
there is potential for an Epac-mediated mechanism whereby the sensitivity of IP3Rs for IP3 
is enhanced on cAMP elevation in non-excitable cells. Phosphorylation of IP3R1 has also 
been linked to enhanced calcium release from the ER (Hajnoczky, Gao et al. 1993, 
Wojcikiewicz and Luo 1998, Bruce, Shuttleworth et al. 2002, Tang, Tu et al. 2003, Dyachok 
and Gylfe 2004), although a decrease in calcium release on IP3R1 phosphorylation has also 
been noted (Volpe and Alderson-Lang 1990, Tertyshnikova and Fein 1998). Such 
phosphorylation can be mediated by non-receptor protein kinases including 
calcium/calmodulin kinase II (CaMKII) (Supattapone, Danoff et al. 1988, Wojcikiewicz and 
Luo 1998, Tang, Tu et al. 2003). This kinase is activated on 8-pCPT application to rat cardiac 
myocytes (Pereira, Métrich et al. 2007), a process which has been shown to involve PKC in 
these cells (Waxham and Aronowski 1993, O-Uchi, Komukai et al. 2005). Indeed, CaMKII 
inhibition through application of the antagonist KN93, completely blocks 8-pCPT-induced 
enhancement of electrically-evoked ER calcium release (Oestreich, Malik et al. 2009). 
Similarly, IP3 recycling-blocking agents L-690.330 and Licl, in addition to the IP3R antagonist 
2-aminoethoxydiphenyl borate (2-APB) and IP3R siRNA knock down, all inhibit β2-
adrenoreceptor-stimulated ER calcium release in endothelial cells (Mayati, Levoin et al. 
2012). 
 
6.3.2.4 - Potential cAMP-mediated calcium-influx mechanisms 
In addition to calcium release, the contribution of calcium influx pathways in HCAECs was 
implied from the apparent faster decline of calcium transient when extracellular calcium 
was omitted. There are three possible mechanisms by which calcium influx could occur in 
these cells; ICRAC, nucleotide-gated cation channels and reverse-mode Na
+/ Ca2+ exchangers.  
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In non-excitable cells, calcium release from the ER is known to induce calcium entry across 
the cell membrane through store-operated calcium entry (SOCE). The process of SOCE and 
the involvement of STIM1 and Orai1 has been previously detailed (Section 6.1.3.2 - Store-
operated calcium entry). It is possible that the difference between 8-pCPT-induced calcium 
transient in the presence and absence of extracellular calcium might be explained by ICRAC in 
HCAECs.  
The second calcium entry pathway is nucleotide-gated (CNG) cation channels. These 
channels are permeable to cations, including calcium, and their gating is directly regulated 
by the intracellular cGMP and cAMP concentrations (Section 6.1.3.3 - Additional calcium-
entry mechanisms). If such channels are to open in HCAECs upon elevation of the 
intracellular cAMP concentration, it could explain the difference between forskolin-induced 
calcium transient in the presence and absence of extracellular calcium. Such channels 
would not, however, explain the differences between the calcium transient induced by 8-
pCPT in the presence and absence of extracellular calcium, as Epac is directly stimulated by 
this agonist without elevation in the intracellular concentration of cAMP.   
The final potential calcium entry pathway is through reverse-mode Na+/ Ca2+ exchangers. 
Generally sodium/calcium exchange across the cell membrane acts as the calcium 
extrusion mechanism (Section 6.1.3.4 – Removal of calcium from cytosol). It has been 
suggested that calcium is able to enter the cell by Na+/ Ca2+ exchangers in the reverse 
mode, whereby sodium ions are extruded in exchange for calcium entry (Hirota, Pertens et 
al. 2007, Liu, Peel et al. 2010, Tykocki, Jackson et al. 2012). However, the equilibrium 
potential for this mechanism is highly unfavourable even at the resting intracellular calcium 
concentration of 100 nM (-44 mV). On the elevation in intracellular calcium concentration 
induced by Epac (~ 800 nM), the equilibrium potential is approximately +10 mV, and thus 
this mechanism of calcium entry is even less feasible. It therefore seems unlikely that the 
Na+/ Ca2+ exchanger is involved in the elevation of intracellular calcium concentration 
observed on 8-pCPT application, however this exchanger should not be ruled out as a 
mechanism for a Epac-induced rise in intracellular calcium concentration under 
pathological conditions where the intracellular sodium concentration is elevated to a level 
that would make the reverse mode possible. 
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6.3.3 - Concluding remarks  
Together, this data suggests that Epac activation in HCAECs triggers calcium release from 
the ER that is mediated by IP3R channels, with the calcium entry pathway potentially 
playing an additional role. This calcium elevation is rapid, with peak elevation at 30 
seconds, and short-lived, declining to baseline levels after 200 seconds of recording. The 
bulk of the elevation in intracellular calcium is independent of PKA, as shown by relatively 
ineffective PKI, but is potentially contributed to by this pathway. In vivo, this Epac-induced 
rise in intracellular calcium concentration may activate endothelial IKca and SKca channels 
which have previously been shown to induce smooth muscle cell hyperpolarisation, and 
therefore relaxation. There are 2 potential mechanisms by which this could occur; (i) 
potassium efflux through activated endothelial IKca and SKca channels triggers smooth 
muscle cell hyperpolarisation through activation of sodium/potassium-ATPase and 
inwardly-rectifying potassium channels on smooth muscle cells, and (ii) the 
hyperpolarisation induced in endothelial cells on potassium efflux is directly transferred to 
smooth muscle cells through electrical communication mediated by gap junctions.  Through 
these mechanisms, and the enhanced GJIC induced by 8-pCPT application, Epac may 
facilitate both endothelial cell-endothelial cell communication and endothelial cell-smooth 
muscle cell communication, thereby creating an efficient and low-resistance pathway for 
direct cell-cell communication and the control of vascular tone.  
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Chapter 7:  
Final Discussion 
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7.1 - Introduction 
The aim of this study was to investigate whether Epac activation in HCAECs affected 
cadherin and connexin distribution, and whether this had a knock-on effect on cell-cell 
communication. Epac activation in HCAECs was found to promote endothelial cell-
endothelial cell contact, and communication via connexins, specifically Cx37. Furthermore, 
Epac activation triggered a transient rise in intracellular calcium concentration that was 
independent of the PKA pathway. As a rise in intracellular calcium has been linked to 
endothelial cell hyperpolarisation, and subsequent smooth muscle cell hyperpolarisation 
(Roberts, Kamishima et al. 2013), this preliminary data indicates that Epac may provide a 
potential mechanism for both endothelial barrier protection and the control of vascular 
tone.  
 
 
7.2 - Epac activation promotes connexin-mediated intercellular communication 
Preliminary data indicates a re-distribution of Cx37 towards sites of cell-cell contact in 
HCAECs on Epac activation (Chapter 5). This re-distribution is mirrored by an increase in VE-
cadherin distribution at the membrane that results in greater cell-cell contact and a tighter 
endothelial barrier. Indeed, it appears that the re-distribution of VE-cadherin is likely to be 
a precursor to the increased distribution of Cx37 at the membrane, as disruption of VE-
cadherin interaction through EGTA addition, or incubation with the VE-cadherin blocking 
antibody, had a subsequent effect on the distribution pattern of Cx37. Gap junctions, 
formed by connexins, allow direct cell-cell communication through the exchange of ions 
and second messenger molecules. Epac appears to promote what is hypothesised to be 
Cx37-mediated intercellular communication in HCAECs, and as such is suggested to 
promote the exchange of second messengers between adjacent cells. The endothelial cell 
layer is well-known for its high degree of intercellular communication and has previously 
been hailed as the primary route for the longitudinal spread of signal along the vessel wall 
(Emerson and Segal 2000). If Epac does result in an enhanced route for EC-EC 
communication, as is indicated here, then this pathway is likely to play a role in the control 
of vascular tone. In addition, preliminary data indicates that Epac also appears to have an 
effect on the distribution of additional connexins, namely Cx43 (Somekawa 2005, 
Duquesnes, Derangeon et al. 2010). Cx43 is considered to be the predominant connexin 
expressed in vascular smooth muscle cells (Haudenschild et al. 1990, Bruzzone, Haefliger et 
al. 1993, Gourdie, Green et al. 1993, Little, Beyer et al. 1995, Van Kempen and Jongsma 
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1999) and as such the Epac-induced re-distribution of Cx43 in HCAECs may also promote 
enhanced EC-SMC communication. If this hypothesis were correct this would further 
support a role for Epac in the control of vascular tone. To determine whether Epac does 
truly promote both EC-EC and EC-SMC communication, the use of a gap junction-blocking 
agent, or connexin siRNA, is required. In addition to the assessment of intercellular 
communication through the use of a Lucifer yellow dye assay (as used here), experiments 
involving the investigation of the spread of electrical current would further elucidate the 
extent to which Epac activation promotes enhanced cell-cell communication. This could be 
achieved through the use of patch clamp equipment and would provide support for our 
hypothesis that Epac promotes direct cell-cell communication and the spread of electrical 
current between adjacent cells. In addition to determining the degree of EC-EC 
communication, co-culture of HCAECs with HCASMCs would allow investigation of the 
proposed Epac-induced increase in EC-SMC communication. Indeed, this method was 
attempted during this study, however due to the specific environment required for each 
cell culture this did not provide beneficial results for examination at this stage.  
 
 
7.3 – Epac activation triggers a transient rise in intracellular calcium concentration 
On Epac activation in HCAECs, a rapid rise in the intracellular calcium concentration was 
detected, followed by a slow decline to base level (Chapter 6). This rise in calcium 
concentration was largely unaffected by either removal of extracellular calcium, pre-
incubation with ryanodine, or pre-incubation with PKI, a PKA inhibitor. As such, the source 
of the calcium was hypothesised to be the endoplasmic reticulum and the mechanism 
proposed to involve the activation of IP3 receptors on the surface of this organelle. Calcium 
elevations in endothelial cells have previously been shown to activate IKca and SKca channels 
in the plasma membrane (Roberts, Kamishima et al. 2013), resulting in an efflux of 
potassium and hyperpolarisation of the cell. Electrical current is able to spread directly 
between adjacent cells through electrotonic spread via gap junction channels (de Wit and 
Griffith 2010), and as such the potential hyperpolarisation induced in endothelial cells by 
Epac activation could spread directly to adjacent endothelial cells. The role of the 
endothelium as a low-resistance pathway for the spread of such signals has already been 
detailed, and such a mechanism may allow for the rapid spread of hyperpolarisation to 
down-stream areas of endothelium (Emerson and Segal 2000). In addition to the spread of 
hyperpolarisation between endothelial cells, gap junctions at the myoendothelial junction 
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(MEJ) also provide a site for direct EC-SMC communication, and therefore may facilitate the 
spread of hyperpolarisation from ECs to SMCs (Sandow, Tare et al. 2002, de Wit and Griffith 
2010). Hyperpolarisation in smooth muscle cells triggers the closure of voltage dependent 
calcium channels (VDCCs), blocking calcium entry and therefore promoting smooth muscle 
relaxation (Figure 7.1). As such, Epac could potentially provide a mechanism for the 
endothelial-mediated control of vascular tone that is currently represented as the ‘classical’ 
endothelial-derived hyperpolarising factor (EDHF) pathway (Edwards, Feletou et al. 2010, 
Roberts, Kamishima et al. 2013). In addition, due to the low-resistance pathway along the 
endothelium, this could provide not only local control of tone but also regulate vascular 
relaxation at sites distant from the initial propagation of signal (Emerson and Segal 2000). 
This mechanism is further supported by the Epac-mediated enhanced GJIC that would 
support this spread of signal between endothelial cells. Furthermore, if Epac does promote 
a re-distribution of Cx43, as indicated in preliminary experiments here, then Epac may also 
support enhanced EC-SMC communication and thus the spread of hyperpolarisation from 
ECs to SMCs. If this hypothesis is to be tested then electrical conductance between HCAECs 
and HCASMCs must be examined, and the effect of Epac activation in endothelial cells on 
the state of VDCCs expressed on SMCs investigated. In addition to the direct spread of 
hyperpolarisation between endothelial and smooth muscle cells, the efflux of potassium 
from the endothelial cells on the activation of IKca channels may have a direct effect on the 
state of the underlying smooth muscle cells. IKca channels have previously been identified 
at the MEJ where endothelial cells and smooth muscle cells are closely apposed (Sandow, 
Neylon et al. 2006). As such, there is evidence to suggest that the efflux of potassium into 
this local environment directly activates sodium/potassium ATPase on the surface of the 
smooth muscle cell, that exchanges 2 potassium ions into the cell for 3 sodium ions out of 
the cell (Edwards, Dora et al. 1998). The resulting hyperpolarisation is further contributed 
to by the action of inwardly-rectifying potassium channels (Kir) which remove the newly-
received potassium. Ultimately, there appears to be two potential pathways through which 
an Epac-mediated hyperpolarisation in HCAECs could trigger HCASMC hyperpolarisation 
and subsequent relaxation. To determine whether either, or both, of these pathways play a 
role in the endothelial –mediated control of vascular tone in the coronary circulation, the 
presence of IKca and SKca channels in HCAECs needs to be determined. In addition, the 
potential identification of IKca channels specifically at the MEJ would support, or refute, the 
role of a local potassium efflux on the smooth muscle contractile state. If such experiments 
determine that Epac activation in HCAECs provides a rapid and direct mechanism for the 
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Figure 7.1: Hypothesised mechanism of Epac-mediated regulation of vascular tone 
This diagram shows the hypothesised hyperpolarisation induced in HCAECs on Epac activation. 
Calcium release from the endoplasmic reticulum activates IKca and SKca channels on the 
endothelial plasma membrane. Potassium efflux results in HCAEC hyperpolarisation. This 
hyperpolarisation spreads directly to the adjacent HCASMCs through gap junctions at the 
myoendothelial junction (MEJ).  It is also hypothesised the IKca channels located at the MEJ result 
in a local rise in the extracellular concentration of potassium that activates sodium/potassium 
ATPase pumps on the membrane of HCASMCs. This results in 2 potassium ions in/ 3 sodium ions 
out, hyperpolarising the HCASMC. The smooth muscle cell is further hyperpolarised by the action 
of inwardly-rectifying potassium channels (Kir) which remove the newly acquired potassium from 
the HCASMC. The hyperpolarisation of the smooth muscle cell blocks the voltage-dependent 
calcium channels (VDCC), inhibiting calcium influx. Calcium is required for smooth muscle cell 
contraction and as such the smooth muscle cell relaxes. 
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regulation of vascular tone then this provides an exciting potential for manipulation of this 
pathway to promote vascular relaxation.  
 
 
7.4 - The potential role of Epac in the treatment of cardiovascular disease 
Cardiovascular disease encompasses a number of conditions, including coronary heart 
disease (CHD) which is the biggest cause of mortality in the UK, responsible for one death 
every 7 minutes (British Heart Foundation 2015). Endothelial dysfunction and hypertension 
are the primary contributing factors in the development of CHD (Vanhoutte 2009), and our 
preliminary data suggests that Epac may play a role in preventing CHD through the 
tightening of the endothelial barrier and vascular relaxation. Endothelial dysfunction is 
induced on disruption of the endothelial barrier which allows the subsequent invasion of 
inflammatory mediators and the development of an atherosclerotic plaque (Wang et al. 
2013). This plaque invades the vessel lumen, restricting blood flow and endangering 
downstream tissues.  Angina Pectoris is the result of insufficient blood flow to the heart 
muscle induced by the build-up of an atherosclerotic plaque in the coronary arteries. If part 
of the plaque detaches this may completely occlude the vessel lumen resulting in a 
complete absence of blood flow to downstream muscle and a myocardial infarction (MI). 
Prevention of endothelial disruption through protection of the endothelial barrier may 
therefore prevent the formation of such atherosclerotic plaques and ultimately reduce the 
incidence of MI. In our preliminary results, Epac has been shown to promote HCAEC-HCAEC 
contact, and formation of a tight endothelial barrier, mediated by VE-cadherin. In addition, 
if Epac promotes endothelial hyperpolarisation which in turn triggers smooth muscle 
hyperpolarisation, facilitated by enhanced GJIC, this would mediate endothelial-induced 
smooth muscle relaxation which may prevent the development of hypertension. It should 
also be noted that even if Epac were only to facilitate one or the other of the pathways 
(tighter endothelial barrier, or endothelial-induced vascular relaxation) the therapeutic 
potential of such a mechanism is still enormous.  
 
The predominant treatment for atherosclerosis involves a change in lifestyle, in 
combination with statins (3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors) to 
lower blood cholesterol levels (Grundy 1998), anti-hypertensive drugs (including calcium 
channel blockers) (Godfraind 2014), and the potential use of invasive procedures including 
percutaneous transluminal coronary angioplasty (PTCA) (Mani et al. 2007). In a large 
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proportion of patients undergoing PTCA, however, restenosis develops within the first 6 
months following surgery (Braun-Dullaeus et al. 1998). The use of drug-eluting stents (DES), 
where an immunosuppressant drug is incorporated into the coating of the stent (Wang et 
al. 2013), has reduced the rate of re-stenosis from approximately 30-40% to 10% (Jukema 
et al. 2012), however in-stent restenosis associated with intimal hyperplasia still remains a 
major limitation of PTCA (Mani et al. 2007). It is also worth noting that DES have been 
linked to lethal late-stage thrombotic events as a direct result of endothelial cell injury 
(Joner et al. 2006). It is well established that restoration of a healthy endothelium is 
required in order to prevent restenosis and/or thrombus formation (Otsuka et al. 2012). 
Statins promote re-endothelialisation in addition to their cholesterol-lowering benefits 
(Walter et al. 2002), and as such our data may therefore suggest Epac activation as a key 
accompaniment to PTCA and statins to promote endothelial stabilisation and to prevent re-
stenosis. This hypothesis is supported by work by Lee et al. (2012), who identified that 
coating of stents with anti-VE-cadherin antibodies accelerated re-endothelialisation and 
reduced neo-intimal formation in a rabbit model of atherosclerosis (Lee et al. 2012). This 
VE-cadherin was found to maximise the capture of endothelial progenitor cells, a 
requirement for successful re-endothelialisation.  As Epac activation has been shown by us, 
and others, to promote VE-cadherin distribution at the membrane, Epac activation 
following PTCA may promote endothelial stabilisation in a similar manner. As previously 
mentioned, calcium channel blockers are also commonly used to treat patients with 
hypertension through inducing vascular smooth muscle relaxation and thereby lowering 
blood pressure. Our data, together with recent work by Roberts et al. (2013), proposes that 
Epac activation promotes vascular smooth muscle relaxation through a rise in the 
intracellular calcium concentration in endothelial cells. As such, Epac activation may also 
provide an additional mechanism for the treatment of hypertension and thus long-term 
treatment for atherosclerosis.  
 
If Epac activation were to be induced, potentially through application of the Epac-selective 
agonist 8-pCPT, as used here, then atherosclerotic plaque formation (and/or re-stenosis) 
and potentially also hypertension, may be inhibited without the need for invasive surgery. 
This mechanism may also bypass many of the non-specific effects of utilising the whole 
cAMP pathway for the treatment of vascular diseases. Phosphodiesterase (PDE) inhibitors 
such as Rolipram have been shown to improve survival rates in animal models of 
inflammation (Lin, Adamson et al. 2012, Schick, Wunder et al. 2012), however, inhibition of 
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PDE activity may result in an increase in the cytosolic concentration of cAMP which can 
lead to barrier disruption and increased permeability (Creighton, Zhu et al. 2008). An 
additional, unrelated, PDE4 inhibitor is Roflumilast (3-cyclopropylmethoxy-4-
difluoromethoxy-N-[3,5-dichloropyrid-4-yl]-benzamide) (Sanz et al. 2007). This PDE4 
inhibitor is currently used as a treatment for chronic obstructive pulmonary disease (COPD) 
(Muñoz-Esquerre et al. 2015). Addition of Roflumilast to human coronary artery smooth 
muscle cells has been shown to suppress tumour necrosis factor (TNF)-α-induced 
expression of vascular cell adhesion molecule 1 (VCAM-1) (Lehrke et al. 2015). The 
expression of such cell adhesion molecules is a prerequisite for leukocyte accumulation and 
sustained inflammation, both of which are triggers for neo-intimal hyperplasia (Shah 2003). 
Roflumilast was found to supress the expression of VCAM-1, and thus monocyte 
transmigration and adhesion to vascular smooth muscles in a novel Epac-dependent, but 
PKA-independent, manner (Lehrke et al. 2015). Indeed, Roflumilast treatment was shown 
to significantly attenuate neo-intima formation by over 40% (Lehrke et al. 2015). 
Furthermore, this reduction in hyperplasia was shown to be induced through addition of 8-
pCPT, as used here, and completely blocked by both ESI-09 and Epac1 siRNA (Lehrke et al. 
2015). This suppression of neo-intimal hyperplasia was found to be at least partly due to 
reduced macrophage infiltration, thus highlighting Epac’s ability to promote a stable 
endothelial barrier. Work by Sanz et al. (2007) also identified that Roflumilast treatment 
was significantly more potent in inhibiting leukocyte-endothelial cell interaction than the 
PDE4 inhibitors Rolipram and Cilomilast (Sanz et al. 2007). PDE4 exists in one of two distinct 
conformations; a high-affinity Rolipram-binding PDE4 (HPDE4) which is primarily identified 
within the central nervous system and parietal glands, and a low-affinity Rolipram-binding 
PDE4 (LPDE4) which is predominantly localised to immunocompetent cells (Torphy et al. 
1999). Rolipram targets HPDE4, while Cilomilast and Roflumilast target LPDE4 thus 
improving the therapeutic potential of these second generation compounds and potentially 
explaining the differences in the results obtained with varying PDE4 inhibitors. In addition,  
Hatzelmann et al. (2001) identified that eosinophils and macrophages are inhibited at 
relatively similar potencies by all PDE4 inhibitors tested (Roflumilast, Roflumilast N-
Oxide, Piclamilast, Rolipram and Cilomilast) while monocytes and CD4+ T cells were 
substantially more inhibited by Roflumilast than both Cilomilast and Rolipram. Roflumilast 
therefore appears to promote a more extensive inhibition of the transmigration of 
inflammatory mediators, potentially explaining its greater anti-inflammatory effects. Sanz 
et al. (2007) also identified that Roflumilast was able to diminish histamine- and thrombin-
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induced permeability in microvascular endothelial cells and HUVECs, respectively, in a 
concentration-dependent manner.  
 
Together, these data highlight the potential therapeutic applications of Epac in the 
treatment of cardiovascular diseases.  
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Figure 7.2: Hypothesised mechanisms of Epac action on HCAECs 
This diagram represents the potential mechanisms through which Epac mediates the re-
distribution of cadherins and connexins and the release of calcium from the endoplasmic 
reticulum. Epac’s activity on the actin cytoskeleton is relatively well detailed in the literature (left 
side of the figure). Also shown, is the potential phosphorylation of the actin-binding protein 
Vinculin, and connexins, by PKCε and/or CaMKII (right side of the figure). In addition, the Epac-
induced release of calcium from the endoplasmic reticulum, mediated by IP3 production, is 
shown at the bottom right of the figure.  
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7.5 - Further work 
This study has identified an exciting area for further research into the role of the Epac 
pathway in the control of the vasculature. Preliminary experiments identified that Epac 
activation promotes a re-distribution of VE-cadherin to the membrane that is hypothesised 
to be a result of actin re-organisation in HCAECs. To elucidate the mechanism through 
which actin may promote VE-cadherin distribution at the membrane, and a tighter 
endothelial barrier, actin staining on the application of the Epac agonist 8-pCPT is required. 
It is hypothesised that the Epac-induced reorganisation of actin from stress fibres to a 
cortical actin rim promotes cell-cell contact and formation of adherens junctions (Figure 
7.2). Pre-treatment of these HCAECs with Epac1 siRNA and/or the Epac antagonists 
HJC0197 and ESI-09, will also provide valuable information on the role of Epac on the 
hypothesised re-distribution of actin.  
 
The investigation of the effect of Epac activation on VE-cadherin and connexin distribution 
in HCAECs in the presence of the VE-cadherin blocking antibody would provide the 
necessary data to interpret whether VE-cadherin re-distribution is a prerequisite for the 
connexin re-distribution induced by Epac activation. Furthermore, the use of a membrane 
marker would allow the quantification of the membranous cadherin and connexin 
distribution. Such markers could include sodium/potassium ATPase or plasma membrane 
calcium ATPase. In addition, fluorescence resonance energy transfer (FRET) analysis could 
provide confirmation that connexins and cadherins are closely associated at the 
membrane, forming a complex that promotes cell-cell communication.  
  
The use of IP3R siRNA, particularly IP3R1, prior to live calcium imaging with the Epac agonist 
8-pCPT could provide the necessary data to support our hypothesis that the calcium peak 
induced by Epac activation is a result of the activation of IP3R’s on the HCAEC endoplasmic 
reticulum. Similarly, the overexpression of Rap1GAP could provide confirmation that the 
Epac pathway alone is responsible for both the calcium transients and the cadherin/ 
connexin redistribution.  
 
To determine whether Epac is able to induce hyperpolarisation in HCAECs, the expression 
of IKca and SKca channels in these cells needs to be confirmed. More specifically, the 
localisation of IKca channels to the MEJ would provide support for the hypothesis that a 
local potassium efflux is able to promote smooth muscle hyperpolarisation subsequent to 
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endothelial cell hyperpolarisation. Similarly, the identification of sodium/potassium ATPase 
pumps on HCASMCs at the MEJ, where HCAECs project through the internal elastic lamina, 
would support our hypothesis that HCAEC hyperpolarisation could directly activate these 
channels on the plasma membrane of HCASMCS triggering SMC hyperpolarisation and 
relaxation. In addition, examination of the electrical conductance between adjacent 
HCAECs and HCAECs/HCASMCs through patch clamp would provide further information on 
the role of Epac in the regulation of vascular tone.  
 
 
7.6 – Concluding remarks 
Epac activation in HCAECs appears to induce a protective phenotype that promotes 
tightening of the endothelial barrier through rearrangement of VE-cadherin to sites of cell-
cell contact. This offers a potential therapeutic mechanism for the Epac pathway in the 
prevention of endothelial disruption and atherosclerotic plaque formation. In addition, 
Epac activation in HCAECs induces a rapid rise in intracellular calcium concentration that 
may play a role in the regulation of vascular tone through the hyperpolarisation of both 
HCAECs and the adjacent HCASMCs. This implies that Epac may also play a role in limiting 
the development of hypertension. Together, these data highlight Epac as a potentially 
invaluable means for the regulation of the vasculature both under normal and disease 
states. More work is needed in this area to elucidate the exact mechanism through which 
Epac exerts its effects on the endothelium, and subsequently the smooth muscle layer; 
however the data shown here provides the foundation for such work to explore this novel 
and exciting pathway in detail.  
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Supplementary Figure for Chapter 3: Characterisation of rat tissues and human cells 
 
Lysate Absorbance (AU) Total protein 
concentration (µg/ml) 
HCASMC P7 0.304 114.78 
HCASMC P8 0.460 298.07 
HCASMC P9 0.407 218.84 
HCASMC P10 0.338 140.04 
HCAEC P7 0.456 290.79 
HCAEC P8 0.449 283.51 
HCAEC P9 0.313 118.20 
HCAEC P10 0.320 122.06 
Heart (5 fold dilution) 0.559 456.10 
 
 
 
 
 
 
 
Supplementary information on the quantification of cadherin and connexin co-localisation 
using Image J plugins 
Three Image J plugins were used to quantify the relative co-localisation between cadherins 
and connexins in confocal images; Manders’ Overlap Coefficient plugin, Co-localisation 
Finder plugin and Intensity Correlation Analysis plugin. The MacBiophotonics Image J 
software, pre-loaded with these plugins, was used for this quantification (full details can be 
found here: http://www.uhnresearch.ca/facilities/wcif/imagej/colour_analysis.htm). The 
quantification process for each plugin is as detailed below: 
1. Manders’ Overlap Coefficient plugin 
Supplementary Figure 1: Total protein concentration of rat tissues, HCAECs and 
HCASMCs 
Related to Figure 3.1 in “Chapter 3: Characterisation of rat tissues and human cells”. Total 
protein concentration for HCAEC lysates between passages 7-10, and rat heart lysate at a 5 fold 
dilution. The protein concentration of HCAEC and HCASMC lysates are comparable while the 
high total protein concentration of rat heart lysate is evident, even at a 5 fold dilution. 
Absorbance recorded using spectrophotometer set at 562 nm. 
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 The individual red (AF595) and green (AF488) images were opened 
within the MacBiophotonics Image J software 
 Both images were converted to 8-bit 
 The Manders’ Overlap Coefficient plugin was selected and all 
settings set to default 
 The “Manders' R” value was used for comparison between images  
 This value ranges between 1 and zero, with 1 being high co-
localisation and zero being low 
 
2. Co-localisation Finder plugin 
 The individual red (AF595) and green (AF488) images were opened 
within the MacBiophotonics Image J software 
 Both images were converted to 8-bit 
 The co-localisation highlighter plugin was selected and all settings 
set to default 
 The co-localisation finder plugin was selected and all settings set to 
default 
 A % co-localisation was obtained and used for comparison between 
images 
 
3. Intensity Correlation Analysis plugin 
 The individual red (AF595) and green (AF488) images were opened 
within the MacBiophotonics Image J software 
 The thresholds of both images were adjusted to default settings 
 The Intensity Correlation Analysis plugin was selected and settings 
altered as follows: 
i. Display intensity counts 
ii. Crosshair = 3 
iii. Select PDM image to be displayed 
iv. Select positive PDMs only  
 The “Manders' R” value was used for comparison between images  
 This value ranges between 1 and zero, with 1 being high co-
localisation and zero being low 
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